biomarkerID,biomarkerName,biomarkerType,curated_disease_name,curated_breed_name,sex,age,weight,organism,conclusion
2409,Alcohol dehydrogenase 1-like,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2409,Alcohol dehydrogenase 1-like,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2409,Alcohol dehydrogenase 1-like,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2409,Alcohol dehydrogenase 1-like,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2409,Alcohol dehydrogenase 1-like,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2409,Alcohol dehydrogenase 1-like,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2409,Alcohol dehydrogenase 1-like,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2409,Alcohol dehydrogenase 1-like,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2409,Alcohol dehydrogenase 1-like,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2410,Cu/Zn superoxide dismutase,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2410,Cu/Zn superoxide dismutase,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2410,Cu/Zn superoxide dismutase,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2410,Cu/Zn superoxide dismutase,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2410,Cu/Zn superoxide dismutase,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2410,Cu/Zn superoxide dismutase,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2410,Cu/Zn superoxide dismutase,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2410,Cu/Zn superoxide dismutase,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2410,Cu/Zn superoxide dismutase,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
710,(Z)-3-peroxyaminoacrylate,metabolite,Cannabidiol,,both,9months-4years,18.2±3.4 kg,9615,Biomarker analysis based on receiver operating characteristic (ROC) curves was performed to identify biomarker candidates (area under ROC ≥ 0.90) of the effects of CBD supplementation.
711,"1,4-diaminobutane",metabolite,Cannabidiol,,both,9months-4years,18.2±3.4 kg,9615,Biomarker analysis based on receiver operating characteristic (ROC) curves was performed to identify biomarker candidates (area under ROC ≥ 0.90) of the effects of CBD supplementation.
712,2’-deamino-2’-hydroxy-6’-dehydroparomamine,metabolite,Cannabidiol,,both,9months-4years,18.2±3.4 kg,9615,Biomarker analysis based on receiver operating characteristic (ROC) curves was performed to identify biomarker candidates (area under ROC ≥ 0.90) of the effects of CBD supplementation.
713,ascorbate ,metabolite,Cannabidiol,,both,9months-4years,18.2±3.4 kg,9615,Biomarker analysis based on receiver operating characteristic (ROC) curves was performed to identify biomarker candidates (area under ROC ≥ 0.90) of the effects of CBD supplementation.
714,D-lysopine,metabolite,Cannabidiol,,both,9months-4years,18.2±3.4 kg,9615,Biomarker analysis based on receiver operating characteristic (ROC) curves was performed to identify biomarker candidates (area under ROC ≥ 0.90) of the effects of CBD supplementation.
715,o-tyrosine,metabolite,Cannabidiol,,both,9months-4years,18.2±3.4 kg,9615,Biomarker analysis based on receiver operating characteristic (ROC) curves was performed to identify biomarker candidates (area under ROC ≥ 0.90) of the effects of CBD supplementation.
716,phenylalanyl-glycine,metabolite,Cannabidiol,,both,9months-4years,18.2±3.4 kg,9615,Biomarker analysis based on receiver operating characteristic (ROC) curves was performed to identify biomarker candidates (area under ROC ≥ 0.90) of the effects of CBD supplementation.
717,"2,4-dihydroxyhept-2-enedioate",metabolite,Cannabidiol,,both,9months-4years,18.2±3.4 kg,9615,Biomarker analysis based on receiver operating characteristic (ROC) curves was performed to identify biomarker candidates (area under ROC ≥ 0.90) of the effects of CBD supplementation.
718,asparaginyl-aspartic acid,metabolite,Cannabidiol,,both,9months-4years,18.2±3.4 kg,9615,Biomarker analysis based on receiver operating characteristic (ROC) curves was performed to identify biomarker candidates (area under ROC ≥ 0.90) of the effects of CBD supplementation.
719,isoferulic acid,metabolite,Cannabidiol,,both,9months-4years,18.2±3.4 kg,9615,Biomarker analysis based on receiver operating characteristic (ROC) curves was performed to identify biomarker candidates (area under ROC ≥ 0.90) of the effects of CBD supplementation.
2411,Meprin A subunit alpha,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2411,Meprin A subunit alpha,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2411,Meprin A subunit alpha,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2411,Meprin A subunit alpha,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2411,Meprin A subunit alpha,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2411,Meprin A subunit alpha,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2411,Meprin A subunit alpha,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2411,Meprin A subunit alpha,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2411,Meprin A subunit alpha,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
720,7-carboxy-7-carbaguanine,metabolite,Cannabidiol,,both,9months-4years,18.2±3.4 kg,9615,Biomarker analysis based on receiver operating characteristic (ROC) curves was performed to identify biomarker candidates (area under ROC ≥ 0.90) of the effects of CBD supplementation.
721,3-(4-hydroxyphenyl)pyruvate,metabolite,Cannabidiol,,both,9months-4years,18.2±3.4 kg,9615,Biomarker analysis based on receiver operating characteristic (ROC) curves was performed to identify biomarker candidates (area under ROC ≥ 0.90) of the effects of CBD supplementation.
722,aspartyl-threonine,metabolite,Cannabidiol,,both,9months-4years,18.2±3.4 kg,9615,Biomarker analysis based on receiver operating characteristic (ROC) curves was performed to identify biomarker candidates (area under ROC ≥ 0.90) of the effects of CBD supplementation.
723,isoleucyl-alanine,metabolite,Cannabidiol,,both,9months-4years,18.2±3.4 kg,9615,Biomarker analysis based on receiver operating characteristic (ROC) curves was performed to identify biomarker candidates (area under ROC ≥ 0.90) of the effects of CBD supplementation.
724,Glucose,metabolite,Cannabidiol,,both,9months-4years,18.2±3.4 kg,9615,Biomarker analysis based on receiver operating characteristic (ROC) curves was performed to identify biomarker candidates (area under ROC ≥ 0.90) of the effects of CBD supplementation.
1016,miR-143,miRNA,melanoma,,,,,9615,"Therefore, these miRNAs can be an incredible biomarker candidate to identify metastatic melanoma and facilitate a better prognosis."
1017,miR-221,miRNA,melanoma,,,,,9615,"Therefore, these miRNAs can be an incredible biomarker candidate to identify metastatic melanoma and facilitate a better prognosis"
2412,NGAL,protein,acute kidney failure,,,,,9615,"For the assay investigated, only NGAL performed well overall, with acceptable precision and accuracy of measurement"
180,BCL2L15,gene,morbid obesity,Miniature Dachshund,,5.75±0.60years,,9615,"This study revealed significant differences in the gene expression of BCL2L15, FOLH1, ALAS2, and  hemoglobin subunits such as LOC100855540 between normal weight and mild to moderate obese dogs, which indicate that these genes may prevent the obesity in dogs and be potentially useful for diagnosis of mild to  moderate obesity"
181,FOLH1,gene,morbid obesity,Miniature Dachshund,,5.75±0.60years,,9615,"This study revealed significant differences in the gene expression of BCL2L15, FOLH1, ALAS2, and  hemoglobin subunits such as LOC100855540 between normal weight and mild to moderate obese dogs, which indicate that these genes may prevent the obesity in dogs and be potentially useful for diagnosis of mild to  moderate obesity"
2413,Cadherin related family member 2,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2413,Cadherin related family member 2,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2413,Cadherin related family member 2,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2413,Cadherin related family member 2,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2413,Cadherin related family member 2,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2413,Cadherin related family member 2,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2413,Cadherin related family member 2,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2413,Cadherin related family member 2,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2413,Cadherin related family member 2,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
182,ALAS2,gene,morbid obesity,Miniature Dachshund,,5.75±0.60years,,9615,"This study revealed significant differences in the gene expression of BCL2L15, FOLH1, ALAS2, and  hemoglobin subunits such as LOC100855540 between normal weight and mild to moderate obese dogs, which indicate that these genes may prevent the obesity in dogs and be potentially useful for diagnosis of mild to  moderate obesity"
183,LOC100855540,gene,morbid obesity,Miniature Dachshund,,5.75±0.60years,,9615,"This study revealed significant differences in the gene expression of BCL2L15, FOLH1, ALAS2, and  hemoglobin subunits such as LOC100855540 between normal weight and mild to moderate obese dogs, which indicate that these genes may prevent the obesity in dogs and be potentially useful for diagnosis of mild to  moderate obesity"
2414,serum cPLI,protein,acute pancreatitis,,,9.5 ± 3.1 years,,9615,These results suggest that serum cPLI and potentially CRP concentrations could be used as objective biomarkers for disease progression and monitoring management success in dogs with acute pancreatitis. Additional studies involving larger numbers of dogs are warranted to evaluate the impact of these findings on the management of dogs with acute pancreatitis.
2415,CRP,protein,acute pancreatitis,,,9.5 ± 3.1 years,,9615,These results suggest that serum cPLI and potentially CRP concentrations could be used as objective biomarkers for disease progression and monitoring management success in dogs with acute pancreatitis. Additional studies involving larger numbers of dogs are warranted to evaluate the impact of these findings on the management of dogs with acute pancreatitis.
2416,SOD,protein,babesiosis,,,2-7years,,9615,antioxidant biomarker and copper and zinc concentrations could be used as indicators of disease severity and prognostic markers
2417,CAT,protein,babesiosis,,,2-7years,,9615,antioxidant biomarker and copper and zinc concentrations could be used as indicators of disease severity and prognostic markers
725,FSSA,metabolite,diabetes mellitus,,both,1-2years,,9615,The elevated FSSA can serve as a predictive and diagnostic biomarker in alloxan-induced T1DM with a co-existing impaired glucose homeostasis and hyperglycaemia
2418,Neurofilament light chain,protein,meningoencephalitis,English Beagle,both,3-7.4 years,2.2-4.2kg,9615,Neurofilament light chain is a potential biomarker for diagnosing MUE and evaluating response to treatment.
2418,Neurofilament light chain,protein,meningoencephalitis,Labrador Retriever,both,3-7.4 years,2.2-4.2kg,9615,Neurofilament light chain is a potential biomarker for diagnosing MUE and evaluating response to treatment.
2418,Neurofilament light chain,protein,meningoencephalitis,Miniature Poodle,both,3-7.4 years,2.2-4.2kg,9615,Neurofilament light chain is a potential biomarker for diagnosing MUE and evaluating response to treatment.
2418,Neurofilament light chain,protein,meningoencephalitis,Bichon Frise,both,3-7.4 years,2.2-4.2kg,9615,Neurofilament light chain is a potential biomarker for diagnosing MUE and evaluating response to treatment.
2418,Neurofilament light chain,protein,meningoencephalitis,Japanese Shiba Inu,both,3-7.4 years,2.2-4.2kg,9615,Neurofilament light chain is a potential biomarker for diagnosing MUE and evaluating response to treatment.
2418,Neurofilament light chain,protein,meningoencephalitis,Cardigan Welsh Corgi,both,3-7.4 years,2.2-4.2kg,9615,Neurofilament light chain is a potential biomarker for diagnosing MUE and evaluating response to treatment.
2418,Neurofilament light chain,protein,meningoencephalitis,Yorkshire Terrier,both,3-7.4 years,2.2-4.2kg,9615,Neurofilament light chain is a potential biomarker for diagnosing MUE and evaluating response to treatment.
2418,Neurofilament light chain,protein,meningoencephalitis,Maltese,both,3-7.4 years,2.2-4.2kg,9615,Neurofilament light chain is a potential biomarker for diagnosing MUE and evaluating response to treatment.
2418,Neurofilament light chain,protein,meningoencephalitis,Pomeranian,both,3-7.4 years,2.2-4.2kg,9615,Neurofilament light chain is a potential biomarker for diagnosing MUE and evaluating response to treatment.
2418,Neurofilament light chain,protein,meningoencephalitis,Miniature Schnauzer,both,3-7.4 years,2.2-4.2kg,9615,Neurofilament light chain is a potential biomarker for diagnosing MUE and evaluating response to treatment.
2418,Neurofilament light chain,protein,meningoencephalitis,Shih Tzu(Chrysanthemum Dog),both,3-7.4 years,2.2-4.2kg,9615,Neurofilament light chain is a potential biomarker for diagnosing MUE and evaluating response to treatment.
2418,Neurofilament light chain,protein,meningoencephalitis,Yorkshire Terrier,both,3-7.4 years,2.2-4.2kg,9615,Neurofilament light chain is a potential biomarker for diagnosing MUE and evaluating response to treatment.
2418,Neurofilament light chain,protein,meningoencephalitis,Chihuahua,both,3-7.4 years,2.2-4.2kg,9615,Neurofilament light chain is a potential biomarker for diagnosing MUE and evaluating response to treatment.
2418,Neurofilament light chain,protein,meningoencephalitis,Pomeranian,both,3-7.4 years,2.2-4.2kg,9615,Neurofilament light chain is a potential biomarker for diagnosing MUE and evaluating response to treatment.
2418,Neurofilament light chain,protein,meningoencephalitis,Miniature Pinscher,both,3-7.4 years,2.2-4.2kg,9615,Neurofilament light chain is a potential biomarker for diagnosing MUE and evaluating response to treatment.
2418,Neurofilament light chain,protein,meningoencephalitis,Toy Poodle,both,3-7.4 years,2.2-4.2kg,9615,Neurofilament light chain is a potential biomarker for diagnosing MUE and evaluating response to treatment.
2418,Neurofilament light chain,protein,meningoencephalitis,Japanese Chin(Japanese Spaniel),both,3-7.4 years,2.2-4.2kg,9615,Neurofilament light chain is a potential biomarker for diagnosing MUE and evaluating response to treatment.
2419,Immunoglobulin heavy chain variable region,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2419,Immunoglobulin heavy chain variable region,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2419,Immunoglobulin heavy chain variable region,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2419,Immunoglobulin heavy chain variable region,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2419,Immunoglobulin heavy chain variable region,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2419,Immunoglobulin heavy chain variable region,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2419,Immunoglobulin heavy chain variable region,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2419,Immunoglobulin heavy chain variable region,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2419,Immunoglobulin heavy chain variable region,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2420,Cerebrospinal fluid VEGF,protein,central nervous system cancer|meningoencephalitis,,both,0.3-15.0years,2.6-56.6kg,9615,Cerebrospinal fluid VEGF concentrations may serve as a marker of neoplastic and inflammatory CNS disorders relative to other conditions.
2421,IGFBP2,protein,mucopolysaccharidosis type 1,,,,,9615,"this study demonstrates that the determination of the CSF levels of NP1, Ch3L1, CD14, IGFBP2, possibly also of other upregulated proteins identified here could be helpful for assessing the course of the disease in infants having received gene therapy. Further validation of these biomarker candidates, e.g., by investigating the correlation between CSF and plasma/serum levels in MPS patients, may offer a less invasive means of routine monitoring."
2422,Canine prostate specific esterase,protein,benign prostatic hyperplasia,,,,,9615,"The results support the use of CPSE for estimating present and future prostatic size in dogs ≥4 years, and the clinical usefulness of prostatic size for predicting development of clinical signs of prostatic disease in the dog."
1018,cfa-miR-130b,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,12.83 ± 2.01years,,9615,This pilot study demonstrates that the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs
1018,cfa-miR-130b,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,12.83 ± 2.01years,,9615,This pilot study demonstrates that the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs
1018,cfa-miR-130b,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,12.83 ± 2.01years,,9615,This pilot study demonstrates that the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs
1018,cfa-miR-130b,miRNA,"mitral valve prolapse, myxomatous 3",Pomeranian,both,12.83 ± 2.01years,,9615,This pilot study demonstrates that the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs
1018,cfa-miR-130b,miRNA,"mitral valve prolapse, myxomatous 3",French Bulldog,both,12.83 ± 2.01years,,9615,This pilot study demonstrates that the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs
1018,cfa-miR-130b,miRNA,"mitral valve prolapse, myxomatous 3",Poodle,both,12.83 ± 2.01years,,9615,This pilot study demonstrates that the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs
2423,Maltase-glucoamylase,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2423,Maltase-glucoamylase,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2423,Maltase-glucoamylase,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2423,Maltase-glucoamylase,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2423,Maltase-glucoamylase,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2423,Maltase-glucoamylase,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2423,Maltase-glucoamylase,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2423,Maltase-glucoamylase,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2423,Maltase-glucoamylase,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2424,albumin,protein,pyometritis,English Beagle,F,6-15 years,,9615,"In addition, the concentration of APPs, including the C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp), were also elevated in dogs with pyometra. The present study provides fundamental data for inflammatory indicators of canine pyometra."
2424,albumin,protein,pyometritis,Maltese,F,6-15 years,,9615,"In addition, the concentration of APPs, including the C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp), were also elevated in dogs with pyometra. The present study provides fundamental data for inflammatory indicators of canine pyometra."
2424,albumin,protein,pyometritis,Yorkshire Terrier,F,6-15 years,,9615,"In addition, the concentration of APPs, including the C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp), were also elevated in dogs with pyometra. The present study provides fundamental data for inflammatory indicators of canine pyometra."
2424,albumin,protein,pyometritis,Shih Tzu(Chrysanthemum Dog),F,6-15 years,,9615,"In addition, the concentration of APPs, including the C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp), were also elevated in dogs with pyometra. The present study provides fundamental data for inflammatory indicators of canine pyometra."
2425,elevated α2-,protein,pyometritis,English Beagle,F,6-15 years,,9615,"In addition, the concentration of APPs, including the C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp), were also elevated in dogs with pyometra. The present study provides fundamental data for inflammatory indicators of canine pyometra."
2425,elevated α2-,protein,pyometritis,Maltese,F,6-15 years,,9615,"In addition, the concentration of APPs, including the C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp), were also elevated in dogs with pyometra. The present study provides fundamental data for inflammatory indicators of canine pyometra."
2425,elevated α2-,protein,pyometritis,Yorkshire Terrier,F,6-15 years,,9615,"In addition, the concentration of APPs, including the C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp), were also elevated in dogs with pyometra. The present study provides fundamental data for inflammatory indicators of canine pyometra."
2425,elevated α2-,protein,pyometritis,Shih Tzu(Chrysanthemum Dog),F,6-15 years,,9615,"In addition, the concentration of APPs, including the C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp), were also elevated in dogs with pyometra. The present study provides fundamental data for inflammatory indicators of canine pyometra."
2426,Selenium binding protein 1 ,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2426,Selenium binding protein 1 ,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2426,Selenium binding protein 1 ,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2426,Selenium binding protein 1 ,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2426,Selenium binding protein 1 ,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2426,Selenium binding protein 1 ,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2426,Selenium binding protein 1 ,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2426,Selenium binding protein 1 ,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2426,Selenium binding protein 1 ,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2427,β-globulin,protein,pyometritis,English Beagle,F,6-15 years,,9615,"In addition, the concentration of APPs, including the C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp), were also elevated in dogs with pyometra. The present study provides fundamental data for inflammatory indicators of canine pyometra."
2427,β-globulin,protein,pyometritis,Maltese,F,6-15 years,,9615,"In addition, the concentration of APPs, including the C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp), were also elevated in dogs with pyometra. The present study provides fundamental data for inflammatory indicators of canine pyometra."
2427,β-globulin,protein,pyometritis,Yorkshire Terrier,F,6-15 years,,9615,"In addition, the concentration of APPs, including the C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp), were also elevated in dogs with pyometra. The present study provides fundamental data for inflammatory indicators of canine pyometra."
2427,β-globulin,protein,pyometritis,Shih Tzu(Chrysanthemum Dog),F,6-15 years,,9615,"In addition, the concentration of APPs, including the C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp), were also elevated in dogs with pyometra. The present study provides fundamental data for inflammatory indicators of canine pyometra."
2415,CRP,protein,pyometritis,English Beagle,F,6-15 years,,9615,"In addition, the concentration of APPs, including the C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp), were also elevated in dogs with pyometra. The present study provides fundamental data for inflammatory indicators of canine pyometra."
2415,CRP,protein,pyometritis,Maltese,F,6-15 years,,9615,"In addition, the concentration of APPs, including the C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp), were also elevated in dogs with pyometra. The present study provides fundamental data for inflammatory indicators of canine pyometra."
2415,CRP,protein,pyometritis,Yorkshire Terrier,F,6-15 years,,9615,"In addition, the concentration of APPs, including the C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp), were also elevated in dogs with pyometra. The present study provides fundamental data for inflammatory indicators of canine pyometra."
2415,CRP,protein,pyometritis,Shih Tzu(Chrysanthemum Dog),F,6-15 years,,9615,"In addition, the concentration of APPs, including the C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp), were also elevated in dogs with pyometra. The present study provides fundamental data for inflammatory indicators of canine pyometra."
2428,SAA,protein,pyometritis,English Beagle,F,6-15 years,,9615,"In addition, the concentration of APPs, including the C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp), were also elevated in dogs with pyometra. The present study provides fundamental data for inflammatory indicators of canine pyometra."
2428,SAA,protein,pyometritis,Maltese,F,6-15 years,,9615,"In addition, the concentration of APPs, including the C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp), were also elevated in dogs with pyometra. The present study provides fundamental data for inflammatory indicators of canine pyometra."
2428,SAA,protein,pyometritis,Yorkshire Terrier,F,6-15 years,,9615,"In addition, the concentration of APPs, including the C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp), were also elevated in dogs with pyometra. The present study provides fundamental data for inflammatory indicators of canine pyometra."
2428,SAA,protein,pyometritis,Shih Tzu(Chrysanthemum Dog),F,6-15 years,,9615,"In addition, the concentration of APPs, including the C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp), were also elevated in dogs with pyometra. The present study provides fundamental data for inflammatory indicators of canine pyometra."
2429,haptoglobin,protein,pyometritis,English Beagle,F,6-15 years,,9615,"In addition, the concentration of APPs, including the C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp), were also elevated in dogs with pyometra. The present study provides fundamental data for inflammatory indicators of canine pyometra."
2429,haptoglobin,protein,pyometritis,Maltese,F,6-15 years,,9615,"In addition, the concentration of APPs, including the C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp), were also elevated in dogs with pyometra. The present study provides fundamental data for inflammatory indicators of canine pyometra."
2429,haptoglobin,protein,pyometritis,Yorkshire Terrier,F,6-15 years,,9615,"In addition, the concentration of APPs, including the C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp), were also elevated in dogs with pyometra. The present study provides fundamental data for inflammatory indicators of canine pyometra."
2429,haptoglobin,protein,pyometritis,Shih Tzu(Chrysanthemum Dog),F,6-15 years,,9615,"In addition, the concentration of APPs, including the C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp), were also elevated in dogs with pyometra. The present study provides fundamental data for inflammatory indicators of canine pyometra."
2430,uKIM-1,protein,Weil's disease,,both,,,9615,Measurement of KIM-1 in the urine of canine patients was able to detect naturally occurring acute and  subacute leptospirosis accompanied by tubular injury in early non azotemic infections
2431,NT-proANP,protein,"mitral valve prolapse, myxomatous 3",,,8-14years,3.3-6.5kg,9615,"In conclusion, plasma NT-proANP , NT-proBNP , and ANP concentrations can increase with LA enlargement with or without clinical signs in dogs with MMVD. Among the four CBs, plasma NT-proANP and NT-proBNP concentrations had comparable  discriminatory abilities to detect cardiac dilatation and CHF in dogs with MMVD."
2432,NT-proBNP,protein,"mitral valve prolapse, myxomatous 3",,,8-14years,3.3-6.5kg,9615,"In conclusion, plasma NT-proANP , NT-proBNP , and ANP concentrations can increase with LA enlargement with or without clinical signs in dogs with MMVD. Among the four CBs, plasma NT-proANP and NT-proBNP concentrations had comparable  discriminatory abilities to detect cardiac dilatation and CHF in dogs with MMVD."
726,sHA,metabolite,cognitive disorder,Maltese,both,2–74 months,1.5–8.4 kg,9615,"In dogs with EHPSS, sHA is a promising non invasive biomarker of liver perfusion that could help to determine the integrity of EHPSS closure after surgical attenuation"
726,sHA,metabolite,cognitive disorder,Dachshund,both,2–74 months,1.5–8.4 kg,9615,"In dogs with EHPSS, sHA is a promising non invasive biomarker of liver perfusion that could help to determine the integrity of EHPSS closure after surgical attenuation"
726,sHA,metabolite,cognitive disorder,Chihuahua,both,2–74 months,1.5–8.4 kg,9615,"In dogs with EHPSS, sHA is a promising non invasive biomarker of liver perfusion that could help to determine the integrity of EHPSS closure after surgical attenuation"
726,sHA,metabolite,cognitive disorder,Shih Tzu(Chrysanthemum Dog),both,2–74 months,1.5–8.4 kg,9615,"In dogs with EHPSS, sHA is a promising non invasive biomarker of liver perfusion that could help to determine the integrity of EHPSS closure after surgical attenuation"
726,sHA,metabolite,cognitive disorder,Miniature Pinscher,both,2–74 months,1.5–8.4 kg,9615,"In dogs with EHPSS, sHA is a promising non invasive biomarker of liver perfusion that could help to determine the integrity of EHPSS closure after surgical attenuation"
726,sHA,metabolite,cognitive disorder,Standard Schnauzer,both,2–74 months,1.5–8.4 kg,9615,"In dogs with EHPSS, sHA is a promising non invasive biomarker of liver perfusion that could help to determine the integrity of EHPSS closure after surgical attenuation"
726,sHA,metabolite,cognitive disorder,Border Collie,both,2–74 months,1.5–8.4 kg,9615,"In dogs with EHPSS, sHA is a promising non invasive biomarker of liver perfusion that could help to determine the integrity of EHPSS closure after surgical attenuation"
726,sHA,metabolite,cognitive disorder,Havanese,both,2–74 months,1.5–8.4 kg,9615,"In dogs with EHPSS, sHA is a promising non invasive biomarker of liver perfusion that could help to determine the integrity of EHPSS closure after surgical attenuation"
726,sHA,metabolite,cognitive disorder,Yorkshire Terrier,both,2–74 months,1.5–8.4 kg,9615,"In dogs with EHPSS, sHA is a promising non invasive biomarker of liver perfusion that could help to determine the integrity of EHPSS closure after surgical attenuation"
726,sHA,metabolite,cognitive disorder,West Highland White Terrier,both,2–74 months,1.5–8.4 kg,9615,"In dogs with EHPSS, sHA is a promising non invasive biomarker of liver perfusion that could help to determine the integrity of EHPSS closure after surgical attenuation"
1858,Cell-free DNA,other,neoplasm,,,,,9615,"Thus, our study shows that ctDNA is detectable in the plasma of cancer-affected dogs and is a promising biomarker for diagnosis and clinical follow-up. ctDNA detection appears to be useful in comparative oncology research due to growing interest in the study of natural canine tumors and exploration of new therapies"
1859,SaCh,other,Parvoviridae infectious disease,Rottweiler,both,,9.6-23.5kg,9615,"This is the first report in which Ch is measured in saliva of dogs and  based in the results of this study, salivary Ch could be potentially used as biomarker of the severity of CP"
1859,SaCh,other,Parvoviridae infectious disease,Anatolian Shepherd Dog,both,,9.6-23.5kg,9615,"This is the first report in which Ch is measured in saliva of dogs and  based in the results of this study, salivary Ch could be potentially used as biomarker of the severity of CP"
1859,SaCh,other,Parvoviridae infectious disease,Golden Retriever,both,,9.6-23.5kg,9615,"This is the first report in which Ch is measured in saliva of dogs and  based in the results of this study, salivary Ch could be potentially used as biomarker of the severity of CP"
1859,SaCh,other,Parvoviridae infectious disease,Labrador Retriever,both,,9.6-23.5kg,9615,"This is the first report in which Ch is measured in saliva of dogs and  based in the results of this study, salivary Ch could be potentially used as biomarker of the severity of CP"
2433,Ectonucleotide pyrophosphatase/phosphodiesterase 3,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2433,Ectonucleotide pyrophosphatase/phosphodiesterase 3,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2433,Ectonucleotide pyrophosphatase/phosphodiesterase 3,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2433,Ectonucleotide pyrophosphatase/phosphodiesterase 3,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2433,Ectonucleotide pyrophosphatase/phosphodiesterase 3,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2433,Ectonucleotide pyrophosphatase/phosphodiesterase 3,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2433,Ectonucleotide pyrophosphatase/phosphodiesterase 3,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2433,Ectonucleotide pyrophosphatase/phosphodiesterase 3,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2433,Ectonucleotide pyrophosphatase/phosphodiesterase 3,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
727,CSF lactate,metabolite,central nervous system disorder,Labrador Retriever,both,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings as it can be measured via a commercially available lactometer immediately after collection without the need for special instrumentation or laboratory personnel.
727,CSF lactate,metabolite,central nervous system disorder,Chihuahua,both,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings as it can be measured via a commercially available lactometer immediately after collection without the need for special instrumentation or laboratory personnel.
727,CSF lactate,metabolite,central nervous system disorder,Maltese,both,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings as it can be measured via a commercially available lactometer immediately after collection without the need for special instrumentation or laboratory personnel.
727,CSF lactate,metabolite,central nervous system disorder,Dachshund,both,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings as it can be measured via a commercially available lactometer immediately after collection without the need for special instrumentation or laboratory personnel.
727,CSF lactate,metabolite,central nervous system disorder,Jack Russell Terrier,both,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings as it can be measured via a commercially available lactometer immediately after collection without the need for special instrumentation or laboratory personnel.
727,CSF lactate,metabolite,central nervous system disorder,Siberian Husky,both,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings as it can be measured via a commercially available lactometer immediately after collection without the need for special instrumentation or laboratory personnel.
727,CSF lactate,metabolite,central nervous system disorder,Golden Retriever,both,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings as it can be measured via a commercially available lactometer immediately after collection without the need for special instrumentation or laboratory personnel.
727,CSF lactate,metabolite,central nervous system disorder,American Bulldog,both,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings as it can be measured via a commercially available lactometer immediately after collection without the need for special instrumentation or laboratory personnel.
727,CSF lactate,metabolite,central nervous system disorder,Toy Poodle,both,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings as it can be measured via a commercially available lactometer immediately after collection without the need for special instrumentation or laboratory personnel.
727,CSF lactate,metabolite,central nervous system disorder,Shih Tzu(Chrysanthemum Dog),both,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings as it can be measured via a commercially available lactometer immediately after collection without the need for special instrumentation or laboratory personnel.
727,CSF lactate,metabolite,central nervous system disorder,American Eskimo Dog,both,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings as it can be measured via a commercially available lactometer immediately after collection without the need for special instrumentation or laboratory personnel.
727,CSF lactate,metabolite,central nervous system disorder,Basenji(African Barkless Dog),both,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings as it can be measured via a commercially available lactometer immediately after collection without the need for special instrumentation or laboratory personnel.
727,CSF lactate,metabolite,central nervous system disorder,Bernese Mountain Dog,both,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings as it can be measured via a commercially available lactometer immediately after collection without the need for special instrumentation or laboratory personnel.
727,CSF lactate,metabolite,central nervous system disorder,Cane Corso(Italian Mastiff),both,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings as it can be measured via a commercially available lactometer immediately after collection without the need for special instrumentation or laboratory personnel.
727,CSF lactate,metabolite,central nervous system disorder,Chinese Crested,both,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings as it can be measured via a commercially available lactometer immediately after collection without the need for special instrumentation or laboratory personnel.
727,CSF lactate,metabolite,central nervous system disorder,French Bulldog,both,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings as it can be measured via a commercially available lactometer immediately after collection without the need for special instrumentation or laboratory personnel.
727,CSF lactate,metabolite,central nervous system disorder,Italian Greyhound,both,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings as it can be measured via a commercially available lactometer immediately after collection without the need for special instrumentation or laboratory personnel.
727,CSF lactate,metabolite,central nervous system disorder,Miniature Schnauzer,both,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings as it can be measured via a commercially available lactometer immediately after collection without the need for special instrumentation or laboratory personnel.
727,CSF lactate,metabolite,central nervous system disorder,Miniature Poodle,both,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings as it can be measured via a commercially available lactometer immediately after collection without the need for special instrumentation or laboratory personnel.
727,CSF lactate,metabolite,central nervous system disorder,American Pit Bull Terrier,both,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings as it can be measured via a commercially available lactometer immediately after collection without the need for special instrumentation or laboratory personnel.
727,CSF lactate,metabolite,central nervous system disorder,Poodle,both,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings as it can be measured via a commercially available lactometer immediately after collection without the need for special instrumentation or laboratory personnel.
727,CSF lactate,metabolite,central nervous system disorder,Standard Schnauzer,both,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings as it can be measured via a commercially available lactometer immediately after collection without the need for special instrumentation or laboratory personnel.
727,CSF lactate,metabolite,central nervous system disorder,Pomeranian,both,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings as it can be measured via a commercially available lactometer immediately after collection without the need for special instrumentation or laboratory personnel.
727,CSF lactate,metabolite,central nervous system disorder,Weimaraner,both,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings as it can be measured via a commercially available lactometer immediately after collection without the need for special instrumentation or laboratory personnel.
727,CSF lactate,metabolite,central nervous system disorder,Yorkshire Terrier,both,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings as it can be measured via a commercially available lactometer immediately after collection without the need for special instrumentation or laboratory personnel.
2434,CILP1,protein,"mitral valve prolapse, myxomatous 3",,both,,,9615,"CILP1 can be an indicator of cardiac remodeling in canines with MMVD and therefore, can be used as an MMVD biomarker"
2435,Cys-C,protein,"mitral valve prolapse, myxomatous 3",Chihuahua,both,3.0-15.0years,2.08-14.04kg,9615,"High serum Cys-C concentrations were associated with a worse prognosis of MMVD. Furthermore, serum Cys-C could be a predictor of MMVD prognosis even in dogs with normal blood creatinine concentration."
2435,Cys-C,protein,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,3.0-15.0years,2.08-14.04kg,9615,"High serum Cys-C concentrations were associated with a worse prognosis of MMVD. Furthermore, serum Cys-C could be a predictor of MMVD prognosis even in dogs with normal blood creatinine concentration."
2435,Cys-C,protein,"mitral valve prolapse, myxomatous 3",Miniature Schnauzer,both,3.0-15.0years,2.08-14.04kg,9615,"High serum Cys-C concentrations were associated with a worse prognosis of MMVD. Furthermore, serum Cys-C could be a predictor of MMVD prognosis even in dogs with normal blood creatinine concentration."
2435,Cys-C,protein,"mitral valve prolapse, myxomatous 3",Pomeranian,both,3.0-15.0years,2.08-14.04kg,9615,"High serum Cys-C concentrations were associated with a worse prognosis of MMVD. Furthermore, serum Cys-C could be a predictor of MMVD prognosis even in dogs with normal blood creatinine concentration."
2435,Cys-C,protein,"mitral valve prolapse, myxomatous 3",Shetland Shepherd Dog,both,3.0-15.0years,2.08-14.04kg,9615,"High serum Cys-C concentrations were associated with a worse prognosis of MMVD. Furthermore, serum Cys-C could be a predictor of MMVD prognosis even in dogs with normal blood creatinine concentration."
2435,Cys-C,protein,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,3.0-15.0years,2.08-14.04kg,9615,"High serum Cys-C concentrations were associated with a worse prognosis of MMVD. Furthermore, serum Cys-C could be a predictor of MMVD prognosis even in dogs with normal blood creatinine concentration."
2435,Cys-C,protein,"mitral valve prolapse, myxomatous 3",Yorkshire Terrier,both,3.0-15.0years,2.08-14.04kg,9615,"High serum Cys-C concentrations were associated with a worse prognosis of MMVD. Furthermore, serum Cys-C could be a predictor of MMVD prognosis even in dogs with normal blood creatinine concentration."
2435,Cys-C,protein,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,3.0-15.0years,2.08-14.04kg,9615,"High serum Cys-C concentrations were associated with a worse prognosis of MMVD. Furthermore, serum Cys-C could be a predictor of MMVD prognosis even in dogs with normal blood creatinine concentration."
2435,Cys-C,protein,"mitral valve prolapse, myxomatous 3",English Beagle,both,3.0-15.0years,2.08-14.04kg,9615,"High serum Cys-C concentrations were associated with a worse prognosis of MMVD. Furthermore, serum Cys-C could be a predictor of MMVD prognosis even in dogs with normal blood creatinine concentration."
2436,C-terminal tensin-like,protein,squamous cell carcinoma,Yorkshire Terrier,both,8.9 ± 3.6 years.,,9615,"therefore revealing CTEN’s potential as a biomarker and a therapeutic target for canine SCC, as well as its possible value in histological grading of invasive fronts"
2436,C-terminal tensin-like,protein,squamous cell carcinoma,German Boxer,both,8.9 ± 3.6 years.,,9615,"therefore revealing CTEN’s potential as a biomarker and a therapeutic target for canine SCC, as well as its possible value in histological grading of invasive fronts"
2436,C-terminal tensin-like,protein,squamous cell carcinoma,Basset Hound,both,8.9 ± 3.6 years.,,9615,"therefore revealing CTEN’s potential as a biomarker and a therapeutic target for canine SCC, as well as its possible value in histological grading of invasive fronts"
2436,C-terminal tensin-like,protein,squamous cell carcinoma,West Highland White Terrier,both,8.9 ± 3.6 years.,,9615,"therefore revealing CTEN’s potential as a biomarker and a therapeutic target for canine SCC, as well as its possible value in histological grading of invasive fronts"
2436,C-terminal tensin-like,protein,squamous cell carcinoma,Poodle,both,8.9 ± 3.6 years.,,9615,"therefore revealing CTEN’s potential as a biomarker and a therapeutic target for canine SCC, as well as its possible value in histological grading of invasive fronts"
2436,C-terminal tensin-like,protein,squamous cell carcinoma,Cao de Castro Laboreiro(Portuguese Cattle Dog),both,8.9 ± 3.6 years.,,9615,"therefore revealing CTEN’s potential as a biomarker and a therapeutic target for canine SCC, as well as its possible value in histological grading of invasive fronts"
2436,C-terminal tensin-like,protein,squamous cell carcinoma,Cocker Spaniel,both,8.9 ± 3.6 years.,,9615,"therefore revealing CTEN’s potential as a biomarker and a therapeutic target for canine SCC, as well as its possible value in histological grading of invasive fronts"
2436,C-terminal tensin-like,protein,squamous cell carcinoma,Border Collie,both,8.9 ± 3.6 years.,,9615,"therefore revealing CTEN’s potential as a biomarker and a therapeutic target for canine SCC, as well as its possible value in histological grading of invasive fronts"
2436,C-terminal tensin-like,protein,squamous cell carcinoma,Dalmatian,both,8.9 ± 3.6 years.,,9615,"therefore revealing CTEN’s potential as a biomarker and a therapeutic target for canine SCC, as well as its possible value in histological grading of invasive fronts"
2436,C-terminal tensin-like,protein,squamous cell carcinoma,Golden Retriever,both,8.9 ± 3.6 years.,,9615,"therefore revealing CTEN’s potential as a biomarker and a therapeutic target for canine SCC, as well as its possible value in histological grading of invasive fronts"
2436,C-terminal tensin-like,protein,squamous cell carcinoma,Siberian Husky,both,8.9 ± 3.6 years.,,9615,"therefore revealing CTEN’s potential as a biomarker and a therapeutic target for canine SCC, as well as its possible value in histological grading of invasive fronts"
2436,C-terminal tensin-like,protein,squamous cell carcinoma,Labrador Retriever,both,8.9 ± 3.6 years.,,9615,"therefore revealing CTEN’s potential as a biomarker and a therapeutic target for canine SCC, as well as its possible value in histological grading of invasive fronts"
2436,C-terminal tensin-like,protein,squamous cell carcinoma,Portuguese Pointer,both,8.9 ± 3.6 years.,,9615,"therefore revealing CTEN’s potential as a biomarker and a therapeutic target for canine SCC, as well as its possible value in histological grading of invasive fronts"
2436,C-terminal tensin-like,protein,squamous cell carcinoma,American Pit Bull Terrier,both,8.9 ± 3.6 years.,,9615,"therefore revealing CTEN’s potential as a biomarker and a therapeutic target for canine SCC, as well as its possible value in histological grading of invasive fronts"
2436,C-terminal tensin-like,protein,squamous cell carcinoma,Spanish Hound,both,8.9 ± 3.6 years.,,9615,"therefore revealing CTEN’s potential as a biomarker and a therapeutic target for canine SCC, as well as its possible value in histological grading of invasive fronts"
2436,C-terminal tensin-like,protein,squamous cell carcinoma,Giant Schnauzer,both,8.9 ± 3.6 years.,,9615,"therefore revealing CTEN’s potential as a biomarker and a therapeutic target for canine SCC, as well as its possible value in histological grading of invasive fronts"
2436,C-terminal tensin-like,protein,squamous cell carcinoma,Estrela Mountain Dog,both,8.9 ± 3.6 years.,,9615,"therefore revealing CTEN’s potential as a biomarker and a therapeutic target for canine SCC, as well as its possible value in histological grading of invasive fronts"
2436,C-terminal tensin-like,protein,squamous cell carcinoma,Irish Setter,both,8.9 ± 3.6 years.,,9615,"therefore revealing CTEN’s potential as a biomarker and a therapeutic target for canine SCC, as well as its possible value in histological grading of invasive fronts"
2436,C-terminal tensin-like,protein,squamous cell carcinoma,Chinese Shar-Pei,both,8.9 ± 3.6 years.,,9615,"therefore revealing CTEN’s potential as a biomarker and a therapeutic target for canine SCC, as well as its possible value in histological grading of invasive fronts"
2437,C-reactive protein,protein,lymphoma,,both,9.72 ± 4.27years,,9615,Serum CRP concentrations can assist clinical decision-making on the WHO stage in lymphoma dogs in clinical applications
2438,thrombomodulin,protein,urolithiasis,,,,,9615,"In this study, hypercalciuric CaOx dogs showed increased level of urinary proteins, including thrombomodulin, which may be used as candidates for urinary tract injury and lead to an enhanced understanding of the pathophysiology of CaOx urolithiasis in dogs."
2439,matrix metalloproteinase 19,protein,mucopolysaccharidosis type 2,,both,,,9615,"Elevated expression of three biomarker candidates, matrix metalloproteinase 19, inter-alpha-trypsin inhibitor heavy-chain 3 and alpha-1-microglobulin, was confirmed in MPS I cartilage, and serum abundance of these molecules was found to correlate with MRI and histological degenerative grades. The candidate biomarkers identified have the potential to improve patient care by facilitating minimally-invasive, specific assessment of joint disease progression and response to therapeutic intervention"
2440,inter-alpha-trypsin inhibitor heavy-chain 3,protein,mucopolysaccharidosis type 2,,both,,,9615,"Elevated expression of three biomarker candidates, matrix metalloproteinase 19, inter-alpha-trypsin inhibitor heavy-chain 3 and alpha-1-microglobulin, was confirmed in MPS I cartilage, and serum abundance of these molecules was found to correlate with MRI and histological degenerative grades. The candidate biomarkers identified have the potential to improve patient care by facilitating minimally-invasive, specific assessment of joint disease progression and response to therapeutic intervention"
2441,alpha-1-microglobulin,protein,mucopolysaccharidosis type 2,,both,,,9615,"Elevated expression of three biomarker candidates, matrix metalloproteinase 19, inter-alpha-trypsin inhibitor heavy-chain 3 and alpha-1-microglobulin, was confirmed in MPS I cartilage, and serum abundance of these molecules was found to correlate with MRI and histological degenerative grades. The candidate biomarkers identified have the potential to improve patient care by facilitating minimally-invasive, specific assessment of joint disease progression and response to therapeutic intervention"
2442,Osteopontin,protein,meningioma,German Shepherd Dog,both,5-16years,2.6-46kg,9615,"OPN may be a valuable therapeutic target in canine meningioma. Secondly, OPN may be used as a post-surgical predictor of recurrence, as a negative correlation of OPN labelling with tissue invasion was found in this population"
2442,Osteopontin,protein,meningioma,German Boxer,both,5-16years,2.6-46kg,9615,"OPN may be a valuable therapeutic target in canine meningioma. Secondly, OPN may be used as a post-surgical predictor of recurrence, as a negative correlation of OPN labelling with tissue invasion was found in this population"
2442,Osteopontin,protein,meningioma,Bearded Collie,both,5-16years,2.6-46kg,9615,"OPN may be a valuable therapeutic target in canine meningioma. Secondly, OPN may be used as a post-surgical predictor of recurrence, as a negative correlation of OPN labelling with tissue invasion was found in this population"
2442,Osteopontin,protein,meningioma,Boston Terrier,both,5-16years,2.6-46kg,9615,"OPN may be a valuable therapeutic target in canine meningioma. Secondly, OPN may be used as a post-surgical predictor of recurrence, as a negative correlation of OPN labelling with tissue invasion was found in this population"
2442,Osteopontin,protein,meningioma,Rottweiler,both,5-16years,2.6-46kg,9615,"OPN may be a valuable therapeutic target in canine meningioma. Secondly, OPN may be used as a post-surgical predictor of recurrence, as a negative correlation of OPN labelling with tissue invasion was found in this population"
2442,Osteopontin,protein,meningioma,German Wire-Haired Pointer,both,5-16years,2.6-46kg,9615,"OPN may be a valuable therapeutic target in canine meningioma. Secondly, OPN may be used as a post-surgical predictor of recurrence, as a negative correlation of OPN labelling with tissue invasion was found in this population"
2442,Osteopontin,protein,meningioma,Belgian Shepherd Dog,both,5-16years,2.6-46kg,9615,"OPN may be a valuable therapeutic target in canine meningioma. Secondly, OPN may be used as a post-surgical predictor of recurrence, as a negative correlation of OPN labelling with tissue invasion was found in this population"
2442,Osteopontin,protein,meningioma,Golden Retriever,both,5-16years,2.6-46kg,9615,"OPN may be a valuable therapeutic target in canine meningioma. Secondly, OPN may be used as a post-surgical predictor of recurrence, as a negative correlation of OPN labelling with tissue invasion was found in this population"
2442,Osteopontin,protein,meningioma,Maltese,both,5-16years,2.6-46kg,9615,"OPN may be a valuable therapeutic target in canine meningioma. Secondly, OPN may be used as a post-surgical predictor of recurrence, as a negative correlation of OPN labelling with tissue invasion was found in this population"
2442,Osteopontin,protein,meningioma,Yorkshire Terrier,both,5-16years,2.6-46kg,9615,"OPN may be a valuable therapeutic target in canine meningioma. Secondly, OPN may be used as a post-surgical predictor of recurrence, as a negative correlation of OPN labelling with tissue invasion was found in this population"
2442,Osteopontin,protein,meningioma,Bavarian Mountain Hound,both,5-16years,2.6-46kg,9615,"OPN may be a valuable therapeutic target in canine meningioma. Secondly, OPN may be used as a post-surgical predictor of recurrence, as a negative correlation of OPN labelling with tissue invasion was found in this population"
2442,Osteopontin,protein,meningioma,Belgian Tervuren,both,5-16years,2.6-46kg,9615,"OPN may be a valuable therapeutic target in canine meningioma. Secondly, OPN may be used as a post-surgical predictor of recurrence, as a negative correlation of OPN labelling with tissue invasion was found in this population"
2442,Osteopontin,protein,meningioma,Havanese,both,5-16years,2.6-46kg,9615,"OPN may be a valuable therapeutic target in canine meningioma. Secondly, OPN may be used as a post-surgical predictor of recurrence, as a negative correlation of OPN labelling with tissue invasion was found in this population"
2443,Cadherin 1,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2443,Cadherin 1,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2443,Cadherin 1,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2443,Cadherin 1,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2443,Cadherin 1,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2443,Cadherin 1,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2443,Cadherin 1,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2443,Cadherin 1,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2443,Cadherin 1,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2444,Interleukin-6,protein,breast neoplasm,,F,10.2±5.6years,14.2±6.04 kg,9615,The results of this study indicated that changes of IL-6 and IL-8 in the tumor microenvironments were closely related to the diseases status and may be used as a potential diagnostic or biomarker in canine mammary gland tumors
2445,Interleukin-8,protein,breast neoplasm,,F,10.2±5.6years,14.2±6.04 kg,9615,The results of this study indicated that changes of IL-6 and IL-8 in the tumor microenvironments were closely related to the diseases status and may be used as a potential diagnostic or biomarker in canine mammary gland tumors
2446,CPSE,protein,benign prostatic hyperplasia,English Beagle,M,,15.50±4.09 kg,9615,CPSE is a potential biomarker to assess the response to PAO in the canine prostate
2447,Carboxyhemoglobin,protein,hemolytic anemia,,,,,9615,"Carboxyhemoglobin proved an excellent predictor of HA in dogs and might constitute a useful, ancillary tool for diagnosing and monitoring hemolytic anemias"
2448,Chymase,protein,patent ductus arteriosus,Pomeranian,both,59–73 days,0.59 ± 0.23 kg,9615,"Therefore, plasma chymase activity may be useful as a novel predictor for understanding the hemodynamics of PDA in veterinary medicine."
2448,Chymase,protein,patent ductus arteriosus,Toy Poodle,both,59–73 days,0.59 ± 0.23 kg,9615,"Therefore, plasma chymase activity may be useful as a novel predictor for understanding the hemodynamics of PDA in veterinary medicine."
2448,Chymase,protein,patent ductus arteriosus,Maltese,both,59–73 days,0.59 ± 0.23 kg,9615,"Therefore, plasma chymase activity may be useful as a novel predictor for understanding the hemodynamics of PDA in veterinary medicine."
2448,Chymase,protein,patent ductus arteriosus,Bichon Frise,both,59–73 days,0.59 ± 0.23 kg,9615,"Therefore, plasma chymase activity may be useful as a novel predictor for understanding the hemodynamics of PDA in veterinary medicine."
2449,FKBP4,protein,melanoma|squamous cell carcinoma,,,,,9615,"FKBP4, ESRRA, IGSF10 and ABCB5 might be potential biomarkers for diagnosis, prognosis and metastasis prediction. "
2450,ESRRA,protein,melanoma|squamous cell carcinoma,,,,,9615,"FKBP4, ESRRA, IGSF10 and ABCB5 might be potential biomarkers for diagnosis, prognosis and metastasis prediction. "
2451,IGSF10,protein,melanoma|squamous cell carcinoma,,,,,9615,"FKBP4, ESRRA, IGSF10 and ABCB5 might be potential biomarkers for diagnosis, prognosis and metastasis prediction. "
2452,ABCB5,protein,melanoma|squamous cell carcinoma,,,,,9615,"FKBP4, ESRRA, IGSF10 and ABCB5 might be potential biomarkers for diagnosis, prognosis and metastasis prediction. "
728,TDP-43,metabolite,neurodegenerative disease,Wire-Haired Fox Terrier,both,8-15years,,9615,Serum-derived exosomal biomolecules can serve as surrogate biomarkers in neurodegenerative diseases.
728,TDP-43,metabolite,neurodegenerative disease,German Boxer,both,8-15years,,9615,Serum-derived exosomal biomolecules can serve as surrogate biomarkers in neurodegenerative diseases.
728,TDP-43,metabolite,neurodegenerative disease,Pembroke Welsh Corgi,both,8-15years,,9615,Serum-derived exosomal biomolecules can serve as surrogate biomarkers in neurodegenerative diseases.
728,TDP-43,metabolite,neurodegenerative disease,English Beagle,both,8-15years,,9615,Serum-derived exosomal biomolecules can serve as surrogate biomarkers in neurodegenerative diseases.
2453,Mucin 2,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2453,Mucin 2,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2453,Mucin 2,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2453,Mucin 2,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2453,Mucin 2,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2453,Mucin 2,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2453,Mucin 2,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2453,Mucin 2,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2453,Mucin 2,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
729,SOD1,metabolite,neurodegenerative disease,Wire-Haired Fox Terrier,both,8-15years,,9615,Serum-derived exosomal biomolecules can serve as surrogate biomarkers in neurodegenerative diseases.
729,SOD1,metabolite,neurodegenerative disease,German Boxer,both,8-15years,,9615,Serum-derived exosomal biomolecules can serve as surrogate biomarkers in neurodegenerative diseases.
729,SOD1,metabolite,neurodegenerative disease,Pembroke Welsh Corgi,both,8-15years,,9615,Serum-derived exosomal biomolecules can serve as surrogate biomarkers in neurodegenerative diseases.
729,SOD1,metabolite,neurodegenerative disease,English Beagle,both,8-15years,,9615,Serum-derived exosomal biomolecules can serve as surrogate biomarkers in neurodegenerative diseases.
184,Klotho,gene,hepatocellular carcinoma,English Beagle,both,8-17years,,9615,"Thus, Klotho was presumed to be a potential clinical prognostic marker for canine HCC."
184,Klotho,gene,hepatocellular carcinoma,Maltese,both,8-17years,,9615,"Thus, Klotho was presumed to be a potential clinical prognostic marker for canine HCC."
184,Klotho,gene,hepatocellular carcinoma,Toy Poodle,both,8-17years,,9615,"Thus, Klotho was presumed to be a potential clinical prognostic marker for canine HCC."
184,Klotho,gene,hepatocellular carcinoma,Yorkshire Terrier,both,8-17years,,9615,"Thus, Klotho was presumed to be a potential clinical prognostic marker for canine HCC."
184,Klotho,gene,hepatocellular carcinoma,Shih Tzu(Chrysanthemum Dog),both,8-17years,,9615,"Thus, Klotho was presumed to be a potential clinical prognostic marker for canine HCC."
184,Klotho,gene,hepatocellular carcinoma,Alaskan Malamute,both,8-17years,,9615,"Thus, Klotho was presumed to be a potential clinical prognostic marker for canine HCC."
184,Klotho,gene,hepatocellular carcinoma,Pomeranian,both,8-17years,,9615,"Thus, Klotho was presumed to be a potential clinical prognostic marker for canine HCC."
184,Klotho,gene,hepatocellular carcinoma,Cocker Spaniel,both,8-17years,,9615,"Thus, Klotho was presumed to be a potential clinical prognostic marker for canine HCC."
184,Klotho,gene,hepatocellular carcinoma,Dachshund,both,8-17years,,9615,"Thus, Klotho was presumed to be a potential clinical prognostic marker for canine HCC."
184,Klotho,gene,hepatocellular carcinoma,Standard Schnauzer,both,8-17years,,9615,"Thus, Klotho was presumed to be a potential clinical prognostic marker for canine HCC."
184,Klotho,gene,hepatocellular carcinoma,Scottish Terrier,both,8-17years,,9615,"Thus, Klotho was presumed to be a potential clinical prognostic marker for canine HCC."
1019,cfa-miR-375,miRNA,acute pancreatitis,Maltese,both,10.7years,3.6kg,9615,"Serum cfa-miR-375 could be a potential biomarker for the diagnosis and evaluation of treatment response of AP in dogs. In addition, miR-216a and miR-375 could be associated with inflammatory processes in  dogs with AP"
1019,cfa-miR-375,miRNA,acute pancreatitis,Poodle,both,10.7years,3.6kg,9615,"Serum cfa-miR-375 could be a potential biomarker for the diagnosis and evaluation of treatment response of AP in dogs. In addition, miR-216a and miR-375 could be associated with inflammatory processes in  dogs with AP"
1019,cfa-miR-375,miRNA,acute pancreatitis,Yorkshire Terrier,both,10.7years,3.6kg,9615,"Serum cfa-miR-375 could be a potential biomarker for the diagnosis and evaluation of treatment response of AP in dogs. In addition, miR-216a and miR-375 could be associated with inflammatory processes in  dogs with AP"
1019,cfa-miR-375,miRNA,acute pancreatitis,Chihuahua,both,10.7years,3.6kg,9615,"Serum cfa-miR-375 could be a potential biomarker for the diagnosis and evaluation of treatment response of AP in dogs. In addition, miR-216a and miR-375 could be associated with inflammatory processes in  dogs with AP"
1019,cfa-miR-375,miRNA,acute pancreatitis,Shih Tzu(Chrysanthemum Dog),both,10.7years,3.6kg,9615,"Serum cfa-miR-375 could be a potential biomarker for the diagnosis and evaluation of treatment response of AP in dogs. In addition, miR-216a and miR-375 could be associated with inflammatory processes in  dogs with AP"
1019,cfa-miR-375,miRNA,acute pancreatitis,Pomeranian,both,10.7years,3.6kg,9615,"Serum cfa-miR-375 could be a potential biomarker for the diagnosis and evaluation of treatment response of AP in dogs. In addition, miR-216a and miR-375 could be associated with inflammatory processes in  dogs with AP"
1019,cfa-miR-375,miRNA,acute pancreatitis,Dachshund,both,10.7years,3.6kg,9615,"Serum cfa-miR-375 could be a potential biomarker for the diagnosis and evaluation of treatment response of AP in dogs. In addition, miR-216a and miR-375 could be associated with inflammatory processes in  dogs with AP"
1019,cfa-miR-375,miRNA,acute pancreatitis,English Beagle,both,10.7years,3.6kg,9615,"Serum cfa-miR-375 could be a potential biomarker for the diagnosis and evaluation of treatment response of AP in dogs. In addition, miR-216a and miR-375 could be associated with inflammatory processes in  dogs with AP"
1019,cfa-miR-375,miRNA,acute pancreatitis,Golden Retriever,both,10.7years,3.6kg,9615,"Serum cfa-miR-375 could be a potential biomarker for the diagnosis and evaluation of treatment response of AP in dogs. In addition, miR-216a and miR-375 could be associated with inflammatory processes in  dogs with AP"
1019,cfa-miR-375,miRNA,acute pancreatitis,Korean Jindo,both,10.7years,3.6kg,9615,"Serum cfa-miR-375 could be a potential biomarker for the diagnosis and evaluation of treatment response of AP in dogs. In addition, miR-216a and miR-375 could be associated with inflammatory processes in  dogs with AP"
730,Tributylcitrate,metabolite,pyometritis,,F,9.33 ± 3.39 years,Canine pyometra,9615,"In this study, we observed that D-Ribulose 5-phosphate, Tributylcitrate, Kynurenic acid, Acetylcysteine, Isoquinoline, Phe-Pro, D-Glucose 6-phosphate and 3-[4-(3,5-dichloro-4-pyridinyl) piperazino]-1,1,1-trifluoro-2-propanol were able to be the potential biomarkers of canine pyom"
731,Acetylcysteine,metabolite,pyometritis,,F,9.33 ± 3.39 years,Canine pyometra,9615,"In this study, we observed that D-Ribulose 5-phosphate, Tributylcitrate, Kynurenic acid, Acetylcysteine, Isoquinoline, Phe-Pro, D-Glucose 6-phosphate and 3-[4-(3,5-dichloro-4-pyridinyl) piperazino]-1,1,1-trifluoro-2-propanol were able to be the potential biomarkers of canine pyom"
732,Isoquinoline,metabolite,pyometritis,,F,9.33 ± 3.39 years,Canine pyometra,9615,"In this study, we observed that D-Ribulose 5-phosphate, Tributylcitrate, Kynurenic acid, Acetylcysteine, Isoquinoline, Phe-Pro, D-Glucose 6-phosphate and 3-[4-(3,5-dichloro-4-pyridinyl) piperazino]-1,1,1-trifluoro-2-propanol were able to be the potential biomarkers of canine pyom"
733,Phe-Pro,metabolite,pyometritis,,F,9.33 ± 3.39 years,Canine pyometra,9615,"In this study, we observed that D-Ribulose 5-phosphate, Tributylcitrate, Kynurenic acid, Acetylcysteine, Isoquinoline, Phe-Pro, D-Glucose 6-phosphate and 3-[4-(3,5-dichloro-4-pyridinyl) piperazino]-1,1,1-trifluoro-2-propanol were able to be the potential biomarkers of canine pyom"
734,D-Glucose 6-phosphate,metabolite,pyometritis,,F,9.33 ± 3.39 years,Canine pyometra,9615,"In this study, we observed that D-Ribulose 5-phosphate, Tributylcitrate, Kynurenic acid, Acetylcysteine, Isoquinoline, Phe-Pro, D-Glucose 6-phosphate and 3-[4-(3,5-dichloro-4-pyridinyl) piperazino]-1,1,1-trifluoro-2-propanol were able to be the potential biomarkers of canine pyom"
735,"3-[4-(3,5-dichloro-4-pyridinyl) piperazino]-1,1,1-trifluoro-2-propanol",metabolite,pyometritis,,F,9.33 ± 3.39 years,Canine pyometra,9615,"In this study, we observed that D-Ribulose 5-phosphate, Tributylcitrate, Kynurenic acid, Acetylcysteine, Isoquinoline, Phe-Pro, D-Glucose 6-phosphate and 3-[4-(3,5-dichloro-4-pyridinyl) piperazino]-1,1,1-trifluoro-2-propanol were able to be the potential biomarkers of canine pyom"
2454,COX-2,protein,hepatocellular carcinoma,Shih Tzu(Chrysanthemum Dog),both,4–15 years,,9615,These results suggest that COX-2 may play a role in the modulation of neoplastic cell growth. These preliminary data lead to further investigation on the potential of COX-2 expression as a prognostic indicator and COX-2 inhibitors for canine HGCs treatment
2454,COX-2,protein,hepatocellular carcinoma,Poodle,both,4–15 years,,9615,These results suggest that COX-2 may play a role in the modulation of neoplastic cell growth. These preliminary data lead to further investigation on the potential of COX-2 expression as a prognostic indicator and COX-2 inhibitors for canine HGCs treatment
2454,COX-2,protein,hepatocellular carcinoma,English Beagle,both,4–15 years,,9615,These results suggest that COX-2 may play a role in the modulation of neoplastic cell growth. These preliminary data lead to further investigation on the potential of COX-2 expression as a prognostic indicator and COX-2 inhibitors for canine HGCs treatment
2454,COX-2,protein,hepatocellular carcinoma,Golden Retriever,both,4–15 years,,9615,These results suggest that COX-2 may play a role in the modulation of neoplastic cell growth. These preliminary data lead to further investigation on the potential of COX-2 expression as a prognostic indicator and COX-2 inhibitors for canine HGCs treatment
2454,COX-2,protein,hepatocellular carcinoma,Siberian Husky,both,4–15 years,,9615,These results suggest that COX-2 may play a role in the modulation of neoplastic cell growth. These preliminary data lead to further investigation on the potential of COX-2 expression as a prognostic indicator and COX-2 inhibitors for canine HGCs treatment
2454,COX-2,protein,hepatocellular carcinoma,Labrador Retriever,both,4–15 years,,9615,These results suggest that COX-2 may play a role in the modulation of neoplastic cell growth. These preliminary data lead to further investigation on the potential of COX-2 expression as a prognostic indicator and COX-2 inhibitors for canine HGCs treatment
2454,COX-2,protein,hepatocellular carcinoma,Chihuahua,both,4–15 years,,9615,These results suggest that COX-2 may play a role in the modulation of neoplastic cell growth. These preliminary data lead to further investigation on the potential of COX-2 expression as a prognostic indicator and COX-2 inhibitors for canine HGCs treatment
2454,COX-2,protein,hepatocellular carcinoma,Jack Russell Terrier,both,4–15 years,,9615,These results suggest that COX-2 may play a role in the modulation of neoplastic cell growth. These preliminary data lead to further investigation on the potential of COX-2 expression as a prognostic indicator and COX-2 inhibitors for canine HGCs treatment
2454,COX-2,protein,hepatocellular carcinoma,Dachshund,both,4–15 years,,9615,These results suggest that COX-2 may play a role in the modulation of neoplastic cell growth. These preliminary data lead to further investigation on the potential of COX-2 expression as a prognostic indicator and COX-2 inhibitors for canine HGCs treatment
2454,COX-2,protein,hepatocellular carcinoma,Thai Ridgeback,both,4–15 years,,9615,These results suggest that COX-2 may play a role in the modulation of neoplastic cell growth. These preliminary data lead to further investigation on the potential of COX-2 expression as a prognostic indicator and COX-2 inhibitors for canine HGCs treatment
2454,COX-2,protein,hepatocellular carcinoma,Thai Bangkaew Dog,both,4–15 years,,9615,These results suggest that COX-2 may play a role in the modulation of neoplastic cell growth. These preliminary data lead to further investigation on the potential of COX-2 expression as a prognostic indicator and COX-2 inhibitors for canine HGCs treatment
2455,Calcium-activated chloride channel regulator 1,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2455,Calcium-activated chloride channel regulator 1,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2455,Calcium-activated chloride channel regulator 1,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2455,Calcium-activated chloride channel regulator 1,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2455,Calcium-activated chloride channel regulator 1,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2455,Calcium-activated chloride channel regulator 1,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2455,Calcium-activated chloride channel regulator 1,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2455,Calcium-activated chloride channel regulator 1,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2455,Calcium-activated chloride channel regulator 1,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2456,serum uromodulin,protein,chronic kidney disease,Maltese,both,4-19 years,1.6-22 kg,9615,"serum uromodulin may be a valuable diagnostic marker for CKD in dogs, particularly in identifying early-stage CKD"
2456,serum uromodulin,protein,chronic kidney disease,Poodle,both,4-19 years,1.6-22 kg,9615,"serum uromodulin may be a valuable diagnostic marker for CKD in dogs, particularly in identifying early-stage CKD"
2456,serum uromodulin,protein,chronic kidney disease,Shih Tzu(Chrysanthemum Dog),both,4-19 years,1.6-22 kg,9615,"serum uromodulin may be a valuable diagnostic marker for CKD in dogs, particularly in identifying early-stage CKD"
2456,serum uromodulin,protein,chronic kidney disease,Bedlington Terrier,both,4-19 years,1.6-22 kg,9615,"serum uromodulin may be a valuable diagnostic marker for CKD in dogs, particularly in identifying early-stage CKD"
2456,serum uromodulin,protein,chronic kidney disease,Bichon Frise,both,4-19 years,1.6-22 kg,9615,"serum uromodulin may be a valuable diagnostic marker for CKD in dogs, particularly in identifying early-stage CKD"
2456,serum uromodulin,protein,chronic kidney disease,Dachshund,both,4-19 years,1.6-22 kg,9615,"serum uromodulin may be a valuable diagnostic marker for CKD in dogs, particularly in identifying early-stage CKD"
2456,serum uromodulin,protein,chronic kidney disease,Pomeranian,both,4-19 years,1.6-22 kg,9615,"serum uromodulin may be a valuable diagnostic marker for CKD in dogs, particularly in identifying early-stage CKD"
2456,serum uromodulin,protein,chronic kidney disease,Chihuahua,both,4-19 years,1.6-22 kg,9615,"serum uromodulin may be a valuable diagnostic marker for CKD in dogs, particularly in identifying early-stage CKD"
2456,serum uromodulin,protein,chronic kidney disease,Coton de Tulear,both,4-19 years,1.6-22 kg,9615,"serum uromodulin may be a valuable diagnostic marker for CKD in dogs, particularly in identifying early-stage CKD"
2456,serum uromodulin,protein,chronic kidney disease,Golden Retriever,both,4-19 years,1.6-22 kg,9615,"serum uromodulin may be a valuable diagnostic marker for CKD in dogs, particularly in identifying early-stage CKD"
2456,serum uromodulin,protein,chronic kidney disease,Papillon(Continental Toy Spaniel),both,4-19 years,1.6-22 kg,9615,"serum uromodulin may be a valuable diagnostic marker for CKD in dogs, particularly in identifying early-stage CKD"
2456,serum uromodulin,protein,chronic kidney disease,Yorkshire Terrier,both,4-19 years,1.6-22 kg,9615,"serum uromodulin may be a valuable diagnostic marker for CKD in dogs, particularly in identifying early-stage CKD"
2456,serum uromodulin,protein,chronic kidney disease,Pekingese,both,4-19 years,1.6-22 kg,9615,"serum uromodulin may be a valuable diagnostic marker for CKD in dogs, particularly in identifying early-stage CKD"
2456,serum uromodulin,protein,chronic kidney disease,Standard Schnauzer,both,4-19 years,1.6-22 kg,9615,"serum uromodulin may be a valuable diagnostic marker for CKD in dogs, particularly in identifying early-stage CKD"
2456,serum uromodulin,protein,chronic kidney disease,Border Collie,both,4-19 years,1.6-22 kg,9615,"serum uromodulin may be a valuable diagnostic marker for CKD in dogs, particularly in identifying early-stage CKD"
2456,serum uromodulin,protein,chronic kidney disease,Silky Terrier,both,4-19 years,1.6-22 kg,9615,"serum uromodulin may be a valuable diagnostic marker for CKD in dogs, particularly in identifying early-stage CKD"
2456,serum uromodulin,protein,chronic kidney disease,West Highland White Terrier,both,4-19 years,1.6-22 kg,9615,"serum uromodulin may be a valuable diagnostic marker for CKD in dogs, particularly in identifying early-stage CKD"
2457,Caveolin-1,protein,urinary bladder cancer,,both,5-15 years,,9615,"GATA-3 and Caveolin-1 have been demonstrated as potential biomarkers of the biological behavior of canine bladder
carcinoma"
2458,GATA-3,protein,urinary bladder cancer,,both,5-15 years,,9615,"GATA-3 and Caveolin-1 have been demonstrated as potential biomarkers of the biological behavior of canine bladder
carcinoma"
2459,serum CRP,protein,diffuse large B-cell lymphoma,,both,1.5–14.3 years,3.4–76.6 kg,9615,"These results suggest that baseline serum CRP concentration is independently associated with progression-free survival in dogs with DLBCL, making it a potentially useful prognostic biomarker for dogs with  this cancer"
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Cocker Spaniel,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Border Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Border Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,English Springer Spaniel,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Pembroke Welsh Corgi,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Cavalier King Charles Spaniel,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Labrador Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Golden Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Chihuahua,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Coton de Tulear,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Chihuahua,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Japanese Spitz,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,French Bulldog,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Nova Scotia Duck Tolling Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Icelandic Shepherd Dog,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Labrador Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Labrador Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Border Collie,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Nova Scotia Duck Tolling Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,French Bulldog,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Kooikerhondje(Little Cager Dog),both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Jack Russell Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Yorkshire Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Samoyed,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Eurasier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Great Pyrenees,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Great Dane,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Eurasier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Shetland Shepherd Dog,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Eurasier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Eurasier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Shih Tzu(Chrysanthemum Dog),both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Golden Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Siberian Husky,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Staffordshire Bull Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1020,miR-451,miRNA,gastric neoplasm|intestinal disorder,Airedale Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Cocker Spaniel,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Border Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Border Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,English Springer Spaniel,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Pembroke Welsh Corgi,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Cavalier King Charles Spaniel,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Labrador Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Golden Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Chihuahua,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Coton de Tulear,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Chihuahua,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Japanese Spitz,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,French Bulldog,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Nova Scotia Duck Tolling Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Icelandic Shepherd Dog,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Labrador Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Labrador Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Border Collie,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Nova Scotia Duck Tolling Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,French Bulldog,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Kooikerhondje(Little Cager Dog),both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Jack Russell Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Yorkshire Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Samoyed,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Eurasier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Great Pyrenees,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Great Dane,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Eurasier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Shetland Shepherd Dog,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Eurasier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Eurasier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Shih Tzu(Chrysanthemum Dog),both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Golden Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Siberian Husky,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Staffordshire Bull Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1021,miR-223,miRNA,gastric neoplasm|intestinal disorder,Airedale Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Cocker Spaniel,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Border Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Border Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,English Springer Spaniel,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Pembroke Welsh Corgi,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Cavalier King Charles Spaniel,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Labrador Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Golden Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Chihuahua,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Coton de Tulear,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Chihuahua,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Japanese Spitz,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,French Bulldog,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Nova Scotia Duck Tolling Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Icelandic Shepherd Dog,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Labrador Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Labrador Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Border Collie,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Nova Scotia Duck Tolling Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,French Bulldog,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Kooikerhondje(Little Cager Dog),both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Jack Russell Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Yorkshire Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Samoyed,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Eurasier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Great Pyrenees,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Great Dane,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Eurasier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Shetland Shepherd Dog,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Eurasier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Eurasier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Shih Tzu(Chrysanthemum Dog),both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Golden Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Siberian Husky,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Staffordshire Bull Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1022,miR-27a,miRNA,gastric neoplasm|intestinal disorder,Airedale Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Cocker Spaniel,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Border Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Border Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,English Springer Spaniel,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Pembroke Welsh Corgi,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Cavalier King Charles Spaniel,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Labrador Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Golden Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Chihuahua,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Coton de Tulear,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Chihuahua,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Japanese Spitz,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,French Bulldog,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Nova Scotia Duck Tolling Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Icelandic Shepherd Dog,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Labrador Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Labrador Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Border Collie,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Nova Scotia Duck Tolling Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,French Bulldog,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Kooikerhondje(Little Cager Dog),both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Jack Russell Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Yorkshire Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Samoyed,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Eurasier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Great Pyrenees,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Great Dane,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Eurasier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Shetland Shepherd Dog,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Eurasier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Eurasier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Shih Tzu(Chrysanthemum Dog),both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Golden Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Siberian Husky,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Staffordshire Bull Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1023,miR-20b,miRNA,gastric neoplasm|intestinal disorder,Airedale Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Cocker Spaniel,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Border Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Border Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,English Springer Spaniel,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Pembroke Welsh Corgi,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Cavalier King Charles Spaniel,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Labrador Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Golden Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Chihuahua,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Coton de Tulear,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Chihuahua,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Japanese Spitz,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,French Bulldog,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Nova Scotia Duck Tolling Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Icelandic Shepherd Dog,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Labrador Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Labrador Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Border Collie,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Nova Scotia Duck Tolling Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,French Bulldog,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Kooikerhondje(Little Cager Dog),both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Jack Russell Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Yorkshire Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Samoyed,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Eurasier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Great Pyrenees,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Great Dane,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Eurasier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Shetland Shepherd Dog,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Eurasier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Eurasier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Shih Tzu(Chrysanthemum Dog),both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Golden Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Siberian Husky,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Staffordshire Bull Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1024,miR-148a-3p,miRNA,gastric neoplasm|intestinal disorder,Airedale Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Cocker Spaniel,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Border Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Border Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,English Springer Spaniel,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Pembroke Welsh Corgi,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Cavalier King Charles Spaniel,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Labrador Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Golden Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Chihuahua,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Coton de Tulear,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Chihuahua,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Japanese Spitz,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,French Bulldog,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Nova Scotia Duck Tolling Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Icelandic Shepherd Dog,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Labrador Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Labrador Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Border Collie,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Nova Scotia Duck Tolling Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,French Bulldog,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Kooikerhondje(Little Cager Dog),both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Jack Russell Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Yorkshire Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Samoyed,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Eurasier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Great Pyrenees,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Great Dane,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Eurasier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Shetland Shepherd Dog,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Eurasier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Eurasier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Shih Tzu(Chrysanthemum Dog),both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Golden Retriever,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Siberian Husky,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Staffordshire Bull Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
1025,miR-652 ,miRNA,gastric neoplasm|intestinal disorder,Airedale Terrier,both,15-192 months,2.4-74kg,9615,"In conclusion, we identified miR-451, miR-223, and miR-27a in feces and miR-20b, miR-148a-3p, miR-652 in serum, as noninvasive biomarker candidates for the optimization of a diagnostic RT-qPCR panel with the potential to differentiate between GIC and CIE in dogs."
2460,Carboxypeptidase O,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2460,Carboxypeptidase O,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2460,Carboxypeptidase O,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2460,Carboxypeptidase O,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2460,Carboxypeptidase O,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2460,Carboxypeptidase O,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2460,Carboxypeptidase O,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2460,Carboxypeptidase O,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2460,Carboxypeptidase O,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2461,Immunoglobulin J chain,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2461,Immunoglobulin J chain,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2461,Immunoglobulin J chain,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2461,Immunoglobulin J chain,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2461,Immunoglobulin J chain,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2461,Immunoglobulin J chain,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2461,Immunoglobulin J chain,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2461,Immunoglobulin J chain,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2461,Immunoglobulin J chain,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
1026,fecal miR-451,miRNA,intestinal disorder,,both,(months)healthy dogs：15-130；CIE dogs：18-132；GIC dogs：27-192,(kg)healthy dogs：6.5-33；CIE dogs：2.6-22；GIC dogs：2.4-74,9615,"When used as part of a diagnostic RT-qPCR panel, the abovementioned miRNAs have the potential to function as noninvasive biomarkers for the differentiation of GIC and CIE in dogs"
1027,fecal miR-223,miRNA,intestinal disorder,,both,(months)healthy dogs：15-130；CIE dogs：18-132；GIC dogs：27-192,(kg)healthy dogs：6.5-33；CIE dogs：2.6-22；GIC dogs：2.4-74,9615,"When used as part of a diagnostic RT-qPCR panel, the abovementioned miRNAs have the potential to function as noninvasive biomarkers for the differentiation of GIC and CIE in dogs"
1028,fecal miR-27a,miRNA,intestinal disorder,,both,(months)healthy dogs：15-130；CIE dogs：18-132；GIC dogs：27-192,(kg)healthy dogs：6.5-33；CIE dogs：2.6-22；GIC dogs：2.4-74,9615,"When used as part of a diagnostic RT-qPCR panel, the abovementioned miRNAs have the potential to function as noninvasive biomarkers for the differentiation of GIC and CIE in dogs"
1029,serum miR-20b,miRNA,intestinal disorder,,both,(months)healthy dogs：15-130；CIE dogs：18-132；GIC dogs：27-192,(kg)healthy dogs：6.5-33；CIE dogs：2.6-22；GIC dogs：2.4-74,9615,"When used as part of a diagnostic RT-qPCR panel, the abovementioned miRNAs have the potential to function as noninvasive biomarkers for the differentiation of GIC and CIE in dogs"
1030,serum miR-148a-3p,miRNA,intestinal disorder,,both,(months)healthy dogs：15-130；CIE dogs：18-132；GIC dogs：27-192,(kg)healthy dogs：6.5-33；CIE dogs：2.6-22；GIC dogs：2.4-74,9615,"When used as part of a diagnostic RT-qPCR panel, the abovementioned miRNAs have the potential to function as noninvasive biomarkers for the differentiation of GIC and CIE in dogs"
1031,serum miR-652,miRNA,intestinal disorder,,both,(months)healthy dogs：15-130；CIE dogs：18-132；GIC dogs：27-192,(kg)healthy dogs：6.5-33；CIE dogs：2.6-22；GIC dogs：2.4-74,9615,"When used as part of a diagnostic RT-qPCR panel, the abovementioned miRNAs have the potential to function as noninvasive biomarkers for the differentiation of GIC and CIE in dogs"
653,Histamine ,metabolite,hypothyroidism,Labrador Retriever,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
653,Histamine ,metabolite,hypothyroidism,English Beagle,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
653,Histamine ,metabolite,hypothyroidism,Yorkshire Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
653,Histamine ,metabolite,hypothyroidism,Neapolitan Mastiff,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
653,Histamine ,metabolite,hypothyroidism,Scottish Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
653,Histamine ,metabolite,hypothyroidism,Greyhound,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
653,Histamine ,metabolite,hypothyroidism,Staffordshire Bull Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
654,Tyrosine ,metabolite,hypothyroidism,Labrador Retriever,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
654,Tyrosine ,metabolite,hypothyroidism,English Beagle,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
654,Tyrosine ,metabolite,hypothyroidism,Yorkshire Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
654,Tyrosine ,metabolite,hypothyroidism,Neapolitan Mastiff,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
654,Tyrosine ,metabolite,hypothyroidism,Scottish Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
654,Tyrosine ,metabolite,hypothyroidism,Greyhound,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
654,Tyrosine ,metabolite,hypothyroidism,Staffordshire Bull Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
655,Lysine ,metabolite,hypothyroidism,Labrador Retriever,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
655,Lysine ,metabolite,hypothyroidism,English Beagle,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
655,Lysine ,metabolite,hypothyroidism,Yorkshire Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
655,Lysine ,metabolite,hypothyroidism,Neapolitan Mastiff,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
655,Lysine ,metabolite,hypothyroidism,Scottish Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
655,Lysine ,metabolite,hypothyroidism,Greyhound,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
655,Lysine ,metabolite,hypothyroidism,Staffordshire Bull Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
656,Ornithine ,metabolite,hypothyroidism,Labrador Retriever,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
656,Ornithine ,metabolite,hypothyroidism,English Beagle,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
656,Ornithine ,metabolite,hypothyroidism,Yorkshire Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
656,Ornithine ,metabolite,hypothyroidism,Neapolitan Mastiff,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
656,Ornithine ,metabolite,hypothyroidism,Scottish Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
656,Ornithine ,metabolite,hypothyroidism,Greyhound,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
656,Ornithine ,metabolite,hypothyroidism,Staffordshire Bull Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
2167,Immunoglobulin heavy chain,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2167,Immunoglobulin heavy chain,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2167,Immunoglobulin heavy chain,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2167,Immunoglobulin heavy chain,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2167,Immunoglobulin heavy chain,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2167,Immunoglobulin heavy chain,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2167,Immunoglobulin heavy chain,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2167,Immunoglobulin heavy chain,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2167,Immunoglobulin heavy chain,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
657,Citrulline ,metabolite,hypothyroidism,Labrador Retriever,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
657,Citrulline ,metabolite,hypothyroidism,English Beagle,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
657,Citrulline ,metabolite,hypothyroidism,Yorkshire Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
657,Citrulline ,metabolite,hypothyroidism,Neapolitan Mastiff,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
657,Citrulline ,metabolite,hypothyroidism,Scottish Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
657,Citrulline ,metabolite,hypothyroidism,Greyhound,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
657,Citrulline ,metabolite,hypothyroidism,Staffordshire Bull Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
658,Phenylalanine ,metabolite,hypothyroidism,Labrador Retriever,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
658,Phenylalanine ,metabolite,hypothyroidism,English Beagle,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
658,Phenylalanine ,metabolite,hypothyroidism,Yorkshire Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
658,Phenylalanine ,metabolite,hypothyroidism,Neapolitan Mastiff,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
658,Phenylalanine ,metabolite,hypothyroidism,Scottish Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
658,Phenylalanine ,metabolite,hypothyroidism,Greyhound,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
658,Phenylalanine ,metabolite,hypothyroidism,Staffordshire Bull Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
659,Glutamine,metabolite,hypothyroidism,Labrador Retriever,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
659,Glutamine,metabolite,hypothyroidism,English Beagle,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
659,Glutamine,metabolite,hypothyroidism,Yorkshire Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
659,Glutamine,metabolite,hypothyroidism,Neapolitan Mastiff,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
659,Glutamine,metabolite,hypothyroidism,Scottish Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
659,Glutamine,metabolite,hypothyroidism,Greyhound,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
659,Glutamine,metabolite,hypothyroidism,Staffordshire Bull Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
660,TG(56:7) ,metabolite,hypothyroidism,Labrador Retriever,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
660,TG(56:7) ,metabolite,hypothyroidism,English Beagle,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
660,TG(56:7) ,metabolite,hypothyroidism,Yorkshire Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
660,TG(56:7) ,metabolite,hypothyroidism,Neapolitan Mastiff,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
660,TG(56:7) ,metabolite,hypothyroidism,Scottish Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
660,TG(56:7) ,metabolite,hypothyroidism,Greyhound,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
660,TG(56:7) ,metabolite,hypothyroidism,Staffordshire Bull Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
661,CE(20:4) ,metabolite,hypothyroidism,Labrador Retriever,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
661,CE(20:4) ,metabolite,hypothyroidism,English Beagle,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
661,CE(20:4) ,metabolite,hypothyroidism,Yorkshire Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
661,CE(20:4) ,metabolite,hypothyroidism,Neapolitan Mastiff,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
661,CE(20:4) ,metabolite,hypothyroidism,Scottish Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
661,CE(20:4) ,metabolite,hypothyroidism,Greyhound,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
661,CE(20:4) ,metabolite,hypothyroidism,Staffordshire Bull Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
662,CE(18:2) ,metabolite,hypothyroidism,Labrador Retriever,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
662,CE(18:2) ,metabolite,hypothyroidism,English Beagle,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
662,CE(18:2) ,metabolite,hypothyroidism,Yorkshire Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
662,CE(18:2) ,metabolite,hypothyroidism,Neapolitan Mastiff,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
662,CE(18:2) ,metabolite,hypothyroidism,Scottish Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
662,CE(18:2) ,metabolite,hypothyroidism,Greyhound,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
662,CE(18:2) ,metabolite,hypothyroidism,Staffordshire Bull Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
663,PC(40:6) ,metabolite,hypothyroidism,Labrador Retriever,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
663,PC(40:6) ,metabolite,hypothyroidism,English Beagle,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
663,PC(40:6) ,metabolite,hypothyroidism,Yorkshire Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
663,PC(40:6) ,metabolite,hypothyroidism,Neapolitan Mastiff,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
663,PC(40:6) ,metabolite,hypothyroidism,Scottish Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
663,PC(40:6) ,metabolite,hypothyroidism,Greyhound,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
663,PC(40:6) ,metabolite,hypothyroidism,Staffordshire Bull Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
664,PC(36:4),metabolite,hypothyroidism,Labrador Retriever,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
664,PC(36:4),metabolite,hypothyroidism,English Beagle,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
664,PC(36:4),metabolite,hypothyroidism,Yorkshire Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
664,PC(36:4),metabolite,hypothyroidism,Neapolitan Mastiff,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
664,PC(36:4),metabolite,hypothyroidism,Scottish Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
664,PC(36:4),metabolite,hypothyroidism,Greyhound,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
664,PC(36:4),metabolite,hypothyroidism,Staffordshire Bull Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
665,PC(38:6) ,metabolite,hypothyroidism,Labrador Retriever,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
665,PC(38:6) ,metabolite,hypothyroidism,English Beagle,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
665,PC(38:6) ,metabolite,hypothyroidism,Yorkshire Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
665,PC(38:6) ,metabolite,hypothyroidism,Neapolitan Mastiff,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
665,PC(38:6) ,metabolite,hypothyroidism,Scottish Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
665,PC(38:6) ,metabolite,hypothyroidism,Greyhound,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
665,PC(38:6) ,metabolite,hypothyroidism,Staffordshire Bull Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
666,PC(34:1) ,metabolite,hypothyroidism,Labrador Retriever,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
666,PC(34:1) ,metabolite,hypothyroidism,English Beagle,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
666,PC(34:1) ,metabolite,hypothyroidism,Yorkshire Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
666,PC(34:1) ,metabolite,hypothyroidism,Neapolitan Mastiff,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
666,PC(34:1) ,metabolite,hypothyroidism,Scottish Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
666,PC(34:1) ,metabolite,hypothyroidism,Greyhound,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
666,PC(34:1) ,metabolite,hypothyroidism,Staffordshire Bull Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
2168,Immunoglobulin heavy chain Constant region CH2,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2168,Immunoglobulin heavy chain Constant region CH2,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2168,Immunoglobulin heavy chain Constant region CH2,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2168,Immunoglobulin heavy chain Constant region CH2,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2168,Immunoglobulin heavy chain Constant region CH2,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2168,Immunoglobulin heavy chain Constant region CH2,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2168,Immunoglobulin heavy chain Constant region CH2,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2168,Immunoglobulin heavy chain Constant region CH2,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2168,Immunoglobulin heavy chain Constant region CH2,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
667,PC(38:5) ,metabolite,hypothyroidism,Labrador Retriever,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
667,PC(38:5) ,metabolite,hypothyroidism,English Beagle,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
667,PC(38:5) ,metabolite,hypothyroidism,Yorkshire Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
667,PC(38:5) ,metabolite,hypothyroidism,Neapolitan Mastiff,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
667,PC(38:5) ,metabolite,hypothyroidism,Scottish Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
667,PC(38:5) ,metabolite,hypothyroidism,Greyhound,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
667,PC(38:5) ,metabolite,hypothyroidism,Staffordshire Bull Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
668,PC(36:1) ,metabolite,hypothyroidism,Labrador Retriever,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
668,PC(36:1) ,metabolite,hypothyroidism,English Beagle,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
668,PC(36:1) ,metabolite,hypothyroidism,Yorkshire Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
668,PC(36:1) ,metabolite,hypothyroidism,Neapolitan Mastiff,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
668,PC(36:1) ,metabolite,hypothyroidism,Scottish Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
668,PC(36:1) ,metabolite,hypothyroidism,Greyhound,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
668,PC(36:1) ,metabolite,hypothyroidism,Staffordshire Bull Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
669,PC(38:4) ,metabolite,hypothyroidism,Labrador Retriever,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
669,PC(38:4) ,metabolite,hypothyroidism,English Beagle,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
669,PC(38:4) ,metabolite,hypothyroidism,Yorkshire Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
669,PC(38:4) ,metabolite,hypothyroidism,Neapolitan Mastiff,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
669,PC(38:4) ,metabolite,hypothyroidism,Scottish Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
669,PC(38:4) ,metabolite,hypothyroidism,Greyhound,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
669,PC(38:4) ,metabolite,hypothyroidism,Staffordshire Bull Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
670,PC(34:2) ,metabolite,hypothyroidism,Labrador Retriever,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
670,PC(34:2) ,metabolite,hypothyroidism,English Beagle,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
670,PC(34:2) ,metabolite,hypothyroidism,Yorkshire Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
670,PC(34:2) ,metabolite,hypothyroidism,Neapolitan Mastiff,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
670,PC(34:2) ,metabolite,hypothyroidism,Scottish Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
670,PC(34:2) ,metabolite,hypothyroidism,Greyhound,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
670,PC(34:2) ,metabolite,hypothyroidism,Staffordshire Bull Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
671,PC(36:5) ,metabolite,hypothyroidism,Labrador Retriever,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
671,PC(36:5) ,metabolite,hypothyroidism,English Beagle,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
671,PC(36:5) ,metabolite,hypothyroidism,Yorkshire Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
671,PC(36:5) ,metabolite,hypothyroidism,Neapolitan Mastiff,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
671,PC(36:5) ,metabolite,hypothyroidism,Scottish Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
671,PC(36:5) ,metabolite,hypothyroidism,Greyhound,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
671,PC(36:5) ,metabolite,hypothyroidism,Staffordshire Bull Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
672,PC(40:5) ,metabolite,hypothyroidism,Labrador Retriever,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
672,PC(40:5) ,metabolite,hypothyroidism,English Beagle,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
672,PC(40:5) ,metabolite,hypothyroidism,Yorkshire Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
672,PC(40:5) ,metabolite,hypothyroidism,Neapolitan Mastiff,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
672,PC(40:5) ,metabolite,hypothyroidism,Scottish Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
672,PC(40:5) ,metabolite,hypothyroidism,Greyhound,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
672,PC(40:5) ,metabolite,hypothyroidism,Staffordshire Bull Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
673,PC(36:2) ,metabolite,hypothyroidism,Labrador Retriever,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
673,PC(36:2) ,metabolite,hypothyroidism,English Beagle,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
673,PC(36:2) ,metabolite,hypothyroidism,Yorkshire Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
673,PC(36:2) ,metabolite,hypothyroidism,Neapolitan Mastiff,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
673,PC(36:2) ,metabolite,hypothyroidism,Scottish Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
673,PC(36:2) ,metabolite,hypothyroidism,Greyhound,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
673,PC(36:2) ,metabolite,hypothyroidism,Staffordshire Bull Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
674,PC(32:1),metabolite,hypothyroidism,Labrador Retriever,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
674,PC(32:1),metabolite,hypothyroidism,English Beagle,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
674,PC(32:1),metabolite,hypothyroidism,Yorkshire Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
674,PC(32:1),metabolite,hypothyroidism,Neapolitan Mastiff,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
674,PC(32:1),metabolite,hypothyroidism,Scottish Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
674,PC(32:1),metabolite,hypothyroidism,Greyhound,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
674,PC(32:1),metabolite,hypothyroidism,Staffordshire Bull Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
675,PC(32:4) ,metabolite,hypothyroidism,Labrador Retriever,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
675,PC(32:4) ,metabolite,hypothyroidism,English Beagle,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
675,PC(32:4) ,metabolite,hypothyroidism,Yorkshire Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
675,PC(32:4) ,metabolite,hypothyroidism,Neapolitan Mastiff,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
675,PC(32:4) ,metabolite,hypothyroidism,Scottish Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
675,PC(32:4) ,metabolite,hypothyroidism,Greyhound,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
675,PC(32:4) ,metabolite,hypothyroidism,Staffordshire Bull Terrier,both,3-14.6years,,9615,"Altogether, it can be stated that hypothyroidism produces changes in the metabolome of saliva that can reflect the metabolic changes presented in the disease, and some of these metabolites such as tyrosine and phenylalanine could serve as a potential biomarker of this condition."
2169,uIL6/uCr,protein,acute kidney failure,,both,,,9615,uIL6/uCr is a potentially sensitive and specific diagnostic marker for AKI in dogs
2170,Glucose-6-phosphate isomerase,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2170,Glucose-6-phosphate isomerase,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2170,Glucose-6-phosphate isomerase,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2170,Glucose-6-phosphate isomerase,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2170,Glucose-6-phosphate isomerase,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2170,Glucose-6-phosphate isomerase,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2170,Glucose-6-phosphate isomerase,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2170,Glucose-6-phosphate isomerase,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2170,Glucose-6-phosphate isomerase,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2171,LDH,protein,melanoma,Labrador Retriever,both,5-13 years,,9615,"This study suggests that serum LDH levels are significantly increased in dogs with OMM compared to healthy controls, paving the way for further research to investigate the prognostic value of this biomarker."
2171,LDH,protein,melanoma,Cocker Spaniel,both,5-13 years,,9615,"This study suggests that serum LDH levels are significantly increased in dogs with OMM compared to healthy controls, paving the way for further research to investigate the prognostic value of this biomarker."
2171,LDH,protein,melanoma,Tibetan Terrier,both,5-13 years,,9615,"This study suggests that serum LDH levels are significantly increased in dogs with OMM compared to healthy controls, paving the way for further research to investigate the prognostic value of this biomarker."
2171,LDH,protein,melanoma,Golden Retriever,both,5-13 years,,9615,"This study suggests that serum LDH levels are significantly increased in dogs with OMM compared to healthy controls, paving the way for further research to investigate the prognostic value of this biomarker."
2171,LDH,protein,melanoma,Irish Setter,both,5-13 years,,9615,"This study suggests that serum LDH levels are significantly increased in dogs with OMM compared to healthy controls, paving the way for further research to investigate the prognostic value of this biomarker."
2171,LDH,protein,melanoma,Border Terrier,both,5-13 years,,9615,"This study suggests that serum LDH levels are significantly increased in dogs with OMM compared to healthy controls, paving the way for further research to investigate the prognostic value of this biomarker."
2171,LDH,protein,melanoma,Hungarian Vizsla,both,5-13 years,,9615,"This study suggests that serum LDH levels are significantly increased in dogs with OMM compared to healthy controls, paving the way for further research to investigate the prognostic value of this biomarker."
2172,p16 protein expression,protein,lymphoma,,,,,9615,These results indicate that p16 protein expression could be a promising biomarker in canine lymphoma cells and might be a treatment target in the future
2173,CXCL‑10,protein,Weil's disease,,,,,9615,"Specifically, IL-1β, CXCL-10, SAA and complement factor C3 may be candidate targets for the development of biomarker-based assays to test Leptospira vaccine potency in vitro"
2174,IL-1β,protein,Weil's disease,,,,,9615,"Specifically, IL-1β, CXCL-10, SAA and complement factor C3 may be candidate targets for the development of biomarker-based assays to test Leptospira vaccine potency in vitro"
2428,SAA,protein,Weil's disease,,,,,9615,"Specifically, IL-1β, CXCL-10, SAA and complement factor C3 may be candidate targets for the development of biomarker-based assays to test Leptospira vaccine potency in vitro"
2175,complement factor C3,protein,Weil's disease,,,,,9615,"Specifically, IL-1β, CXCL-10, SAA and complement factor C3 may be candidate targets for the development of biomarker-based assays to test Leptospira vaccine potency in vitro"
2176,Nectin-4 ,protein,lung adenocarcinoma,Miniature Dachshund,Gender was evenly distributed in this cohort of animals: 15 males (12 castrated) and 19 females (18 spayed),11.9 (9–11)years,8.8 (2.8–38.3) kg,9615,"In conclusion, our study demonstrated that Nectin-4 is highly expressed in CPLA and thus is a promising biomarker for CPLA. Further investigations on nectin-4 in CPLA are warranted for its diagnostic utility and as a potential novel target for oncolytic virotherapy."
2176,Nectin-4 ,protein,lung adenocarcinoma,Toy Poodle,Gender was evenly distributed in this cohort of animals: 15 males (12 castrated) and 19 females (18 spayed),11.9 (9–11)years,8.8 (2.8–38.3) kg,9615,"In conclusion, our study demonstrated that Nectin-4 is highly expressed in CPLA and thus is a promising biomarker for CPLA. Further investigations on nectin-4 in CPLA are warranted for its diagnostic utility and as a potential novel target for oncolytic virotherapy."
2176,Nectin-4 ,protein,lung adenocarcinoma,Miniature Schnauzer,Gender was evenly distributed in this cohort of animals: 15 males (12 castrated) and 19 females (18 spayed),11.9 (9–11)years,8.8 (2.8–38.3) kg,9615,"In conclusion, our study demonstrated that Nectin-4 is highly expressed in CPLA and thus is a promising biomarker for CPLA. Further investigations on nectin-4 in CPLA are warranted for its diagnostic utility and as a potential novel target for oncolytic virotherapy."
2176,Nectin-4 ,protein,lung adenocarcinoma,Chihuahua,Gender was evenly distributed in this cohort of animals: 15 males (12 castrated) and 19 females (18 spayed),11.9 (9–11)years,8.8 (2.8–38.3) kg,9615,"In conclusion, our study demonstrated that Nectin-4 is highly expressed in CPLA and thus is a promising biomarker for CPLA. Further investigations on nectin-4 in CPLA are warranted for its diagnostic utility and as a potential novel target for oncolytic virotherapy."
2176,Nectin-4 ,protein,lung adenocarcinoma,French Bulldog,Gender was evenly distributed in this cohort of animals: 15 males (12 castrated) and 19 females (18 spayed),11.9 (9–11)years,8.8 (2.8–38.3) kg,9615,"In conclusion, our study demonstrated that Nectin-4 is highly expressed in CPLA and thus is a promising biomarker for CPLA. Further investigations on nectin-4 in CPLA are warranted for its diagnostic utility and as a potential novel target for oncolytic virotherapy."
2176,Nectin-4 ,protein,lung adenocarcinoma,Cardigan Welsh Corgi,Gender was evenly distributed in this cohort of animals: 15 males (12 castrated) and 19 females (18 spayed),11.9 (9–11)years,8.8 (2.8–38.3) kg,9615,"In conclusion, our study demonstrated that Nectin-4 is highly expressed in CPLA and thus is a promising biomarker for CPLA. Further investigations on nectin-4 in CPLA are warranted for its diagnostic utility and as a potential novel target for oncolytic virotherapy."
2176,Nectin-4 ,protein,lung adenocarcinoma,Border Collie,Gender was evenly distributed in this cohort of animals: 15 males (12 castrated) and 19 females (18 spayed),11.9 (9–11)years,8.8 (2.8–38.3) kg,9615,"In conclusion, our study demonstrated that Nectin-4 is highly expressed in CPLA and thus is a promising biomarker for CPLA. Further investigations on nectin-4 in CPLA are warranted for its diagnostic utility and as a potential novel target for oncolytic virotherapy."
2176,Nectin-4 ,protein,lung adenocarcinoma,Golden Retriever,Gender was evenly distributed in this cohort of animals: 15 males (12 castrated) and 19 females (18 spayed),11.9 (9–11)years,8.8 (2.8–38.3) kg,9615,"In conclusion, our study demonstrated that Nectin-4 is highly expressed in CPLA and thus is a promising biomarker for CPLA. Further investigations on nectin-4 in CPLA are warranted for its diagnostic utility and as a potential novel target for oncolytic virotherapy."
2176,Nectin-4 ,protein,lung adenocarcinoma,Bernese Mountain Dog,Gender was evenly distributed in this cohort of animals: 15 males (12 castrated) and 19 females (18 spayed),11.9 (9–11)years,8.8 (2.8–38.3) kg,9615,"In conclusion, our study demonstrated that Nectin-4 is highly expressed in CPLA and thus is a promising biomarker for CPLA. Further investigations on nectin-4 in CPLA are warranted for its diagnostic utility and as a potential novel target for oncolytic virotherapy."
2176,Nectin-4 ,protein,lung adenocarcinoma,Norfolk Terrier,Gender was evenly distributed in this cohort of animals: 15 males (12 castrated) and 19 females (18 spayed),11.9 (9–11)years,8.8 (2.8–38.3) kg,9615,"In conclusion, our study demonstrated that Nectin-4 is highly expressed in CPLA and thus is a promising biomarker for CPLA. Further investigations on nectin-4 in CPLA are warranted for its diagnostic utility and as a potential novel target for oncolytic virotherapy."
2176,Nectin-4 ,protein,lung adenocarcinoma,Shih Tzu(Chrysanthemum Dog),Gender was evenly distributed in this cohort of animals: 15 males (12 castrated) and 19 females (18 spayed),11.9 (9–11)years,8.8 (2.8–38.3) kg,9615,"In conclusion, our study demonstrated that Nectin-4 is highly expressed in CPLA and thus is a promising biomarker for CPLA. Further investigations on nectin-4 in CPLA are warranted for its diagnostic utility and as a potential novel target for oncolytic virotherapy."
2176,Nectin-4 ,protein,lung adenocarcinoma,Pekingese,Gender was evenly distributed in this cohort of animals: 15 males (12 castrated) and 19 females (18 spayed),11.9 (9–11)years,8.8 (2.8–38.3) kg,9615,"In conclusion, our study demonstrated that Nectin-4 is highly expressed in CPLA and thus is a promising biomarker for CPLA. Further investigations on nectin-4 in CPLA are warranted for its diagnostic utility and as a potential novel target for oncolytic virotherapy."
2176,Nectin-4 ,protein,lung adenocarcinoma,American Cocker Spaniel,Gender was evenly distributed in this cohort of animals: 15 males (12 castrated) and 19 females (18 spayed),11.9 (9–11)years,8.8 (2.8–38.3) kg,9615,"In conclusion, our study demonstrated that Nectin-4 is highly expressed in CPLA and thus is a promising biomarker for CPLA. Further investigations on nectin-4 in CPLA are warranted for its diagnostic utility and as a potential novel target for oncolytic virotherapy."
185,EZH2,gene,breast neoplasm,Poodle,F,3-15years,4.52 ± 2.63 kg,9615,"These findings 
suggest that the EZH2 level is positively associated with the malignancy degree and could be a potential molecular marker in CMCs diagnosis and therapy"
185,EZH2,gene,breast neoplasm,Bichon Frise,F,3-15years,4.52 ± 2.63 kg,9615,"These findings 
suggest that the EZH2 level is positively associated with the malignancy degree and could be a potential molecular marker in CMCs diagnosis and therapy"
185,EZH2,gene,breast neoplasm,Pekingese,F,3-15years,4.52 ± 2.63 kg,9615,"These findings 
suggest that the EZH2 level is positively associated with the malignancy degree and could be a potential molecular marker in CMCs diagnosis and therapy"
185,EZH2,gene,breast neoplasm,Cocker Spaniel,F,3-15years,4.52 ± 2.63 kg,9615,"These findings 
suggest that the EZH2 level is positively associated with the malignancy degree and could be a potential molecular marker in CMCs diagnosis and therapy"
185,EZH2,gene,breast neoplasm,Golden Retriever,F,3-15years,4.52 ± 2.63 kg,9615,"These findings 
suggest that the EZH2 level is positively associated with the malignancy degree and could be a potential molecular marker in CMCs diagnosis and therapy"
2177,p-S6,protein,oral cavity squamous cell carcinoma,,both,1-15years,,9615,"Our data suggest that p-mTOR and p-S6 proteins are commonly expressed in canine OSCC, and p-S6 expression is correlated with poor CSS in dogs with OSCC"
2178,beta-2 microglobulin,protein,leishmaniasis,,both,1-10 years,,9615,"In this filtered set, 12 proteins were obtained, all of which were increased in dogs with kidney disease secondary to leishmaniosis，These are potential candidates to become biomarkers for the diagnosis, classification, and monitoring of this disease"
2179,Ig lambda chain V–I region BL2,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2179,Ig lambda chain V–I region BL2,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2179,Ig lambda chain V–I region BL2,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2179,Ig lambda chain V–I region BL2,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2179,Ig lambda chain V–I region BL2,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2179,Ig lambda chain V–I region BL2,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2179,Ig lambda chain V–I region BL2,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2179,Ig lambda chain V–I region BL2,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2179,Ig lambda chain V–I region BL2,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2180,C4a,protein,leishmaniasis,,both,1-10 years,,9615,"In this filtered set, 12 proteins were obtained, all of which were increased in dogs with kidney disease secondary to leishmaniosis，These are potential candidates to become biomarkers for the diagnosis, classification, and monitoring of this disease"
2429,Haptoglobin,protein,leishmaniasis,,both,1-10 years,,9615,"In this filtered set, 12 proteins were obtained, all of which were increased in dogs with kidney disease secondary to leishmaniosis，These are potential candidates to become biomarkers for the diagnosis, classification, and monitoring of this disease"
2181,Apolipoprotein-A1,protein,leishmaniasis,,both,1-10 years,,9615,"In this filtered set, 12 proteins were obtained, all of which were increased in dogs with kidney disease secondary to leishmaniosis，These are potential candidates to become biomarkers for the diagnosis, classification, and monitoring of this disease"
2182,an immunoglobulin-like domain-containing protein,protein,leishmaniasis,,both,1-10 years,,9615,"In this filtered set, 12 proteins were obtained, all of which were increased in dogs with kidney disease secondary to leishmaniosis，These are potential candidates to become biomarkers for the diagnosis, classification, and monitoring of this disease"
2183,peptidase S1 domain containing protein,protein,leishmaniasis,,both,1-10 years,,9615,"In this filtered set, 12 proteins were obtained, all of which were increased in dogs with kidney disease secondary to leishmaniosis，These are potential candidates to become biomarkers for the diagnosis, classification, and monitoring of this disease"
2184,leucine-rich alpha-2-glycoprotein 1,protein,leishmaniasis,,both,1-10 years,,9615,"In this filtered set, 12 proteins were obtained, all of which were increased in dogs with kidney disease secondary to leishmaniosis，These are potential candidates to become biomarkers for the diagnosis, classification, and monitoring of this disease"
2185,"an uncharacterized protein similar to immunoglobulin gamma-1 heavy chain in humans (70,3% identity)",protein,leishmaniasis,,both,1-10 years,,9615,"In this filtered set, 12 proteins were obtained, all of which were increased in dogs with kidney disease secondary to leishmaniosis，These are potential candidates to become biomarkers for the diagnosis, classification, and monitoring of this disease"
2186,amyloid beta precursor protein binding family B member,protein,leishmaniasis,,both,1-10 years,,9615,"In this filtered set, 12 proteins were obtained, all of which were increased in dogs with kidney disease secondary to leishmaniosis，These are potential candidates to become biomarkers for the diagnosis, classification, and monitoring of this disease"
2187,fetuin B,protein,leishmaniasis,,both,1-10 years,,9615,"In this filtered set, 12 proteins were obtained, all of which were increased in dogs with kidney disease secondary to leishmaniosis，These are potential candidates to become biomarkers for the diagnosis, classification, and monitoring of this disease"
2188,"an uncharacterized protein similar to immunoglobulin lambda fractions in humans (86,7% identity)",protein,leishmaniasis,,both,1-10 years,,9615,"In this filtered set, 12 proteins were obtained, all of which were increased in dogs with kidney disease secondary to leishmaniosis，These are potential candidates to become biomarkers for the diagnosis, classification, and monitoring of this disease"
2189,Glycoprotein 2,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2189,Glycoprotein 2,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2189,Glycoprotein 2,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2189,Glycoprotein 2,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2189,Glycoprotein 2,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2189,Glycoprotein 2,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2189,Glycoprotein 2,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2189,Glycoprotein 2,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2189,Glycoprotein 2,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2182,an immunoglobulin-like domain-containing protein,protein,leishmaniasis,,both,1-10 years,,9615,"In this filtered set, 12 proteins were obtained, all of which were increased in dogs with kidney disease secondary to leishmaniosis，These are potential candidates to become biomarkers for the diagnosis, classification, and monitoring of this disease"
2190,ACTB,protein,lymphoma,American Pit Bull Terrier,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2190,ACTB,protein,lymphoma,Labrador Retriever,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2190,ACTB,protein,lymphoma,Shih Tzu(Chrysanthemum Dog),both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2190,ACTB,protein,lymphoma,Golden Retriever,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2190,ACTB,protein,lymphoma,Shih Tzu(Chrysanthemum Dog),both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2190,ACTB,protein,lymphoma,Saint Bernard,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2190,ACTB,protein,lymphoma,American Pit Bull Terrier,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2190,ACTB,protein,lymphoma,American Cocker Spaniel,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2190,ACTB,protein,lymphoma,Thai Ridgeback,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2190,ACTB,protein,lymphoma,Italian Greyhound,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2190,ACTB,protein,lymphoma,German Shepherd Dog,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2190,ACTB,protein,lymphoma,American Bully,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2190,ACTB,protein,lymphoma,Pomeranian,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2190,ACTB,protein,lymphoma,Labrador Retriever,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2191,β2M,protein,lymphoma,American Pit Bull Terrier,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2191,β2M,protein,lymphoma,Labrador Retriever,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2191,β2M,protein,lymphoma,Shih Tzu(Chrysanthemum Dog),both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2191,β2M,protein,lymphoma,Golden Retriever,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2191,β2M,protein,lymphoma,Shih Tzu(Chrysanthemum Dog),both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2191,β2M,protein,lymphoma,Saint Bernard,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2191,β2M,protein,lymphoma,American Pit Bull Terrier,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2191,β2M,protein,lymphoma,American Cocker Spaniel,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2191,β2M,protein,lymphoma,Thai Ridgeback,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2191,β2M,protein,lymphoma,Italian Greyhound,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2191,β2M,protein,lymphoma,German Shepherd Dog,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2191,β2M,protein,lymphoma,American Bully,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2191,β2M,protein,lymphoma,Pomeranian,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2191,β2M,protein,lymphoma,Labrador Retriever,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2192,TIMP-1,protein,lymphoma,American Pit Bull Terrier,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2192,TIMP-1,protein,lymphoma,Labrador Retriever,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2192,TIMP-1,protein,lymphoma,Shih Tzu(Chrysanthemum Dog),both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2192,TIMP-1,protein,lymphoma,Golden Retriever,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2192,TIMP-1,protein,lymphoma,Shih Tzu(Chrysanthemum Dog),both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2192,TIMP-1,protein,lymphoma,Saint Bernard,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2192,TIMP-1,protein,lymphoma,American Pit Bull Terrier,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2192,TIMP-1,protein,lymphoma,American Cocker Spaniel,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2192,TIMP-1,protein,lymphoma,Thai Ridgeback,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2192,TIMP-1,protein,lymphoma,Italian Greyhound,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2192,TIMP-1,protein,lymphoma,German Shepherd Dog,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2192,TIMP-1,protein,lymphoma,American Bully,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2192,TIMP-1,protein,lymphoma,Pomeranian,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2192,TIMP-1,protein,lymphoma,Labrador Retriever,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2193,CD44 antigen,protein,lymphoma,American Pit Bull Terrier,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2193,CD44 antigen,protein,lymphoma,Labrador Retriever,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2193,CD44 antigen,protein,lymphoma,Shih Tzu(Chrysanthemum Dog),both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2193,CD44 antigen,protein,lymphoma,Golden Retriever,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2193,CD44 antigen,protein,lymphoma,Shih Tzu(Chrysanthemum Dog),both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2193,CD44 antigen,protein,lymphoma,Saint Bernard,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2193,CD44 antigen,protein,lymphoma,American Pit Bull Terrier,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2193,CD44 antigen,protein,lymphoma,American Cocker Spaniel,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2193,CD44 antigen,protein,lymphoma,Thai Ridgeback,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2193,CD44 antigen,protein,lymphoma,Italian Greyhound,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2193,CD44 antigen,protein,lymphoma,German Shepherd Dog,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2193,CD44 antigen,protein,lymphoma,American Bully,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2193,CD44 antigen,protein,lymphoma,Pomeranian,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2193,CD44 antigen,protein,lymphoma,Labrador Retriever,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2194,Ig heavy chain V region GOM,protein,lymphoma,American Pit Bull Terrier,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2194,Ig heavy chain V region GOM,protein,lymphoma,Labrador Retriever,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2194,Ig heavy chain V region GOM,protein,lymphoma,Shih Tzu(Chrysanthemum Dog),both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2194,Ig heavy chain V region GOM,protein,lymphoma,Golden Retriever,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2194,Ig heavy chain V region GOM,protein,lymphoma,Shih Tzu(Chrysanthemum Dog),both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2194,Ig heavy chain V region GOM,protein,lymphoma,Saint Bernard,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2194,Ig heavy chain V region GOM,protein,lymphoma,American Pit Bull Terrier,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2194,Ig heavy chain V region GOM,protein,lymphoma,American Cocker Spaniel,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2194,Ig heavy chain V region GOM,protein,lymphoma,Thai Ridgeback,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2194,Ig heavy chain V region GOM,protein,lymphoma,Italian Greyhound,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2194,Ig heavy chain V region GOM,protein,lymphoma,German Shepherd Dog,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2194,Ig heavy chain V region GOM,protein,lymphoma,American Bully,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2194,Ig heavy chain V region GOM,protein,lymphoma,Pomeranian,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2194,Ig heavy chain V region GOM,protein,lymphoma,Labrador Retriever,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2195,APOC1,protein,lymphoma,American Pit Bull Terrier,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2195,APOC1,protein,lymphoma,Labrador Retriever,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2195,APOC1,protein,lymphoma,Shih Tzu(Chrysanthemum Dog),both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2195,APOC1,protein,lymphoma,Golden Retriever,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2195,APOC1,protein,lymphoma,Shih Tzu(Chrysanthemum Dog),both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2195,APOC1,protein,lymphoma,Saint Bernard,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2195,APOC1,protein,lymphoma,American Pit Bull Terrier,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2195,APOC1,protein,lymphoma,American Cocker Spaniel,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2195,APOC1,protein,lymphoma,Thai Ridgeback,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2195,APOC1,protein,lymphoma,Italian Greyhound,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2195,APOC1,protein,lymphoma,German Shepherd Dog,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2195,APOC1,protein,lymphoma,American Bully,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2195,APOC1,protein,lymphoma,Pomeranian,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2195,APOC1,protein,lymphoma,Labrador Retriever,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2196,APOH,protein,lymphoma,American Pit Bull Terrier,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2196,APOH,protein,lymphoma,Labrador Retriever,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2196,APOH,protein,lymphoma,Shih Tzu(Chrysanthemum Dog),both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2196,APOH,protein,lymphoma,Golden Retriever,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2196,APOH,protein,lymphoma,Shih Tzu(Chrysanthemum Dog),both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2196,APOH,protein,lymphoma,Saint Bernard,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2196,APOH,protein,lymphoma,American Pit Bull Terrier,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2196,APOH,protein,lymphoma,American Cocker Spaniel,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2196,APOH,protein,lymphoma,Thai Ridgeback,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2196,APOH,protein,lymphoma,Italian Greyhound,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2196,APOH,protein,lymphoma,German Shepherd Dog,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2196,APOH,protein,lymphoma,American Bully,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2196,APOH,protein,lymphoma,Pomeranian,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2196,APOH,protein,lymphoma,Labrador Retriever,both,control group:3-9years;lymphoma group:2.3-15.7years,,9615,"These findings were investigated quantitative serum proteomes between B- and T-cell lymphomas using TMT-based MS. ACTB, β2M, APOH, TIMP-1, CD44 antigen, Ig heavy chain V region GOM, and APOC1 are novel candidate proteins and might serve as a lymphoma biomarker in dogs"
2197,IL-1R8,protein,intestinal disorder,,both,,,9615,"highlight the potential utilization of IL-1R8 as a diagnostic, prognostic and therapeutic biomarker for
canine chronic enteropathy ."
1860,urinary neurotransmitter,other,epilepsy,,both,,,9615,Urinary neurotransmitters have the potential to serve as valuable biomarkers for diagnostics and treatment monitoring in canine epilepsy
2198,Pancreatitis-associated protein,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2198,Pancreatitis-associated protein,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2198,Pancreatitis-associated protein,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2198,Pancreatitis-associated protein,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2198,Pancreatitis-associated protein,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2198,Pancreatitis-associated protein,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2198,Pancreatitis-associated protein,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2198,Pancreatitis-associated protein,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2198,Pancreatitis-associated protein,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2199,Ki-67,protein,neoplasm,Labrador Retriever,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Bavarian Mountain Hound,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,English Beagle,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Collie,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,German Shepherd Dog,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,German Boxer,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Cocker Spaniel,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Entlebucher Mountain Dog,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Golden Retriever,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Havanese,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Hovawart,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Hungarian Vizsla,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Miniature Schnauzer,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,German Shepherd Dog,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,American Pit Bull Terrier,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Rhodesian Ridgeback,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Samoyed,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Standard Schnauzer,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Shetland Shepherd Dog,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Welsh Terrier,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Standard Wire-Haired Dachshund,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Jack Russell Terrier,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Labrador Retriever,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Bernese Mountain Dog,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,German Shepherd Dog,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Australian Shepherd,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,English Beagle,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,German Boxer,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Golden Retriever,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Kooikerhondje(Little Cager Dog),,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Podenco Canario(Canary Islands Hound),,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Rottweiler,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Alaskan Malamute,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Cocker Spaniel,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Dandie Dinmont Terrier,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Spanish Greyhound,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,German Shepherd Dog,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Golden Retriever,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Gordon Setter,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Great Dane,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Irish Terrier,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Jack Russell Terrier,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Miniature Schnauzer,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Rhodesian Ridgeback,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2199,Ki-67,protein,neoplasm,Rottweiler,,4.5-16 years,,9615,Our results suggest that serum Ki-67 may be useful as a non-selective screening tool for malignancy in health-checks especially in older dogs or in those with increased breed-specific cancer risk
2200,Urine NGAL,protein,acute kidney failure,Greyhound,M,,28-32kg,9615,"Urinary NGAL, CysC and GGT concentrations, and UPC were consistently elevated within 1 hour of severe hypotension, suggesting that proximal renal tubules are damaged in the earliest stage of ischaemia-reperfusion AKI. Measurement of urinary biomarkers may allow early diagnosis of AKI in anaesthetized dogs."
2201,Urine Cysc,protein,acute kidney failure,Greyhound,M,,28-32kg,9615,"Urinary NGAL, CysC and GGT concentrations, and UPC were consistently elevated within 1 hour of severe hypotension, suggesting that proximal renal tubules are damaged in the earliest stage of ischaemia-reperfusion AKI. Measurement of urinary biomarkers may allow early diagnosis of AKI in anaesthetized dogs."
2202,Urine GGT,protein,acute kidney failure,Greyhound,M,,28-32kg,9615,"Urinary NGAL, CysC and GGT concentrations, and UPC were consistently elevated within 1 hour of severe hypotension, suggesting that proximal renal tubules are damaged in the earliest stage of ischaemia-reperfusion AKI. Measurement of urinary biomarkers may allow early diagnosis of AKI in anaesthetized dogs."
2203,TK1a,protein,hematopoietic and lymphoid system neoplasm,,both,2-14.8 years,,9615,The present results establish that using TK1a and TK1p as biomarkers in dogs with hematological malignancies has significant diagnostic capacity
2204,TK1p,protein,hematopoietic and lymphoid system neoplasm,,both,2-14.8 years,,9615,The present results establish that using TK1a and TK1p as biomarkers in dogs with hematological malignancies has significant diagnostic capacity
676,oleoythanolamide,metabolite,lymphoma,Golden Retriever,both,5.57–16.85years,6.3–54kg,9615,"Overall, dogs with lymphoma have elevated levels of OEA, AEA, and PEA. PEA levels have the potential to be a prognostic biomarker"
676,oleoythanolamide,metabolite,lymphoma,German Boxer,both,5.57–16.85years,6.3–54kg,9615,"Overall, dogs with lymphoma have elevated levels of OEA, AEA, and PEA. PEA levels have the potential to be a prognostic biomarker"
677,N-arachidonoylethanolamine,metabolite,lymphoma,Golden Retriever,both,5.57–16.85years,6.3–54kg,9615,"Overall, dogs with lymphoma have elevated levels of OEA, AEA, and PEA. PEA levels have the potential to be a prognostic biomarker"
677,N-arachidonoylethanolamine,metabolite,lymphoma,German Boxer,both,5.57–16.85years,6.3–54kg,9615,"Overall, dogs with lymphoma have elevated levels of OEA, AEA, and PEA. PEA levels have the potential to be a prognostic biomarker"
678,palmitoylethanolamide,metabolite,lymphoma,Golden Retriever,both,5.57–16.85years,6.3–54kg,9615,"Overall, dogs with lymphoma have elevated levels of OEA, AEA, and PEA. PEA levels have the potential to be a prognostic biomarker"
678,palmitoylethanolamide,metabolite,lymphoma,German Boxer,both,5.57–16.85years,6.3–54kg,9615,"Overall, dogs with lymphoma have elevated levels of OEA, AEA, and PEA. PEA levels have the potential to be a prognostic biomarker"
2205,Angiotensinogen,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2205,Angiotensinogen,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2205,Angiotensinogen,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2205,Angiotensinogen,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2205,Angiotensinogen,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2206,Immunoglobulin lambda light chain variable region,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2206,Immunoglobulin lambda light chain variable region,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2206,Immunoglobulin lambda light chain variable region,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2206,Immunoglobulin lambda light chain variable region,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2206,Immunoglobulin lambda light chain variable region,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2206,Immunoglobulin lambda light chain variable region,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2206,Immunoglobulin lambda light chain variable region,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2206,Immunoglobulin lambda light chain variable region,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2206,Immunoglobulin lambda light chain variable region,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2207,Immunoglobulin iota chain-like,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2207,Immunoglobulin iota chain-like,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2207,Immunoglobulin iota chain-like,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2207,Immunoglobulin iota chain-like,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2207,Immunoglobulin iota chain-like,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2208,Lipopolysaccharide-binding protein,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2208,Lipopolysaccharide-binding protein,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2208,Lipopolysaccharide-binding protein,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2208,Lipopolysaccharide-binding protein,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2208,Lipopolysaccharide-binding protein,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2209,Carboxypeptidase N subunit 2,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2209,Carboxypeptidase N subunit 2,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2209,Carboxypeptidase N subunit 2,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2209,Carboxypeptidase N subunit 2,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2209,Carboxypeptidase N subunit 2,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2210,Carboxypeptidase N catalytic chain isoform X1,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2210,Carboxypeptidase N catalytic chain isoform X1,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2210,Carboxypeptidase N catalytic chain isoform X1,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2210,Carboxypeptidase N catalytic chain isoform X1,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2210,Carboxypeptidase N catalytic chain isoform X1,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2211,Complement C3,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2211,Complement C3,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2211,Complement C3,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2211,Complement C3,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2211,Complement C3,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2212,Argininosuccinate lyase isoform X2,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2212,Argininosuccinate lyase isoform X2,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2212,Argininosuccinate lyase isoform X2,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2212,Argininosuccinate lyase isoform X2,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2212,Argininosuccinate lyase isoform X2,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2213,Inter-alpha-trypsin inhibitor heavy chain H4 isoform X1,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2213,Inter-alpha-trypsin inhibitor heavy chain H4 isoform X1,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2213,Inter-alpha-trypsin inhibitor heavy chain H4 isoform X1,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2213,Inter-alpha-trypsin inhibitor heavy chain H4 isoform X1,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2213,Inter-alpha-trypsin inhibitor heavy chain H4 isoform X1,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2214,Inter-alpha-trypsin inhibitor heavy chain H4 isoform X3,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2214,Inter-alpha-trypsin inhibitor heavy chain H4 isoform X3,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2214,Inter-alpha-trypsin inhibitor heavy chain H4 isoform X3,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2214,Inter-alpha-trypsin inhibitor heavy chain H4 isoform X3,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2214,Inter-alpha-trypsin inhibitor heavy chain H4 isoform X3,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2215,Inter-alpha-trypsin inhibitor heavy chain H2,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2215,Inter-alpha-trypsin inhibitor heavy chain H2,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2215,Inter-alpha-trypsin inhibitor heavy chain H2,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2215,Inter-alpha-trypsin inhibitor heavy chain H2,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2215,Inter-alpha-trypsin inhibitor heavy chain H2,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2429,Haptoglobin,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2429,Haptoglobin,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2429,Haptoglobin,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2429,Haptoglobin,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2429,Haptoglobin,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2429,Haptoglobin,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2429,Haptoglobin,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2429,Haptoglobin,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2429,Haptoglobin,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2216,Complement component C7 isoform X2,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2216,Complement component C7 isoform X2,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2216,Complement component C7 isoform X2,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2216,Complement component C7 isoform X2,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2216,Complement component C7 isoform X2,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2217,Hemopexin,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2217,Hemopexin,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2217,Hemopexin,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2217,Hemopexin,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2217,Hemopexin,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2218,Complement factor D isoform X1,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2218,Complement factor D isoform X1,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2218,Complement factor D isoform X1,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2218,Complement factor D isoform X1,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2218,Complement factor D isoform X1,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2219,Apolipoprotein C-II precursor,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2219,Apolipoprotein C-II precursor,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2219,Apolipoprotein C-II precursor,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2219,Apolipoprotein C-II precursor,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2219,Apolipoprotein C-II precursor,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2220,Pigment epithelium-derived factor,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2220,Pigment epithelium-derived factor,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2220,Pigment epithelium-derived factor,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2220,Pigment epithelium-derived factor,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2220,Pigment epithelium-derived factor,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2221,Complement C4-A,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2221,Complement C4-A,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2221,Complement C4-A,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2221,Complement C4-A,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2221,Complement C4-A,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2222,Complement component C8 alpha chain isoform X1,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2222,Complement component C8 alpha chain isoform X1,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2222,Complement component C8 alpha chain isoform X1,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2222,Complement component C8 alpha chain isoform X1,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2222,Complement component C8 alpha chain isoform X1,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2223,Complement factor I isoform X3 ,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2223,Complement factor I isoform X3 ,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2223,Complement factor I isoform X3 ,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2223,Complement factor I isoform X3 ,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2223,Complement factor I isoform X3 ,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2224,"Actin, cytoplasmic 1",protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2224,"Actin, cytoplasmic 1",protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2224,"Actin, cytoplasmic 1",protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2224,"Actin, cytoplasmic 1",protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2224,"Actin, cytoplasmic 1",protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2208,Lipopolysaccharide-binding protein,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2208,Lipopolysaccharide-binding protein,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2208,Lipopolysaccharide-binding protein,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2208,Lipopolysaccharide-binding protein,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2208,Lipopolysaccharide-binding protein,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2225,Haptoglobin-like,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2225,Haptoglobin-like,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2225,Haptoglobin-like,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2225,Haptoglobin-like,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2225,Haptoglobin-like,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2225,Haptoglobin-like,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2225,Haptoglobin-like,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2225,Haptoglobin-like,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2225,Haptoglobin-like,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2205,Angiotensinogen,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2205,Angiotensinogen,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2205,Angiotensinogen,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2205,Angiotensinogen,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2205,Angiotensinogen,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2226,Nuclear mitotic apparatus protein 1 isoform X2,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2226,Nuclear mitotic apparatus protein 1 isoform X2,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2226,Nuclear mitotic apparatus protein 1 isoform X2,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2226,Nuclear mitotic apparatus protein 1 isoform X2,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2226,Nuclear mitotic apparatus protein 1 isoform X2,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2227,Serum albumin precursor,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2227,Serum albumin precursor,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2227,Serum albumin precursor,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2227,Serum albumin precursor,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2227,Serum albumin precursor,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2228,Serum albumin isoform X1,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2228,Serum albumin isoform X1,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2228,Serum albumin isoform X1,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2228,Serum albumin isoform X1,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2228,Serum albumin isoform X1,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2229,Immunoglobulin lambda-1 light chain isoform X38,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2229,Immunoglobulin lambda-1 light chain isoform X38,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2229,Immunoglobulin lambda-1 light chain isoform X38,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2229,Immunoglobulin lambda-1 light chain isoform X38,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2229,Immunoglobulin lambda-1 light chain isoform X38,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2230,Serum paraoxonase/arylesterase 1,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2230,Serum paraoxonase/arylesterase 1,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2230,Serum paraoxonase/arylesterase 1,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2230,Serum paraoxonase/arylesterase 1,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2230,Serum paraoxonase/arylesterase 1,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2231,Tetranectin,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2231,Tetranectin,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2231,Tetranectin,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2231,Tetranectin,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2231,Tetranectin,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2232,Fetuin-B,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2232,Fetuin-B,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2232,Fetuin-B,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2232,Fetuin-B,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2232,Fetuin-B,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2233,Platelet basic protein precursor,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2233,Platelet basic protein precursor,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2233,Platelet basic protein precursor,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2233,Platelet basic protein precursor,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2233,Platelet basic protein precursor,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2224,"Actin, cytoplasmic 1",protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2224,"Actin, cytoplasmic 1",protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2224,"Actin, cytoplasmic 1",protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2224,"Actin, cytoplasmic 1",protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2224,"Actin, cytoplasmic 1",protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2234,X-prolyl aminopeptidase 2,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2234,X-prolyl aminopeptidase 2,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2234,X-prolyl aminopeptidase 2,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2234,X-prolyl aminopeptidase 2,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2234,X-prolyl aminopeptidase 2,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2234,X-prolyl aminopeptidase 2,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2234,X-prolyl aminopeptidase 2,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2234,X-prolyl aminopeptidase 2,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2234,X-prolyl aminopeptidase 2,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2235,Lactotransferrin,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2235,Lactotransferrin,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2235,Lactotransferrin,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2235,Lactotransferrin,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2235,Lactotransferrin,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2235,Lactotransferrin,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2235,Lactotransferrin,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2235,Lactotransferrin,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2235,Lactotransferrin,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2236,Adiponectin isoform X2,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2236,Adiponectin isoform X2,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2236,Adiponectin isoform X2,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2236,Adiponectin isoform X2,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2236,Adiponectin isoform X2,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2205,Angiotensinogen,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2205,Angiotensinogen,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2205,Angiotensinogen,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2205,Angiotensinogen,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2205,Angiotensinogen,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2237,complement factor H,protein,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2237,complement factor H,protein,"mitral valve prolapse, myxomatous 3",English Bull Terrier,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2237,complement factor H,protein,"mitral valve prolapse, myxomatous 3",Anatolian Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2237,complement factor H,protein,"mitral valve prolapse, myxomatous 3",German Shepherd Dog,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
2237,complement factor H,protein,"mitral valve prolapse, myxomatous 3",Cocker Spaniel,both,3–11 years,11–42 kg,9615,"These proteins indicate different pathophysiological changes occurring at the different stages of CHF, and could be potential biomarkers for diagnosis and treatment monitoring of this condition."
679,5-aminolevulinic acid,metabolite,urinary bladder cancer,Chihuahua,both,10-15years,,9615,"This study showed that 5-ALA can be used to detect urothelial carcinoma cells in dogs with relatively high diagnostic accuracy. Further, the fluorescence intensity of tumor cells caused by 5-ALA correlated with the clinical condition of urothelial carcinoma cases, which suggested that 5-ALA could be used as a prognostic marker for canine urothelial carcinoma."
679,5-aminolevulinic acid,metabolite,urinary bladder cancer,Pug,both,10-15years,,9615,"This study showed that 5-ALA can be used to detect urothelial carcinoma cells in dogs with relatively high diagnostic accuracy. Further, the fluorescence intensity of tumor cells caused by 5-ALA correlated with the clinical condition of urothelial carcinoma cases, which suggested that 5-ALA could be used as a prognostic marker for canine urothelial carcinoma."
679,5-aminolevulinic acid,metabolite,urinary bladder cancer,Toy Poodle,both,10-15years,,9615,"This study showed that 5-ALA can be used to detect urothelial carcinoma cells in dogs with relatively high diagnostic accuracy. Further, the fluorescence intensity of tumor cells caused by 5-ALA correlated with the clinical condition of urothelial carcinoma cases, which suggested that 5-ALA could be used as a prognostic marker for canine urothelial carcinoma."
679,5-aminolevulinic acid,metabolite,urinary bladder cancer,Border Collie,both,10-15years,,9615,"This study showed that 5-ALA can be used to detect urothelial carcinoma cells in dogs with relatively high diagnostic accuracy. Further, the fluorescence intensity of tumor cells caused by 5-ALA correlated with the clinical condition of urothelial carcinoma cases, which suggested that 5-ALA could be used as a prognostic marker for canine urothelial carcinoma."
679,5-aminolevulinic acid,metabolite,urinary bladder cancer,Miniature Schnauzer,both,10-15years,,9615,"This study showed that 5-ALA can be used to detect urothelial carcinoma cells in dogs with relatively high diagnostic accuracy. Further, the fluorescence intensity of tumor cells caused by 5-ALA correlated with the clinical condition of urothelial carcinoma cases, which suggested that 5-ALA could be used as a prognostic marker for canine urothelial carcinoma."
679,5-aminolevulinic acid,metabolite,urinary bladder cancer,Toy Poodle,both,10-15years,,9615,"This study showed that 5-ALA can be used to detect urothelial carcinoma cells in dogs with relatively high diagnostic accuracy. Further, the fluorescence intensity of tumor cells caused by 5-ALA correlated with the clinical condition of urothelial carcinoma cases, which suggested that 5-ALA could be used as a prognostic marker for canine urothelial carcinoma."
679,5-aminolevulinic acid,metabolite,urinary bladder cancer,Miniature Pinscher,both,10-15years,,9615,"This study showed that 5-ALA can be used to detect urothelial carcinoma cells in dogs with relatively high diagnostic accuracy. Further, the fluorescence intensity of tumor cells caused by 5-ALA correlated with the clinical condition of urothelial carcinoma cases, which suggested that 5-ALA could be used as a prognostic marker for canine urothelial carcinoma."
679,5-aminolevulinic acid,metabolite,urinary bladder cancer,Shetland Shepherd Dog,both,10-15years,,9615,"This study showed that 5-ALA can be used to detect urothelial carcinoma cells in dogs with relatively high diagnostic accuracy. Further, the fluorescence intensity of tumor cells caused by 5-ALA correlated with the clinical condition of urothelial carcinoma cases, which suggested that 5-ALA could be used as a prognostic marker for canine urothelial carcinoma."
679,5-aminolevulinic acid,metabolite,urinary bladder cancer,Cavalier King Charles Spaniel,both,10-15years,,9615,"This study showed that 5-ALA can be used to detect urothelial carcinoma cells in dogs with relatively high diagnostic accuracy. Further, the fluorescence intensity of tumor cells caused by 5-ALA correlated with the clinical condition of urothelial carcinoma cases, which suggested that 5-ALA could be used as a prognostic marker for canine urothelial carcinoma."
679,5-aminolevulinic acid,metabolite,urinary bladder cancer,Cairn Terrier,both,10-15years,,9615,"This study showed that 5-ALA can be used to detect urothelial carcinoma cells in dogs with relatively high diagnostic accuracy. Further, the fluorescence intensity of tumor cells caused by 5-ALA correlated with the clinical condition of urothelial carcinoma cases, which suggested that 5-ALA could be used as a prognostic marker for canine urothelial carcinoma."
679,5-aminolevulinic acid,metabolite,urinary bladder cancer,Papillon(Continental Toy Spaniel),both,10-15years,,9615,"This study showed that 5-ALA can be used to detect urothelial carcinoma cells in dogs with relatively high diagnostic accuracy. Further, the fluorescence intensity of tumor cells caused by 5-ALA correlated with the clinical condition of urothelial carcinoma cases, which suggested that 5-ALA could be used as a prognostic marker for canine urothelial carcinoma."
679,5-aminolevulinic acid,metabolite,urinary bladder cancer,Maltese,both,10-15years,,9615,"This study showed that 5-ALA can be used to detect urothelial carcinoma cells in dogs with relatively high diagnostic accuracy. Further, the fluorescence intensity of tumor cells caused by 5-ALA correlated with the clinical condition of urothelial carcinoma cases, which suggested that 5-ALA could be used as a prognostic marker for canine urothelial carcinoma."
2238,Anti-Müllerian hormone,protein,fertility trait,,M,1-13years,,9615,The negative associations between serum AMH and semen motility and morphology found in this study make AMH a potential biomarker of spermatogenesis and thus predictor of semen quality in dogs when serum AMH concentration is low
2239,AgNOR,protein,leishmaniasis,,,,,9615,We propose that the detection of AgNOR proteins could be used to better estimate the kidney tubular damage at the time of examination in Leishmania-infected dogs as a marker to estimate renal impairment in dogs with CanL
1032,cfa-miR-1-3p,miRNA,breast neoplasm,,F,,,9615,"Accordingly, we suggest these four miRNAs are promising potential biomarker candidates for canine mammary gland tumors warranting further investigation."
1033,cfa-miR-133a-3p,miRNA,breast neoplasm,,F,,,9615,"Accordingly, we suggest these four miRNAs are promising potential biomarker candidates for canine mammary gland tumors warranting further investigation."
1034,cfa-miR-133b-3p,miRNA,breast neoplasm,,F,,,9615,"Accordingly, we suggest these four miRNAs are promising potential biomarker candidates for canine mammary gland tumors warranting further investigation."
1035,cfa-miR-133c-3p,miRNA,breast neoplasm,,F,,,9615,"Accordingly, we suggest these four miRNAs are promising potential biomarker candidates for canine mammary gland tumors warranting further investigation."
2240,Carboxypeptidase A1,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2240,Carboxypeptidase A1,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2240,Carboxypeptidase A1,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2240,Carboxypeptidase A1,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2240,Carboxypeptidase A1,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2240,Carboxypeptidase A1,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2240,Carboxypeptidase A1,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2240,Carboxypeptidase A1,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2240,Carboxypeptidase A1,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2241,ΔNp63,protein,transitional cell carcinoma,Shih Tzu(Chrysanthemum Dog),,the mean age for dogs with polypoid cystitis and TCC was 9.6 ± 3.7 and 9.7 ± 2.4 years,,9615,"These results indicate that ΔNp63 expression could serve as a valuable biomarker for invasion, metastasis, and prognosis of canine TCC of the urinary bladder"
2241,ΔNp63,protein,transitional cell carcinoma,Miniature Schnauzer,,the mean age for dogs with polypoid cystitis and TCC was 9.6 ± 3.7 and 9.7 ± 2.4 years,,9615,"These results indicate that ΔNp63 expression could serve as a valuable biomarker for invasion, metastasis, and prognosis of canine TCC of the urinary bladder"
2241,ΔNp63,protein,transitional cell carcinoma,Papillon(Continental Toy Spaniel),,the mean age for dogs with polypoid cystitis and TCC was 9.6 ± 3.7 and 9.7 ± 2.4 years,,9615,"These results indicate that ΔNp63 expression could serve as a valuable biomarker for invasion, metastasis, and prognosis of canine TCC of the urinary bladder"
2241,ΔNp63,protein,transitional cell carcinoma,Siberian Husky,,the mean age for dogs with polypoid cystitis and TCC was 9.6 ± 3.7 and 9.7 ± 2.4 years,,9615,"These results indicate that ΔNp63 expression could serve as a valuable biomarker for invasion, metastasis, and prognosis of canine TCC of the urinary bladder"
2241,ΔNp63,protein,transitional cell carcinoma,Shetland Shepherd Dog,,the mean age for dogs with polypoid cystitis and TCC was 9.6 ± 3.7 and 9.7 ± 2.4 years,,9615,"These results indicate that ΔNp63 expression could serve as a valuable biomarker for invasion, metastasis, and prognosis of canine TCC of the urinary bladder"
2241,ΔNp63,protein,transitional cell carcinoma,Japanese Shiba Inu,,the mean age for dogs with polypoid cystitis and TCC was 9.6 ± 3.7 and 9.7 ± 2.4 years,,9615,"These results indicate that ΔNp63 expression could serve as a valuable biomarker for invasion, metastasis, and prognosis of canine TCC of the urinary bladder"
2241,ΔNp63,protein,transitional cell carcinoma,Maltese,,the mean age for dogs with polypoid cystitis and TCC was 9.6 ± 3.7 and 9.7 ± 2.4 years,,9615,"These results indicate that ΔNp63 expression could serve as a valuable biomarker for invasion, metastasis, and prognosis of canine TCC of the urinary bladder"
2241,ΔNp63,protein,transitional cell carcinoma,English Beagle,,the mean age for dogs with polypoid cystitis and TCC was 9.6 ± 3.7 and 9.7 ± 2.4 years,,9615,"These results indicate that ΔNp63 expression could serve as a valuable biomarker for invasion, metastasis, and prognosis of canine TCC of the urinary bladder"
2241,ΔNp63,protein,transitional cell carcinoma,Dalmatian,,the mean age for dogs with polypoid cystitis and TCC was 9.6 ± 3.7 and 9.7 ± 2.4 years,,9615,"These results indicate that ΔNp63 expression could serve as a valuable biomarker for invasion, metastasis, and prognosis of canine TCC of the urinary bladder"
2241,ΔNp63,protein,transitional cell carcinoma,French Bulldog,,the mean age for dogs with polypoid cystitis and TCC was 9.6 ± 3.7 and 9.7 ± 2.4 years,,9615,"These results indicate that ΔNp63 expression could serve as a valuable biomarker for invasion, metastasis, and prognosis of canine TCC of the urinary bladder"
2241,ΔNp63,protein,transitional cell carcinoma,Great Pyrenees,,the mean age for dogs with polypoid cystitis and TCC was 9.6 ± 3.7 and 9.7 ± 2.4 years,,9615,"These results indicate that ΔNp63 expression could serve as a valuable biomarker for invasion, metastasis, and prognosis of canine TCC of the urinary bladder"
2241,ΔNp63,protein,transitional cell carcinoma,Miniature Dachshund,,the mean age for dogs with polypoid cystitis and TCC was 9.6 ± 3.7 and 9.7 ± 2.4 years,,9615,"These results indicate that ΔNp63 expression could serve as a valuable biomarker for invasion, metastasis, and prognosis of canine TCC of the urinary bladder"
2241,ΔNp63,protein,transitional cell carcinoma,Miniature Pinscher,,the mean age for dogs with polypoid cystitis and TCC was 9.6 ± 3.7 and 9.7 ± 2.4 years,,9615,"These results indicate that ΔNp63 expression could serve as a valuable biomarker for invasion, metastasis, and prognosis of canine TCC of the urinary bladder"
2241,ΔNp63,protein,transitional cell carcinoma,Pomeranian,,the mean age for dogs with polypoid cystitis and TCC was 9.6 ± 3.7 and 9.7 ± 2.4 years,,9615,"These results indicate that ΔNp63 expression could serve as a valuable biomarker for invasion, metastasis, and prognosis of canine TCC of the urinary bladder"
2241,ΔNp63,protein,transitional cell carcinoma,Samoyed,,the mean age for dogs with polypoid cystitis and TCC was 9.6 ± 3.7 and 9.7 ± 2.4 years,,9615,"These results indicate that ΔNp63 expression could serve as a valuable biomarker for invasion, metastasis, and prognosis of canine TCC of the urinary bladder"
2241,ΔNp63,protein,transitional cell carcinoma,Scottish Terrier,,the mean age for dogs with polypoid cystitis and TCC was 9.6 ± 3.7 and 9.7 ± 2.4 years,,9615,"These results indicate that ΔNp63 expression could serve as a valuable biomarker for invasion, metastasis, and prognosis of canine TCC of the urinary bladder"
2241,ΔNp63,protein,transitional cell carcinoma,Japanese Spitz,,the mean age for dogs with polypoid cystitis and TCC was 9.6 ± 3.7 and 9.7 ± 2.4 years,,9615,"These results indicate that ΔNp63 expression could serve as a valuable biomarker for invasion, metastasis, and prognosis of canine TCC of the urinary bladder"
2241,ΔNp63,protein,transitional cell carcinoma,West Highland White Terrier,,the mean age for dogs with polypoid cystitis and TCC was 9.6 ± 3.7 and 9.7 ± 2.4 years,,9615,"These results indicate that ΔNp63 expression could serve as a valuable biomarker for invasion, metastasis, and prognosis of canine TCC of the urinary bladder"
2242,PCT,protein,dysentery,,both,1-15 years,,9615,"The results of the present study indicate that PCT and Bdef2 are potential biomarkers that can provide information on the severity, course, and prognosis of acute diarrhea in dogs"
2243,Bdef2,protein,dysentery,,both,1-15 years,,9615,"The results of the present study indicate that PCT and Bdef2 are potential biomarkers that can provide information on the severity, course, and prognosis of acute diarrhea in dogs"
2244,cardiac troponin I,protein,perinatal asphyxia,,,,,9615,"This study showed that asphyxiated
newborn dogs have higher serum cTnI levels than nonasphyxiated newborn dogs; thus, the cTnI can be used as a marker of severe hypoxia and ischemic myocardial damage in newborn dogs."
2245,Podoplanin,protein,gastrointestinal stromal tumor,Golden Retriever,both,4-14years,2.6-46.3kg,9615,"As in humans, PDPN may be an effective marker for stromal sarcomas of the canine spleen and immunopositivity suggests a fibroblastic reticular or follicular dendritic cell origin"
2245,Podoplanin,protein,gastrointestinal stromal tumor,English Cocker Spaniel,both,4-14years,2.6-46.3kg,9615,"As in humans, PDPN may be an effective marker for stromal sarcomas of the canine spleen and immunopositivity suggests a fibroblastic reticular or follicular dendritic cell origin"
2245,Podoplanin,protein,gastrointestinal stromal tumor,Maltese,both,4-14years,2.6-46.3kg,9615,"As in humans, PDPN may be an effective marker for stromal sarcomas of the canine spleen and immunopositivity suggests a fibroblastic reticular or follicular dendritic cell origin"
2246,eAGR2,protein,breast carcinoma,,F,,,9615,"Area under the time-dependent ROC curve (AUC) of serum eAGR2 level as a prognostic indicator was 0.839. Collectively, this study uncovered that serum eAGR2 level is significantly associated with an adverse outcome of MMT dogs and holds a predictive potential in MMT prognosis"
2247,TFF1,protein,gastric neoplasm,German Boxer,both,9-16 years,,9615,"These findings suggest that TFF1 protein may play a role in canine gastric carcinogenesis, and further studies are necessary to define its usefulness as a prognostic indicator in canine gastric carcinoma."
2247,TFF1,protein,gastric neoplasm,Basset Hound,both,9-16 years,,9615,"These findings suggest that TFF1 protein may play a role in canine gastric carcinogenesis, and further studies are necessary to define its usefulness as a prognostic indicator in canine gastric carcinoma."
2247,TFF1,protein,gastric neoplasm,Yorkshire Terrier,both,9-16 years,,9615,"These findings suggest that TFF1 protein may play a role in canine gastric carcinogenesis, and further studies are necessary to define its usefulness as a prognostic indicator in canine gastric carcinoma."
2247,TFF1,protein,gastric neoplasm,Poodle,both,9-16 years,,9615,"These findings suggest that TFF1 protein may play a role in canine gastric carcinogenesis, and further studies are necessary to define its usefulness as a prognostic indicator in canine gastric carcinoma."
2247,TFF1,protein,gastric neoplasm,German Shepherd Dog,both,9-16 years,,9615,"These findings suggest that TFF1 protein may play a role in canine gastric carcinogenesis, and further studies are necessary to define its usefulness as a prognostic indicator in canine gastric carcinoma."
2247,TFF1,protein,gastric neoplasm,Irish Setter,both,9-16 years,,9615,"These findings suggest that TFF1 protein may play a role in canine gastric carcinogenesis, and further studies are necessary to define its usefulness as a prognostic indicator in canine gastric carcinoma."
2247,TFF1,protein,gastric neoplasm,Dogo Argentino,both,9-16 years,,9615,"These findings suggest that TFF1 protein may play a role in canine gastric carcinogenesis, and further studies are necessary to define its usefulness as a prognostic indicator in canine gastric carcinoma."
2247,TFF1,protein,gastric neoplasm,Cocker Spaniel,both,9-16 years,,9615,"These findings suggest that TFF1 protein may play a role in canine gastric carcinogenesis, and further studies are necessary to define its usefulness as a prognostic indicator in canine gastric carcinoma."
2247,TFF1,protein,gastric neoplasm,Chow Chow,both,9-16 years,,9615,"These findings suggest that TFF1 protein may play a role in canine gastric carcinogenesis, and further studies are necessary to define its usefulness as a prognostic indicator in canine gastric carcinoma."
2247,TFF1,protein,gastric neoplasm,Shih Tzu(Chrysanthemum Dog),both,9-16 years,,9615,"These findings suggest that TFF1 protein may play a role in canine gastric carcinogenesis, and further studies are necessary to define its usefulness as a prognostic indicator in canine gastric carcinoma."
2247,TFF1,protein,gastric neoplasm,English Bulldog,both,9-16 years,,9615,"These findings suggest that TFF1 protein may play a role in canine gastric carcinogenesis, and further studies are necessary to define its usefulness as a prognostic indicator in canine gastric carcinoma."
2247,TFF1,protein,gastric neoplasm,Labrador Retriever,both,9-16 years,,9615,"These findings suggest that TFF1 protein may play a role in canine gastric carcinogenesis, and further studies are necessary to define its usefulness as a prognostic indicator in canine gastric carcinoma."
2247,TFF1,protein,gastric neoplasm,Chinese Shar-Pei,both,9-16 years,,9615,"These findings suggest that TFF1 protein may play a role in canine gastric carcinogenesis, and further studies are necessary to define its usefulness as a prognostic indicator in canine gastric carcinoma."
2247,TFF1,protein,gastric neoplasm,Belgian Shepherd Dog,both,9-16 years,,9615,"These findings suggest that TFF1 protein may play a role in canine gastric carcinogenesis, and further studies are necessary to define its usefulness as a prognostic indicator in canine gastric carcinoma."
2247,TFF1,protein,gastric neoplasm,Golden Retriever,both,9-16 years,,9615,"These findings suggest that TFF1 protein may play a role in canine gastric carcinogenesis, and further studies are necessary to define its usefulness as a prognostic indicator in canine gastric carcinoma."
2247,TFF1,protein,gastric neoplasm,Siberian Husky,both,9-16 years,,9615,"These findings suggest that TFF1 protein may play a role in canine gastric carcinogenesis, and further studies are necessary to define its usefulness as a prognostic indicator in canine gastric carcinoma."
2247,TFF1,protein,gastric neoplasm,Akita,both,9-16 years,,9615,"These findings suggest that TFF1 protein may play a role in canine gastric carcinogenesis, and further studies are necessary to define its usefulness as a prognostic indicator in canine gastric carcinoma."
2247,TFF1,protein,gastric neoplasm,Collie,both,9-16 years,,9615,"These findings suggest that TFF1 protein may play a role in canine gastric carcinogenesis, and further studies are necessary to define its usefulness as a prognostic indicator in canine gastric carcinoma."
2247,TFF1,protein,gastric neoplasm,Alaskan Malamute,both,9-16 years,,9615,"These findings suggest that TFF1 protein may play a role in canine gastric carcinogenesis, and further studies are necessary to define its usefulness as a prognostic indicator in canine gastric carcinoma."
2247,TFF1,protein,gastric neoplasm,English Pointer,both,9-16 years,,9615,"These findings suggest that TFF1 protein may play a role in canine gastric carcinogenesis, and further studies are necessary to define its usefulness as a prognostic indicator in canine gastric carcinoma."
2247,TFF1,protein,gastric neoplasm,West Highland White Terrier,both,9-16 years,,9615,"These findings suggest that TFF1 protein may play a role in canine gastric carcinogenesis, and further studies are necessary to define its usefulness as a prognostic indicator in canine gastric carcinoma."
2247,TFF1,protein,gastric neoplasm,Poodle,both,9-16 years,,9615,"These findings suggest that TFF1 protein may play a role in canine gastric carcinogenesis, and further studies are necessary to define its usefulness as a prognostic indicator in canine gastric carcinoma."
2247,TFF1,protein,gastric neoplasm,Miniature Poodle,both,9-16 years,,9615,"These findings suggest that TFF1 protein may play a role in canine gastric carcinogenesis, and further studies are necessary to define its usefulness as a prognostic indicator in canine gastric carcinoma."
2415,CRP,protein,primary intestinal lymphangiectasia,,both,3-8 years,,9615,"Although further studies are needed, C-reactive protein, bacterial lipopolysaccharide, cleaved cytokeratin 18, and zonulin (in both serum and feces)
resulted as promising markers for canine IL; similarly, fecal proteomics represents a road worthy of being pursued in the search for candidate biomarkers."
2248,bacterial LPS,protein,primary intestinal lymphangiectasia,,both,3-8 years,,9615,"Although further studies are needed, C-reactive protein, bacterial lipopolysaccharide, cleaved cytokeratin 18, and zonulin (in both serum and feces)
resulted as promising markers for canine IL; similarly, fecal proteomics represents a road worthy of being pursued in the search for candidate biomarkers."
2249,cCK18,protein,primary intestinal lymphangiectasia,,both,3-8 years,,9615,"Although further studies are needed, C-reactive protein, bacterial lipopolysaccharide, cleaved cytokeratin 18, and zonulin (in both serum and feces)
resulted as promising markers for canine IL; similarly, fecal proteomics represents a road worthy of being pursued in the search for candidate biomarkers."
2250,Carboxypeptidase B1,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2250,Carboxypeptidase B1,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2250,Carboxypeptidase B1,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2250,Carboxypeptidase B1,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2250,Carboxypeptidase B1,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2250,Carboxypeptidase B1,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2250,Carboxypeptidase B1,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2250,Carboxypeptidase B1,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2250,Carboxypeptidase B1,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
1861,zonulin,other,primary intestinal lymphangiectasia,,both,3-8 years,,9615,"Although further studies are needed, C-reactive protein, bacterial lipopolysaccharide, cleaved cytokeratin 18, and zonulin (in both serum and feces)
resulted as promising markers for canine IL; similarly, fecal proteomics represents a road worthy of being pursued in the search for candidate biomarkers."
2251,arginase-1,protein,hepatocellular carcinoma,,,,,9615,"The results of this study suggest that downregulation of arginase-1 and 
P-glycoprotein is a feature of canine hepatocellular carcinoma; thus, those markers are potential candidates for use in differentiating hepatocellular carcinomas from non-neoplastic liver lesions in dogs"
2252,P-glycoprotein,protein,hepatocellular carcinoma,,,,,9615,"The results of this study suggest that downregulation of arginase-1 and 
P-glycoprotein is a feature of canine hepatocellular carcinoma; thus, those markers are potential candidates for use in differentiating hepatocellular carcinomas from non-neoplastic liver lesions in dogs"
2253,Antioxidant enzyme SOD,protein,obstructive lung disease,French Bulldog,both,1.08-8.88years,5.75-12.53kg,9615,Antioxidant enzyme SOD may play an important role in BOAS and can be used as a biomarker of antioxidant status assessment in BOAS patients.
2253,Antioxidant enzyme SOD,protein,obstructive lung disease,Pug,both,1.08-8.88years,5.75-12.53kg,9615,Antioxidant enzyme SOD may play an important role in BOAS and can be used as a biomarker of antioxidant status assessment in BOAS patients.
2253,Antioxidant enzyme SOD,protein,obstructive lung disease,Boston Terrier,both,1.08-8.88years,5.75-12.53kg,9615,Antioxidant enzyme SOD may play an important role in BOAS and can be used as a biomarker of antioxidant status assessment in BOAS patients.
2253,Antioxidant enzyme SOD,protein,obstructive lung disease,English Bulldog,both,1.08-8.88years,5.75-12.53kg,9615,Antioxidant enzyme SOD may play an important role in BOAS and can be used as a biomarker of antioxidant status assessment in BOAS patients.
2253,Antioxidant enzyme SOD,protein,obstructive lung disease,Yorkshire Terrier,both,1.08-8.88years,5.75-12.53kg,9615,Antioxidant enzyme SOD may play an important role in BOAS and can be used as a biomarker of antioxidant status assessment in BOAS patients.
2253,Antioxidant enzyme SOD,protein,obstructive lung disease,Japanese Chin(Japanese Spaniel),both,1.08-8.88years,5.75-12.53kg,9615,Antioxidant enzyme SOD may play an important role in BOAS and can be used as a biomarker of antioxidant status assessment in BOAS patients.
2253,Antioxidant enzyme SOD,protein,obstructive lung disease,Cavalier King Charles Spaniel,both,1.08-8.88years,5.75-12.53kg,9615,Antioxidant enzyme SOD may play an important role in BOAS and can be used as a biomarker of antioxidant status assessment in BOAS patients.
2254,superoxide dismutase,protein,babesiosis,,1-7years,,,9615,"Oxidative stress can be posited as one of the mechanisms leading to anaemia in dogs with babesiosis, and therefore antioxidant biomarker and copper and zinc concentrations could be used as indicators of disease severity and prognostic markers."
680,copper,metabolite,babesiosis,,1-7years,,,9615,"Oxidative stress can be posited as one of the mechanisms leading to anaemia in dogs with babesiosis, and therefore antioxidant biomarker and copper and zinc concentrations could be used as indicators of disease severity and prognostic markers."
681,zinc,metabolite,babesiosis,,1-7years,,,9615,"Oxidative stress can be posited as one of the mechanisms leading to anaemia in dogs with babesiosis, and therefore antioxidant biomarker and copper and zinc concentrations could be used as indicators of disease severity and prognostic markers."
499,lnc-42060,lncRNA,breast neoplasm,,,,,9615,lnc-42060 served as a novel marker that may be used as an important biomarker for future diagnosis and treatment.
2255,DEPDC1B,protein,lymphoma,,,,,9615,"In conclusion, we identified DEPDC1B as overexpressed in canine lymphoma. Our findings suggest that DEPDC1B may serve as a new biomarker or therapeutic target. Further study will be required to confirm the role and functional activity of DEPDC1B with respect to oncogenic mechanisms and progression of malignancy"
1862,Vascular endothelial growth factor,other,central nervous system cancer,,both,0.3-15years,2.6-56.6kg,9615,Cerebrospinal fluid VEGF concentrations may serve as a marker of neoplastic and inflammatory CNS disorders relative to other conditions
2256,Sox-2,protein,cutaneous mastocytoma,,,,,9615,The study finding has indicated that the level of Sox-2 expression may be a useful tumorigenic and prognostic biomarker because it correlates to the 2-tier grades but not dog breeds.
2257,NP1,protein,mucopolysaccharidosis type 1,,,,,9615,"this study demonstrates that the
determination of the CSF levels of NP1, Ch3L1, CD14, IGFBP2,possibly also of other upregulated proteins identified here could
be helpful for assessing the course of the disease in infants having received gene therapy."
2258,Ch3L1,protein,mucopolysaccharidosis type 1,,,,,9615,"this study demonstrates that the
determination of the CSF levels of NP1, Ch3L1, CD14, IGFBP2,possibly also of other upregulated proteins identified here could
be helpful for assessing the course of the disease in infants having received gene therapy."
2259,CD14,protein,mucopolysaccharidosis type 1,,,,,9615,"this study demonstrates that the
determination of the CSF levels of NP1, Ch3L1, CD14, IGFBP2,possibly also of other upregulated proteins identified here could
be helpful for assessing the course of the disease in infants having received gene therapy."
2421,IGFBP2,protein,mucopolysaccharidosis type 1,,,,,9615,"this study demonstrates that the
determination of the CSF levels of NP1, Ch3L1, CD14, IGFBP2,possibly also of other upregulated proteins identified here could
be helpful for assessing the course of the disease in infants having received gene therapy."
186,CDKN2A ,gene,aging,Border Collie,both,Study1:1-18years;Study2:9months-15years,2.1-37.4kg,9615,"Our results suggest that CDKN2A might be a potential blood-borne biomarker of aging in dogs, although the
validation and optimization will require further, more focused research"
186,CDKN2A ,gene,aging,German Boxer,both,Study1:1-18years;Study2:9months-15years,2.1-37.4kg,9615,"Our results suggest that CDKN2A might be a potential blood-borne biomarker of aging in dogs, although the
validation and optimization will require further, more focused research"
186,CDKN2A ,gene,aging,Chihuahua,both,Study1:1-18years;Study2:9months-15years,2.1-37.4kg,9615,"Our results suggest that CDKN2A might be a potential blood-borne biomarker of aging in dogs, although the
validation and optimization will require further, more focused research"
186,CDKN2A ,gene,aging,English Beagle,both,Study1:1-18years;Study2:9months-15years,2.1-37.4kg,9615,"Our results suggest that CDKN2A might be a potential blood-borne biomarker of aging in dogs, although the
validation and optimization will require further, more focused research"
186,CDKN2A ,gene,aging,German Shepherd Dog,both,Study1:1-18years;Study2:9months-15years,2.1-37.4kg,9615,"Our results suggest that CDKN2A might be a potential blood-borne biomarker of aging in dogs, although the
validation and optimization will require further, more focused research"
186,CDKN2A ,gene,aging,Gordon Setter,both,Study1:1-18years;Study2:9months-15years,2.1-37.4kg,9615,"Our results suggest that CDKN2A might be a potential blood-borne biomarker of aging in dogs, although the
validation and optimization will require further, more focused research"
186,CDKN2A ,gene,aging,Yorkshire Terrier,both,Study1:1-18years;Study2:9months-15years,2.1-37.4kg,9615,"Our results suggest that CDKN2A might be a potential blood-borne biomarker of aging in dogs, although the
validation and optimization will require further, more focused research"
186,CDKN2A ,gene,aging,Doberman Pinscher,both,Study1:1-18years;Study2:9months-15years,2.1-37.4kg,9615,"Our results suggest that CDKN2A might be a potential blood-borne biomarker of aging in dogs, although the
validation and optimization will require further, more focused research"
186,CDKN2A ,gene,aging,Golden Retriever,both,Study1:1-18years;Study2:9months-15years,2.1-37.4kg,9615,"Our results suggest that CDKN2A might be a potential blood-borne biomarker of aging in dogs, although the
validation and optimization will require further, more focused research"
186,CDKN2A ,gene,aging,Hungarian Vizsla,both,Study1:1-18years;Study2:9months-15years,2.1-37.4kg,9615,"Our results suggest that CDKN2A might be a potential blood-borne biomarker of aging in dogs, although the
validation and optimization will require further, more focused research"
186,CDKN2A ,gene,aging,Labrador Retriever,both,Study1:1-18years;Study2:9months-15years,2.1-37.4kg,9615,"Our results suggest that CDKN2A might be a potential blood-borne biomarker of aging in dogs, although the
validation and optimization will require further, more focused research"
186,CDKN2A ,gene,aging,Dachshund,both,Study1:1-18years;Study2:9months-15years,2.1-37.4kg,9615,"Our results suggest that CDKN2A might be a potential blood-borne biomarker of aging in dogs, although the
validation and optimization will require further, more focused research"
186,CDKN2A ,gene,aging,Small Munsterlander Pointer,both,Study1:1-18years;Study2:9months-15years,2.1-37.4kg,9615,"Our results suggest that CDKN2A might be a potential blood-borne biomarker of aging in dogs, although the
validation and optimization will require further, more focused research"
186,CDKN2A ,gene,aging,Border Collie,both,Study1:1-18years;Study2:9months-15years,2.1-37.4kg,9615,"Our results suggest that CDKN2A might be a potential blood-borne biomarker of aging in dogs, although the
validation and optimization will require further, more focused research"
2260,pSTAT3,protein,intestinal disorder,English Beagle,both,0.5-11years,3.5-38kg,9615,"We therefore conclude that pSTAT3 may be useful as an additional activity
marker of inflammation in dogs with CIE and may act as a possible therapeutic target in the future"
2260,pSTAT3,protein,intestinal disorder,German Boxer,both,0.5-11years,3.5-38kg,9615,"We therefore conclude that pSTAT3 may be useful as an additional activity
marker of inflammation in dogs with CIE and may act as a possible therapeutic target in the future"
2260,pSTAT3,protein,intestinal disorder,French Bulldog,both,0.5-11years,3.5-38kg,9615,"We therefore conclude that pSTAT3 may be useful as an additional activity
marker of inflammation in dogs with CIE and may act as a possible therapeutic target in the future"
2260,pSTAT3,protein,intestinal disorder,Belgian Shepherd Dog,both,0.5-11years,3.5-38kg,9615,"We therefore conclude that pSTAT3 may be useful as an additional activity
marker of inflammation in dogs with CIE and may act as a possible therapeutic target in the future"
2260,pSTAT3,protein,intestinal disorder,Jack Russell Terrier,both,0.5-11years,3.5-38kg,9615,"We therefore conclude that pSTAT3 may be useful as an additional activity
marker of inflammation in dogs with CIE and may act as a possible therapeutic target in the future"
2260,pSTAT3,protein,intestinal disorder,Labrador Retriever,both,0.5-11years,3.5-38kg,9615,"We therefore conclude that pSTAT3 may be useful as an additional activity
marker of inflammation in dogs with CIE and may act as a possible therapeutic target in the future"
2260,pSTAT3,protein,intestinal disorder,American Bulldog,both,0.5-11years,3.5-38kg,9615,"We therefore conclude that pSTAT3 may be useful as an additional activity
marker of inflammation in dogs with CIE and may act as a possible therapeutic target in the future"
2260,pSTAT3,protein,intestinal disorder,English Bull Terrier,both,0.5-11years,3.5-38kg,9615,"We therefore conclude that pSTAT3 may be useful as an additional activity
marker of inflammation in dogs with CIE and may act as a possible therapeutic target in the future"
2260,pSTAT3,protein,intestinal disorder,Spanish Greyhound,both,0.5-11years,3.5-38kg,9615,"We therefore conclude that pSTAT3 may be useful as an additional activity
marker of inflammation in dogs with CIE and may act as a possible therapeutic target in the future"
2260,pSTAT3,protein,intestinal disorder,German Shepherd Dog,both,0.5-11years,3.5-38kg,9615,"We therefore conclude that pSTAT3 may be useful as an additional activity
marker of inflammation in dogs with CIE and may act as a possible therapeutic target in the future"
2260,pSTAT3,protein,intestinal disorder,Rottweiler,both,0.5-11years,3.5-38kg,9615,"We therefore conclude that pSTAT3 may be useful as an additional activity
marker of inflammation in dogs with CIE and may act as a possible therapeutic target in the future"
2260,pSTAT3,protein,intestinal disorder,Chinese Shar-Pei,both,0.5-11years,3.5-38kg,9615,"We therefore conclude that pSTAT3 may be useful as an additional activity
marker of inflammation in dogs with CIE and may act as a possible therapeutic target in the future"
2260,pSTAT3,protein,intestinal disorder,Border Terrier,both,0.5-11years,3.5-38kg,9615,"We therefore conclude that pSTAT3 may be useful as an additional activity
marker of inflammation in dogs with CIE and may act as a possible therapeutic target in the future"
2260,pSTAT3,protein,intestinal disorder,Irish Blue Terrier,both,0.5-11years,3.5-38kg,9615,"We therefore conclude that pSTAT3 may be useful as an additional activity
marker of inflammation in dogs with CIE and may act as a possible therapeutic target in the future"
2260,pSTAT3,protein,intestinal disorder,Papillon(Continental Toy Spaniel),both,0.5-11years,3.5-38kg,9615,"We therefore conclude that pSTAT3 may be useful as an additional activity
marker of inflammation in dogs with CIE and may act as a possible therapeutic target in the future"
2260,pSTAT3,protein,intestinal disorder,Pug,both,0.5-11years,3.5-38kg,9615,"We therefore conclude that pSTAT3 may be useful as an additional activity
marker of inflammation in dogs with CIE and may act as a possible therapeutic target in the future"
2260,pSTAT3,protein,intestinal disorder,Rottweiler,both,0.5-11years,3.5-38kg,9615,"We therefore conclude that pSTAT3 may be useful as an additional activity
marker of inflammation in dogs with CIE and may act as a possible therapeutic target in the future"
2260,pSTAT3,protein,intestinal disorder,Staffordshire Bull Terrier,both,0.5-11years,3.5-38kg,9615,"We therefore conclude that pSTAT3 may be useful as an additional activity
marker of inflammation in dogs with CIE and may act as a possible therapeutic target in the future"
2260,pSTAT3,protein,intestinal disorder,Tibetan Terrier,both,0.5-11years,3.5-38kg,9615,"We therefore conclude that pSTAT3 may be useful as an additional activity
marker of inflammation in dogs with CIE and may act as a possible therapeutic target in the future"
1036,cfamiR-130b,miRNA,hypertrophic cardiomyopathy,English Beagle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1036,cfamiR-130b,miRNA,hypertrophic cardiomyopathy,Maltese,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1036,cfamiR-130b,miRNA,hypertrophic cardiomyopathy,Shih Tzu(Chrysanthemum Dog),both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1036,cfamiR-130b,miRNA,hypertrophic cardiomyopathy,Pomeranian,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1036,cfamiR-130b,miRNA,hypertrophic cardiomyopathy,French Bulldog,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1036,cfamiR-130b,miRNA,hypertrophic cardiomyopathy,Poodle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1019,cfa-miR-375,miRNA,hypertrophic cardiomyopathy,English Beagle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1019,cfa-miR-375,miRNA,hypertrophic cardiomyopathy,Maltese,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1019,cfa-miR-375,miRNA,hypertrophic cardiomyopathy,Shih Tzu(Chrysanthemum Dog),both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1019,cfa-miR-375,miRNA,hypertrophic cardiomyopathy,Pomeranian,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1019,cfa-miR-375,miRNA,hypertrophic cardiomyopathy,French Bulldog,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1019,cfa-miR-375,miRNA,hypertrophic cardiomyopathy,Poodle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1037,cfa-miR-425,miRNA,hypertrophic cardiomyopathy,English Beagle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1037,cfa-miR-425,miRNA,hypertrophic cardiomyopathy,Maltese,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1037,cfa-miR-425,miRNA,hypertrophic cardiomyopathy,Shih Tzu(Chrysanthemum Dog),both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1037,cfa-miR-425,miRNA,hypertrophic cardiomyopathy,Pomeranian,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1037,cfa-miR-425,miRNA,hypertrophic cardiomyopathy,French Bulldog,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1037,cfa-miR-425,miRNA,hypertrophic cardiomyopathy,Poodle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1038,cfa-miR-30d,miRNA,hypertrophic cardiomyopathy,English Beagle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1038,cfa-miR-30d,miRNA,hypertrophic cardiomyopathy,Maltese,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1038,cfa-miR-30d,miRNA,hypertrophic cardiomyopathy,Shih Tzu(Chrysanthemum Dog),both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1038,cfa-miR-30d,miRNA,hypertrophic cardiomyopathy,Pomeranian,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1038,cfa-miR-30d,miRNA,hypertrophic cardiomyopathy,French Bulldog,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1038,cfa-miR-30d,miRNA,hypertrophic cardiomyopathy,Poodle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
2261,N-terminal pro-BNP,protein,dilated cardiomyopathy,Doberman Pinscher,,,,9615,Cardiac biomarker screening may be useful to select Dobermanns which would benefit from further assessment by echocardiography and Holter
1039,cfa-miR-30c,miRNA,hypertrophic cardiomyopathy,English Beagle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1039,cfa-miR-30c,miRNA,hypertrophic cardiomyopathy,Maltese,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1039,cfa-miR-30c,miRNA,hypertrophic cardiomyopathy,Shih Tzu(Chrysanthemum Dog),both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1039,cfa-miR-30c,miRNA,hypertrophic cardiomyopathy,Pomeranian,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1039,cfa-miR-30c,miRNA,hypertrophic cardiomyopathy,French Bulldog,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1039,cfa-miR-30c,miRNA,hypertrophic cardiomyopathy,Poodle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1040,cfa-miR-151,miRNA,hypertrophic cardiomyopathy,English Beagle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1040,cfa-miR-151,miRNA,hypertrophic cardiomyopathy,Maltese,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1040,cfa-miR-151,miRNA,hypertrophic cardiomyopathy,Shih Tzu(Chrysanthemum Dog),both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1040,cfa-miR-151,miRNA,hypertrophic cardiomyopathy,Pomeranian,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1040,cfa-miR-151,miRNA,hypertrophic cardiomyopathy,French Bulldog,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1040,cfa-miR-151,miRNA,hypertrophic cardiomyopathy,Poodle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1041,cfa-let-7b,miRNA,hypertrophic cardiomyopathy,English Beagle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1041,cfa-let-7b,miRNA,hypertrophic cardiomyopathy,Maltese,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1041,cfa-let-7b,miRNA,hypertrophic cardiomyopathy,Shih Tzu(Chrysanthemum Dog),both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1041,cfa-let-7b,miRNA,hypertrophic cardiomyopathy,Pomeranian,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1041,cfa-let-7b,miRNA,hypertrophic cardiomyopathy,French Bulldog,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1041,cfa-let-7b,miRNA,hypertrophic cardiomyopathy,Poodle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1042,cfa-miR-19b,miRNA,hypertrophic cardiomyopathy,English Beagle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1042,cfa-miR-19b,miRNA,hypertrophic cardiomyopathy,Maltese,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1042,cfa-miR-19b,miRNA,hypertrophic cardiomyopathy,Shih Tzu(Chrysanthemum Dog),both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1042,cfa-miR-19b,miRNA,hypertrophic cardiomyopathy,Pomeranian,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1042,cfa-miR-19b,miRNA,hypertrophic cardiomyopathy,French Bulldog,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1042,cfa-miR-19b,miRNA,hypertrophic cardiomyopathy,Poodle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1043,cfa-let-7g,miRNA,hypertrophic cardiomyopathy,English Beagle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1043,cfa-let-7g,miRNA,hypertrophic cardiomyopathy,Maltese,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1043,cfa-let-7g,miRNA,hypertrophic cardiomyopathy,Shih Tzu(Chrysanthemum Dog),both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1043,cfa-let-7g,miRNA,hypertrophic cardiomyopathy,Pomeranian,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1043,cfa-let-7g,miRNA,hypertrophic cardiomyopathy,French Bulldog,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1043,cfa-let-7g,miRNA,hypertrophic cardiomyopathy,Poodle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1044,cfa-miR-346,miRNA,hypertrophic cardiomyopathy,English Beagle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1044,cfa-miR-346,miRNA,hypertrophic cardiomyopathy,Maltese,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1044,cfa-miR-346,miRNA,hypertrophic cardiomyopathy,Shih Tzu(Chrysanthemum Dog),both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1044,cfa-miR-346,miRNA,hypertrophic cardiomyopathy,Pomeranian,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1044,cfa-miR-346,miRNA,hypertrophic cardiomyopathy,French Bulldog,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1044,cfa-miR-346,miRNA,hypertrophic cardiomyopathy,Poodle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1039,cfa-miR-30c,miRNA,hypertrophic cardiomyopathy,English Beagle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1039,cfa-miR-30c,miRNA,hypertrophic cardiomyopathy,Maltese,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1039,cfa-miR-30c,miRNA,hypertrophic cardiomyopathy,Shih Tzu(Chrysanthemum Dog),both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1039,cfa-miR-30c,miRNA,hypertrophic cardiomyopathy,Pomeranian,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1039,cfa-miR-30c,miRNA,hypertrophic cardiomyopathy,French Bulldog,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1039,cfa-miR-30c,miRNA,hypertrophic cardiomyopathy,Poodle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1041,cfa-let-7b,miRNA,hypertrophic cardiomyopathy,English Beagle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1041,cfa-let-7b,miRNA,hypertrophic cardiomyopathy,Maltese,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1041,cfa-let-7b,miRNA,hypertrophic cardiomyopathy,Shih Tzu(Chrysanthemum Dog),both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1041,cfa-let-7b,miRNA,hypertrophic cardiomyopathy,Pomeranian,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1041,cfa-let-7b,miRNA,hypertrophic cardiomyopathy,French Bulldog,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1041,cfa-let-7b,miRNA,hypertrophic cardiomyopathy,Poodle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1045,cfa-miR-505,miRNA,hypertrophic cardiomyopathy,English Beagle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1045,cfa-miR-505,miRNA,hypertrophic cardiomyopathy,Maltese,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1045,cfa-miR-505,miRNA,hypertrophic cardiomyopathy,Shih Tzu(Chrysanthemum Dog),both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1045,cfa-miR-505,miRNA,hypertrophic cardiomyopathy,Pomeranian,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1045,cfa-miR-505,miRNA,hypertrophic cardiomyopathy,French Bulldog,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
1045,cfa-miR-505,miRNA,hypertrophic cardiomyopathy,Poodle,both,12.83years,,9615,"This pilot study demonstrates that
the microRNAs identified in this study could be possible candidates for novel biomarker or therapeutic target related to cardiac hypertrophy in dogs"
2262,Kidney Injury Molecule-1,protein,Weil's disease,,,,,9615,Measurement of KIM-1 in the urine of canine patients was able to detect naturally occurring acute and  subacute leptospirosis accompanied by tubular injury in early non azotemic infections. 
2244,cardiac Troponin I,protein,dilated cardiomyopathy,Doberman Pinscher,,,,9615,Cardiac biomarker screening may be useful to select Dobermanns which would benefit from further assessment by echocardiography and Holter
1863,Circulating tumor DNA,other,neoplasm,Bernese Mountain Dog,,,,9615,"Thus, our study shows that ctDNA is detectable in the plasma of cancer-afected dogs and is a promising biomarker for diagnosis and clinical follow-up."
1863,Circulating tumor DNA,other,neoplasm,Flat-Coated Retriever,,,,9615,"Thus, our study shows that ctDNA is detectable in the plasma of cancer-afected dogs and is a promising biomarker for diagnosis and clinical follow-up."
187,Spexin hormone,gene,morbid obesity,Labrador Retriever,both,2-8years,12.5-30kg,9615,"Spexin could be involved in pathogenesis of obesity in dogs, and might be considered as a potential marker for obesity"
187,Spexin hormone,gene,morbid obesity,German Shepherd Dog,both,2-8years,12.5-30kg,9615,"Spexin could be involved in pathogenesis of obesity in dogs, and might be considered as a potential marker for obesity"
682,choline,metabolite,Parvoviridae infectious disease,,,,,9615,"This is the first report in which Ch is measured in saliva of dogs and based in the results of this study, salivary Ch could be potentially used as biomarker of the severity of CP. "
683,Cerebrospinal fluid lactate,metabolite,central nervous system disorder,Labrador Retriever,,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings
683,Cerebrospinal fluid lactate,metabolite,central nervous system disorder,Chihuahua,,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings
683,Cerebrospinal fluid lactate,metabolite,central nervous system disorder,Maltese,,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings
683,Cerebrospinal fluid lactate,metabolite,central nervous system disorder,Dachshund,,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings
683,Cerebrospinal fluid lactate,metabolite,central nervous system disorder,Jack Russell Terrier,,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings
683,Cerebrospinal fluid lactate,metabolite,central nervous system disorder,Siberian Husky,,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings
683,Cerebrospinal fluid lactate,metabolite,central nervous system disorder,Golden Retriever,,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings
683,Cerebrospinal fluid lactate,metabolite,central nervous system disorder,American Bulldog,,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings
683,Cerebrospinal fluid lactate,metabolite,central nervous system disorder,Toy Poodle,,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings
683,Cerebrospinal fluid lactate,metabolite,central nervous system disorder,Shih Tzu(Chrysanthemum Dog),,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings
683,Cerebrospinal fluid lactate,metabolite,central nervous system disorder,American Eskimo Dog,,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings
683,Cerebrospinal fluid lactate,metabolite,central nervous system disorder,Basenji(African Barkless Dog),,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings
683,Cerebrospinal fluid lactate,metabolite,central nervous system disorder,Bernese Mountain Dog,,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings
683,Cerebrospinal fluid lactate,metabolite,central nervous system disorder,Cane Corso(Italian Mastiff),,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings
683,Cerebrospinal fluid lactate,metabolite,central nervous system disorder,Chinese Crested,,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings
683,Cerebrospinal fluid lactate,metabolite,central nervous system disorder,French Bulldog,,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings
683,Cerebrospinal fluid lactate,metabolite,central nervous system disorder,Italian Greyhound,,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings
683,Cerebrospinal fluid lactate,metabolite,central nervous system disorder,Miniature Schnauzer,,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings
683,Cerebrospinal fluid lactate,metabolite,central nervous system disorder,Miniature Poodle,,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings
683,Cerebrospinal fluid lactate,metabolite,central nervous system disorder,American Pit Bull Terrier,,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings
683,Cerebrospinal fluid lactate,metabolite,central nervous system disorder,Poodle,,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings
683,Cerebrospinal fluid lactate,metabolite,central nervous system disorder,Standard Schnauzer,,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings
683,Cerebrospinal fluid lactate,metabolite,central nervous system disorder,Pomeranian,,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings
683,Cerebrospinal fluid lactate,metabolite,central nervous system disorder,Weimaraner,,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings
683,Cerebrospinal fluid lactate,metabolite,central nervous system disorder,Yorkshire Terrier,,6 months-14 years,1.7-54.7 kg,9615,Cerebrospinal fluid lactate can be used as a biomarker in clinical settings
2437,C-reactive protein,protein,infectious discitis,Labrador Retriever,both,1-12years,4.7-79kg,9615,"C-reactive protein is a sensitive, but nonspecific biomarker for diskospondylitis which may prove useful as an adjunctive diagnostic test in patients with suspicious clinical signs and may help predict prognosis."
2437,C-reactive protein,protein,infectious discitis,Rhodesian Ridgeback,both,1-12years,4.7-79kg,9615,"C-reactive protein is a sensitive, but nonspecific biomarker for diskospondylitis which may prove useful as an adjunctive diagnostic test in patients with suspicious clinical signs and may help predict prognosis."
2437,C-reactive protein,protein,infectious discitis,German Shepherd Dog,both,1-12years,4.7-79kg,9615,"C-reactive protein is a sensitive, but nonspecific biomarker for diskospondylitis which may prove useful as an adjunctive diagnostic test in patients with suspicious clinical signs and may help predict prognosis."
2437,C-reactive protein,protein,infectious discitis,German Boxer,both,1-12years,4.7-79kg,9615,"C-reactive protein is a sensitive, but nonspecific biomarker for diskospondylitis which may prove useful as an adjunctive diagnostic test in patients with suspicious clinical signs and may help predict prognosis."
2437,C-reactive protein,protein,infectious discitis,English Mastiff,both,1-12years,4.7-79kg,9615,"C-reactive protein is a sensitive, but nonspecific biomarker for diskospondylitis which may prove useful as an adjunctive diagnostic test in patients with suspicious clinical signs and may help predict prognosis."
2437,C-reactive protein,protein,infectious discitis,Newfoundland,both,1-12years,4.7-79kg,9615,"C-reactive protein is a sensitive, but nonspecific biomarker for diskospondylitis which may prove useful as an adjunctive diagnostic test in patients with suspicious clinical signs and may help predict prognosis."
2437,C-reactive protein,protein,infectious discitis,Doberman Pinscher,both,1-12years,4.7-79kg,9615,"C-reactive protein is a sensitive, but nonspecific biomarker for diskospondylitis which may prove useful as an adjunctive diagnostic test in patients with suspicious clinical signs and may help predict prognosis."
2437,C-reactive protein,protein,infectious discitis,English Bulldog,both,1-12years,4.7-79kg,9615,"C-reactive protein is a sensitive, but nonspecific biomarker for diskospondylitis which may prove useful as an adjunctive diagnostic test in patients with suspicious clinical signs and may help predict prognosis."
2437,C-reactive protein,protein,infectious discitis,German Short-Haired  Pointer,both,1-12years,4.7-79kg,9615,"C-reactive protein is a sensitive, but nonspecific biomarker for diskospondylitis which may prove useful as an adjunctive diagnostic test in patients with suspicious clinical signs and may help predict prognosis."
2437,C-reactive protein,protein,infectious discitis,Saint Bernard,both,1-12years,4.7-79kg,9615,"C-reactive protein is a sensitive, but nonspecific biomarker for diskospondylitis which may prove useful as an adjunctive diagnostic test in patients with suspicious clinical signs and may help predict prognosis."
2437,C-reactive protein,protein,infectious discitis,English Beagle,both,1-12years,4.7-79kg,9615,"C-reactive protein is a sensitive, but nonspecific biomarker for diskospondylitis which may prove useful as an adjunctive diagnostic test in patients with suspicious clinical signs and may help predict prognosis."
2263,Neutrophil gelatinase-associated lipocalin,protein,acute kidney failure,English Beagle,male,3years,10-12kg,9615,"There is potential for NGAL to be used as a sensitive biomarker for early diagnosis of 
canine I-AKI."
2264,LCAT,protein,breast neoplasm,,,,,9615,"In conclusion, we identified a possible 
common plasma protein biomarker, LCAT, that is highly expressed in aggressive human breast cancer and canine mammary 
tumor"
1046,miR-15b,miRNA,acute kidney failure,English Beagle,male,,,9615,Our data concluded that miR-15b and -30a may be promising biomarkers for renal toxicity.
1047,miR-30a,miRNA,acute kidney failure,English Beagle,male,,,9615,Our data concluded that miR-15b and -30a may be promising biomarkers for renal toxicity.
2265,IL-17,protein,hemolytic anemia,American Cocker Spaniel,both,1.5-11.9years,,9615,"Serum IL-17 concentration remained significantly higher in nonsurviving IMHA dogs whereas it significantly decreased during hospitalization in survivors, making serum IL-17 concentration a potential biomarker for severity and response to treatment in IMHA."
2265,IL-17,protein,hemolytic anemia,Shih Tzu(Chrysanthemum Dog),both,1.5-11.9years,,9615,"Serum IL-17 concentration remained significantly higher in nonsurviving IMHA dogs whereas it significantly decreased during hospitalization in survivors, making serum IL-17 concentration a potential biomarker for severity and response to treatment in IMHA."
2265,IL-17,protein,hemolytic anemia,Dachshund,both,1.5-11.9years,,9615,"Serum IL-17 concentration remained significantly higher in nonsurviving IMHA dogs whereas it significantly decreased during hospitalization in survivors, making serum IL-17 concentration a potential biomarker for severity and response to treatment in IMHA."
2265,IL-17,protein,hemolytic anemia,Airedale Terrier,both,1.5-11.9years,,9615,"Serum IL-17 concentration remained significantly higher in nonsurviving IMHA dogs whereas it significantly decreased during hospitalization in survivors, making serum IL-17 concentration a potential biomarker for severity and response to treatment in IMHA."
2265,IL-17,protein,hemolytic anemia,Maltese,both,1.5-11.9years,,9615,"Serum IL-17 concentration remained significantly higher in nonsurviving IMHA dogs whereas it significantly decreased during hospitalization in survivors, making serum IL-17 concentration a potential biomarker for severity and response to treatment in IMHA."
2265,IL-17,protein,hemolytic anemia,Australian Shepherd,both,1.5-11.9years,,9615,"Serum IL-17 concentration remained significantly higher in nonsurviving IMHA dogs whereas it significantly decreased during hospitalization in survivors, making serum IL-17 concentration a potential biomarker for severity and response to treatment in IMHA."
2265,IL-17,protein,hemolytic anemia,Golden Retriever,both,1.5-11.9years,,9615,"Serum IL-17 concentration remained significantly higher in nonsurviving IMHA dogs whereas it significantly decreased during hospitalization in survivors, making serum IL-17 concentration a potential biomarker for severity and response to treatment in IMHA."
2265,IL-17,protein,hemolytic anemia,Greyhound,both,1.5-11.9years,,9615,"Serum IL-17 concentration remained significantly higher in nonsurviving IMHA dogs whereas it significantly decreased during hospitalization in survivors, making serum IL-17 concentration a potential biomarker for severity and response to treatment in IMHA."
2265,IL-17,protein,hemolytic anemia,Siberian Husky,both,1.5-11.9years,,9615,"Serum IL-17 concentration remained significantly higher in nonsurviving IMHA dogs whereas it significantly decreased during hospitalization in survivors, making serum IL-17 concentration a potential biomarker for severity and response to treatment in IMHA."
2265,IL-17,protein,hemolytic anemia,Jack Russell Terrier,both,1.5-11.9years,,9615,"Serum IL-17 concentration remained significantly higher in nonsurviving IMHA dogs whereas it significantly decreased during hospitalization in survivors, making serum IL-17 concentration a potential biomarker for severity and response to treatment in IMHA."
2265,IL-17,protein,hemolytic anemia,Irish Blue Terrier,both,1.5-11.9years,,9615,"Serum IL-17 concentration remained significantly higher in nonsurviving IMHA dogs whereas it significantly decreased during hospitalization in survivors, making serum IL-17 concentration a potential biomarker for severity and response to treatment in IMHA."
2265,IL-17,protein,hemolytic anemia,Pomeranian,both,1.5-11.9years,,9615,"Serum IL-17 concentration remained significantly higher in nonsurviving IMHA dogs whereas it significantly decreased during hospitalization in survivors, making serum IL-17 concentration a potential biomarker for severity and response to treatment in IMHA."
2265,IL-17,protein,hemolytic anemia,Poodle,both,1.5-11.9years,,9615,"Serum IL-17 concentration remained significantly higher in nonsurviving IMHA dogs whereas it significantly decreased during hospitalization in survivors, making serum IL-17 concentration a potential biomarker for severity and response to treatment in IMHA."
2265,IL-17,protein,hemolytic anemia,Rottweiler,both,1.5-11.9years,,9615,"Serum IL-17 concentration remained significantly higher in nonsurviving IMHA dogs whereas it significantly decreased during hospitalization in survivors, making serum IL-17 concentration a potential biomarker for severity and response to treatment in IMHA."
2265,IL-17,protein,hemolytic anemia,Scottish Terrier,both,1.5-11.9years,,9615,"Serum IL-17 concentration remained significantly higher in nonsurviving IMHA dogs whereas it significantly decreased during hospitalization in survivors, making serum IL-17 concentration a potential biomarker for severity and response to treatment in IMHA."
2265,IL-17,protein,hemolytic anemia,Yorkshire Terrier,both,1.5-11.9years,,9615,"Serum IL-17 concentration remained significantly higher in nonsurviving IMHA dogs whereas it significantly decreased during hospitalization in survivors, making serum IL-17 concentration a potential biomarker for severity and response to treatment in IMHA."
2266,valine,metabolite,diabetes mellitus,Rottweiler,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2266,valine,metabolite,diabetes mellitus,Pomeranian,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2266,valine,metabolite,diabetes mellitus,Miniature Pinscher,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2266,valine,metabolite,diabetes mellitus,Bichon Frise,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2266,valine,metabolite,diabetes mellitus,Silky Terrier,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2266,valine,metabolite,diabetes mellitus,Maltese,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2266,valine,metabolite,diabetes mellitus,Cavalier King Charles Spaniel,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2266,valine,metabolite,diabetes mellitus,Labrador Retriever,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2266,valine,metabolite,diabetes mellitus,Australian Shepherd,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2266,valine,metabolite,diabetes mellitus,Miniature Schnauzer,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2267,Cystatin C,protein,chronic kidney disease,Labrador Retriever,both,7.5 ± 4.2,3.9−15.8 kg,9615,"In conclusion, serum CysC concentrations are the useful indirect markers for determining changes in GFR, notably among dogs that weigh <20 kg. Definition of a reference range and/or cut-off values for dogs of different weights and breeds will be needed in order to use this information to assess kidney function in dogs."
2267,Cystatin C,protein,chronic kidney disease,English Beagle,both,7.5 ± 4.2,3.9−15.8 kg,9615,"In conclusion, serum CysC concentrations are the useful indirect markers for determining changes in GFR, notably among dogs that weigh <20 kg. Definition of a reference range and/or cut-off values for dogs of different weights and breeds will be needed in order to use this information to assess kidney function in dogs."
2267,Cystatin C,protein,chronic kidney disease,Golden Retriever,both,7.5 ± 4.2,3.9−15.8 kg,9615,"In conclusion, serum CysC concentrations are the useful indirect markers for determining changes in GFR, notably among dogs that weigh <20 kg. Definition of a reference range and/or cut-off values for dogs of different weights and breeds will be needed in order to use this information to assess kidney function in dogs."
2267,Cystatin C,protein,chronic kidney disease,Border Collie,both,7.5 ± 4.2,3.9−15.8 kg,9615,"In conclusion, serum CysC concentrations are the useful indirect markers for determining changes in GFR, notably among dogs that weigh <20 kg. Definition of a reference range and/or cut-off values for dogs of different weights and breeds will be needed in order to use this information to assess kidney function in dogs."
2267,Cystatin C,protein,chronic kidney disease,Miniature Dachshund,both,7.5 ± 4.2,3.9−15.8 kg,9615,"In conclusion, serum CysC concentrations are the useful indirect markers for determining changes in GFR, notably among dogs that weigh <20 kg. Definition of a reference range and/or cut-off values for dogs of different weights and breeds will be needed in order to use this information to assess kidney function in dogs."
2268,HMGB1,protein,epilepsy,,,,,9615,Serum HMGB1 could be a biomarker of epilepsy.
2269,uPIIINP ,protein,chronic kidney disease,Shih Tzu(Chrysanthemum Dog),both,2-21years,1.2-39.4kg,9615,"Therefore, the uPIIINP level might be a non-invasive, complementary, and promising biomarker for evaluating renal fibrosis in canine CKD"
2269,uPIIINP ,protein,chronic kidney disease,Yorkshire Terrier,both,2-21years,1.2-39.4kg,9615,"Therefore, the uPIIINP level might be a non-invasive, complementary, and promising biomarker for evaluating renal fibrosis in canine CKD"
2269,uPIIINP ,protein,chronic kidney disease,Siberian Husky,both,2-21years,1.2-39.4kg,9615,"Therefore, the uPIIINP level might be a non-invasive, complementary, and promising biomarker for evaluating renal fibrosis in canine CKD"
2269,uPIIINP ,protein,chronic kidney disease,Cardigan Welsh Corgi,both,2-21years,1.2-39.4kg,9615,"Therefore, the uPIIINP level might be a non-invasive, complementary, and promising biomarker for evaluating renal fibrosis in canine CKD"
2269,uPIIINP ,protein,chronic kidney disease,Cocker Spaniel,both,2-21years,1.2-39.4kg,9615,"Therefore, the uPIIINP level might be a non-invasive, complementary, and promising biomarker for evaluating renal fibrosis in canine CKD"
2269,uPIIINP ,protein,chronic kidney disease,Poodle,both,2-21years,1.2-39.4kg,9615,"Therefore, the uPIIINP level might be a non-invasive, complementary, and promising biomarker for evaluating renal fibrosis in canine CKD"
2269,uPIIINP ,protein,chronic kidney disease,Chihuahua,both,2-21years,1.2-39.4kg,9615,"Therefore, the uPIIINP level might be a non-invasive, complementary, and promising biomarker for evaluating renal fibrosis in canine CKD"
2269,uPIIINP ,protein,chronic kidney disease,Shih Tzu(Chrysanthemum Dog),both,2-21years,1.2-39.4kg,9615,"Therefore, the uPIIINP level might be a non-invasive, complementary, and promising biomarker for evaluating renal fibrosis in canine CKD"
2269,uPIIINP ,protein,chronic kidney disease,Chihuahua,both,2-21years,1.2-39.4kg,9615,"Therefore, the uPIIINP level might be a non-invasive, complementary, and promising biomarker for evaluating renal fibrosis in canine CKD"
2269,uPIIINP ,protein,chronic kidney disease,Siberian Husky,both,2-21years,1.2-39.4kg,9615,"Therefore, the uPIIINP level might be a non-invasive, complementary, and promising biomarker for evaluating renal fibrosis in canine CKD"
2269,uPIIINP ,protein,chronic kidney disease,American Pit Bull Terrier,both,2-21years,1.2-39.4kg,9615,"Therefore, the uPIIINP level might be a non-invasive, complementary, and promising biomarker for evaluating renal fibrosis in canine CKD"
2269,uPIIINP ,protein,chronic kidney disease,Thai Ridgeback,both,2-21years,1.2-39.4kg,9615,"Therefore, the uPIIINP level might be a non-invasive, complementary, and promising biomarker for evaluating renal fibrosis in canine CKD"
2270,Lubricin,protein, rupture of cranial cruciate ligament ,,,,,9615,"Synovial fuid lubricin concentrations were  correlated with the presence of radiographic OA and were elevated in three animals sustaining RCCL injury prior to the radiographic manifestation of OA, indicating that lubricin may be a potential biomarker for early joint injury."
1864,N-glycan 3_2_0_0_0,other,osteoarthritis,,,,,9615,"Sixteen N-glycans were discovered that
exhibited AUCs more than 0.9 to 1.0 with excellent diagnostic stability. Although a wide range of validation has to be followed, this study suggests the strong potentials that the alteration of serum N-glycans expression could be an emerging indicator of in vitro diagnostics (IVD) in veterinary clinics."
1865,N-glycan 3_2_1_0_0,other,osteoarthritis,,,,,9615,"Sixteen N-glycans were discovered that
exhibited AUCs more than 0.9 to 1.0 with excellent diagnostic stability. Although a wide range of validation has to be followed, this study suggests the strong potentials that the alteration of serum N-glycans expression could be an emerging indicator of in vitro diagnostics (IVD) in veterinary clinics."
1866,N-glycan 4_4_2_1_0,other,osteoarthritis,,,,,9615,"Sixteen N-glycans were discovered that
exhibited AUCs more than 0.9 to 1.0 with excellent diagnostic stability. Although a wide range of validation has to be followed, this study suggests the strong potentials that the alteration of serum N-glycans expression could be an emerging indicator of in vitro diagnostics (IVD) in veterinary clinics."
1867,N-glycan 6_5_0_1_0,other,osteoarthritis,,,,,9615,"Sixteen N-glycans were discovered that
exhibited AUCs more than 0.9 to 1.0 with excellent diagnostic stability. Although a wide range of validation has to be followed, this study suggests the strong potentials that the alteration of serum N-glycans expression could be an emerging indicator of in vitro diagnostics (IVD) in veterinary clinics."
1868,N-glycan 5_4_1_2_0,other,osteoarthritis,,,,,9615,"Sixteen N-glycans were discovered that
exhibited AUCs more than 0.9 to 1.0 with excellent diagnostic stability. Although a wide range of validation has to be followed, this study suggests the strong potentials that the alteration of serum N-glycans expression could be an emerging indicator of in vitro diagnostics (IVD) in veterinary clinics."
1869,N-glycan 3_4_3_0_0,other,osteoarthritis,,,,,9615,"Sixteen N-glycans were discovered that
exhibited AUCs more than 0.9 to 1.0 with excellent diagnostic stability. Although a wide range of validation has to be followed, this study suggests the strong potentials that the alteration of serum N-glycans expression could be an emerging indicator of in vitro diagnostics (IVD) in veterinary clinics."
684,gamma amino butyric acid,metabolite,diabetes mellitus,Rottweiler,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
684,gamma amino butyric acid,metabolite,diabetes mellitus,Pomeranian,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
684,gamma amino butyric acid,metabolite,diabetes mellitus,Miniature Pinscher,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
684,gamma amino butyric acid,metabolite,diabetes mellitus,Bichon Frise,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
684,gamma amino butyric acid,metabolite,diabetes mellitus,Silky Terrier,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
684,gamma amino butyric acid,metabolite,diabetes mellitus,Maltese,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
684,gamma amino butyric acid,metabolite,diabetes mellitus,Cavalier King Charles Spaniel,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
684,gamma amino butyric acid,metabolite,diabetes mellitus,Labrador Retriever,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
684,gamma amino butyric acid,metabolite,diabetes mellitus,Australian Shepherd,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
684,gamma amino butyric acid,metabolite,diabetes mellitus,Miniature Schnauzer,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
1870,N-glycan 4_4_3_0_0,other,osteoarthritis,,,,,9615,"Sixteen N-glycans were discovered that
exhibited AUCs more than 0.9 to 1.0 with excellent diagnostic stability. Although a wide range of validation has to be followed, this study suggests the strong potentials that the alteration of serum N-glycans expression could be an emerging indicator of in vitro diagnostics (IVD) in veterinary clinics."
1871,N-glycan 7_7_5_2_2,other,osteoarthritis,,,,,9615,"Sixteen N-glycans were discovered that
exhibited AUCs more than 0.9 to 1.0 with excellent diagnostic stability. Although a wide range of validation has to be followed, this study suggests the strong potentials that the alteration of serum N-glycans expression could be an emerging indicator of in vitro diagnostics (IVD) in veterinary clinics."
1872,N-glycan 5_4_3_0_0,other,osteoarthritis,,,,,9615,"Sixteen N-glycans were discovered that
exhibited AUCs more than 0.9 to 1.0 with excellent diagnostic stability. Although a wide range of validation has to be followed, this study suggests the strong potentials that the alteration of serum N-glycans expression could be an emerging indicator of in vitro diagnostics (IVD) in veterinary clinics."
1873,N-glycan 4_5_2_0_0,other,osteoarthritis,,,,,9615,"Sixteen N-glycans were discovered that
exhibited AUCs more than 0.9 to 1.0 with excellent diagnostic stability. Although a wide range of validation has to be followed, this study suggests the strong potentials that the alteration of serum N-glycans expression could be an emerging indicator of in vitro diagnostics (IVD) in veterinary clinics."
1874,N-glycan 7_7_3_2_1,other,osteoarthritis,,,,,9615,"Sixteen N-glycans were discovered that
exhibited AUCs more than 0.9 to 1.0 with excellent diagnostic stability. Although a wide range of validation has to be followed, this study suggests the strong potentials that the alteration of serum N-glycans expression could be an emerging indicator of in vitro diagnostics (IVD) in veterinary clinics."
1875,N-glycan 6_7_4_0_0,other,osteoarthritis,,,,,9615,"Sixteen N-glycans were discovered that
exhibited AUCs more than 0.9 to 1.0 with excellent diagnostic stability. Although a wide range of validation has to be followed, this study suggests the strong potentials that the alteration of serum N-glycans expression could be an emerging indicator of in vitro diagnostics (IVD) in veterinary clinics."
1876,N-glycan 7_4_0_0_0,other,osteoarthritis,,,,,9615,"Sixteen N-glycans were discovered that
exhibited AUCs more than 0.9 to 1.0 with excellent diagnostic stability. Although a wide range of validation has to be followed, this study suggests the strong potentials that the alteration of serum N-glycans expression could be an emerging indicator of in vitro diagnostics (IVD) in veterinary clinics."
1877,N-glycan 7_6_3_2_1,other,osteoarthritis,,,,,9615,"Sixteen N-glycans were discovered that
exhibited AUCs more than 0.9 to 1.0 with excellent diagnostic stability. Although a wide range of validation has to be followed, this study suggests the strong potentials that the alteration of serum N-glycans expression could be an emerging indicator of in vitro diagnostics (IVD) in veterinary clinics."
1878,N-glycan 7_6_1_0_1,other,osteoarthritis,,,,,9615,"Sixteen N-glycans were discovered that
exhibited AUCs more than 0.9 to 1.0 with excellent diagnostic stability. Although a wide range of validation has to be followed, this study suggests the strong potentials that the alteration of serum N-glycans expression could be an emerging indicator of in vitro diagnostics (IVD) in veterinary clinics."
1879,N-glycan 6_3_1_1_0,other,osteoarthritis,,,,,9615,"Sixteen N-glycans were discovered that
exhibited AUCs more than 0.9 to 1.0 with excellent diagnostic stability. Although a wide range of validation has to be followed, this study suggests the strong potentials that the alteration of serum N-glycans expression could be an emerging indicator of in vitro diagnostics (IVD) in veterinary clinics."
2271,N-acetyl-L-aspartic acid,protein,diabetes mellitus,Rottweiler,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2271,N-acetyl-L-aspartic acid,protein,diabetes mellitus,Pomeranian,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2271,N-acetyl-L-aspartic acid,protein,diabetes mellitus,Miniature Pinscher,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2271,N-acetyl-L-aspartic acid,protein,diabetes mellitus,Bichon Frise,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2271,N-acetyl-L-aspartic acid,protein,diabetes mellitus,Silky Terrier,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2271,N-acetyl-L-aspartic acid,protein,diabetes mellitus,Maltese,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2271,N-acetyl-L-aspartic acid,protein,diabetes mellitus,Cavalier King Charles Spaniel,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2271,N-acetyl-L-aspartic acid,protein,diabetes mellitus,Labrador Retriever,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2271,N-acetyl-L-aspartic acid,protein,diabetes mellitus,Australian Shepherd,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2271,N-acetyl-L-aspartic acid,protein,diabetes mellitus,Miniature Schnauzer,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2272,Ki67,protein,small intestine lymphoma,,both,4.8-16.9years,2.2-35.2kg,9615,The results suggested that indices of Ki67 and MGMT might be reliable therapeutic biomarkers to select either chemotherapy or surgery for dogs with localized SIL.
2273,MGMT,protein,small intestine lymphoma,,both,4.8-16.9years,2.2-35.2kg,9615,The results suggested that indices of Ki67 and MGMT might be reliable therapeutic biomarkers to select either chemotherapy or surgery for dogs with localized SIL.
2274,resistin,protein,neoplasm,,F,4-13 years,,9615,"These results showed an important
relationship between hyperresistinemia, tumor proliferative potential and excessive body fat, suggesting that resistin levels may act as an interesting prognostic marker in patients with CBMT"
1880,Pretreatment D-dimer,other,non-Hodgkin lymphoma,,both,3-14years,8-51.4kg,9615,This study suggests that pretreatment plasma D-dimer level can serve as a predictor of prognosis in dogs with intermediate to high-grade NHL. Further studies are warranted to confirm these findings.
2275,IL-2,protein,visceral leishmaniasis,,both,20.25-84months,5.2-23kg,9615,"Through the quantification of cytokines, IL-2 proved to be a potential therapeutic marker for the monitoring and follow-up of dogs with CVL"
2276,I-FABP,protein,Parvoviridae infectious disease,,,2-6months,,9615,"In conclusion, it was determined that I-FABP and TFF-3 for the intestinal injury and mortality prediction, and CK-MB and cTnI for the cardiac injury were useful and reliable biomarkers to determine the damage caused by parvovirus in dogs."
2277,TFF-3,protein,Parvoviridae infectious disease,,,2-6months,,9615,"In conclusion, it was determined that I-FABP and TFF-3 for the intestinal injury and mortality prediction, and CK-MB and cTnI for the cardiac injury were useful and reliable biomarkers to determine the damage caused by parvovirus in dogs."
2278,CK-MB,protein,Parvoviridae infectious disease,,,2-6months,,9615,"In conclusion, it was determined that I-FABP and TFF-3 for the intestinal injury and mortality prediction, and CK-MB and cTnI for the cardiac injury were useful and reliable biomarkers to determine the damage caused by parvovirus in dogs."
2279,cTnI,protein,Parvoviridae infectious disease,,,2-6months,,9615,"In conclusion, it was determined that I-FABP and TFF-3 for the intestinal injury and mortality prediction, and CK-MB and cTnI for the cardiac injury were useful and reliable biomarkers to determine the damage caused by parvovirus in dogs."
2280,E-cadherin,protein,melanoma,German Shepherd Dog,both,8-12years,,9615,"However, cutaneous melanomas without E-cadherin expression frequently had a favorable clinical outcome. Hence, its importance as prognostic factor should be carefully considered depending on
the tumor origin."
2280,E-cadherin,protein,melanoma,Rottweiler,both,8-12years,,9615,"However, cutaneous melanomas without E-cadherin expression frequently had a favorable clinical outcome. Hence, its importance as prognostic factor should be carefully considered depending on
the tumor origin."
2280,E-cadherin,protein,melanoma,Dachshund,both,8-12years,,9615,"However, cutaneous melanomas without E-cadherin expression frequently had a favorable clinical outcome. Hence, its importance as prognostic factor should be carefully considered depending on
the tumor origin."
2281,indoxyl sulfate,protein,diabetes mellitus,Rottweiler,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2281,indoxyl sulfate,protein,diabetes mellitus,Pomeranian,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2281,indoxyl sulfate,protein,diabetes mellitus,Miniature Pinscher,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2281,indoxyl sulfate,protein,diabetes mellitus,Bichon Frise,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2281,indoxyl sulfate,protein,diabetes mellitus,Silky Terrier,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2281,indoxyl sulfate,protein,diabetes mellitus,Maltese,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2281,indoxyl sulfate,protein,diabetes mellitus,Cavalier King Charles Spaniel,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2281,indoxyl sulfate,protein,diabetes mellitus,Labrador Retriever,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2281,indoxyl sulfate,protein,diabetes mellitus,Australian Shepherd,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2281,indoxyl sulfate,protein,diabetes mellitus,Miniature Schnauzer,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2282,DMBT1,protein,pyometritis,Labrador Retriever,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2282,DMBT1,protein,pyometritis,German Shepherd Dog,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2282,DMBT1,protein,pyometritis,Siberian Husky,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2282,DMBT1,protein,pyometritis,English Bull Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2282,DMBT1,protein,pyometritis,Dachshund,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2282,DMBT1,protein,pyometritis,Pekingese,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2282,DMBT1,protein,pyometritis,Yorkshire Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2283,PLG,protein,pyometritis,Labrador Retriever,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2283,PLG,protein,pyometritis,German Shepherd Dog,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2283,PLG,protein,pyometritis,Siberian Husky,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2283,PLG,protein,pyometritis,English Bull Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2283,PLG,protein,pyometritis,Dachshund,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2283,PLG,protein,pyometritis,Pekingese,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2283,PLG,protein,pyometritis,Yorkshire Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2284,HPX,protein,pyometritis,Labrador Retriever,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2284,HPX,protein,pyometritis,German Shepherd Dog,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2284,HPX,protein,pyometritis,Siberian Husky,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2284,HPX,protein,pyometritis,English Bull Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2284,HPX,protein,pyometritis,Dachshund,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2284,HPX,protein,pyometritis,Pekingese,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2284,HPX,protein,pyometritis,Yorkshire Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2285,ARF1,protein,pyometritis,Labrador Retriever,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2285,ARF1,protein,pyometritis,German Shepherd Dog,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2285,ARF1,protein,pyometritis,Siberian Husky,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2285,ARF1,protein,pyometritis,English Bull Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2285,ARF1,protein,pyometritis,Dachshund,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2285,ARF1,protein,pyometritis,Pekingese,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2285,ARF1,protein,pyometritis,Yorkshire Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2286,ARF17,protein,pyometritis,Labrador Retriever,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2286,ARF17,protein,pyometritis,German Shepherd Dog,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2286,ARF17,protein,pyometritis,Siberian Husky,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2286,ARF17,protein,pyometritis,English Bull Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2286,ARF17,protein,pyometritis,Dachshund,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2286,ARF17,protein,pyometritis,Pekingese,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2286,ARF17,protein,pyometritis,Yorkshire Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2287,ARF3,protein,pyometritis,Labrador Retriever,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2287,ARF3,protein,pyometritis,German Shepherd Dog,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2287,ARF3,protein,pyometritis,Siberian Husky,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2287,ARF3,protein,pyometritis,English Bull Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2287,ARF3,protein,pyometritis,Dachshund,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2287,ARF3,protein,pyometritis,Pekingese,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2287,ARF3,protein,pyometritis,Yorkshire Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2288,LDHA,protein,pyometritis,Labrador Retriever,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2288,LDHA,protein,pyometritis,German Shepherd Dog,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2288,LDHA,protein,pyometritis,Siberian Husky,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2288,LDHA,protein,pyometritis,English Bull Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2288,LDHA,protein,pyometritis,Dachshund,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2288,LDHA,protein,pyometritis,Pekingese,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2288,LDHA,protein,pyometritis,Yorkshire Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2289,MDH1,protein,pyometritis,Labrador Retriever,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2289,MDH1,protein,pyometritis,German Shepherd Dog,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2289,MDH1,protein,pyometritis,Siberian Husky,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2289,MDH1,protein,pyometritis,English Bull Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2289,MDH1,protein,pyometritis,Dachshund,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2289,MDH1,protein,pyometritis,Pekingese,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2289,MDH1,protein,pyometritis,Yorkshire Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2290,CFL1,protein,pyometritis,Labrador Retriever,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2290,CFL1,protein,pyometritis,German Shepherd Dog,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2290,CFL1,protein,pyometritis,Siberian Husky,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2290,CFL1,protein,pyometritis,English Bull Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2290,CFL1,protein,pyometritis,Dachshund,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2290,CFL1,protein,pyometritis,Pekingese,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2290,CFL1,protein,pyometritis,Yorkshire Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2291,IDH1,protein,pyometritis,Labrador Retriever,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2291,IDH1,protein,pyometritis,German Shepherd Dog,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2291,IDH1,protein,pyometritis,Siberian Husky,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2291,IDH1,protein,pyometritis,English Bull Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2291,IDH1,protein,pyometritis,Dachshund,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2291,IDH1,protein,pyometritis,Pekingese,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2291,IDH1,protein,pyometritis,Yorkshire Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2292,Carcinoembryonic antigen-related cell adhesion molecule 1,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2292,Carcinoembryonic antigen-related cell adhesion molecule 1,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2292,Carcinoembryonic antigen-related cell adhesion molecule 1,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2292,Carcinoembryonic antigen-related cell adhesion molecule 1,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2292,Carcinoembryonic antigen-related cell adhesion molecule 1,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2292,Carcinoembryonic antigen-related cell adhesion molecule 1,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2292,Carcinoembryonic antigen-related cell adhesion molecule 1,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2292,Carcinoembryonic antigen-related cell adhesion molecule 1,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2292,Carcinoembryonic antigen-related cell adhesion molecule 1,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2293,2-hydroxyisobutyric acid,protein,diabetes mellitus,Rottweiler,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2293,2-hydroxyisobutyric acid,protein,diabetes mellitus,Pomeranian,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2293,2-hydroxyisobutyric acid,protein,diabetes mellitus,Miniature Pinscher,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2293,2-hydroxyisobutyric acid,protein,diabetes mellitus,Bichon Frise,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2293,2-hydroxyisobutyric acid,protein,diabetes mellitus,Silky Terrier,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2293,2-hydroxyisobutyric acid,protein,diabetes mellitus,Maltese,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2293,2-hydroxyisobutyric acid,protein,diabetes mellitus,Cavalier King Charles Spaniel,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2293,2-hydroxyisobutyric acid,protein,diabetes mellitus,Labrador Retriever,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2293,2-hydroxyisobutyric acid,protein,diabetes mellitus,Australian Shepherd,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2293,2-hydroxyisobutyric acid,protein,diabetes mellitus,Miniature Schnauzer,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2294,LRG1,protein,pyometritis,Labrador Retriever,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2294,LRG1,protein,pyometritis,German Shepherd Dog,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2294,LRG1,protein,pyometritis,Siberian Husky,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2294,LRG1,protein,pyometritis,English Bull Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2294,LRG1,protein,pyometritis,Dachshund,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2294,LRG1,protein,pyometritis,Pekingese,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2294,LRG1,protein,pyometritis,Yorkshire Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2295,ENO3,protein,pyometritis,Labrador Retriever,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2295,ENO3,protein,pyometritis,German Shepherd Dog,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2295,ENO3,protein,pyometritis,Siberian Husky,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2295,ENO3,protein,pyometritis,English Bull Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2295,ENO3,protein,pyometritis,Dachshund,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2295,ENO3,protein,pyometritis,Pekingese,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2295,ENO3,protein,pyometritis,Yorkshire Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2296,ENO1,protein,pyometritis,Labrador Retriever,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2296,ENO1,protein,pyometritis,German Shepherd Dog,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2296,ENO1,protein,pyometritis,Siberian Husky,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2296,ENO1,protein,pyometritis,English Bull Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2296,ENO1,protein,pyometritis,Dachshund,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2296,ENO1,protein,pyometritis,Pekingese,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2296,ENO1,protein,pyometritis,Yorkshire Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2297,HP,protein,pyometritis,Labrador Retriever,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2297,HP,protein,pyometritis,German Shepherd Dog,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2297,HP,protein,pyometritis,Siberian Husky,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2297,HP,protein,pyometritis,English Bull Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2297,HP,protein,pyometritis,Dachshund,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2297,HP,protein,pyometritis,Pekingese,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2297,HP,protein,pyometritis,Yorkshire Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2298,VIM,protein,pyometritis,Labrador Retriever,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2298,VIM,protein,pyometritis,German Shepherd Dog,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2298,VIM,protein,pyometritis,Siberian Husky,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2298,VIM,protein,pyometritis,English Bull Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2298,VIM,protein,pyometritis,Dachshund,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2298,VIM,protein,pyometritis,Pekingese,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2298,VIM,protein,pyometritis,Yorkshire Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2299,S100A12,protein,pyometritis,Labrador Retriever,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2299,S100A12,protein,pyometritis,German Shepherd Dog,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2299,S100A12,protein,pyometritis,Siberian Husky,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2299,S100A12,protein,pyometritis,English Bull Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2299,S100A12,protein,pyometritis,Dachshund,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2299,S100A12,protein,pyometritis,Pekingese,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2299,S100A12,protein,pyometritis,Yorkshire Terrier,F,,,9615,"In conclusion, it can be stated that there are changes in various proteins in saliva in canine pyometra reflecting different physiopathological changes occurring in this disease."
2300,"Haptoglobin light chain, HpL chain [dogs, Peptide, 83 aa]",protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2225,Haptoglobin-like,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2301,RecName: Full = Haptoglobin,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2302,"Haptoglobin heavy chain, HpH chain [dogs, Peptide, 245 aa]",protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
685,Kynurenine,metabolite,diabetes mellitus,Rottweiler,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
685,Kynurenine,metabolite,diabetes mellitus,Pomeranian,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
685,Kynurenine,metabolite,diabetes mellitus,Miniature Pinscher,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
685,Kynurenine,metabolite,diabetes mellitus,Bichon Frise,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
685,Kynurenine,metabolite,diabetes mellitus,Silky Terrier,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
685,Kynurenine,metabolite,diabetes mellitus,Maltese,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
685,Kynurenine,metabolite,diabetes mellitus,Cavalier King Charles Spaniel,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
685,Kynurenine,metabolite,diabetes mellitus,Labrador Retriever,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
685,Kynurenine,metabolite,diabetes mellitus,Australian Shepherd,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
685,Kynurenine,metabolite,diabetes mellitus,Miniature Schnauzer,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2303,Alpha-1-acid glycoprotein 1,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2304,C-reactive protein precursor,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2208,Lipopolysaccharide-binding protein,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2305,Interleukin-13 receptor subunit alpha-2 precursor,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2306,Immunoglobulin gamma heavy chain C,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2307,Alpha-2-macroglobulin,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2308,C4b-binding protein alpha chain,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2217,Hemopexin,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2309,Ceruloplasmin isoform X2,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2310,Ceruloplasmin isoform X1,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2311,Anthranilic acid,protein,diabetes mellitus,Rottweiler,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2311,Anthranilic acid,protein,diabetes mellitus,Pomeranian,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2311,Anthranilic acid,protein,diabetes mellitus,Miniature Pinscher,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2311,Anthranilic acid,protein,diabetes mellitus,Bichon Frise,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2311,Anthranilic acid,protein,diabetes mellitus,Silky Terrier,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2311,Anthranilic acid,protein,diabetes mellitus,Maltese,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2311,Anthranilic acid,protein,diabetes mellitus,Cavalier King Charles Spaniel,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2311,Anthranilic acid,protein,diabetes mellitus,Labrador Retriever,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2311,Anthranilic acid,protein,diabetes mellitus,Australian Shepherd,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2311,Anthranilic acid,protein,diabetes mellitus,Miniature Schnauzer,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2312,"Ceruloplasmin, partial",protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2313,Vitamin K-dependent protein S,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2314,Inter-alpha-trypsin inhibitor heavy chain H1 isoform X1,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2315,Alpha-2-antiplasmin isoform X2,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2316,Alpha-2-antiplasmin isoform X1,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2317,Plasma serine protease inhibitor,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2318,Inter-alpha-trypsin inhibitor heavy chain H1 isoform X2,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2319,Protein AMBP,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2230,Serum paraoxonase/arylesterase 1,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2215,Inter-alpha-trypsin inhibitor heavy chain H2,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2320,Citramalate,protein,diabetes mellitus,Rottweiler,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2320,Citramalate,protein,diabetes mellitus,Pomeranian,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2320,Citramalate,protein,diabetes mellitus,Miniature Pinscher,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2320,Citramalate,protein,diabetes mellitus,Bichon Frise,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2320,Citramalate,protein,diabetes mellitus,Silky Terrier,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2320,Citramalate,protein,diabetes mellitus,Maltese,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2320,Citramalate,protein,diabetes mellitus,Cavalier King Charles Spaniel,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2320,Citramalate,protein,diabetes mellitus,Labrador Retriever,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2320,Citramalate,protein,diabetes mellitus,Australian Shepherd,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2320,Citramalate,protein,diabetes mellitus,Miniature Schnauzer,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2321,antithrombin,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2322,Serotransferrin,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2323,Hemoglobin subunit beta-like,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2324,Transferrin receptor,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2325,Transferrin receptor protein 1 isoform X1,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2326,Vitamin D-binding protein,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2327,"Chain B, Crystal Structure Of Dog (Canis familiaris) Hemoglobin",protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2328,Alpha-2-HS-glycoprotein,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2329,Gelsolin,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2330,Transthyretin,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2331,L-Glutamine,metabolite,diabetes mellitus,Rottweiler,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2331,L-Glutamine,metabolite,diabetes mellitus,Pomeranian,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2331,L-Glutamine,metabolite,diabetes mellitus,Miniature Pinscher,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2331,L-Glutamine,metabolite,diabetes mellitus,Bichon Frise,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2331,L-Glutamine,metabolite,diabetes mellitus,Silky Terrier,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2331,L-Glutamine,metabolite,diabetes mellitus,Maltese,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2331,L-Glutamine,metabolite,diabetes mellitus,Cavalier King Charles Spaniel,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2331,L-Glutamine,metabolite,diabetes mellitus,Labrador Retriever,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2331,L-Glutamine,metabolite,diabetes mellitus,Australian Shepherd,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2331,L-Glutamine,metabolite,diabetes mellitus,Miniature Schnauzer,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2332,"Immunoglobulin heavy chain variable region, partial",protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2333,Retinol-binding protein 4,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2334,Histidine-rich glycoprotein isoform X1,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
2335,Plasma kallikrein,protein,pyometritis,,,5months-8years,,9615,"APPs play an important role in modulating the inflammatory immunological response, and their blood concentrations reflect the intensity of inflammation, which makes APP determination of diagnostic and prognostic value in pyometra. Determination of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic function impairment."
686,Asymmetric dimethylarginine,metabolite,acute pancreatitis,Poodle,both,10.4 ± 3.5 years,26 ± 19 kg,9615,"Because serum ADMA concentrations were
higher in AP dogs compared with the CG, it may have value as a biomarker in the diagnosis of AP in dogs. In addition, because ADMA was associated with mortality, it may have prognostic value"
686,Asymmetric dimethylarginine,metabolite,acute pancreatitis,German Shepherd Dog,both,10.4 ± 3.5 years,26 ± 19 kg,9615,"Because serum ADMA concentrations were
higher in AP dogs compared with the CG, it may have value as a biomarker in the diagnosis of AP in dogs. In addition, because ADMA was associated with mortality, it may have prognostic value"
686,Asymmetric dimethylarginine,metabolite,acute pancreatitis,Lagotto Romagnolo(Romagna Water Dog),both,10.4 ± 3.5 years,26 ± 19 kg,9615,"Because serum ADMA concentrations were
higher in AP dogs compared with the CG, it may have value as a biomarker in the diagnosis of AP in dogs. In addition, because ADMA was associated with mortality, it may have prognostic value"
686,Asymmetric dimethylarginine,metabolite,acute pancreatitis,Labrador Retriever,both,10.4 ± 3.5 years,26 ± 19 kg,9615,"Because serum ADMA concentrations were
higher in AP dogs compared with the CG, it may have value as a biomarker in the diagnosis of AP in dogs. In addition, because ADMA was associated with mortality, it may have prognostic value"
686,Asymmetric dimethylarginine,metabolite,acute pancreatitis,English Beagle,both,10.4 ± 3.5 years,26 ± 19 kg,9615,"Because serum ADMA concentrations were
higher in AP dogs compared with the CG, it may have value as a biomarker in the diagnosis of AP in dogs. In addition, because ADMA was associated with mortality, it may have prognostic value"
686,Asymmetric dimethylarginine,metabolite,acute pancreatitis,Jack Russell Terrier,both,10.4 ± 3.5 years,26 ± 19 kg,9615,"Because serum ADMA concentrations were
higher in AP dogs compared with the CG, it may have value as a biomarker in the diagnosis of AP in dogs. In addition, because ADMA was associated with mortality, it may have prognostic value"
686,Asymmetric dimethylarginine,metabolite,acute pancreatitis,English Springer Spaniel,both,10.4 ± 3.5 years,26 ± 19 kg,9615,"Because serum ADMA concentrations were
higher in AP dogs compared with the CG, it may have value as a biomarker in the diagnosis of AP in dogs. In addition, because ADMA was associated with mortality, it may have prognostic value"
686,Asymmetric dimethylarginine,metabolite,acute pancreatitis,Shih Tzu(Chrysanthemum Dog),both,10.4 ± 3.5 years,26 ± 19 kg,9615,"Because serum ADMA concentrations were
higher in AP dogs compared with the CG, it may have value as a biomarker in the diagnosis of AP in dogs. In addition, because ADMA was associated with mortality, it may have prognostic value"
686,Asymmetric dimethylarginine,metabolite,acute pancreatitis,Bloodhound,both,10.4 ± 3.5 years,26 ± 19 kg,9615,"Because serum ADMA concentrations were
higher in AP dogs compared with the CG, it may have value as a biomarker in the diagnosis of AP in dogs. In addition, because ADMA was associated with mortality, it may have prognostic value"
686,Asymmetric dimethylarginine,metabolite,acute pancreatitis,Border Collie,both,10.4 ± 3.5 years,26 ± 19 kg,9615,"Because serum ADMA concentrations were
higher in AP dogs compared with the CG, it may have value as a biomarker in the diagnosis of AP in dogs. In addition, because ADMA was associated with mortality, it may have prognostic value"
686,Asymmetric dimethylarginine,metabolite,acute pancreatitis,Bouvier des Flandres(Flanders Cattle Dog),both,10.4 ± 3.5 years,26 ± 19 kg,9615,"Because serum ADMA concentrations were
higher in AP dogs compared with the CG, it may have value as a biomarker in the diagnosis of AP in dogs. In addition, because ADMA was associated with mortality, it may have prognostic value"
686,Asymmetric dimethylarginine,metabolite,acute pancreatitis,German Boxer,both,10.4 ± 3.5 years,26 ± 19 kg,9615,"Because serum ADMA concentrations were
higher in AP dogs compared with the CG, it may have value as a biomarker in the diagnosis of AP in dogs. In addition, because ADMA was associated with mortality, it may have prognostic value"
686,Asymmetric dimethylarginine,metabolite,acute pancreatitis,Cavalier King Charles Spaniel,both,10.4 ± 3.5 years,26 ± 19 kg,9615,"Because serum ADMA concentrations were
higher in AP dogs compared with the CG, it may have value as a biomarker in the diagnosis of AP in dogs. In addition, because ADMA was associated with mortality, it may have prognostic value"
686,Asymmetric dimethylarginine,metabolite,acute pancreatitis,Cocker Spaniel,both,10.4 ± 3.5 years,26 ± 19 kg,9615,"Because serum ADMA concentrations were
higher in AP dogs compared with the CG, it may have value as a biomarker in the diagnosis of AP in dogs. In addition, because ADMA was associated with mortality, it may have prognostic value"
686,Asymmetric dimethylarginine,metabolite,acute pancreatitis,Dachshund,both,10.4 ± 3.5 years,26 ± 19 kg,9615,"Because serum ADMA concentrations were
higher in AP dogs compared with the CG, it may have value as a biomarker in the diagnosis of AP in dogs. In addition, because ADMA was associated with mortality, it may have prognostic value"
686,Asymmetric dimethylarginine,metabolite,acute pancreatitis,English Setter,both,10.4 ± 3.5 years,26 ± 19 kg,9615,"Because serum ADMA concentrations were
higher in AP dogs compared with the CG, it may have value as a biomarker in the diagnosis of AP in dogs. In addition, because ADMA was associated with mortality, it may have prognostic value"
686,Asymmetric dimethylarginine,metabolite,acute pancreatitis,Brittany,both,10.4 ± 3.5 years,26 ± 19 kg,9615,"Because serum ADMA concentrations were
higher in AP dogs compared with the CG, it may have value as a biomarker in the diagnosis of AP in dogs. In addition, because ADMA was associated with mortality, it may have prognostic value"
686,Asymmetric dimethylarginine,metabolite,acute pancreatitis,Flat-Coated Retriever,both,10.4 ± 3.5 years,26 ± 19 kg,9615,"Because serum ADMA concentrations were
higher in AP dogs compared with the CG, it may have value as a biomarker in the diagnosis of AP in dogs. In addition, because ADMA was associated with mortality, it may have prognostic value"
686,Asymmetric dimethylarginine,metabolite,acute pancreatitis,French Bulldog,both,10.4 ± 3.5 years,26 ± 19 kg,9615,"Because serum ADMA concentrations were
higher in AP dogs compared with the CG, it may have value as a biomarker in the diagnosis of AP in dogs. In addition, because ADMA was associated with mortality, it may have prognostic value"
686,Asymmetric dimethylarginine,metabolite,acute pancreatitis,English Bulldog,both,10.4 ± 3.5 years,26 ± 19 kg,9615,"Because serum ADMA concentrations were
higher in AP dogs compared with the CG, it may have value as a biomarker in the diagnosis of AP in dogs. In addition, because ADMA was associated with mortality, it may have prognostic value"
686,Asymmetric dimethylarginine,metabolite,acute pancreatitis,Golden Retriever,both,10.4 ± 3.5 years,26 ± 19 kg,9615,"Because serum ADMA concentrations were
higher in AP dogs compared with the CG, it may have value as a biomarker in the diagnosis of AP in dogs. In addition, because ADMA was associated with mortality, it may have prognostic value"
686,Asymmetric dimethylarginine,metabolite,acute pancreatitis,Great Dane,both,10.4 ± 3.5 years,26 ± 19 kg,9615,"Because serum ADMA concentrations were
higher in AP dogs compared with the CG, it may have value as a biomarker in the diagnosis of AP in dogs. In addition, because ADMA was associated with mortality, it may have prognostic value"
686,Asymmetric dimethylarginine,metabolite,acute pancreatitis,Bracco Italiano(Italian Pointer),both,10.4 ± 3.5 years,26 ± 19 kg,9615,"Because serum ADMA concentrations were
higher in AP dogs compared with the CG, it may have value as a biomarker in the diagnosis of AP in dogs. In addition, because ADMA was associated with mortality, it may have prognostic value"
686,Asymmetric dimethylarginine,metabolite,acute pancreatitis,Pug,both,10.4 ± 3.5 years,26 ± 19 kg,9615,"Because serum ADMA concentrations were
higher in AP dogs compared with the CG, it may have value as a biomarker in the diagnosis of AP in dogs. In addition, because ADMA was associated with mortality, it may have prognostic value"
686,Asymmetric dimethylarginine,metabolite,acute pancreatitis,Yorkshire Terrier,both,10.4 ± 3.5 years,26 ± 19 kg,9615,"Because serum ADMA concentrations were
higher in AP dogs compared with the CG, it may have value as a biomarker in the diagnosis of AP in dogs. In addition, because ADMA was associated with mortality, it may have prognostic value"
2336,POSTN,protein,neoplasm,Yorkshire Terrier,F,average：9years,,9615,"Moreover, POSTN may prove to be a useful marker in the evaluation of cancerous stroma of mammary tumours in female dogs, and may have prognostic significance."
2336,POSTN,protein,neoplasm,German Shepherd Dog,F,average：9years,,9615,"Moreover, POSTN may prove to be a useful marker in the evaluation of cancerous stroma of mammary tumours in female dogs, and may have prognostic significance."
2336,POSTN,protein,neoplasm,Standard Schnauzer,F,average：9years,,9615,"Moreover, POSTN may prove to be a useful marker in the evaluation of cancerous stroma of mammary tumours in female dogs, and may have prognostic significance."
2336,POSTN,protein,neoplasm,Shih Tzu(Chrysanthemum Dog),F,average：9years,,9615,"Moreover, POSTN may prove to be a useful marker in the evaluation of cancerous stroma of mammary tumours in female dogs, and may have prognostic significance."
2336,POSTN,protein,neoplasm,Dachshund,F,average：9years,,9615,"Moreover, POSTN may prove to be a useful marker in the evaluation of cancerous stroma of mammary tumours in female dogs, and may have prognostic significance."
2336,POSTN,protein,neoplasm,West Highland White Terrier,F,average：9years,,9615,"Moreover, POSTN may prove to be a useful marker in the evaluation of cancerous stroma of mammary tumours in female dogs, and may have prognostic significance."
2336,POSTN,protein,neoplasm,Golden Retriever,F,average：9years,,9615,"Moreover, POSTN may prove to be a useful marker in the evaluation of cancerous stroma of mammary tumours in female dogs, and may have prognostic significance."
2336,POSTN,protein,neoplasm,Siberian Husky,F,average：9years,,9615,"Moreover, POSTN may prove to be a useful marker in the evaluation of cancerous stroma of mammary tumours in female dogs, and may have prognostic significance."
2336,POSTN,protein,neoplasm,American Bulldog,F,average：9years,,9615,"Moreover, POSTN may prove to be a useful marker in the evaluation of cancerous stroma of mammary tumours in female dogs, and may have prognostic significance."
2336,POSTN,protein,neoplasm,English Beagle,F,average：9years,,9615,"Moreover, POSTN may prove to be a useful marker in the evaluation of cancerous stroma of mammary tumours in female dogs, and may have prognostic significance."
2336,POSTN,protein,neoplasm,Alpine Spaniel,F,average：9years,,9615,"Moreover, POSTN may prove to be a useful marker in the evaluation of cancerous stroma of mammary tumours in female dogs, and may have prognostic significance."
2336,POSTN,protein,neoplasm,Bolognese,F,average：9years,,9615,"Moreover, POSTN may prove to be a useful marker in the evaluation of cancerous stroma of mammary tumours in female dogs, and may have prognostic significance."
2336,POSTN,protein,neoplasm,Boston Terrier,F,average：9years,,9615,"Moreover, POSTN may prove to be a useful marker in the evaluation of cancerous stroma of mammary tumours in female dogs, and may have prognostic significance."
2336,POSTN,protein,neoplasm,German Boxer,F,average：9years,,9615,"Moreover, POSTN may prove to be a useful marker in the evaluation of cancerous stroma of mammary tumours in female dogs, and may have prognostic significance."
2336,POSTN,protein,neoplasm,Cocker Spaniel,F,average：9years,,9615,"Moreover, POSTN may prove to be a useful marker in the evaluation of cancerous stroma of mammary tumours in female dogs, and may have prognostic significance."
2336,POSTN,protein,neoplasm,Labrador Retriever,F,average：9years,,9615,"Moreover, POSTN may prove to be a useful marker in the evaluation of cancerous stroma of mammary tumours in female dogs, and may have prognostic significance."
2336,POSTN,protein,neoplasm,Lhasa Apso(Long-Haired Lhasa Dog),F,average：9years,,9615,"Moreover, POSTN may prove to be a useful marker in the evaluation of cancerous stroma of mammary tumours in female dogs, and may have prognostic significance."
2336,POSTN,protein,neoplasm,Maltese,F,average：9years,,9615,"Moreover, POSTN may prove to be a useful marker in the evaluation of cancerous stroma of mammary tumours in female dogs, and may have prognostic significance."
2336,POSTN,protein,neoplasm,Black Russian Terrier,F,average：9years,,9615,"Moreover, POSTN may prove to be a useful marker in the evaluation of cancerous stroma of mammary tumours in female dogs, and may have prognostic significance."
2336,POSTN,protein,neoplasm,American Staffordshire Terrier,F,average：9years,,9615,"Moreover, POSTN may prove to be a useful marker in the evaluation of cancerous stroma of mammary tumours in female dogs, and may have prognostic significance."
2336,POSTN,protein,neoplasm,Irish Setter,F,average：9years,,9615,"Moreover, POSTN may prove to be a useful marker in the evaluation of cancerous stroma of mammary tumours in female dogs, and may have prognostic significance."
2336,POSTN,protein,neoplasm,Pug,F,average：9years,,9615,"Moreover, POSTN may prove to be a useful marker in the evaluation of cancerous stroma of mammary tumours in female dogs, and may have prognostic significance."
2337,complement component C6 (Canis lupus dingo),protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2338,complement component C6 [Canis lupus familiaris],protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2339,"IgA heavy chain constant region, partial (Canis lupus familiaris]",protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2340,pigment epithelium-derived factor [Canis lupus familiaris),protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2341,Tauroursodeoxycholic acid,protein,diabetes mellitus,Rottweiler,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2341,Tauroursodeoxycholic acid,protein,diabetes mellitus,Pomeranian,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2341,Tauroursodeoxycholic acid,protein,diabetes mellitus,Miniature Pinscher,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2341,Tauroursodeoxycholic acid,protein,diabetes mellitus,Bichon Frise,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2341,Tauroursodeoxycholic acid,protein,diabetes mellitus,Silky Terrier,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2341,Tauroursodeoxycholic acid,protein,diabetes mellitus,Maltese,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2341,Tauroursodeoxycholic acid,protein,diabetes mellitus,Cavalier King Charles Spaniel,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2341,Tauroursodeoxycholic acid,protein,diabetes mellitus,Labrador Retriever,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2341,Tauroursodeoxycholic acid,protein,diabetes mellitus,Australian Shepherd,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2341,Tauroursodeoxycholic acid,protein,diabetes mellitus,Miniature Schnauzer,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2342,pigment epithelium-derived factor isoform X1 [Canis lupus familiaris],protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2343,protein AMBP [Canis lupus dingo),protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2344,protein AMBP Canis lupus familiaris,protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2345,"unnamed protein product, partial (Canis lupus familiaris]",protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2346,"unnamed protein product, partial [Canis lupus familiaris]",protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2347,angiotensinogen [Canis lupus familiaris],protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2348,"angiotensinogen, partial (Canis lupus familiaris]",protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2349,complement C5 [Canis lupus dingo),protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2350,complement C5 [Canis lupus familiaris),protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2351,"fibrinogen A-alpha chain, partial [Canis lupus familiaris)",protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
654,Tyrosine,protein,diabetes mellitus,Rottweiler,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
654,Tyrosine,protein,diabetes mellitus,Pomeranian,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
654,Tyrosine,protein,diabetes mellitus,Miniature Pinscher,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
654,Tyrosine,protein,diabetes mellitus,Bichon Frise,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
654,Tyrosine,protein,diabetes mellitus,Silky Terrier,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
654,Tyrosine,protein,diabetes mellitus,Maltese,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
654,Tyrosine,protein,diabetes mellitus,Cavalier King Charles Spaniel,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
654,Tyrosine,protein,diabetes mellitus,Labrador Retriever,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
654,Tyrosine,protein,diabetes mellitus,Australian Shepherd,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
654,Tyrosine,protein,diabetes mellitus,Miniature Schnauzer,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2353,fibrinogen-alpha chain [Canis lupus dingo),protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2354,fibrinogen-alpha chain [Canis lupus familiaris),protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2355,"fibronectin, partial [Canis lupus familiaris]",protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2356,gelsolin isoform X1 [Canis lupus dingo),protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2357,gelsolin isoform X2 [Canis lupus dingo],protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2358,gelsolin isoform X3 [Canis lupus dingo],protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2359,immunoglobulin gamma-heavy chain D [Canis lupus familiaris],protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2360,interleukin-13 receptor subunit alpha-2 precursor [Canis lupus familiaris],protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2361,unnamed protein product [Canis lupus familiaris],protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2362,Isoleucine,metabolite,diabetes mellitus,Rottweiler,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2362,Isoleucine,metabolite,diabetes mellitus,Pomeranian,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2362,Isoleucine,metabolite,diabetes mellitus,Miniature Pinscher,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2362,Isoleucine,metabolite,diabetes mellitus,Bichon Frise,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2362,Isoleucine,metabolite,diabetes mellitus,Silky Terrier,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2362,Isoleucine,metabolite,diabetes mellitus,Maltese,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2362,Isoleucine,metabolite,diabetes mellitus,Cavalier King Charles Spaniel,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2362,Isoleucine,metabolite,diabetes mellitus,Labrador Retriever,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2362,Isoleucine,metabolite,diabetes mellitus,Australian Shepherd,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2362,Isoleucine,metabolite,diabetes mellitus,Miniature Schnauzer,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2346,"unnamed protein product, partial [Canis lupus familiaris]",protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2363,apolipoprotein H; beta-2-glycoprotein I [Canis lupus familiaris],protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2364,gelsolin (Canis lupus familiaris],protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2365,"haptoglobin heavy chain, HpH chain [dogs, Peptide, 245 aa)",protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2366,heparin cofactor 2 [Canis lupus familiaris],protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2367,LOW QUALITY PROTEIN: heparin cofactor 2 [Canis lupus dingo),protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2346,"unnamed protein product, partial [Canis lupus familiaris]",protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2368,albumin (Canis lupus familiaris],protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2369,ficolin-2 isoform X1 [Canis lupus familiaris],protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2370,ficolin-2 isoform X2 [Canis lupus familiaris),protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
2371,Leucine,metabolite,diabetes mellitus,Rottweiler,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2371,Leucine,metabolite,diabetes mellitus,Pomeranian,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2371,Leucine,metabolite,diabetes mellitus,Miniature Pinscher,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2371,Leucine,metabolite,diabetes mellitus,Bichon Frise,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2371,Leucine,metabolite,diabetes mellitus,Silky Terrier,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2371,Leucine,metabolite,diabetes mellitus,Maltese,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2371,Leucine,metabolite,diabetes mellitus,Cavalier King Charles Spaniel,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2371,Leucine,metabolite,diabetes mellitus,Labrador Retriever,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2371,Leucine,metabolite,diabetes mellitus,Australian Shepherd,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2371,Leucine,metabolite,diabetes mellitus,Miniature Schnauzer,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2372,LOW QUALITY PROTEIN: serum albumin-like [Canis lupus dingo],protein,breast carcinoma,,F,12.0 ± 1.93 years,,9615,"Proteins such as kallikrein-1 and immunoglobulin gamma-heavy chains A and D were related to CMT in this study for the first time, and could be considered as potential novel CMT biomarkers"
687,HIS,metabolite,intestinal disorder,German Shepherd Dog,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
687,HIS,metabolite,intestinal disorder,Maltese,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
687,HIS,metabolite,intestinal disorder,Dachshund,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
687,HIS,metabolite,intestinal disorder,Affenpinshcher(Monkey Terrier),both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
687,HIS,metabolite,intestinal disorder,Rottweiler,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
687,HIS,metabolite,intestinal disorder,Yorkshire Terrier,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
687,HIS,metabolite,intestinal disorder,Jack Russell Terrier,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
687,HIS,metabolite,intestinal disorder,Spanish Greyhound,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
687,HIS,metabolite,intestinal disorder,Cavalier King Charles Spaniel,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
687,HIS,metabolite,intestinal disorder,Weimaraner,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
687,HIS,metabolite,intestinal disorder,West Highland White Terrier,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
687,HIS,metabolite,intestinal disorder,Cocker Spaniel,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
687,HIS,metabolite,intestinal disorder,Bernese Mountain Dog,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
687,HIS,metabolite,intestinal disorder,Bolognese,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
687,HIS,metabolite,intestinal disorder,English Springer Spaniel,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
687,HIS,metabolite,intestinal disorder,German Boxer,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
687,HIS,metabolite,intestinal disorder,Doberman Pinscher,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
687,HIS,metabolite,intestinal disorder,Pug,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
687,HIS,metabolite,intestinal disorder,Italian Greyhound,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
687,HIS,metabolite,intestinal disorder,English Beagle,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
687,HIS,metabolite,intestinal disorder,Irish Setter,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
687,HIS,metabolite,intestinal disorder,Hungarian Vizsla,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
687,HIS,metabolite,intestinal disorder,Basenji(African Barkless Dog),both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
688,PHE,metabolite,intestinal disorder,German Shepherd Dog,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
688,PHE,metabolite,intestinal disorder,Maltese,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
688,PHE,metabolite,intestinal disorder,Dachshund,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
688,PHE,metabolite,intestinal disorder,Affenpinshcher(Monkey Terrier),both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
688,PHE,metabolite,intestinal disorder,Rottweiler,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
688,PHE,metabolite,intestinal disorder,Yorkshire Terrier,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
688,PHE,metabolite,intestinal disorder,Jack Russell Terrier,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
688,PHE,metabolite,intestinal disorder,Spanish Greyhound,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
688,PHE,metabolite,intestinal disorder,Cavalier King Charles Spaniel,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
688,PHE,metabolite,intestinal disorder,Weimaraner,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
688,PHE,metabolite,intestinal disorder,West Highland White Terrier,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
688,PHE,metabolite,intestinal disorder,Cocker Spaniel,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
688,PHE,metabolite,intestinal disorder,Bernese Mountain Dog,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
688,PHE,metabolite,intestinal disorder,Bolognese,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
688,PHE,metabolite,intestinal disorder,English Springer Spaniel,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
688,PHE,metabolite,intestinal disorder,German Boxer,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
688,PHE,metabolite,intestinal disorder,Doberman Pinscher,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
688,PHE,metabolite,intestinal disorder,Pug,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
688,PHE,metabolite,intestinal disorder,Italian Greyhound,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
688,PHE,metabolite,intestinal disorder,English Beagle,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
688,PHE,metabolite,intestinal disorder,Irish Setter,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
688,PHE,metabolite,intestinal disorder,Hungarian Vizsla,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
688,PHE,metabolite,intestinal disorder,Basenji(African Barkless Dog),both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
689,TRP,metabolite,intestinal disorder,German Shepherd Dog,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
689,TRP,metabolite,intestinal disorder,Maltese,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
689,TRP,metabolite,intestinal disorder,Dachshund,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
689,TRP,metabolite,intestinal disorder,Affenpinshcher(Monkey Terrier),both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
689,TRP,metabolite,intestinal disorder,Rottweiler,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
689,TRP,metabolite,intestinal disorder,Yorkshire Terrier,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
689,TRP,metabolite,intestinal disorder,Jack Russell Terrier,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
689,TRP,metabolite,intestinal disorder,Spanish Greyhound,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
689,TRP,metabolite,intestinal disorder,Cavalier King Charles Spaniel,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
689,TRP,metabolite,intestinal disorder,Weimaraner,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
689,TRP,metabolite,intestinal disorder,West Highland White Terrier,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
689,TRP,metabolite,intestinal disorder,Cocker Spaniel,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
689,TRP,metabolite,intestinal disorder,Bernese Mountain Dog,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
689,TRP,metabolite,intestinal disorder,Bolognese,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
689,TRP,metabolite,intestinal disorder,English Springer Spaniel,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
689,TRP,metabolite,intestinal disorder,German Boxer,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
689,TRP,metabolite,intestinal disorder,Doberman Pinscher,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
689,TRP,metabolite,intestinal disorder,Pug,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
689,TRP,metabolite,intestinal disorder,Italian Greyhound,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
689,TRP,metabolite,intestinal disorder,English Beagle,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
689,TRP,metabolite,intestinal disorder,Irish Setter,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
689,TRP,metabolite,intestinal disorder,Hungarian Vizsla,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
689,TRP,metabolite,intestinal disorder,Basenji(African Barkless Dog),both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
690,TYR,metabolite,intestinal disorder,German Shepherd Dog,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
690,TYR,metabolite,intestinal disorder,Maltese,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
690,TYR,metabolite,intestinal disorder,Dachshund,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
690,TYR,metabolite,intestinal disorder,Affenpinshcher(Monkey Terrier),both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
690,TYR,metabolite,intestinal disorder,Rottweiler,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
690,TYR,metabolite,intestinal disorder,Yorkshire Terrier,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
690,TYR,metabolite,intestinal disorder,Jack Russell Terrier,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
690,TYR,metabolite,intestinal disorder,Spanish Greyhound,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
690,TYR,metabolite,intestinal disorder,Cavalier King Charles Spaniel,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
690,TYR,metabolite,intestinal disorder,Weimaraner,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
690,TYR,metabolite,intestinal disorder,West Highland White Terrier,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
690,TYR,metabolite,intestinal disorder,Cocker Spaniel,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
690,TYR,metabolite,intestinal disorder,Bernese Mountain Dog,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
690,TYR,metabolite,intestinal disorder,Bolognese,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
690,TYR,metabolite,intestinal disorder,English Springer Spaniel,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
690,TYR,metabolite,intestinal disorder,German Boxer,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
690,TYR,metabolite,intestinal disorder,Doberman Pinscher,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
690,TYR,metabolite,intestinal disorder,Pug,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
690,TYR,metabolite,intestinal disorder,Italian Greyhound,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
690,TYR,metabolite,intestinal disorder,English Beagle,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
690,TYR,metabolite,intestinal disorder,Irish Setter,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
690,TYR,metabolite,intestinal disorder,Hungarian Vizsla,both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
690,TYR,metabolite,intestinal disorder,Basenji(African Barkless Dog),both,5.3 ± 3.7 years,,9615,"This study may suggest further investigation on serum, HIS, PHE, TRP and TYR as markers of intestinal disease and proposed HIS, PHE and TRP as prognostic marker for response to therapy."
681,serum zinc,metabolite,lymphocytic colitis,,,,,9615,These findings suggest that the serum zinc concentration is a useful biomarker for LPE severity and prognosis in dogs.
1048,miR-16,miRNA,inflammatory bowel disease,Chihuahua,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1048,miR-16,miRNA,inflammatory bowel disease,American Pit Bull Terrier,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1048,miR-16,miRNA,inflammatory bowel disease,Miniature Pinscher,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1048,miR-16,miRNA,inflammatory bowel disease,Labrador Retriever,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1048,miR-16,miRNA,inflammatory bowel disease,Maltese,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1048,miR-16,miRNA,inflammatory bowel disease,Pug,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1048,miR-16,miRNA,inflammatory bowel disease,Yorkshire Terrier,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1048,miR-16,miRNA,inflammatory bowel disease,German Shepherd Dog,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1048,miR-16,miRNA,inflammatory bowel disease,Bichon Frise,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1049,miR-21,miRNA,inflammatory bowel disease,Chihuahua,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1049,miR-21,miRNA,inflammatory bowel disease,American Pit Bull Terrier,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1049,miR-21,miRNA,inflammatory bowel disease,Miniature Pinscher,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1049,miR-21,miRNA,inflammatory bowel disease,Labrador Retriever,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1049,miR-21,miRNA,inflammatory bowel disease,Maltese,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1049,miR-21,miRNA,inflammatory bowel disease,Pug,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1049,miR-21,miRNA,inflammatory bowel disease,Yorkshire Terrier,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1049,miR-21,miRNA,inflammatory bowel disease,German Shepherd Dog,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1049,miR-21,miRNA,inflammatory bowel disease,Bichon Frise,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1050,miR-122 ,miRNA,inflammatory bowel disease,Chihuahua,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1050,miR-122 ,miRNA,inflammatory bowel disease,American Pit Bull Terrier,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1050,miR-122 ,miRNA,inflammatory bowel disease,Miniature Pinscher,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1050,miR-122 ,miRNA,inflammatory bowel disease,Labrador Retriever,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1050,miR-122 ,miRNA,inflammatory bowel disease,Maltese,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1050,miR-122 ,miRNA,inflammatory bowel disease,Pug,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1050,miR-122 ,miRNA,inflammatory bowel disease,Yorkshire Terrier,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1050,miR-122 ,miRNA,inflammatory bowel disease,German Shepherd Dog,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1050,miR-122 ,miRNA,inflammatory bowel disease,Bichon Frise,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1051,miR-147,miRNA,inflammatory bowel disease,Chihuahua,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1051,miR-147,miRNA,inflammatory bowel disease,American Pit Bull Terrier,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1051,miR-147,miRNA,inflammatory bowel disease,Miniature Pinscher,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1051,miR-147,miRNA,inflammatory bowel disease,Labrador Retriever,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1051,miR-147,miRNA,inflammatory bowel disease,Maltese,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1051,miR-147,miRNA,inflammatory bowel disease,Pug,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1051,miR-147,miRNA,inflammatory bowel disease,Yorkshire Terrier,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1051,miR-147,miRNA,inflammatory bowel disease,German Shepherd Dog,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1051,miR-147,miRNA,inflammatory bowel disease,Bichon Frise,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
2373,Tryptophan,metabolite,diabetes mellitus,Rottweiler,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2373,Tryptophan,metabolite,diabetes mellitus,Pomeranian,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2373,Tryptophan,metabolite,diabetes mellitus,Miniature Pinscher,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2373,Tryptophan,metabolite,diabetes mellitus,Bichon Frise,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2373,Tryptophan,metabolite,diabetes mellitus,Silky Terrier,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2373,Tryptophan,metabolite,diabetes mellitus,Maltese,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2373,Tryptophan,metabolite,diabetes mellitus,Cavalier King Charles Spaniel,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2373,Tryptophan,metabolite,diabetes mellitus,Labrador Retriever,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2373,Tryptophan,metabolite,diabetes mellitus,Australian Shepherd,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
2373,Tryptophan,metabolite,diabetes mellitus,Miniature Schnauzer,The diabetic group (n=15) consisted of five females (all spayed) and ten males (nine neutered),5-13years,5.4-57.7 kg,9615,"Of the biomarkers found to be statistically significant, valine, GABA, N-acetyl-L aspartic acid, and indoxyl sulfate were among those that distinguished diseased from healthy groups"
1052,miR-185,miRNA,inflammatory bowel disease,Chihuahua,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1052,miR-185,miRNA,inflammatory bowel disease,American Pit Bull Terrier,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1052,miR-185,miRNA,inflammatory bowel disease,Miniature Pinscher,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1052,miR-185,miRNA,inflammatory bowel disease,Labrador Retriever,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1052,miR-185,miRNA,inflammatory bowel disease,Maltese,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1052,miR-185,miRNA,inflammatory bowel disease,Pug,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1052,miR-185,miRNA,inflammatory bowel disease,Yorkshire Terrier,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1052,miR-185,miRNA,inflammatory bowel disease,German Shepherd Dog,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1052,miR-185,miRNA,inflammatory bowel disease,Bichon Frise,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1053,miR-192,miRNA,inflammatory bowel disease,Chihuahua,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1053,miR-192,miRNA,inflammatory bowel disease,American Pit Bull Terrier,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1053,miR-192,miRNA,inflammatory bowel disease,Miniature Pinscher,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1053,miR-192,miRNA,inflammatory bowel disease,Labrador Retriever,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1053,miR-192,miRNA,inflammatory bowel disease,Maltese,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1053,miR-192,miRNA,inflammatory bowel disease,Pug,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1053,miR-192,miRNA,inflammatory bowel disease,Yorkshire Terrier,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1053,miR-192,miRNA,inflammatory bowel disease,German Shepherd Dog,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1053,miR-192,miRNA,inflammatory bowel disease,Bichon Frise,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1021,miR-223,miRNA,inflammatory bowel disease,Chihuahua,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1021,miR-223,miRNA,inflammatory bowel disease,American Pit Bull Terrier,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1021,miR-223,miRNA,inflammatory bowel disease,Miniature Pinscher,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1021,miR-223,miRNA,inflammatory bowel disease,Labrador Retriever,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1021,miR-223,miRNA,inflammatory bowel disease,Maltese,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1021,miR-223,miRNA,inflammatory bowel disease,Pug,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1021,miR-223,miRNA,inflammatory bowel disease,Yorkshire Terrier,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1021,miR-223,miRNA,inflammatory bowel disease,German Shepherd Dog,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
1021,miR-223,miRNA,inflammatory bowel disease,Bichon Frise,both,2.5-15years,1.72-36.5kg,9615,Our data suggest the existence of dysregulated miRs expression patterns in canine IBD and support the potential future use of serum miRs as useful noninvasive biomarkers.
2374,PTHR1,protein,osteosarcoma,Staffordshire Bull Terrier,both,1-15years,,9615,The results of this study indicate that increased expression of PTHR1 antigen in canine OS is associated with poor prognosis. This suggests that PTHR1 may be useful as a prognostic  indicator in canine OS.
2374,PTHR1,protein,osteosarcoma,Greyhound,both,1-15years,,9615,The results of this study indicate that increased expression of PTHR1 antigen in canine OS is associated with poor prognosis. This suggests that PTHR1 may be useful as a prognostic  indicator in canine OS.
2374,PTHR1,protein,osteosarcoma,Rottweiler,both,1-15years,,9615,The results of this study indicate that increased expression of PTHR1 antigen in canine OS is associated with poor prognosis. This suggests that PTHR1 may be useful as a prognostic  indicator in canine OS.
2374,PTHR1,protein,osteosarcoma,English Mastiff,both,1-15years,,9615,The results of this study indicate that increased expression of PTHR1 antigen in canine OS is associated with poor prognosis. This suggests that PTHR1 may be useful as a prognostic  indicator in canine OS.
2374,PTHR1,protein,osteosarcoma,English Bulldog,both,1-15years,,9615,The results of this study indicate that increased expression of PTHR1 antigen in canine OS is associated with poor prognosis. This suggests that PTHR1 may be useful as a prognostic  indicator in canine OS.
2374,PTHR1,protein,osteosarcoma,Labrador Retriever,both,1-15years,,9615,The results of this study indicate that increased expression of PTHR1 antigen in canine OS is associated with poor prognosis. This suggests that PTHR1 may be useful as a prognostic  indicator in canine OS.
2374,PTHR1,protein,osteosarcoma,Giant Schnauzer,both,1-15years,,9615,The results of this study indicate that increased expression of PTHR1 antigen in canine OS is associated with poor prognosis. This suggests that PTHR1 may be useful as a prognostic  indicator in canine OS.
2374,PTHR1,protein,osteosarcoma,German Boxer,both,1-15years,,9615,The results of this study indicate that increased expression of PTHR1 antigen in canine OS is associated with poor prognosis. This suggests that PTHR1 may be useful as a prognostic  indicator in canine OS.
2374,PTHR1,protein,osteosarcoma,German Shepherd Dog,both,1-15years,,9615,The results of this study indicate that increased expression of PTHR1 antigen in canine OS is associated with poor prognosis. This suggests that PTHR1 may be useful as a prognostic  indicator in canine OS.
2374,PTHR1,protein,osteosarcoma,Poodle,both,1-15years,,9615,The results of this study indicate that increased expression of PTHR1 antigen in canine OS is associated with poor prognosis. This suggests that PTHR1 may be useful as a prognostic  indicator in canine OS.
2374,PTHR1,protein,osteosarcoma,Doberman Pinscher,both,1-15years,,9615,The results of this study indicate that increased expression of PTHR1 antigen in canine OS is associated with poor prognosis. This suggests that PTHR1 may be useful as a prognostic  indicator in canine OS.
2374,PTHR1,protein,osteosarcoma,Golden Retriever,both,1-15years,,9615,The results of this study indicate that increased expression of PTHR1 antigen in canine OS is associated with poor prognosis. This suggests that PTHR1 may be useful as a prognostic  indicator in canine OS.
2374,PTHR1,protein,osteosarcoma,Australian Cattle Dog,both,1-15years,,9615,The results of this study indicate that increased expression of PTHR1 antigen in canine OS is associated with poor prognosis. This suggests that PTHR1 may be useful as a prognostic  indicator in canine OS.
2374,PTHR1,protein,osteosarcoma,Cairn Terrier,both,1-15years,,9615,The results of this study indicate that increased expression of PTHR1 antigen in canine OS is associated with poor prognosis. This suggests that PTHR1 may be useful as a prognostic  indicator in canine OS.
2374,PTHR1,protein,osteosarcoma,Jack Russell Terrier,both,1-15years,,9615,The results of this study indicate that increased expression of PTHR1 antigen in canine OS is associated with poor prognosis. This suggests that PTHR1 may be useful as a prognostic  indicator in canine OS.
2374,PTHR1,protein,osteosarcoma,Border Collie,both,1-15years,,9615,The results of this study indicate that increased expression of PTHR1 antigen in canine OS is associated with poor prognosis. This suggests that PTHR1 may be useful as a prognostic  indicator in canine OS.
2374,PTHR1,protein,osteosarcoma,Labrador Retriever,both,1-15years,,9615,The results of this study indicate that increased expression of PTHR1 antigen in canine OS is associated with poor prognosis. This suggests that PTHR1 may be useful as a prognostic  indicator in canine OS.
2374,PTHR1,protein,osteosarcoma,American Staffordshire Terrier,both,1-15years,,9615,The results of this study indicate that increased expression of PTHR1 antigen in canine OS is associated with poor prognosis. This suggests that PTHR1 may be useful as a prognostic  indicator in canine OS.
2374,PTHR1,protein,osteosarcoma,White Swiss Shepherd Dog,both,1-15years,,9615,The results of this study indicate that increased expression of PTHR1 antigen in canine OS is associated with poor prognosis. This suggests that PTHR1 may be useful as a prognostic  indicator in canine OS.
2374,PTHR1,protein,osteosarcoma,Alaskan Malamute,both,1-15years,,9615,The results of this study indicate that increased expression of PTHR1 antigen in canine OS is associated with poor prognosis. This suggests that PTHR1 may be useful as a prognostic  indicator in canine OS.
2374,PTHR1,protein,osteosarcoma,Curly-Coated Retriever,both,1-15years,,9615,The results of this study indicate that increased expression of PTHR1 antigen in canine OS is associated with poor prognosis. This suggests that PTHR1 may be useful as a prognostic  indicator in canine OS.
2375,Procalcitonin,protein,sepsis,,male, 6 to 12 months,18.7 and 22.4 kg,9615,Procalcitonin expression is likely to be a clinically useful biomarker for sepsis in dogs and might have an additional role in prognostication and therapeutic decision-making
2376,uNGAL,protein,acute kidney failure,,,,,9615,"Although, uNGAL is a promising renal biomarker, further research is needed to define dog-specific reference values and to develop either an autoanalyzer or point-of-care test to enable the use of uNGAL in private practice."
2377,Galectin (Gal)-3,protein,melanoma,Poodle,both,13±2.98 years,,9615,We have confirmed the importance of nuclear atypia for MMs and suggest that Gal-3 is a valuable prognostic indicator for this neoplasm. More in-depth studies are needed to unveil Gal-3 functions in canine MMs using larger sample sizes.
2377,Galectin (Gal)-3,protein,melanoma,Cocker Spaniel,both,13±2.98 years,,9615,We have confirmed the importance of nuclear atypia for MMs and suggest that Gal-3 is a valuable prognostic indicator for this neoplasm. More in-depth studies are needed to unveil Gal-3 functions in canine MMs using larger sample sizes.
2377,Galectin (Gal)-3,protein,melanoma,Golden Retriever,both,13±2.98 years,,9615,We have confirmed the importance of nuclear atypia for MMs and suggest that Gal-3 is a valuable prognostic indicator for this neoplasm. More in-depth studies are needed to unveil Gal-3 functions in canine MMs using larger sample sizes.
2377,Galectin (Gal)-3,protein,melanoma,Standard Schnauzer,both,13±2.98 years,,9615,We have confirmed the importance of nuclear atypia for MMs and suggest that Gal-3 is a valuable prognostic indicator for this neoplasm. More in-depth studies are needed to unveil Gal-3 functions in canine MMs using larger sample sizes.
2377,Galectin (Gal)-3,protein,melanoma,Rottweiler,both,13±2.98 years,,9615,We have confirmed the importance of nuclear atypia for MMs and suggest that Gal-3 is a valuable prognostic indicator for this neoplasm. More in-depth studies are needed to unveil Gal-3 functions in canine MMs using larger sample sizes.
2377,Galectin (Gal)-3,protein,melanoma,Dachshund,both,13±2.98 years,,9615,We have confirmed the importance of nuclear atypia for MMs and suggest that Gal-3 is a valuable prognostic indicator for this neoplasm. More in-depth studies are needed to unveil Gal-3 functions in canine MMs using larger sample sizes.
2377,Galectin (Gal)-3,protein,melanoma,Siberian Husky,both,13±2.98 years,,9615,We have confirmed the importance of nuclear atypia for MMs and suggest that Gal-3 is a valuable prognostic indicator for this neoplasm. More in-depth studies are needed to unveil Gal-3 functions in canine MMs using larger sample sizes.
2377,Galectin (Gal)-3,protein,melanoma,Shih Tzu(Chrysanthemum Dog),both,13±2.98 years,,9615,We have confirmed the importance of nuclear atypia for MMs and suggest that Gal-3 is a valuable prognostic indicator for this neoplasm. More in-depth studies are needed to unveil Gal-3 functions in canine MMs using larger sample sizes.
2377,Galectin (Gal)-3,protein,melanoma,Weimaraner,both,13±2.98 years,,9615,We have confirmed the importance of nuclear atypia for MMs and suggest that Gal-3 is a valuable prognostic indicator for this neoplasm. More in-depth studies are needed to unveil Gal-3 functions in canine MMs using larger sample sizes.
2377,Galectin (Gal)-3,protein,melanoma,Lhasa Apso(Long-Haired Lhasa Dog),both,13±2.98 years,,9615,We have confirmed the importance of nuclear atypia for MMs and suggest that Gal-3 is a valuable prognostic indicator for this neoplasm. More in-depth studies are needed to unveil Gal-3 functions in canine MMs using larger sample sizes.
2377,Galectin (Gal)-3,protein,melanoma,Yorkshire Terrier,both,13±2.98 years,,9615,We have confirmed the importance of nuclear atypia for MMs and suggest that Gal-3 is a valuable prognostic indicator for this neoplasm. More in-depth studies are needed to unveil Gal-3 functions in canine MMs using larger sample sizes.
1054,miR-181,miRNA,lymphoma,,,,,9615,This study highlights microRNAs of interest for canine multicentric lymphoma. Future goals include development of microRNA panels that may be useful as biomarkers with the intent to provide improved outcome prediction to veterinary cancer patients.
1055,miR-29b,miRNA,lymphoma,,,,,9615,This study highlights microRNAs of interest for canine multicentric lymphoma. Future goals include development of microRNA panels that may be useful as biomarkers with the intent to provide improved outcome prediction to veterinary cancer patients.
1056,miR-101,miRNA,lymphoma,,,,,9615,This study highlights microRNAs of interest for canine multicentric lymphoma. Future goals include development of microRNA panels that may be useful as biomarkers with the intent to provide improved outcome prediction to veterinary cancer patients.
2378,Immunoglobulin gamma heavy chain D,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2378,Immunoglobulin gamma heavy chain D,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2378,Immunoglobulin gamma heavy chain D,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2378,Immunoglobulin gamma heavy chain D,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2378,Immunoglobulin gamma heavy chain D,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2378,Immunoglobulin gamma heavy chain D,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2378,Immunoglobulin gamma heavy chain D,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2378,Immunoglobulin gamma heavy chain D,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2378,Immunoglobulin gamma heavy chain D,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
188,CDC6,gene,neoplasm,,F:10;M:10,5-14years,,9615,"In conclusion, in this study we have discovered CDC6 as a potential tumour biomarker candidate"
1057,miR-150,miRNA,lymphoma,,,,,9615,This study highlights microRNAs of interest for canine multicentric lymphoma. Future goals include development of microRNA panels that may be useful as biomarkers with the intent to provide improved outcome prediction to veterinary cancer patients.
1058,miR-19a,miRNA,lymphoma,,,,,9615,This study highlights microRNAs of interest for canine multicentric lymphoma. Future goals include development of microRNA panels that may be useful as biomarkers with the intent to provide improved outcome prediction to veterinary cancer patients.
1059,miR-19b,miRNA,lymphoma,,,,,9615,This study highlights microRNAs of interest for canine multicentric lymphoma. Future goals include development of microRNA panels that may be useful as biomarkers with the intent to provide improved outcome prediction to veterinary cancer patients.
1060,miR-148,miRNA,lymphoma,,,,,9615,This study highlights microRNAs of interest for canine multicentric lymphoma. Future goals include development of microRNA panels that may be useful as biomarkers with the intent to provide improved outcome prediction to veterinary cancer patients.
2379,YKL-40,protein,neoplasm,,,,,9615,The results imply that plasma YKL-40 levels might have the potential to be developed as a marker of malignancy progression and prognosis in canine cancers.
2380,High mobility group box 1,protein,acute pancreatitis,Poodle,both,4-18years,1.36-3.5kg,9615,Results indicate that HMGB1 might be a useful biomarker for the progression of AP and may play a role in progression of AP into SIRS in dogs
2380,High mobility group box 1,protein,acute pancreatitis,Cocker Spaniel,both,4-18years,1.36-3.5kg,9615,Results indicate that HMGB1 might be a useful biomarker for the progression of AP and may play a role in progression of AP into SIRS in dogs
2380,High mobility group box 1,protein,acute pancreatitis,Golden Retriever,both,4-18years,1.36-3.5kg,9615,Results indicate that HMGB1 might be a useful biomarker for the progression of AP and may play a role in progression of AP into SIRS in dogs
2380,High mobility group box 1,protein,acute pancreatitis,Standard Schnauzer,both,4-18years,1.36-3.5kg,9615,Results indicate that HMGB1 might be a useful biomarker for the progression of AP and may play a role in progression of AP into SIRS in dogs
2380,High mobility group box 1,protein,acute pancreatitis,Rottweiler,both,4-18years,1.36-3.5kg,9615,Results indicate that HMGB1 might be a useful biomarker for the progression of AP and may play a role in progression of AP into SIRS in dogs
2380,High mobility group box 1,protein,acute pancreatitis,Dachshund,both,4-18years,1.36-3.5kg,9615,Results indicate that HMGB1 might be a useful biomarker for the progression of AP and may play a role in progression of AP into SIRS in dogs
2380,High mobility group box 1,protein,acute pancreatitis,Siberian Husky,both,4-18years,1.36-3.5kg,9615,Results indicate that HMGB1 might be a useful biomarker for the progression of AP and may play a role in progression of AP into SIRS in dogs
2380,High mobility group box 1,protein,acute pancreatitis,Shih Tzu(Chrysanthemum Dog),both,4-18years,1.36-3.5kg,9615,Results indicate that HMGB1 might be a useful biomarker for the progression of AP and may play a role in progression of AP into SIRS in dogs
2380,High mobility group box 1,protein,acute pancreatitis,Weimaraner,both,4-18years,1.36-3.5kg,9615,Results indicate that HMGB1 might be a useful biomarker for the progression of AP and may play a role in progression of AP into SIRS in dogs
2380,High mobility group box 1,protein,acute pancreatitis,Lhasa Apso(Long-Haired Lhasa Dog),both,4-18years,1.36-3.5kg,9615,Results indicate that HMGB1 might be a useful biomarker for the progression of AP and may play a role in progression of AP into SIRS in dogs
2380,High mobility group box 1,protein,acute pancreatitis,Yorkshire Terrier,both,4-18years,1.36-3.5kg,9615,Results indicate that HMGB1 might be a useful biomarker for the progression of AP and may play a role in progression of AP into SIRS in dogs
2380,High mobility group box 1,protein,acute pancreatitis,Maltese,both,4-18years,1.36-3.5kg,9615,Results indicate that HMGB1 might be a useful biomarker for the progression of AP and may play a role in progression of AP into SIRS in dogs
2380,High mobility group box 1,protein,acute pancreatitis,Miniature Poodle,both,4-18years,1.36-3.5kg,9615,Results indicate that HMGB1 might be a useful biomarker for the progression of AP and may play a role in progression of AP into SIRS in dogs
2380,High mobility group box 1,protein,acute pancreatitis,Pomeranian,both,4-18years,1.36-3.5kg,9615,Results indicate that HMGB1 might be a useful biomarker for the progression of AP and may play a role in progression of AP into SIRS in dogs
2380,High mobility group box 1,protein,acute pancreatitis,English Beagle,both,4-18years,1.36-3.5kg,9615,Results indicate that HMGB1 might be a useful biomarker for the progression of AP and may play a role in progression of AP into SIRS in dogs
2380,High mobility group box 1,protein,acute pancreatitis,Pekingese,both,4-18years,1.36-3.5kg,9615,Results indicate that HMGB1 might be a useful biomarker for the progression of AP and may play a role in progression of AP into SIRS in dogs
2380,High mobility group box 1,protein,acute pancreatitis,Miniature Schnauzer,both,4-18years,1.36-3.5kg,9615,Results indicate that HMGB1 might be a useful biomarker for the progression of AP and may play a role in progression of AP into SIRS in dogs
2381,Leptin,protein,bile duct cyst,Cocker Spaniel,both,11-13years,,9615,These results indicate that leptin is a potential biomarker reflecting the severity and prognosis of GBM and cholelithiasis both before and after cholecystectomy in dogs.
2381,Leptin,protein,bile duct cyst,Maltese,both,11-13years,,9615,These results indicate that leptin is a potential biomarker reflecting the severity and prognosis of GBM and cholelithiasis both before and after cholecystectomy in dogs.
2381,Leptin,protein,bile duct cyst,Pomeranian,both,11-13years,,9615,These results indicate that leptin is a potential biomarker reflecting the severity and prognosis of GBM and cholelithiasis both before and after cholecystectomy in dogs.
2381,Leptin,protein,bile duct cyst,Poodle,both,11-13years,,9615,These results indicate that leptin is a potential biomarker reflecting the severity and prognosis of GBM and cholelithiasis both before and after cholecystectomy in dogs.
2381,Leptin,protein,bile duct cyst,Standard Schnauzer,both,11-13years,,9615,These results indicate that leptin is a potential biomarker reflecting the severity and prognosis of GBM and cholelithiasis both before and after cholecystectomy in dogs.
2381,Leptin,protein,bile duct cyst,Dachshund,both,11-13years,,9615,These results indicate that leptin is a potential biomarker reflecting the severity and prognosis of GBM and cholelithiasis both before and after cholecystectomy in dogs.
2381,Leptin,protein,bile duct cyst,Shih Tzu(Chrysanthemum Dog),both,11-13years,,9615,These results indicate that leptin is a potential biomarker reflecting the severity and prognosis of GBM and cholelithiasis both before and after cholecystectomy in dogs.
2381,Leptin,protein,bile duct cyst,Yorkshire Terrier,both,11-13years,,9615,These results indicate that leptin is a potential biomarker reflecting the severity and prognosis of GBM and cholelithiasis both before and after cholecystectomy in dogs.
2382,KMO,protein,breast carcinoma,,,,,9615,"Taken together, the fndings indicated that KMO is a potential biomarker for tumor diagnosis, and this might open up new perspectives for clinical applications of CMT."
1061,miR-26b ,miRNA,neurodegenerative disease,Pembroke Welsh Corgi,,,,9615,These results suggest that plasma miR-26b is a potential novel diagnostic biomarker of DM.
691,Plasma serine concentration,metabolite,lymphocytic colitis,Miniature Dachshund,both,4.7-12.8 years,2.5-14.3 kg,9615,Plasma serine concentration might represent a novel maker of IBD in dogs.
691,Plasma serine concentration,metabolite,lymphocytic colitis,Boston Terrier,both,4.7-12.8 years,2.5-14.3 kg,9615,Plasma serine concentration might represent a novel maker of IBD in dogs.
691,Plasma serine concentration,metabolite,lymphocytic colitis,Italian Greyhound,both,4.7-12.8 years,2.5-14.3 kg,9615,Plasma serine concentration might represent a novel maker of IBD in dogs.
691,Plasma serine concentration,metabolite,lymphocytic colitis,Miniature Schnauzer,both,4.7-12.8 years,2.5-14.3 kg,9615,Plasma serine concentration might represent a novel maker of IBD in dogs.
691,Plasma serine concentration,metabolite,lymphocytic colitis,Papillon(Continental Toy Spaniel),both,4.7-12.8 years,2.5-14.3 kg,9615,Plasma serine concentration might represent a novel maker of IBD in dogs.
691,Plasma serine concentration,metabolite,lymphocytic colitis,Shih Tzu(Chrysanthemum Dog),both,4.7-12.8 years,2.5-14.3 kg,9615,Plasma serine concentration might represent a novel maker of IBD in dogs.
691,Plasma serine concentration,metabolite,lymphocytic colitis,Toy Poodle,both,4.7-12.8 years,2.5-14.3 kg,9615,Plasma serine concentration might represent a novel maker of IBD in dogs.
2383,uALP/uCr,protein,acute kidney failure,German Shepherd Dog,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2383,uALP/uCr,protein,acute kidney failure,Miniature Poodle,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2383,uALP/uCr,protein,acute kidney failure,Cane Corso(Italian Mastiff),"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2383,uALP/uCr,protein,acute kidney failure,Pekingese,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2383,uALP/uCr,protein,acute kidney failure,Labrador Retriever,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2383,uALP/uCr,protein,acute kidney failure,Golden Retriever,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2383,uALP/uCr,protein,acute kidney failure,Cocker Spaniel,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2383,uALP/uCr,protein,acute kidney failure,Doberman Pinscher,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2383,uALP/uCr,protein,acute kidney failure,Border Collie,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2384,heart-fatty acid binding protein,protein,MVP1,Golden Retriever,,2-14years,2.4-53kg,9615,"The elevation of HFABP in dogs with MVD and DCM in comparison to controls, its association with disease severity, and its potential in predicting reduced survival, suggest that HFABP might be useful as marker for canine MVD and DCM"
2384,heart-fatty acid binding protein,protein,MVP1,Labrador Retriever,,2-14years,2.4-53kg,9615,"The elevation of HFABP in dogs with MVD and DCM in comparison to controls, its association with disease severity, and its potential in predicting reduced survival, suggest that HFABP might be useful as marker for canine MVD and DCM"
2384,heart-fatty acid binding protein,protein,MVP1,German Boxer,,2-14years,2.4-53kg,9615,"The elevation of HFABP in dogs with MVD and DCM in comparison to controls, its association with disease severity, and its potential in predicting reduced survival, suggest that HFABP might be useful as marker for canine MVD and DCM"
2384,heart-fatty acid binding protein,protein,MVP1,Dogue de Bordeaux(French Mastiff),,2-14years,2.4-53kg,9615,"The elevation of HFABP in dogs with MVD and DCM in comparison to controls, its association with disease severity, and its potential in predicting reduced survival, suggest that HFABP might be useful as marker for canine MVD and DCM"
2384,heart-fatty acid binding protein,protein,MVP1,American Cocker Spaniel,,2-14years,2.4-53kg,9615,"The elevation of HFABP in dogs with MVD and DCM in comparison to controls, its association with disease severity, and its potential in predicting reduced survival, suggest that HFABP might be useful as marker for canine MVD and DCM"
2384,heart-fatty acid binding protein,protein,MVP1,Dachshund,,2-14years,2.4-53kg,9615,"The elevation of HFABP in dogs with MVD and DCM in comparison to controls, its association with disease severity, and its potential in predicting reduced survival, suggest that HFABP might be useful as marker for canine MVD and DCM"
2384,heart-fatty acid binding protein,protein,MVP1,Chihuahua,,2-14years,2.4-53kg,9615,"The elevation of HFABP in dogs with MVD and DCM in comparison to controls, its association with disease severity, and its potential in predicting reduced survival, suggest that HFABP might be useful as marker for canine MVD and DCM"
2384,heart-fatty acid binding protein,protein,MVP1,Doberman Pinscher,,2-14years,2.4-53kg,9615,"The elevation of HFABP in dogs with MVD and DCM in comparison to controls, its association with disease severity, and its potential in predicting reduced survival, suggest that HFABP might be useful as marker for canine MVD and DCM"
2384,heart-fatty acid binding protein,protein,MVP1,English Bulldog,,2-14years,2.4-53kg,9615,"The elevation of HFABP in dogs with MVD and DCM in comparison to controls, its association with disease severity, and its potential in predicting reduced survival, suggest that HFABP might be useful as marker for canine MVD and DCM"
2384,heart-fatty acid binding protein,protein,MVP1,Bouvier des Flandres(Flanders Cattle Dog),,2-14years,2.4-53kg,9615,"The elevation of HFABP in dogs with MVD and DCM in comparison to controls, its association with disease severity, and its potential in predicting reduced survival, suggest that HFABP might be useful as marker for canine MVD and DCM"
2384,heart-fatty acid binding protein,protein,MVP1,Border Collie,,2-14years,2.4-53kg,9615,"The elevation of HFABP in dogs with MVD and DCM in comparison to controls, its association with disease severity, and its potential in predicting reduced survival, suggest that HFABP might be useful as marker for canine MVD and DCM"
2384,heart-fatty acid binding protein,protein,MVP1,Border Terrier,,2-14years,2.4-53kg,9615,"The elevation of HFABP in dogs with MVD and DCM in comparison to controls, its association with disease severity, and its potential in predicting reduced survival, suggest that HFABP might be useful as marker for canine MVD and DCM"
2384,heart-fatty acid binding protein,protein,MVP1,English Springer Spaniel,,2-14years,2.4-53kg,9615,"The elevation of HFABP in dogs with MVD and DCM in comparison to controls, its association with disease severity, and its potential in predicting reduced survival, suggest that HFABP might be useful as marker for canine MVD and DCM"
2384,heart-fatty acid binding protein,protein,MVP1,English Setter,,2-14years,2.4-53kg,9615,"The elevation of HFABP in dogs with MVD and DCM in comparison to controls, its association with disease severity, and its potential in predicting reduced survival, suggest that HFABP might be useful as marker for canine MVD and DCM"
2384,heart-fatty acid binding protein,protein,MVP1,Weimaraner,,2-14years,2.4-53kg,9615,"The elevation of HFABP in dogs with MVD and DCM in comparison to controls, its association with disease severity, and its potential in predicting reduced survival, suggest that HFABP might be useful as marker for canine MVD and DCM"
2384,heart-fatty acid binding protein,protein,MVP1,Jack Russell Terrier,,2-14years,2.4-53kg,9615,"The elevation of HFABP in dogs with MVD and DCM in comparison to controls, its association with disease severity, and its potential in predicting reduced survival, suggest that HFABP might be useful as marker for canine MVD and DCM"
2384,heart-fatty acid binding protein,protein,MVP1,Papillon(Continental Toy Spaniel),,2-14years,2.4-53kg,9615,"The elevation of HFABP in dogs with MVD and DCM in comparison to controls, its association with disease severity, and its potential in predicting reduced survival, suggest that HFABP might be useful as marker for canine MVD and DCM"
2384,heart-fatty acid binding protein,protein,MVP1,English Cocker Spaniel,,2-14years,2.4-53kg,9615,"The elevation of HFABP in dogs with MVD and DCM in comparison to controls, its association with disease severity, and its potential in predicting reduced survival, suggest that HFABP might be useful as marker for canine MVD and DCM"
2384,heart-fatty acid binding protein,protein,MVP1,German Shepherd Dog,,2-14years,2.4-53kg,9615,"The elevation of HFABP in dogs with MVD and DCM in comparison to controls, its association with disease severity, and its potential in predicting reduced survival, suggest that HFABP might be useful as marker for canine MVD and DCM"
2384,heart-fatty acid binding protein,protein,MVP1,Labrador Retriever,,2-14years,2.4-53kg,9615,"The elevation of HFABP in dogs with MVD and DCM in comparison to controls, its association with disease severity, and its potential in predicting reduced survival, suggest that HFABP might be useful as marker for canine MVD and DCM"
2384,heart-fatty acid binding protein,protein,MVP1,Standard Schnauzer,,2-14years,2.4-53kg,9615,"The elevation of HFABP in dogs with MVD and DCM in comparison to controls, its association with disease severity, and its potential in predicting reduced survival, suggest that HFABP might be useful as marker for canine MVD and DCM"
1062,Circulating miR-214,miRNA,osteosarcoma,Labrador Retriever,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1062,Circulating miR-214,miRNA,osteosarcoma,Golden Retriever,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1062,Circulating miR-214,miRNA,osteosarcoma,Great Dane,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1062,Circulating miR-214,miRNA,osteosarcoma,Rottweiler,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1062,Circulating miR-214,miRNA,osteosarcoma,American Staffordshire Terrier,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1062,Circulating miR-214,miRNA,osteosarcoma,English Bulldog,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1062,Circulating miR-214,miRNA,osteosarcoma,Greyhound,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1062,Circulating miR-214,miRNA,osteosarcoma,Akita,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1062,Circulating miR-214,miRNA,osteosarcoma,Bernese Mountain Dog,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1062,Circulating miR-214,miRNA,osteosarcoma,Great Pyrenees,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1062,Circulating miR-214,miRNA,osteosarcoma,Irish Setter,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1062,Circulating miR-214,miRNA,osteosarcoma,English Mastiff,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1062,Circulating miR-214,miRNA,osteosarcoma,Saint Bernard,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1062,Circulating miR-214,miRNA,osteosarcoma,Anatolian Shepherd Dog,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1062,Circulating miR-214,miRNA,osteosarcoma,Bullmastiff,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1062,Circulating miR-214,miRNA,osteosarcoma,Doberman Pinscher,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1062,Circulating miR-214,miRNA,osteosarcoma,Flat-Coated Retriever,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1062,Circulating miR-214,miRNA,osteosarcoma,German Shepherd Dog,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1062,Circulating miR-214,miRNA,osteosarcoma,German Wire-Haired Pointer,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1062,Circulating miR-214,miRNA,osteosarcoma,Norwegian Elkhound,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1062,Circulating miR-214,miRNA,osteosarcoma,Old English Shepherd Dog,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1062,Circulating miR-214,miRNA,osteosarcoma,Rhodesian Ridgeback,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1062,Circulating miR-214,miRNA,osteosarcoma,Swiss Mountain Dog,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1063,Circulating miR-126,miRNA,osteosarcoma,Labrador Retriever,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1063,Circulating miR-126,miRNA,osteosarcoma,Golden Retriever,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1063,Circulating miR-126,miRNA,osteosarcoma,Great Dane,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1063,Circulating miR-126,miRNA,osteosarcoma,Rottweiler,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1063,Circulating miR-126,miRNA,osteosarcoma,American Staffordshire Terrier,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1063,Circulating miR-126,miRNA,osteosarcoma,English Bulldog,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1063,Circulating miR-126,miRNA,osteosarcoma,Greyhound,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1063,Circulating miR-126,miRNA,osteosarcoma,Akita,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1063,Circulating miR-126,miRNA,osteosarcoma,Bernese Mountain Dog,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1063,Circulating miR-126,miRNA,osteosarcoma,Great Pyrenees,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1063,Circulating miR-126,miRNA,osteosarcoma,Irish Setter,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1063,Circulating miR-126,miRNA,osteosarcoma,English Mastiff,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1063,Circulating miR-126,miRNA,osteosarcoma,Saint Bernard,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1063,Circulating miR-126,miRNA,osteosarcoma,Anatolian Shepherd Dog,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1063,Circulating miR-126,miRNA,osteosarcoma,Bullmastiff,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1063,Circulating miR-126,miRNA,osteosarcoma,Doberman Pinscher,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1063,Circulating miR-126,miRNA,osteosarcoma,Flat-Coated Retriever,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1063,Circulating miR-126,miRNA,osteosarcoma,German Shepherd Dog,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1063,Circulating miR-126,miRNA,osteosarcoma,German Wire-Haired Pointer,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1063,Circulating miR-126,miRNA,osteosarcoma,Norwegian Elkhound,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1063,Circulating miR-126,miRNA,osteosarcoma,Old English Shepherd Dog,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1063,Circulating miR-126,miRNA,osteosarcoma,Rhodesian Ridgeback,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
1063,Circulating miR-126,miRNA,osteosarcoma,Swiss Mountain Dog,both,median age:8.2years,median weight:36kg,9615,"Circulating miR-214, − 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy."
2437,C-reactive protein,protein,breast carcinoma,,F,6-13years,,9615,"Higher concentrations of serum CRP in dogs with advanced stages of malignant tumours  may suggest that CRP could be a potential prognostic marker in canine malignant mammary tumours, but this hypothesis needs further study."
692,Humanin,metabolite,heart failure,,both,8.88-13.71years,4.31-5.9kg,9615,These findings suggest that a decreased plasma HN level can be used as a biomarker to identify dogs with MMVD-induced HF. 
2385,Angiopoietin-2,protein,systemic inflammatory response syndrome,,both,4.9-10.4years,12.7-36.7kg,9615,Ang-2 may represent a useful additional prognostic marker in dogs with SIRS
2386,ECPKA-Ab,protein,neoplasm,English Beagle,both,0.25-18years,,9615,"In conclusion, ECPKA-Ab is a potential serum biomarker for a broad spectrum of cancers. Combined measurement of CRP and ECPKA-Ab levels in serum improves the sensitivity and accuracy of a diagnosis of cancer in dogs."
2386,ECPKA-Ab,protein,neoplasm,Miniature Poodle,both,0.25-18years,,9615,"In conclusion, ECPKA-Ab is a potential serum biomarker for a broad spectrum of cancers. Combined measurement of CRP and ECPKA-Ab levels in serum improves the sensitivity and accuracy of a diagnosis of cancer in dogs."
2386,ECPKA-Ab,protein,neoplasm,Maltese,both,0.25-18years,,9615,"In conclusion, ECPKA-Ab is a potential serum biomarker for a broad spectrum of cancers. Combined measurement of CRP and ECPKA-Ab levels in serum improves the sensitivity and accuracy of a diagnosis of cancer in dogs."
2386,ECPKA-Ab,protein,neoplasm,Pomeranian,both,0.25-18years,,9615,"In conclusion, ECPKA-Ab is a potential serum biomarker for a broad spectrum of cancers. Combined measurement of CRP and ECPKA-Ab levels in serum improves the sensitivity and accuracy of a diagnosis of cancer in dogs."
2386,ECPKA-Ab,protein,neoplasm,Bichon Frise,both,0.25-18years,,9615,"In conclusion, ECPKA-Ab is a potential serum biomarker for a broad spectrum of cancers. Combined measurement of CRP and ECPKA-Ab levels in serum improves the sensitivity and accuracy of a diagnosis of cancer in dogs."
2386,ECPKA-Ab,protein,neoplasm,Shih Tzu(Chrysanthemum Dog),both,0.25-18years,,9615,"In conclusion, ECPKA-Ab is a potential serum biomarker for a broad spectrum of cancers. Combined measurement of CRP and ECPKA-Ab levels in serum improves the sensitivity and accuracy of a diagnosis of cancer in dogs."
2386,ECPKA-Ab,protein,neoplasm,Miniature Schnauzer,both,0.25-18years,,9615,"In conclusion, ECPKA-Ab is a potential serum biomarker for a broad spectrum of cancers. Combined measurement of CRP and ECPKA-Ab levels in serum improves the sensitivity and accuracy of a diagnosis of cancer in dogs."
2386,ECPKA-Ab,protein,neoplasm,Cocker Spaniel,both,0.25-18years,,9615,"In conclusion, ECPKA-Ab is a potential serum biomarker for a broad spectrum of cancers. Combined measurement of CRP and ECPKA-Ab levels in serum improves the sensitivity and accuracy of a diagnosis of cancer in dogs."
2386,ECPKA-Ab,protein,neoplasm,Yorkshire Terrier,both,0.25-18years,,9615,"In conclusion, ECPKA-Ab is a potential serum biomarker for a broad spectrum of cancers. Combined measurement of CRP and ECPKA-Ab levels in serum improves the sensitivity and accuracy of a diagnosis of cancer in dogs."
2387,FGF-23,protein,chronic kidney disease,Labrador Retriever,both,,,9615,"Multiple variables, including FGF-23, were associated with duration of survival in CKD dogs. FGF-23 could be a prognostic marker in dogs with CKD"
2387,FGF-23,protein,chronic kidney disease,Cocker Spaniel,both,,,9615,"Multiple variables, including FGF-23, were associated with duration of survival in CKD dogs. FGF-23 could be a prognostic marker in dogs with CKD"
2387,FGF-23,protein,chronic kidney disease,Shetland Shepherd Dog,both,,,9615,"Multiple variables, including FGF-23, were associated with duration of survival in CKD dogs. FGF-23 could be a prognostic marker in dogs with CKD"
2387,FGF-23,protein,chronic kidney disease,German Boxer,both,,,9615,"Multiple variables, including FGF-23, were associated with duration of survival in CKD dogs. FGF-23 could be a prognostic marker in dogs with CKD"
2387,FGF-23,protein,chronic kidney disease,Toy Fox Terrier,both,,,9615,"Multiple variables, including FGF-23, were associated with duration of survival in CKD dogs. FGF-23 could be a prognostic marker in dogs with CKD"
2387,FGF-23,protein,chronic kidney disease,German Shepherd Dog,both,,,9615,"Multiple variables, including FGF-23, were associated with duration of survival in CKD dogs. FGF-23 could be a prognostic marker in dogs with CKD"
2387,FGF-23,protein,chronic kidney disease,Greyhound,both,,,9615,"Multiple variables, including FGF-23, were associated with duration of survival in CKD dogs. FGF-23 could be a prognostic marker in dogs with CKD"
2387,FGF-23,protein,chronic kidney disease,Jack Russell Terrier,both,,,9615,"Multiple variables, including FGF-23, were associated with duration of survival in CKD dogs. FGF-23 could be a prognostic marker in dogs with CKD"
2387,FGF-23,protein,chronic kidney disease,Miniature Schnauzer,both,,,9615,"Multiple variables, including FGF-23, were associated with duration of survival in CKD dogs. FGF-23 could be a prognostic marker in dogs with CKD"
2387,FGF-23,protein,chronic kidney disease,Pekingese,both,,,9615,"Multiple variables, including FGF-23, were associated with duration of survival in CKD dogs. FGF-23 could be a prognostic marker in dogs with CKD"
2387,FGF-23,protein,chronic kidney disease,Pomeranian,both,,,9615,"Multiple variables, including FGF-23, were associated with duration of survival in CKD dogs. FGF-23 could be a prognostic marker in dogs with CKD"
2387,FGF-23,protein,chronic kidney disease,Shih Tzu(Chrysanthemum Dog),both,,,9615,"Multiple variables, including FGF-23, were associated with duration of survival in CKD dogs. FGF-23 could be a prognostic marker in dogs with CKD"
2387,FGF-23,protein,chronic kidney disease,Hungarian Vizsla,both,,,9615,"Multiple variables, including FGF-23, were associated with duration of survival in CKD dogs. FGF-23 could be a prognostic marker in dogs with CKD"
2387,FGF-23,protein,chronic kidney disease,English Whippet,both,,,9615,"Multiple variables, including FGF-23, were associated with duration of survival in CKD dogs. FGF-23 could be a prognostic marker in dogs with CKD"
693,SDMA,metabolite,"mitral valve prolapse, myxomatous 3",,both,median age：11.5years,median body weight：13.8kg,9615,"Blood concentration of SDMA resulted not influenced by the variables mentioned above, so it could be considered a reliable marker of early renal impairment in dogs affected by mitral valve disease."
2388,p21,protein,hepatitis,English Cocker Spaniel,both,0.75-12years,,9615,Marked p21 immunopositivity in dogs with CH might be indicative of widespread hepatocellular senescence. A significant association with survival time also suggests a potential value for p21 quantification in determining prognosis.
2388,p21,protein,hepatitis,Labrador Retriever,both,0.75-12years,,9615,Marked p21 immunopositivity in dogs with CH might be indicative of widespread hepatocellular senescence. A significant association with survival time also suggests a potential value for p21 quantification in determining prognosis.
2388,p21,protein,hepatitis,English Springer Spaniel,both,0.75-12years,,9615,Marked p21 immunopositivity in dogs with CH might be indicative of widespread hepatocellular senescence. A significant association with survival time also suggests a potential value for p21 quantification in determining prognosis.
2388,p21,protein,hepatitis,Bedlington Terrier,both,0.75-12years,,9615,Marked p21 immunopositivity in dogs with CH might be indicative of widespread hepatocellular senescence. A significant association with survival time also suggests a potential value for p21 quantification in determining prognosis.
2388,p21,protein,hepatitis,American Cocker Spaniel,both,0.75-12years,,9615,Marked p21 immunopositivity in dogs with CH might be indicative of widespread hepatocellular senescence. A significant association with survival time also suggests a potential value for p21 quantification in determining prognosis.
2388,p21,protein,hepatitis,Rottweiler,both,0.75-12years,,9615,Marked p21 immunopositivity in dogs with CH might be indicative of widespread hepatocellular senescence. A significant association with survival time also suggests a potential value for p21 quantification in determining prognosis.
2388,p21,protein,hepatitis,Tibetan Terrier,both,0.75-12years,,9615,Marked p21 immunopositivity in dogs with CH might be indicative of widespread hepatocellular senescence. A significant association with survival time also suggests a potential value for p21 quantification in determining prognosis.
2388,p21,protein,hepatitis,Golden Retriever,both,0.75-12years,,9615,Marked p21 immunopositivity in dogs with CH might be indicative of widespread hepatocellular senescence. A significant association with survival time also suggests a potential value for p21 quantification in determining prognosis.
2388,p21,protein,hepatitis,Doberman Pinscher,both,0.75-12years,,9615,Marked p21 immunopositivity in dogs with CH might be indicative of widespread hepatocellular senescence. A significant association with survival time also suggests a potential value for p21 quantification in determining prognosis.
2388,p21,protein,hepatitis,Welsh Springer Spaniel,both,0.75-12years,,9615,Marked p21 immunopositivity in dogs with CH might be indicative of widespread hepatocellular senescence. A significant association with survival time also suggests a potential value for p21 quantification in determining prognosis.
2388,p21,protein,hepatitis,Staffordshire Bull Terrier,both,0.75-12years,,9615,Marked p21 immunopositivity in dogs with CH might be indicative of widespread hepatocellular senescence. A significant association with survival time also suggests a potential value for p21 quantification in determining prognosis.
2388,p21,protein,hepatitis,Jack Russell Terrier,both,0.75-12years,,9615,Marked p21 immunopositivity in dogs with CH might be indicative of widespread hepatocellular senescence. A significant association with survival time also suggests a potential value for p21 quantification in determining prognosis.
2388,p21,protein,hepatitis,Poodle,both,0.75-12years,,9615,Marked p21 immunopositivity in dogs with CH might be indicative of widespread hepatocellular senescence. A significant association with survival time also suggests a potential value for p21 quantification in determining prognosis.
2389,uGGT/uCr,protein,acute kidney failure,German Shepherd Dog,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2389,uGGT/uCr,protein,acute kidney failure,Miniature Poodle,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2389,uGGT/uCr,protein,acute kidney failure,Cane Corso(Italian Mastiff),"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2389,uGGT/uCr,protein,acute kidney failure,Pekingese,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2389,uGGT/uCr,protein,acute kidney failure,Labrador Retriever,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2389,uGGT/uCr,protein,acute kidney failure,Golden Retriever,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2389,uGGT/uCr,protein,acute kidney failure,Cocker Spaniel,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2389,uGGT/uCr,protein,acute kidney failure,Doberman Pinscher,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2389,uGGT/uCr,protein,acute kidney failure,Border Collie,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
1064,miRNA-122,miRNA,hepatitis,,,,,9615,"Serum hepatocyte-derived miRNA-122 is of diagnostic value and highly stable blood indicator for the detection  of hepatocellular injury in dogs than aminotransferases, especially in cases where aminotransferases do not exceed normal 
serum level."
2390,fecal cCP,protein,inflammatory bowel disease,West Highland White Terrier,both,2–14 years,,9615,Our data indicate that measurement of fecal cCP concentration is a useful biomarker for noninvasive evaluation of intestinal inflammation. Dogs with severe signs of GI disease more often have abnormal markers than dogs having less severe disease
2390,fecal cCP,protein,inflammatory bowel disease,Yorkshire Terrier,both,2–14 years,,9615,Our data indicate that measurement of fecal cCP concentration is a useful biomarker for noninvasive evaluation of intestinal inflammation. Dogs with severe signs of GI disease more often have abnormal markers than dogs having less severe disease
2390,fecal cCP,protein,inflammatory bowel disease,Scottish Terrier,both,2–14 years,,9615,Our data indicate that measurement of fecal cCP concentration is a useful biomarker for noninvasive evaluation of intestinal inflammation. Dogs with severe signs of GI disease more often have abnormal markers than dogs having less severe disease
2390,fecal cCP,protein,inflammatory bowel disease,Poodle,both,2–14 years,,9615,Our data indicate that measurement of fecal cCP concentration is a useful biomarker for noninvasive evaluation of intestinal inflammation. Dogs with severe signs of GI disease more often have abnormal markers than dogs having less severe disease
2390,fecal cCP,protein,inflammatory bowel disease,Collie,both,2–14 years,,9615,Our data indicate that measurement of fecal cCP concentration is a useful biomarker for noninvasive evaluation of intestinal inflammation. Dogs with severe signs of GI disease more often have abnormal markers than dogs having less severe disease
2390,fecal cCP,protein,inflammatory bowel disease,Labrador Retriever,both,2–14 years,,9615,Our data indicate that measurement of fecal cCP concentration is a useful biomarker for noninvasive evaluation of intestinal inflammation. Dogs with severe signs of GI disease more often have abnormal markers than dogs having less severe disease
2390,fecal cCP,protein,inflammatory bowel disease,Dachshund,both,2–14 years,,9615,Our data indicate that measurement of fecal cCP concentration is a useful biomarker for noninvasive evaluation of intestinal inflammation. Dogs with severe signs of GI disease more often have abnormal markers than dogs having less severe disease
2390,fecal cCP,protein,inflammatory bowel disease,Shih Tzu(Chrysanthemum Dog),both,2–14 years,,9615,Our data indicate that measurement of fecal cCP concentration is a useful biomarker for noninvasive evaluation of intestinal inflammation. Dogs with severe signs of GI disease more often have abnormal markers than dogs having less severe disease
2390,fecal cCP,protein,inflammatory bowel disease,English Beagle,both,2–14 years,,9615,Our data indicate that measurement of fecal cCP concentration is a useful biomarker for noninvasive evaluation of intestinal inflammation. Dogs with severe signs of GI disease more often have abnormal markers than dogs having less severe disease
2390,fecal cCP,protein,inflammatory bowel disease,Havanese,both,2–14 years,,9615,Our data indicate that measurement of fecal cCP concentration is a useful biomarker for noninvasive evaluation of intestinal inflammation. Dogs with severe signs of GI disease more often have abnormal markers than dogs having less severe disease
2390,fecal cCP,protein,inflammatory bowel disease,German Shepherd Dog,both,2–14 years,,9615,Our data indicate that measurement of fecal cCP concentration is a useful biomarker for noninvasive evaluation of intestinal inflammation. Dogs with severe signs of GI disease more often have abnormal markers than dogs having less severe disease
2391,apo A-I,protein,osteoarthritis,German Shepherd Dog,,0.6 to 13 years, 7 to 40 kg,9615,Results indicated that quantification of synovial fluid total protein and apo A-I concentrations might facilitate diagnosis of osteoarthritis secondary to CCLR in dogs. Further research and validation of synovial fluid apo A-I concentration as a biomarker for osteoarthritis in dogs are necessary before it can be recommended for clinical use. 
2391,apo A-I,protein,osteoarthritis,Jack Russell Terrier,,0.6 to 13 years, 7 to 40 kg,9615,Results indicated that quantification of synovial fluid total protein and apo A-I concentrations might facilitate diagnosis of osteoarthritis secondary to CCLR in dogs. Further research and validation of synovial fluid apo A-I concentration as a biomarker for osteoarthritis in dogs are necessary before it can be recommended for clinical use. 
2391,apo A-I,protein,osteoarthritis,American Staffordshire Terrier,,0.6 to 13 years, 7 to 40 kg,9615,Results indicated that quantification of synovial fluid total protein and apo A-I concentrations might facilitate diagnosis of osteoarthritis secondary to CCLR in dogs. Further research and validation of synovial fluid apo A-I concentration as a biomarker for osteoarthritis in dogs are necessary before it can be recommended for clinical use. 
2392,Fecal calprotectin,protein,intestinal disorder,,both,4-9years,4.7-26.7kg,9615,"Fecal calprotectin could be a useful surrogate marker of disease severity in dogs with CIE, but larger longitudinal studies are needed to evaluate its utility in predicting the response to treatment."
2393,14-3-3σ,protein,renal cell carcinoma,Labrador Retriever,both,2-12 years,,9615,These results suggest that 14-3-3s is a potential negative prognostic factor and a possible therapeutic target
2393,14-3-3σ,protein,renal cell carcinoma,German Boxer,both,2-12 years,,9615,These results suggest that 14-3-3s is a potential negative prognostic factor and a possible therapeutic target
2393,14-3-3σ,protein,renal cell carcinoma,Golden Retriever,both,2-12 years,,9615,These results suggest that 14-3-3s is a potential negative prognostic factor and a possible therapeutic target
2393,14-3-3σ,protein,renal cell carcinoma,German Shepherd Dog,both,2-12 years,,9615,These results suggest that 14-3-3s is a potential negative prognostic factor and a possible therapeutic target
2393,14-3-3σ,protein,renal cell carcinoma,Dalmatian,both,2-12 years,,9615,These results suggest that 14-3-3s is a potential negative prognostic factor and a possible therapeutic target
2393,14-3-3σ,protein,renal cell carcinoma,Cocker Spaniel,both,2-12 years,,9615,These results suggest that 14-3-3s is a potential negative prognostic factor and a possible therapeutic target
2393,14-3-3σ,protein,renal cell carcinoma,Rottweiler,both,2-12 years,,9615,These results suggest that 14-3-3s is a potential negative prognostic factor and a possible therapeutic target
2393,14-3-3σ,protein,renal cell carcinoma,Weimaraner,both,2-12 years,,9615,These results suggest that 14-3-3s is a potential negative prognostic factor and a possible therapeutic target
2393,14-3-3σ,protein,renal cell carcinoma,Akita,both,2-12 years,,9615,These results suggest that 14-3-3s is a potential negative prognostic factor and a possible therapeutic target
2393,14-3-3σ,protein,renal cell carcinoma,Spanish Greyhound,both,2-12 years,,9615,These results suggest that 14-3-3s is a potential negative prognostic factor and a possible therapeutic target
2393,14-3-3σ,protein,renal cell carcinoma,Bullmastiff,both,2-12 years,,9615,These results suggest that 14-3-3s is a potential negative prognostic factor and a possible therapeutic target
2393,14-3-3σ,protein,renal cell carcinoma,English Bulldog,both,2-12 years,,9615,These results suggest that 14-3-3s is a potential negative prognostic factor and a possible therapeutic target
2393,14-3-3σ,protein,renal cell carcinoma,Collie,both,2-12 years,,9615,These results suggest that 14-3-3s is a potential negative prognostic factor and a possible therapeutic target
1065,cfa-miR-124,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1065,cfa-miR-124,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1065,cfa-miR-124,miRNA,melanoma,Weimaraner,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1065,cfa-miR-124,miRNA,melanoma,Bernese Mountain Dog,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1065,cfa-miR-124,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1065,cfa-miR-124,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1065,cfa-miR-124,miRNA,melanoma,Miniature Schnauzer,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1065,cfa-miR-124,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1065,cfa-miR-124,miRNA,melanoma,Border Collie,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1065,cfa-miR-124,miRNA,melanoma,Jack Russell Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1065,cfa-miR-124,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1065,cfa-miR-124,miRNA,melanoma,Shih Tzu(Chrysanthemum Dog),both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1065,cfa-miR-124,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1065,cfa-miR-124,miRNA,melanoma,Golden Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1065,cfa-miR-124,miRNA,melanoma,Toy Fox Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1065,cfa-miR-124,miRNA,melanoma,Doberman Pinscher,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1018,cfa-miR-130b,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1018,cfa-miR-130b,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1018,cfa-miR-130b,miRNA,melanoma,Weimaraner,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1018,cfa-miR-130b,miRNA,melanoma,Bernese Mountain Dog,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1018,cfa-miR-130b,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1018,cfa-miR-130b,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1018,cfa-miR-130b,miRNA,melanoma,Miniature Schnauzer,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1018,cfa-miR-130b,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1018,cfa-miR-130b,miRNA,melanoma,Border Collie,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1018,cfa-miR-130b,miRNA,melanoma,Jack Russell Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1018,cfa-miR-130b,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1018,cfa-miR-130b,miRNA,melanoma,Shih Tzu(Chrysanthemum Dog),both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1018,cfa-miR-130b,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1018,cfa-miR-130b,miRNA,melanoma,Golden Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1018,cfa-miR-130b,miRNA,melanoma,Toy Fox Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1018,cfa-miR-130b,miRNA,melanoma,Doberman Pinscher,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1066,cfa-miR-155,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1066,cfa-miR-155,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1066,cfa-miR-155,miRNA,melanoma,Weimaraner,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1066,cfa-miR-155,miRNA,melanoma,Bernese Mountain Dog,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1066,cfa-miR-155,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1066,cfa-miR-155,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1066,cfa-miR-155,miRNA,melanoma,Miniature Schnauzer,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1066,cfa-miR-155,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1066,cfa-miR-155,miRNA,melanoma,Border Collie,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1066,cfa-miR-155,miRNA,melanoma,Jack Russell Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1066,cfa-miR-155,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1066,cfa-miR-155,miRNA,melanoma,Shih Tzu(Chrysanthemum Dog),both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1066,cfa-miR-155,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1066,cfa-miR-155,miRNA,melanoma,Golden Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1066,cfa-miR-155,miRNA,melanoma,Toy Fox Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1066,cfa-miR-155,miRNA,melanoma,Doberman Pinscher,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1067,cfa-miR-182,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1067,cfa-miR-182,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1067,cfa-miR-182,miRNA,melanoma,Weimaraner,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1067,cfa-miR-182,miRNA,melanoma,Bernese Mountain Dog,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1067,cfa-miR-182,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1067,cfa-miR-182,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1067,cfa-miR-182,miRNA,melanoma,Miniature Schnauzer,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1067,cfa-miR-182,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1067,cfa-miR-182,miRNA,melanoma,Border Collie,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1067,cfa-miR-182,miRNA,melanoma,Jack Russell Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1067,cfa-miR-182,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1067,cfa-miR-182,miRNA,melanoma,Shih Tzu(Chrysanthemum Dog),both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1067,cfa-miR-182,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1067,cfa-miR-182,miRNA,melanoma,Golden Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1067,cfa-miR-182,miRNA,melanoma,Toy Fox Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1067,cfa-miR-182,miRNA,melanoma,Doberman Pinscher,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1068,cfa-miR-362,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1068,cfa-miR-362,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1068,cfa-miR-362,miRNA,melanoma,Weimaraner,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1068,cfa-miR-362,miRNA,melanoma,Bernese Mountain Dog,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1068,cfa-miR-362,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1068,cfa-miR-362,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1068,cfa-miR-362,miRNA,melanoma,Miniature Schnauzer,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1068,cfa-miR-362,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1068,cfa-miR-362,miRNA,melanoma,Border Collie,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1068,cfa-miR-362,miRNA,melanoma,Jack Russell Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1068,cfa-miR-362,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1068,cfa-miR-362,miRNA,melanoma,Shih Tzu(Chrysanthemum Dog),both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1068,cfa-miR-362,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1068,cfa-miR-362,miRNA,melanoma,Golden Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1068,cfa-miR-362,miRNA,melanoma,Toy Fox Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1068,cfa-miR-362,miRNA,melanoma,Doberman Pinscher,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
2394,uHSP70/uCr,protein,acute kidney failure,German Shepherd Dog,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2394,uHSP70/uCr,protein,acute kidney failure,Miniature Poodle,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2394,uHSP70/uCr,protein,acute kidney failure,Cane Corso(Italian Mastiff),"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2394,uHSP70/uCr,protein,acute kidney failure,Pekingese,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2394,uHSP70/uCr,protein,acute kidney failure,Labrador Retriever,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2394,uHSP70/uCr,protein,acute kidney failure,Golden Retriever,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2394,uHSP70/uCr,protein,acute kidney failure,Cocker Spaniel,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2394,uHSP70/uCr,protein,acute kidney failure,Doberman Pinscher,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2394,uHSP70/uCr,protein,acute kidney failure,Border Collie,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
1069,hsa-miR-4430,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1069,hsa-miR-4430,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1069,hsa-miR-4430,miRNA,melanoma,Weimaraner,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1069,hsa-miR-4430,miRNA,melanoma,Bernese Mountain Dog,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1069,hsa-miR-4430,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1069,hsa-miR-4430,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1069,hsa-miR-4430,miRNA,melanoma,Miniature Schnauzer,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1069,hsa-miR-4430,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1069,hsa-miR-4430,miRNA,melanoma,Border Collie,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1069,hsa-miR-4430,miRNA,melanoma,Jack Russell Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1069,hsa-miR-4430,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1069,hsa-miR-4430,miRNA,melanoma,Shih Tzu(Chrysanthemum Dog),both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1069,hsa-miR-4430,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1069,hsa-miR-4430,miRNA,melanoma,Golden Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1069,hsa-miR-4430,miRNA,melanoma,Toy Fox Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1069,hsa-miR-4430,miRNA,melanoma,Doberman Pinscher,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1070,hsa-miR-4454,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1070,hsa-miR-4454,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1070,hsa-miR-4454,miRNA,melanoma,Weimaraner,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1070,hsa-miR-4454,miRNA,melanoma,Bernese Mountain Dog,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1070,hsa-miR-4454,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1070,hsa-miR-4454,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1070,hsa-miR-4454,miRNA,melanoma,Miniature Schnauzer,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1070,hsa-miR-4454,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1070,hsa-miR-4454,miRNA,melanoma,Border Collie,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1070,hsa-miR-4454,miRNA,melanoma,Jack Russell Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1070,hsa-miR-4454,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1070,hsa-miR-4454,miRNA,melanoma,Shih Tzu(Chrysanthemum Dog),both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1070,hsa-miR-4454,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1070,hsa-miR-4454,miRNA,melanoma,Golden Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1070,hsa-miR-4454,miRNA,melanoma,Toy Fox Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1070,hsa-miR-4454,miRNA,melanoma,Doberman Pinscher,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1071,hsa-miR-4742-5p,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1071,hsa-miR-4742-5p,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1071,hsa-miR-4742-5p,miRNA,melanoma,Weimaraner,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1071,hsa-miR-4742-5p,miRNA,melanoma,Bernese Mountain Dog,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1071,hsa-miR-4742-5p,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1071,hsa-miR-4742-5p,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1071,hsa-miR-4742-5p,miRNA,melanoma,Miniature Schnauzer,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1071,hsa-miR-4742-5p,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1071,hsa-miR-4742-5p,miRNA,melanoma,Border Collie,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1071,hsa-miR-4742-5p,miRNA,melanoma,Jack Russell Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1071,hsa-miR-4742-5p,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1071,hsa-miR-4742-5p,miRNA,melanoma,Shih Tzu(Chrysanthemum Dog),both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1071,hsa-miR-4742-5p,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1071,hsa-miR-4742-5p,miRNA,melanoma,Golden Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1071,hsa-miR-4742-5p,miRNA,melanoma,Toy Fox Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1071,hsa-miR-4742-5p,miRNA,melanoma,Doberman Pinscher,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1072,hsa-miR-500a,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1072,hsa-miR-500a,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1072,hsa-miR-500a,miRNA,melanoma,Weimaraner,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1072,hsa-miR-500a,miRNA,melanoma,Bernese Mountain Dog,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1072,hsa-miR-500a,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1072,hsa-miR-500a,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1072,hsa-miR-500a,miRNA,melanoma,Miniature Schnauzer,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1072,hsa-miR-500a,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1072,hsa-miR-500a,miRNA,melanoma,Border Collie,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1072,hsa-miR-500a,miRNA,melanoma,Jack Russell Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1072,hsa-miR-500a,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1072,hsa-miR-500a,miRNA,melanoma,Shih Tzu(Chrysanthemum Dog),both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1072,hsa-miR-500a,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1072,hsa-miR-500a,miRNA,melanoma,Golden Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1072,hsa-miR-500a,miRNA,melanoma,Toy Fox Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1072,hsa-miR-500a,miRNA,melanoma,Doberman Pinscher,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1073,mml-miR-548c,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1073,mml-miR-548c,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1073,mml-miR-548c,miRNA,melanoma,Weimaraner,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1073,mml-miR-548c,miRNA,melanoma,Bernese Mountain Dog,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1073,mml-miR-548c,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1073,mml-miR-548c,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1073,mml-miR-548c,miRNA,melanoma,Miniature Schnauzer,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1073,mml-miR-548c,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1073,mml-miR-548c,miRNA,melanoma,Border Collie,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1073,mml-miR-548c,miRNA,melanoma,Jack Russell Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1073,mml-miR-548c,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1073,mml-miR-548c,miRNA,melanoma,Shih Tzu(Chrysanthemum Dog),both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1073,mml-miR-548c,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1073,mml-miR-548c,miRNA,melanoma,Golden Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1073,mml-miR-548c,miRNA,melanoma,Toy Fox Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1073,mml-miR-548c,miRNA,melanoma,Doberman Pinscher,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1074,bta-miR-2287,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1074,bta-miR-2287,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1074,bta-miR-2287,miRNA,melanoma,Weimaraner,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1074,bta-miR-2287,miRNA,melanoma,Bernese Mountain Dog,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1074,bta-miR-2287,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1074,bta-miR-2287,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1074,bta-miR-2287,miRNA,melanoma,Miniature Schnauzer,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1074,bta-miR-2287,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1074,bta-miR-2287,miRNA,melanoma,Border Collie,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1074,bta-miR-2287,miRNA,melanoma,Jack Russell Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1074,bta-miR-2287,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1074,bta-miR-2287,miRNA,melanoma,Shih Tzu(Chrysanthemum Dog),both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1074,bta-miR-2287,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1074,bta-miR-2287,miRNA,melanoma,Golden Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1074,bta-miR-2287,miRNA,melanoma,Toy Fox Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1074,bta-miR-2287,miRNA,melanoma,Doberman Pinscher,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1075,bta-miR-2382,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1075,bta-miR-2382,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1075,bta-miR-2382,miRNA,melanoma,Weimaraner,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1075,bta-miR-2382,miRNA,melanoma,Bernese Mountain Dog,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1075,bta-miR-2382,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1075,bta-miR-2382,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1075,bta-miR-2382,miRNA,melanoma,Miniature Schnauzer,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1075,bta-miR-2382,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1075,bta-miR-2382,miRNA,melanoma,Border Collie,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1075,bta-miR-2382,miRNA,melanoma,Jack Russell Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1075,bta-miR-2382,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1075,bta-miR-2382,miRNA,melanoma,Shih Tzu(Chrysanthemum Dog),both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1075,bta-miR-2382,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1075,bta-miR-2382,miRNA,melanoma,Golden Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1075,bta-miR-2382,miRNA,melanoma,Toy Fox Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1075,bta-miR-2382,miRNA,melanoma,Doberman Pinscher,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1076,bta-miR-2398,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1076,bta-miR-2398,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1076,bta-miR-2398,miRNA,melanoma,Weimaraner,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1076,bta-miR-2398,miRNA,melanoma,Bernese Mountain Dog,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1076,bta-miR-2398,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1076,bta-miR-2398,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1076,bta-miR-2398,miRNA,melanoma,Miniature Schnauzer,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1076,bta-miR-2398,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1076,bta-miR-2398,miRNA,melanoma,Border Collie,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1076,bta-miR-2398,miRNA,melanoma,Jack Russell Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1076,bta-miR-2398,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1076,bta-miR-2398,miRNA,melanoma,Shih Tzu(Chrysanthemum Dog),both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1076,bta-miR-2398,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1076,bta-miR-2398,miRNA,melanoma,Golden Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1076,bta-miR-2398,miRNA,melanoma,Toy Fox Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1076,bta-miR-2398,miRNA,melanoma,Doberman Pinscher,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1077,bta-miR-2411,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1077,bta-miR-2411,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1077,bta-miR-2411,miRNA,melanoma,Weimaraner,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1077,bta-miR-2411,miRNA,melanoma,Bernese Mountain Dog,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1077,bta-miR-2411,miRNA,melanoma,Flat-Coated Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1077,bta-miR-2411,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1077,bta-miR-2411,miRNA,melanoma,Miniature Schnauzer,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1077,bta-miR-2411,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1077,bta-miR-2411,miRNA,melanoma,Border Collie,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1077,bta-miR-2411,miRNA,melanoma,Jack Russell Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1077,bta-miR-2411,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1077,bta-miR-2411,miRNA,melanoma,Shih Tzu(Chrysanthemum Dog),both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1077,bta-miR-2411,miRNA,melanoma,Labrador Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1077,bta-miR-2411,miRNA,melanoma,Golden Retriever,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1077,bta-miR-2411,miRNA,melanoma,Toy Fox Terrier,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
1077,bta-miR-2411,miRNA,melanoma,Doberman Pinscher,both,0.27-17.58years,,9615,"miRNA expression profiles may potentially be used to identify UMs that will metastasize, and miRNAs that are up-regulated in metastasizing tumours may be targets for therapeutic intervention"
12897,cfa-let-7a,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12897,cfa-let-7a,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12897,cfa-let-7a,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12897,cfa-let-7a,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12897,cfa-let-7a,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12897,cfa-let-7a,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12897,cfa-let-7a,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12897,cfa-let-7a,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12897,cfa-let-7a,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12897,cfa-let-7a,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
2395,uIL-6/uCr,protein,acute kidney failure,German Shepherd Dog,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2395,uIL-6/uCr,protein,acute kidney failure,Miniature Poodle,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2395,uIL-6/uCr,protein,acute kidney failure,Cane Corso(Italian Mastiff),"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2395,uIL-6/uCr,protein,acute kidney failure,Pekingese,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2395,uIL-6/uCr,protein,acute kidney failure,Labrador Retriever,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2395,uIL-6/uCr,protein,acute kidney failure,Golden Retriever,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2395,uIL-6/uCr,protein,acute kidney failure,Cocker Spaniel,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2395,uIL-6/uCr,protein,acute kidney failure,Doberman Pinscher,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2395,uIL-6/uCr,protein,acute kidney failure,Border Collie,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
12898,cfa-miR-105a,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12898,cfa-miR-105a,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12898,cfa-miR-105a,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12898,cfa-miR-105a,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12898,cfa-miR-105a,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12898,cfa-miR-105a,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12898,cfa-miR-105a,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12898,cfa-miR-105a,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12898,cfa-miR-105a,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12898,cfa-miR-105a,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12899,cfa-miR-105b,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12899,cfa-miR-105b,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12899,cfa-miR-105b,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12899,cfa-miR-105b,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12899,cfa-miR-105b,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12899,cfa-miR-105b,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12899,cfa-miR-105b,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12899,cfa-miR-105b,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12899,cfa-miR-105b,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12899,cfa-miR-105b,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1063,cfa-miR-126,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1063,cfa-miR-126,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1063,cfa-miR-126,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1063,cfa-miR-126,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1063,cfa-miR-126,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1063,cfa-miR-126,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1063,cfa-miR-126,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1063,cfa-miR-126,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1063,cfa-miR-126,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1063,cfa-miR-126,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12900,cfa-miR-1271,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12900,cfa-miR-1271,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12900,cfa-miR-1271,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12900,cfa-miR-1271,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12900,cfa-miR-1271,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12900,cfa-miR-1271,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12900,cfa-miR-1271,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12900,cfa-miR-1271,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12900,cfa-miR-1271,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12900,cfa-miR-1271,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12901,cfa-miR-129,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12901,cfa-miR-129,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12901,cfa-miR-129,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12901,cfa-miR-129,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12901,cfa-miR-129,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12901,cfa-miR-129,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12901,cfa-miR-129,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12901,cfa-miR-129,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12901,cfa-miR-129,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12901,cfa-miR-129,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12902,cfa-miR-1307,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12902,cfa-miR-1307,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12902,cfa-miR-1307,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12902,cfa-miR-1307,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12902,cfa-miR-1307,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12902,cfa-miR-1307,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12902,cfa-miR-1307,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12902,cfa-miR-1307,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12902,cfa-miR-1307,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12902,cfa-miR-1307,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1033,cfa-miR-133a,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1033,cfa-miR-133a,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1033,cfa-miR-133a,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1033,cfa-miR-133a,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1033,cfa-miR-133a,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1033,cfa-miR-133a,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1033,cfa-miR-133a,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1033,cfa-miR-133a,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1033,cfa-miR-133a,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1033,cfa-miR-133a,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12903,cfa-miR-138b,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12903,cfa-miR-138b,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12903,cfa-miR-138b,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12903,cfa-miR-138b,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12903,cfa-miR-138b,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12903,cfa-miR-138b,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12903,cfa-miR-138b,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12903,cfa-miR-138b,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12903,cfa-miR-138b,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12903,cfa-miR-138b,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12904,cfa-miR-139,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12904,cfa-miR-139,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12904,cfa-miR-139,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12904,cfa-miR-139,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12904,cfa-miR-139,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12904,cfa-miR-139,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12904,cfa-miR-139,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12904,cfa-miR-139,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12904,cfa-miR-139,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12904,cfa-miR-139,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12905,cfa-miR-142,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12905,cfa-miR-142,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12905,cfa-miR-142,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12905,cfa-miR-142,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12905,cfa-miR-142,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12905,cfa-miR-142,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12905,cfa-miR-142,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12905,cfa-miR-142,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12905,cfa-miR-142,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12905,cfa-miR-142,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
2396,uIL-18/uCr,protein,acute kidney failure,German Shepherd Dog,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2396,uIL-18/uCr,protein,acute kidney failure,Miniature Poodle,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2396,uIL-18/uCr,protein,acute kidney failure,Cane Corso(Italian Mastiff),"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2396,uIL-18/uCr,protein,acute kidney failure,Pekingese,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2396,uIL-18/uCr,protein,acute kidney failure,Labrador Retriever,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2396,uIL-18/uCr,protein,acute kidney failure,Golden Retriever,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2396,uIL-18/uCr,protein,acute kidney failure,Cocker Spaniel,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2396,uIL-18/uCr,protein,acute kidney failure,Doberman Pinscher,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
2396,uIL-18/uCr,protein,acute kidney failure,Border Collie,"comprised 63 males (intact, 24; castrated, 39) and 55 females (intact, 24;spayed, 31)",120months,,9615,"Urinary (u) activity of γ-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP), and concentrations of heat-shock protein 70 (HSP70) and interleukins (ILs) -6 and -18, are predictive biomarkers for AKI and survival"
12906,cfa-miR-149,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12906,cfa-miR-149,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12906,cfa-miR-149,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12906,cfa-miR-149,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12906,cfa-miR-149,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12906,cfa-miR-149,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12906,cfa-miR-149,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12906,cfa-miR-149,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12906,cfa-miR-149,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12906,cfa-miR-149,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12907,cfa-miR-181d,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12907,cfa-miR-181d,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12907,cfa-miR-181d,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12907,cfa-miR-181d,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12907,cfa-miR-181d,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12907,cfa-miR-181d,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12907,cfa-miR-181d,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12907,cfa-miR-181d,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12907,cfa-miR-181d,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12907,cfa-miR-181d,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12908,cfa-miR-186,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12908,cfa-miR-186,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12908,cfa-miR-186,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12908,cfa-miR-186,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12908,cfa-miR-186,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12908,cfa-miR-186,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12908,cfa-miR-186,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12908,cfa-miR-186,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12908,cfa-miR-186,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12908,cfa-miR-186,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12909,cfa-miR-196a,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12909,cfa-miR-196a,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12909,cfa-miR-196a,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12909,cfa-miR-196a,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12909,cfa-miR-196a,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12909,cfa-miR-196a,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12909,cfa-miR-196a,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12909,cfa-miR-196a,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12909,cfa-miR-196a,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12909,cfa-miR-196a,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12910,cfa-miR-196b,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12910,cfa-miR-196b,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12910,cfa-miR-196b,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12910,cfa-miR-196b,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12910,cfa-miR-196b,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12910,cfa-miR-196b,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12910,cfa-miR-196b,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12910,cfa-miR-196b,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12910,cfa-miR-196b,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12910,cfa-miR-196b,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12911,cfa-miR-200b,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12911,cfa-miR-200b,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12911,cfa-miR-200b,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12911,cfa-miR-200b,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12911,cfa-miR-200b,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12911,cfa-miR-200b,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12911,cfa-miR-200b,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12911,cfa-miR-200b,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12911,cfa-miR-200b,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12911,cfa-miR-200b,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12912,cfa-miR-202,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12912,cfa-miR-202,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12912,cfa-miR-202,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12912,cfa-miR-202,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12912,cfa-miR-202,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12912,cfa-miR-202,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12912,cfa-miR-202,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12912,cfa-miR-202,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12912,cfa-miR-202,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12912,cfa-miR-202,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12913,cfa-miR-212,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12913,cfa-miR-212,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12913,cfa-miR-212,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12913,cfa-miR-212,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12913,cfa-miR-212,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12913,cfa-miR-212,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12913,cfa-miR-212,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12913,cfa-miR-212,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12913,cfa-miR-212,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12913,cfa-miR-212,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12914,cfa-miR-217,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12914,cfa-miR-217,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12914,cfa-miR-217,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12914,cfa-miR-217,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12914,cfa-miR-217,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12914,cfa-miR-217,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12914,cfa-miR-217,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12914,cfa-miR-217,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12914,cfa-miR-217,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12914,cfa-miR-217,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12915,cfa-miR-218,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12915,cfa-miR-218,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12915,cfa-miR-218,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12915,cfa-miR-218,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12915,cfa-miR-218,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12915,cfa-miR-218,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12915,cfa-miR-218,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12915,cfa-miR-218,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12915,cfa-miR-218,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12915,cfa-miR-218,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1018,cfa-miR-130b,miRNA,heart disorder,,,11.72 ± 2.43years,,9615,"Based on these results, cfa-miR-130b was selected as a candidate for promising common biomarker in various heart diseases."
12916,cfa-miR-219-5p,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12916,cfa-miR-219-5p,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12916,cfa-miR-219-5p,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12916,cfa-miR-219-5p,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12916,cfa-miR-219-5p,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12916,cfa-miR-219-5p,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12916,cfa-miR-219-5p,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12916,cfa-miR-219-5p,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12916,cfa-miR-219-5p,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12916,cfa-miR-219-5p,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12917,cfa-miR-29a,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12917,cfa-miR-29a,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12917,cfa-miR-29a,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12917,cfa-miR-29a,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12917,cfa-miR-29a,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12917,cfa-miR-29a,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12917,cfa-miR-29a,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12917,cfa-miR-29a,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12917,cfa-miR-29a,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12917,cfa-miR-29a,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12918,cfa-miR-30b,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12918,cfa-miR-30b,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12918,cfa-miR-30b,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12918,cfa-miR-30b,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12918,cfa-miR-30b,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12918,cfa-miR-30b,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12918,cfa-miR-30b,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12918,cfa-miR-30b,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12918,cfa-miR-30b,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12918,cfa-miR-30b,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12919,cfa-miR-325,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12919,cfa-miR-325,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12919,cfa-miR-325,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12919,cfa-miR-325,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12919,cfa-miR-325,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12919,cfa-miR-325,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12919,cfa-miR-325,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12919,cfa-miR-325,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12919,cfa-miR-325,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12919,cfa-miR-325,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12920,cfa-miR-329a,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12920,cfa-miR-329a,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12920,cfa-miR-329a,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12920,cfa-miR-329a,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12920,cfa-miR-329a,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12920,cfa-miR-329a,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12920,cfa-miR-329a,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12920,cfa-miR-329a,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12920,cfa-miR-329a,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12920,cfa-miR-329a,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12921,cfa-miR-335,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12921,cfa-miR-335,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12921,cfa-miR-335,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12921,cfa-miR-335,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12921,cfa-miR-335,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12921,cfa-miR-335,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12921,cfa-miR-335,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12921,cfa-miR-335,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12921,cfa-miR-335,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12921,cfa-miR-335,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12922,cfa-miR-338,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12922,cfa-miR-338,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12922,cfa-miR-338,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12922,cfa-miR-338,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12922,cfa-miR-338,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12922,cfa-miR-338,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12922,cfa-miR-338,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12922,cfa-miR-338,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12922,cfa-miR-338,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12922,cfa-miR-338,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1081,cfa-miR-345,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1081,cfa-miR-345,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1081,cfa-miR-345,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1081,cfa-miR-345,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1081,cfa-miR-345,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1081,cfa-miR-345,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1081,cfa-miR-345,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1081,cfa-miR-345,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1081,cfa-miR-345,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1081,cfa-miR-345,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12923,cfa-miR-34c,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12923,cfa-miR-34c,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12923,cfa-miR-34c,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12923,cfa-miR-34c,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12923,cfa-miR-34c,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12923,cfa-miR-34c,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12923,cfa-miR-34c,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12923,cfa-miR-34c,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12923,cfa-miR-34c,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12923,cfa-miR-34c,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12924,cfa-miR-363,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12924,cfa-miR-363,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12924,cfa-miR-363,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12924,cfa-miR-363,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12924,cfa-miR-363,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12924,cfa-miR-363,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12924,cfa-miR-363,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12924,cfa-miR-363,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12924,cfa-miR-363,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12924,cfa-miR-363,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1881,survivin,other,neoplasm,,,0.5-15.5years,,9615,"Therefore, survivin can provide information on the presence of malignant tumors and be used as a tumor marker in dogs."
12925,cfa-miR-374b,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12925,cfa-miR-374b,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12925,cfa-miR-374b,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12925,cfa-miR-374b,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12925,cfa-miR-374b,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12925,cfa-miR-374b,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12925,cfa-miR-374b,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12925,cfa-miR-374b,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12925,cfa-miR-374b,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12925,cfa-miR-374b,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12926,cfa-miR-376a,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12926,cfa-miR-376a,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12926,cfa-miR-376a,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12926,cfa-miR-376a,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12926,cfa-miR-376a,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12926,cfa-miR-376a,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12926,cfa-miR-376a,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12926,cfa-miR-376a,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12926,cfa-miR-376a,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12926,cfa-miR-376a,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12927,cfa-miR-379,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12927,cfa-miR-379,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12927,cfa-miR-379,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12927,cfa-miR-379,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12927,cfa-miR-379,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12927,cfa-miR-379,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12927,cfa-miR-379,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12927,cfa-miR-379,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12927,cfa-miR-379,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12927,cfa-miR-379,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12928,cfa-miR-380,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12928,cfa-miR-380,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12928,cfa-miR-380,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12928,cfa-miR-380,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12928,cfa-miR-380,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12928,cfa-miR-380,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12928,cfa-miR-380,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12928,cfa-miR-380,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12928,cfa-miR-380,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12928,cfa-miR-380,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12929,cfa-miR-382,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12929,cfa-miR-382,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12929,cfa-miR-382,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12929,cfa-miR-382,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12929,cfa-miR-382,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12929,cfa-miR-382,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12929,cfa-miR-382,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12929,cfa-miR-382,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12929,cfa-miR-382,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12929,cfa-miR-382,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12930,cfa-miR-384,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12930,cfa-miR-384,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12930,cfa-miR-384,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12930,cfa-miR-384,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12930,cfa-miR-384,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12930,cfa-miR-384,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12930,cfa-miR-384,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12930,cfa-miR-384,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12930,cfa-miR-384,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12930,cfa-miR-384,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12931,cfa-miR-421,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12931,cfa-miR-421,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12931,cfa-miR-421,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12931,cfa-miR-421,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12931,cfa-miR-421,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12931,cfa-miR-421,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12931,cfa-miR-421,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12931,cfa-miR-421,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12931,cfa-miR-421,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12931,cfa-miR-421,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12932,cfa-miR-429,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12932,cfa-miR-429,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12932,cfa-miR-429,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12932,cfa-miR-429,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12932,cfa-miR-429,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12932,cfa-miR-429,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12932,cfa-miR-429,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12932,cfa-miR-429,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12932,cfa-miR-429,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12932,cfa-miR-429,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12933,cfa-miR-487a,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12933,cfa-miR-487a,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12933,cfa-miR-487a,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12933,cfa-miR-487a,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12933,cfa-miR-487a,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12933,cfa-miR-487a,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12933,cfa-miR-487a,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12933,cfa-miR-487a,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12933,cfa-miR-487a,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12933,cfa-miR-487a,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12934,cfa-miR-489,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12934,cfa-miR-489,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12934,cfa-miR-489,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12934,cfa-miR-489,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12934,cfa-miR-489,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12934,cfa-miR-489,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12934,cfa-miR-489,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12934,cfa-miR-489,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12934,cfa-miR-489,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12934,cfa-miR-489,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1858,Cell-free DNA,other,neoplasm,,both,3-20years,,9615,"Overall, the results suggest that plasma cfDNA is a potentially useful indicator for monitoring treatment response and disease progression in dogs with tumors. Further large-scale studies are needed to determine the role of cfDNA as a surrogate biomarker in dogs with neoplastic diseases."
12935,cfa-miR-491,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12935,cfa-miR-491,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12935,cfa-miR-491,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12935,cfa-miR-491,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12935,cfa-miR-491,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12935,cfa-miR-491,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12935,cfa-miR-491,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12935,cfa-miR-491,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12935,cfa-miR-491,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12935,cfa-miR-491,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12936,cfa-miR-495,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12936,cfa-miR-495,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12936,cfa-miR-495,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12936,cfa-miR-495,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12936,cfa-miR-495,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12936,cfa-miR-495,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12936,cfa-miR-495,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12936,cfa-miR-495,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12936,cfa-miR-495,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12936,cfa-miR-495,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12937,cfa-miR-496,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12937,cfa-miR-496,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12937,cfa-miR-496,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12937,cfa-miR-496,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12937,cfa-miR-496,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12937,cfa-miR-496,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12937,cfa-miR-496,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12937,cfa-miR-496,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12937,cfa-miR-496,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12937,cfa-miR-496,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12938,cfa-miR-504,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12938,cfa-miR-504,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12938,cfa-miR-504,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12938,cfa-miR-504,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12938,cfa-miR-504,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12938,cfa-miR-504,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12938,cfa-miR-504,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12938,cfa-miR-504,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12938,cfa-miR-504,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12938,cfa-miR-504,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12939,cfa-miR-514,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12939,cfa-miR-514,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12939,cfa-miR-514,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12939,cfa-miR-514,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12939,cfa-miR-514,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12939,cfa-miR-514,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12939,cfa-miR-514,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12939,cfa-miR-514,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12939,cfa-miR-514,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12939,cfa-miR-514,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12940,cfa-miR-545,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12940,cfa-miR-545,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12940,cfa-miR-545,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12940,cfa-miR-545,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12940,cfa-miR-545,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12940,cfa-miR-545,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12940,cfa-miR-545,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12940,cfa-miR-545,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12940,cfa-miR-545,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12940,cfa-miR-545,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12941,cfa-miR-551a,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12941,cfa-miR-551a,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12941,cfa-miR-551a,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12941,cfa-miR-551a,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12941,cfa-miR-551a,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12941,cfa-miR-551a,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12941,cfa-miR-551a,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12941,cfa-miR-551a,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12941,cfa-miR-551a,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12941,cfa-miR-551a,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12942,cfa-miR-568,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12942,cfa-miR-568,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12942,cfa-miR-568,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12942,cfa-miR-568,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12942,cfa-miR-568,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12942,cfa-miR-568,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12942,cfa-miR-568,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12942,cfa-miR-568,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12942,cfa-miR-568,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12942,cfa-miR-568,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12943,cfa-miR-578,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12943,cfa-miR-578,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12943,cfa-miR-578,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12943,cfa-miR-578,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12943,cfa-miR-578,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12943,cfa-miR-578,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12943,cfa-miR-578,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12943,cfa-miR-578,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12943,cfa-miR-578,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12943,cfa-miR-578,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12944,cfa-miR-592,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12944,cfa-miR-592,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12944,cfa-miR-592,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12944,cfa-miR-592,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12944,cfa-miR-592,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12944,cfa-miR-592,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12944,cfa-miR-592,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12944,cfa-miR-592,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12944,cfa-miR-592,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12944,cfa-miR-592,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1882,cfDNA,other,pyometritis,Maltese,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
1882,cfDNA,other,pyometritis,Shih Tzu(Chrysanthemum Dog),female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
1882,cfDNA,other,pyometritis,Yorkshire Terrier,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
1882,cfDNA,other,pyometritis,Miniature Poodle,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
1882,cfDNA,other,pyometritis,Miniature Schnauzer,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
1882,cfDNA,other,pyometritis,Pomeranian,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
1882,cfDNA,other,pyometritis,Miniature Pinscher,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
1882,cfDNA,other,pyometritis,Dachshund,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
1882,cfDNA,other,pyometritis,French Bulldog,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
1882,cfDNA,other,pyometritis,Korean Jindo,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
1882,cfDNA,other,pyometritis,Chow Chow,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
1882,cfDNA,other,pyometritis,Cocker Spaniel,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
1882,cfDNA,other,pyometritis,Golden Retriever,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
1882,cfDNA,other,pyometritis,English Pointer,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
1882,cfDNA,other,pyometritis,Japanese Shiba Inu,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
12945,cfa-miR-708,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12945,cfa-miR-708,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12945,cfa-miR-708,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12945,cfa-miR-708,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12945,cfa-miR-708,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12945,cfa-miR-708,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12945,cfa-miR-708,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12945,cfa-miR-708,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12945,cfa-miR-708,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12945,cfa-miR-708,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12946,cfa-miR-759,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12946,cfa-miR-759,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12946,cfa-miR-759,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12946,cfa-miR-759,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12946,cfa-miR-759,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12946,cfa-miR-759,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12946,cfa-miR-759,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12946,cfa-miR-759,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12946,cfa-miR-759,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12946,cfa-miR-759,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12947,cfa-miR-761,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12947,cfa-miR-761,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12947,cfa-miR-761,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12947,cfa-miR-761,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12947,cfa-miR-761,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12947,cfa-miR-761,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12947,cfa-miR-761,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12947,cfa-miR-761,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12947,cfa-miR-761,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12947,cfa-miR-761,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12948,cfa-miR-764,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12948,cfa-miR-764,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12948,cfa-miR-764,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12948,cfa-miR-764,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12948,cfa-miR-764,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12948,cfa-miR-764,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12948,cfa-miR-764,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12948,cfa-miR-764,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12948,cfa-miR-764,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12948,cfa-miR-764,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12949,cfa-miR-802,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12949,cfa-miR-802,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12949,cfa-miR-802,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12949,cfa-miR-802,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12949,cfa-miR-802,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12949,cfa-miR-802,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12949,cfa-miR-802,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12949,cfa-miR-802,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12949,cfa-miR-802,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12949,cfa-miR-802,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12950,cfa-miR-872,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12950,cfa-miR-872,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12950,cfa-miR-872,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12950,cfa-miR-872,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12950,cfa-miR-872,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12950,cfa-miR-872,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12950,cfa-miR-872,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12950,cfa-miR-872,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12950,cfa-miR-872,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12950,cfa-miR-872,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12951,cfa-miR-99b,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12951,cfa-miR-99b,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12951,cfa-miR-99b,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12951,cfa-miR-99b,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12951,cfa-miR-99b,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12951,cfa-miR-99b,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12951,cfa-miR-99b,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12951,cfa-miR-99b,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12951,cfa-miR-99b,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12951,cfa-miR-99b,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12952,cfa-let-7f,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12952,cfa-let-7f,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12952,cfa-let-7f,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12952,cfa-let-7f,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12952,cfa-let-7f,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12952,cfa-let-7f,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12952,cfa-let-7f,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12952,cfa-let-7f,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12952,cfa-let-7f,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12952,cfa-let-7f,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1043,cfa-let-7g,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1043,cfa-let-7g,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1043,cfa-let-7g,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1043,cfa-let-7g,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1043,cfa-let-7g,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1043,cfa-let-7g,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1043,cfa-let-7g,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1043,cfa-let-7g,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1043,cfa-let-7g,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1043,cfa-let-7g,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12898,cfa-miR-105a,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12898,cfa-miR-105a,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12898,cfa-miR-105a,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12898,cfa-miR-105a,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12898,cfa-miR-105a,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12898,cfa-miR-105a,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12898,cfa-miR-105a,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12898,cfa-miR-105a,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12898,cfa-miR-105a,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12898,cfa-miR-105a,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
2397,N-acetylated alpha-linked acidic dipeptidase like 1,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2397,N-acetylated alpha-linked acidic dipeptidase like 1,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2397,N-acetylated alpha-linked acidic dipeptidase like 1,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2397,N-acetylated alpha-linked acidic dipeptidase like 1,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2397,N-acetylated alpha-linked acidic dipeptidase like 1,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2397,N-acetylated alpha-linked acidic dipeptidase like 1,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2397,N-acetylated alpha-linked acidic dipeptidase like 1,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2397,N-acetylated alpha-linked acidic dipeptidase like 1,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2397,N-acetylated alpha-linked acidic dipeptidase like 1,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2415,CRP,protein,pyometritis,Maltese,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2415,CRP,protein,pyometritis,Shih Tzu(Chrysanthemum Dog),female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2415,CRP,protein,pyometritis,Yorkshire Terrier,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2415,CRP,protein,pyometritis,Miniature Poodle,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2415,CRP,protein,pyometritis,Miniature Schnauzer,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2415,CRP,protein,pyometritis,Pomeranian,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2415,CRP,protein,pyometritis,Miniature Pinscher,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2415,CRP,protein,pyometritis,Dachshund,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2415,CRP,protein,pyometritis,French Bulldog,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2415,CRP,protein,pyometritis,Korean Jindo,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2415,CRP,protein,pyometritis,Chow Chow,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2415,CRP,protein,pyometritis,Cocker Spaniel,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2415,CRP,protein,pyometritis,Golden Retriever,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2415,CRP,protein,pyometritis,English Pointer,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2415,CRP,protein,pyometritis,Japanese Shiba Inu,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
12899,cfa-miR-105b,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12899,cfa-miR-105b,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12899,cfa-miR-105b,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12899,cfa-miR-105b,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12899,cfa-miR-105b,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12899,cfa-miR-105b,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12899,cfa-miR-105b,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12899,cfa-miR-105b,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12899,cfa-miR-105b,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12899,cfa-miR-105b,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1063,cfa-miR-126,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1063,cfa-miR-126,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1063,cfa-miR-126,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1063,cfa-miR-126,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1063,cfa-miR-126,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1063,cfa-miR-126,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1063,cfa-miR-126,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1063,cfa-miR-126,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1063,cfa-miR-126,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1063,cfa-miR-126,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12902,cfa-miR-1307,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12902,cfa-miR-1307,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12902,cfa-miR-1307,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12902,cfa-miR-1307,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12902,cfa-miR-1307,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12902,cfa-miR-1307,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12902,cfa-miR-1307,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12902,cfa-miR-1307,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12902,cfa-miR-1307,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12902,cfa-miR-1307,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1033,cfa-miR-133a,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1033,cfa-miR-133a,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1033,cfa-miR-133a,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1033,cfa-miR-133a,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1033,cfa-miR-133a,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1033,cfa-miR-133a,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1033,cfa-miR-133a,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1033,cfa-miR-133a,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1033,cfa-miR-133a,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1033,cfa-miR-133a,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12904,cfa-miR-139,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12904,cfa-miR-139,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12904,cfa-miR-139,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12904,cfa-miR-139,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12904,cfa-miR-139,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12904,cfa-miR-139,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12904,cfa-miR-139,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12904,cfa-miR-139,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12904,cfa-miR-139,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12904,cfa-miR-139,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12953,cfa-miR-141,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12953,cfa-miR-141,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12953,cfa-miR-141,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12953,cfa-miR-141,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12953,cfa-miR-141,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12953,cfa-miR-141,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12953,cfa-miR-141,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12953,cfa-miR-141,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12953,cfa-miR-141,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12953,cfa-miR-141,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12905,cfa-miR-142,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12905,cfa-miR-142,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12905,cfa-miR-142,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12905,cfa-miR-142,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12905,cfa-miR-142,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12905,cfa-miR-142,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12905,cfa-miR-142,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12905,cfa-miR-142,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12905,cfa-miR-142,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12905,cfa-miR-142,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12906,cfa-miR-149,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12906,cfa-miR-149,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12906,cfa-miR-149,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12906,cfa-miR-149,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12906,cfa-miR-149,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12906,cfa-miR-149,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12906,cfa-miR-149,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12906,cfa-miR-149,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12906,cfa-miR-149,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12906,cfa-miR-149,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12907,cfa-miR-181d,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12907,cfa-miR-181d,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12907,cfa-miR-181d,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12907,cfa-miR-181d,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12907,cfa-miR-181d,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12907,cfa-miR-181d,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12907,cfa-miR-181d,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12907,cfa-miR-181d,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12907,cfa-miR-181d,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12907,cfa-miR-181d,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12954,cfa-miR-1836,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12954,cfa-miR-1836,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12954,cfa-miR-1836,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12954,cfa-miR-1836,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12954,cfa-miR-1836,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12954,cfa-miR-1836,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12954,cfa-miR-1836,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12954,cfa-miR-1836,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12954,cfa-miR-1836,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12954,cfa-miR-1836,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
2428,SAA,protein,pyometritis,Maltese,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2428,SAA,protein,pyometritis,Shih Tzu(Chrysanthemum Dog),female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2428,SAA,protein,pyometritis,Yorkshire Terrier,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2428,SAA,protein,pyometritis,Miniature Poodle,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2428,SAA,protein,pyometritis,Miniature Schnauzer,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2428,SAA,protein,pyometritis,Pomeranian,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2428,SAA,protein,pyometritis,Miniature Pinscher,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2428,SAA,protein,pyometritis,Dachshund,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2428,SAA,protein,pyometritis,French Bulldog,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2428,SAA,protein,pyometritis,Korean Jindo,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2428,SAA,protein,pyometritis,Chow Chow,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2428,SAA,protein,pyometritis,Cocker Spaniel,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2428,SAA,protein,pyometritis,Golden Retriever,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2428,SAA,protein,pyometritis,English Pointer,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2428,SAA,protein,pyometritis,Japanese Shiba Inu,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
12955,cfa-miR-193a,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12955,cfa-miR-193a,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12955,cfa-miR-193a,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12955,cfa-miR-193a,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12955,cfa-miR-193a,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12955,cfa-miR-193a,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12955,cfa-miR-193a,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12955,cfa-miR-193a,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12955,cfa-miR-193a,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12955,cfa-miR-193a,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12909,cfa-miR-196a,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12909,cfa-miR-196a,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12909,cfa-miR-196a,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12909,cfa-miR-196a,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12909,cfa-miR-196a,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12909,cfa-miR-196a,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12909,cfa-miR-196a,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12909,cfa-miR-196a,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12909,cfa-miR-196a,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12909,cfa-miR-196a,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12911,cfa-miR-200b,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12911,cfa-miR-200b,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12911,cfa-miR-200b,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12911,cfa-miR-200b,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12911,cfa-miR-200b,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12911,cfa-miR-200b,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12911,cfa-miR-200b,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12911,cfa-miR-200b,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12911,cfa-miR-200b,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12911,cfa-miR-200b,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12912,cfa-miR-202,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12912,cfa-miR-202,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12912,cfa-miR-202,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12912,cfa-miR-202,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12912,cfa-miR-202,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12912,cfa-miR-202,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12912,cfa-miR-202,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12912,cfa-miR-202,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12912,cfa-miR-202,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12912,cfa-miR-202,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12913,cfa-miR-212,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12913,cfa-miR-212,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12913,cfa-miR-212,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12913,cfa-miR-212,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12913,cfa-miR-212,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12913,cfa-miR-212,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12913,cfa-miR-212,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12913,cfa-miR-212,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12913,cfa-miR-212,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12913,cfa-miR-212,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12914,cfa-miR-217,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12914,cfa-miR-217,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12914,cfa-miR-217,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12914,cfa-miR-217,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12914,cfa-miR-217,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12914,cfa-miR-217,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12914,cfa-miR-217,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12914,cfa-miR-217,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12914,cfa-miR-217,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12914,cfa-miR-217,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12915,cfa-miR-218,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12915,cfa-miR-218,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12915,cfa-miR-218,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12915,cfa-miR-218,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12915,cfa-miR-218,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12915,cfa-miR-218,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12915,cfa-miR-218,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12915,cfa-miR-218,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12915,cfa-miR-218,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12915,cfa-miR-218,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12916,cfa-miR-219-5p,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12916,cfa-miR-219-5p,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12916,cfa-miR-219-5p,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12916,cfa-miR-219-5p,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12916,cfa-miR-219-5p,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12916,cfa-miR-219-5p,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12916,cfa-miR-219-5p,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12916,cfa-miR-219-5p,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12916,cfa-miR-219-5p,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12916,cfa-miR-219-5p,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1027,cfa-miR-223,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1027,cfa-miR-223,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1027,cfa-miR-223,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1027,cfa-miR-223,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1027,cfa-miR-223,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1027,cfa-miR-223,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1027,cfa-miR-223,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1027,cfa-miR-223,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1027,cfa-miR-223,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1027,cfa-miR-223,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12956,cfa-miR-23a,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12956,cfa-miR-23a,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12956,cfa-miR-23a,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12956,cfa-miR-23a,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12956,cfa-miR-23a,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12956,cfa-miR-23a,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12956,cfa-miR-23a,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12956,cfa-miR-23a,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12956,cfa-miR-23a,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12956,cfa-miR-23a,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
2242,PCT,protein,pyometritis,Maltese,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2242,PCT,protein,pyometritis,Shih Tzu(Chrysanthemum Dog),female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2242,PCT,protein,pyometritis,Yorkshire Terrier,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2242,PCT,protein,pyometritis,Miniature Poodle,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2242,PCT,protein,pyometritis,Miniature Schnauzer,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2242,PCT,protein,pyometritis,Pomeranian,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2242,PCT,protein,pyometritis,Miniature Pinscher,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2242,PCT,protein,pyometritis,Dachshund,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2242,PCT,protein,pyometritis,French Bulldog,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2242,PCT,protein,pyometritis,Korean Jindo,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2242,PCT,protein,pyometritis,Chow Chow,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2242,PCT,protein,pyometritis,Cocker Spaniel,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2242,PCT,protein,pyometritis,Golden Retriever,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2242,PCT,protein,pyometritis,English Pointer,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2242,PCT,protein,pyometritis,Japanese Shiba Inu,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
12917,cfa-miR-29a,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12917,cfa-miR-29a,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12917,cfa-miR-29a,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12917,cfa-miR-29a,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12917,cfa-miR-29a,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12917,cfa-miR-29a,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12917,cfa-miR-29a,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12917,cfa-miR-29a,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12917,cfa-miR-29a,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12917,cfa-miR-29a,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1047,cfa-miR-30a,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1047,cfa-miR-30a,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1047,cfa-miR-30a,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1047,cfa-miR-30a,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1047,cfa-miR-30a,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1047,cfa-miR-30a,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1047,cfa-miR-30a,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1047,cfa-miR-30a,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1047,cfa-miR-30a,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1047,cfa-miR-30a,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12919,cfa-miR-325,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12919,cfa-miR-325,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12919,cfa-miR-325,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12919,cfa-miR-325,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12919,cfa-miR-325,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12919,cfa-miR-325,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12919,cfa-miR-325,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12919,cfa-miR-325,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12919,cfa-miR-325,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12919,cfa-miR-325,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12920,cfa-miR-329a,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12920,cfa-miR-329a,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12920,cfa-miR-329a,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12920,cfa-miR-329a,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12920,cfa-miR-329a,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12920,cfa-miR-329a,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12920,cfa-miR-329a,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12920,cfa-miR-329a,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12920,cfa-miR-329a,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12920,cfa-miR-329a,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12922,cfa-miR-338,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12922,cfa-miR-338,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12922,cfa-miR-338,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12922,cfa-miR-338,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12922,cfa-miR-338,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12922,cfa-miR-338,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12922,cfa-miR-338,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12922,cfa-miR-338,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12922,cfa-miR-338,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12922,cfa-miR-338,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12924,cfa-miR-363,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12924,cfa-miR-363,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12924,cfa-miR-363,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12924,cfa-miR-363,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12924,cfa-miR-363,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12924,cfa-miR-363,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12924,cfa-miR-363,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12924,cfa-miR-363,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12924,cfa-miR-363,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12924,cfa-miR-363,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12957,cfa-miR-367,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12957,cfa-miR-367,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12957,cfa-miR-367,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12957,cfa-miR-367,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12957,cfa-miR-367,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12957,cfa-miR-367,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12957,cfa-miR-367,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12957,cfa-miR-367,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12957,cfa-miR-367,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12957,cfa-miR-367,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12925,cfa-miR-374b,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12925,cfa-miR-374b,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12925,cfa-miR-374b,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12925,cfa-miR-374b,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12925,cfa-miR-374b,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12925,cfa-miR-374b,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12925,cfa-miR-374b,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12925,cfa-miR-374b,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12925,cfa-miR-374b,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12925,cfa-miR-374b,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12926,cfa-miR-376a,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12926,cfa-miR-376a,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12926,cfa-miR-376a,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12926,cfa-miR-376a,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12926,cfa-miR-376a,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12926,cfa-miR-376a,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12926,cfa-miR-376a,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12926,cfa-miR-376a,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12926,cfa-miR-376a,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12926,cfa-miR-376a,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12927,cfa-miR-379,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12927,cfa-miR-379,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12927,cfa-miR-379,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12927,cfa-miR-379,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12927,cfa-miR-379,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12927,cfa-miR-379,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12927,cfa-miR-379,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12927,cfa-miR-379,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12927,cfa-miR-379,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12927,cfa-miR-379,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
2398,IL-6,protein,pyometritis,Maltese,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2398,IL-6,protein,pyometritis,Shih Tzu(Chrysanthemum Dog),female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2398,IL-6,protein,pyometritis,Yorkshire Terrier,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2398,IL-6,protein,pyometritis,Miniature Poodle,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2398,IL-6,protein,pyometritis,Miniature Schnauzer,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2398,IL-6,protein,pyometritis,Pomeranian,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2398,IL-6,protein,pyometritis,Miniature Pinscher,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2398,IL-6,protein,pyometritis,Dachshund,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2398,IL-6,protein,pyometritis,French Bulldog,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2398,IL-6,protein,pyometritis,Korean Jindo,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2398,IL-6,protein,pyometritis,Chow Chow,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2398,IL-6,protein,pyometritis,Cocker Spaniel,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2398,IL-6,protein,pyometritis,Golden Retriever,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2398,IL-6,protein,pyometritis,English Pointer,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2398,IL-6,protein,pyometritis,Japanese Shiba Inu,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
12929,cfa-miR-382,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12929,cfa-miR-382,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12929,cfa-miR-382,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12929,cfa-miR-382,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12929,cfa-miR-382,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12929,cfa-miR-382,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12929,cfa-miR-382,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12929,cfa-miR-382,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12929,cfa-miR-382,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12929,cfa-miR-382,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12930,cfa-miR-384,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12930,cfa-miR-384,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12930,cfa-miR-384,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12930,cfa-miR-384,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12930,cfa-miR-384,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12930,cfa-miR-384,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12930,cfa-miR-384,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12930,cfa-miR-384,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12930,cfa-miR-384,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12930,cfa-miR-384,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12958,cfa-miR-452,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12958,cfa-miR-452,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12958,cfa-miR-452,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12958,cfa-miR-452,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12958,cfa-miR-452,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12958,cfa-miR-452,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12958,cfa-miR-452,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12958,cfa-miR-452,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12958,cfa-miR-452,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12958,cfa-miR-452,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12959,cfa-miR-454,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12959,cfa-miR-454,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12959,cfa-miR-454,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12959,cfa-miR-454,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12959,cfa-miR-454,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12959,cfa-miR-454,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12959,cfa-miR-454,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12959,cfa-miR-454,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12959,cfa-miR-454,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12959,cfa-miR-454,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12935,cfa-miR-491,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12935,cfa-miR-491,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12935,cfa-miR-491,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12935,cfa-miR-491,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12935,cfa-miR-491,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12935,cfa-miR-491,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12935,cfa-miR-491,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12935,cfa-miR-491,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12935,cfa-miR-491,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12935,cfa-miR-491,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12936,cfa-miR-495,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12936,cfa-miR-495,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12936,cfa-miR-495,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12936,cfa-miR-495,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12936,cfa-miR-495,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12936,cfa-miR-495,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12936,cfa-miR-495,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12936,cfa-miR-495,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12936,cfa-miR-495,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12936,cfa-miR-495,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12937,cfa-miR-496,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12937,cfa-miR-496,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12937,cfa-miR-496,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12937,cfa-miR-496,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12937,cfa-miR-496,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12937,cfa-miR-496,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12937,cfa-miR-496,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12937,cfa-miR-496,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12937,cfa-miR-496,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12937,cfa-miR-496,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12938,cfa-miR-504,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12938,cfa-miR-504,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12938,cfa-miR-504,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12938,cfa-miR-504,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12938,cfa-miR-504,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12938,cfa-miR-504,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12938,cfa-miR-504,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12938,cfa-miR-504,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12938,cfa-miR-504,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12938,cfa-miR-504,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12939,cfa-miR-514,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12939,cfa-miR-514,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12939,cfa-miR-514,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12939,cfa-miR-514,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12939,cfa-miR-514,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12939,cfa-miR-514,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12939,cfa-miR-514,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12939,cfa-miR-514,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12939,cfa-miR-514,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12939,cfa-miR-514,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12960,cfa-miR-544,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12960,cfa-miR-544,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12960,cfa-miR-544,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12960,cfa-miR-544,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12960,cfa-miR-544,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12960,cfa-miR-544,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12960,cfa-miR-544,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12960,cfa-miR-544,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12960,cfa-miR-544,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12960,cfa-miR-544,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
2268,HMGB1,protein,pyometritis,Maltese,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2268,HMGB1,protein,pyometritis,Shih Tzu(Chrysanthemum Dog),female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2268,HMGB1,protein,pyometritis,Yorkshire Terrier,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2268,HMGB1,protein,pyometritis,Miniature Poodle,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2268,HMGB1,protein,pyometritis,Miniature Schnauzer,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2268,HMGB1,protein,pyometritis,Pomeranian,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2268,HMGB1,protein,pyometritis,Miniature Pinscher,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2268,HMGB1,protein,pyometritis,Dachshund,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2268,HMGB1,protein,pyometritis,French Bulldog,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2268,HMGB1,protein,pyometritis,Korean Jindo,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2268,HMGB1,protein,pyometritis,Chow Chow,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2268,HMGB1,protein,pyometritis,Cocker Spaniel,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2268,HMGB1,protein,pyometritis,Golden Retriever,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2268,HMGB1,protein,pyometritis,English Pointer,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
2268,HMGB1,protein,pyometritis,Japanese Shiba Inu,female,1-15years,,9615,"These findings indicate that cfDNA, CRP , and SAA are potential clinical biomarkers of systemic inflammation in dogs with pyometra and PCT, IL-6, and HMGB1 are potential biomarkers of clinical recovery"
12940,cfa-miR-545,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12940,cfa-miR-545,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12940,cfa-miR-545,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12940,cfa-miR-545,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12940,cfa-miR-545,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12940,cfa-miR-545,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12940,cfa-miR-545,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12940,cfa-miR-545,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12940,cfa-miR-545,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12940,cfa-miR-545,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12941,cfa-miR-551a,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12941,cfa-miR-551a,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12941,cfa-miR-551a,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12941,cfa-miR-551a,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12941,cfa-miR-551a,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12941,cfa-miR-551a,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12941,cfa-miR-551a,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12941,cfa-miR-551a,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12941,cfa-miR-551a,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12941,cfa-miR-551a,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12942,cfa-miR-568,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12942,cfa-miR-568,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12942,cfa-miR-568,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12942,cfa-miR-568,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12942,cfa-miR-568,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12942,cfa-miR-568,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12942,cfa-miR-568,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12942,cfa-miR-568,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12942,cfa-miR-568,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12942,cfa-miR-568,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12943,cfa-miR-578,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12943,cfa-miR-578,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12943,cfa-miR-578,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12943,cfa-miR-578,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12943,cfa-miR-578,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12943,cfa-miR-578,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12943,cfa-miR-578,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12943,cfa-miR-578,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12943,cfa-miR-578,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12943,cfa-miR-578,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12944,cfa-miR-592,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12944,cfa-miR-592,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12944,cfa-miR-592,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12944,cfa-miR-592,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12944,cfa-miR-592,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12944,cfa-miR-592,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12944,cfa-miR-592,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12944,cfa-miR-592,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12944,cfa-miR-592,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12944,cfa-miR-592,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1031,cfa-miR-652,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1031,cfa-miR-652,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1031,cfa-miR-652,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1031,cfa-miR-652,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1031,cfa-miR-652,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1031,cfa-miR-652,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1031,cfa-miR-652,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1031,cfa-miR-652,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1031,cfa-miR-652,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
1031,cfa-miR-652,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12961,cfa-miR-665,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12961,cfa-miR-665,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12961,cfa-miR-665,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12961,cfa-miR-665,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12961,cfa-miR-665,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12961,cfa-miR-665,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12961,cfa-miR-665,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12961,cfa-miR-665,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12961,cfa-miR-665,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12961,cfa-miR-665,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12945,cfa-miR-708,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12945,cfa-miR-708,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12945,cfa-miR-708,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12945,cfa-miR-708,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12945,cfa-miR-708,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12945,cfa-miR-708,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12945,cfa-miR-708,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12945,cfa-miR-708,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12945,cfa-miR-708,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12945,cfa-miR-708,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12946,cfa-miR-759,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12946,cfa-miR-759,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12946,cfa-miR-759,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12946,cfa-miR-759,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12946,cfa-miR-759,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12946,cfa-miR-759,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12946,cfa-miR-759,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12946,cfa-miR-759,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12946,cfa-miR-759,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12946,cfa-miR-759,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12947,cfa-miR-761,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12947,cfa-miR-761,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12947,cfa-miR-761,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12947,cfa-miR-761,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12947,cfa-miR-761,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12947,cfa-miR-761,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12947,cfa-miR-761,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12947,cfa-miR-761,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12947,cfa-miR-761,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12947,cfa-miR-761,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
2399,Urinary cystatin B,protein,acute kidney failure,,both,6 months-18years,Median：19kg,9615,The increased urinary cystatin B concentrations observed in dogs envenomated by V. berus in comparison to controls may indicate renal tubular injury in these patients.
12949,cfa-miR-802,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12949,cfa-miR-802,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12949,cfa-miR-802,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12949,cfa-miR-802,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12949,cfa-miR-802,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12949,cfa-miR-802,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12949,cfa-miR-802,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12949,cfa-miR-802,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12949,cfa-miR-802,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12949,cfa-miR-802,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12950,cfa-miR-872,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12950,cfa-miR-872,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12950,cfa-miR-872,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12950,cfa-miR-872,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12950,cfa-miR-872,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12950,cfa-miR-872,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12950,cfa-miR-872,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12950,cfa-miR-872,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12950,cfa-miR-872,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12950,cfa-miR-872,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12962,cfa-miR-876,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12962,cfa-miR-876,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12962,cfa-miR-876,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12962,cfa-miR-876,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12962,cfa-miR-876,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12962,cfa-miR-876,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12962,cfa-miR-876,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12962,cfa-miR-876,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12962,cfa-miR-876,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12962,cfa-miR-876,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12963,miR-96,miRNA,"mitral valve prolapse, myxomatous 3",English Beagle,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12963,miR-96,miRNA,"mitral valve prolapse, myxomatous 3",Labrador Retriever,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12963,miR-96,miRNA,"mitral valve prolapse, myxomatous 3",Gordon Setter,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12963,miR-96,miRNA,"mitral valve prolapse, myxomatous 3",American Pit Bull Terrier,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12963,miR-96,miRNA,"mitral valve prolapse, myxomatous 3",German Short-Haired  Pointer,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12963,miR-96,miRNA,"mitral valve prolapse, myxomatous 3",Shih Tzu(Chrysanthemum Dog),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12963,miR-96,miRNA,"mitral valve prolapse, myxomatous 3",Maltese,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12963,miR-96,miRNA,"mitral valve prolapse, myxomatous 3",Cavalier King Charles Spaniel,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12963,miR-96,miRNA,"mitral valve prolapse, myxomatous 3",Papillon(Continental Toy Spaniel),both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12963,miR-96,miRNA,"mitral valve prolapse, myxomatous 3",Chihuahua,both,"normal group(year): 2-7, MMVD group(year): 5-13,  MMVD with CHF(year): 8-13","normal group(kg): 10-36; MMVD group(kg): 8-40, MMVD with CHF(kg):5-13",9615,"Plasma ex-miRNA show great promise as biomarkers for MMVD disease monitoring and may also help elucidate the pathophysiology of the disease and subsequently help devise therapeutic strategies. The present data show that cfa-miR-9, cfa-miR-181c, cfa-miR-495 and cfa-miR-599 expressions not only change with disease progression and development of heart failure, but also exhibit changes as a function of age."
12964,miR-216a,miRNA,acute pancreatitis,English Beagle,,6-8 months,,9615,Our results further support the translational potential of pancreas-enriched microRNAs as sensitive biomarkers of acinar cell injury with evidence from an additional non-clinical model system
12965,miR-216b,miRNA,acute pancreatitis,English Beagle,,6-8 months,,9615,Our results further support the translational potential of pancreas-enriched microRNAs as sensitive biomarkers of acinar cell injury with evidence from an additional non-clinical model system
12914,miR-217,miRNA,acute pancreatitis,English Beagle,,6-8 months,,9615,Our results further support the translational potential of pancreas-enriched microRNAs as sensitive biomarkers of acinar cell injury with evidence from an additional non-clinical model system
1019,miR-375,miRNA,acute pancreatitis,English Beagle,,6-8 months,,9615,Our results further support the translational potential of pancreas-enriched microRNAs as sensitive biomarkers of acinar cell injury with evidence from an additional non-clinical model system
1030,miR-148a,miRNA,acute pancreatitis,English Beagle,,6-8 months,,9615,Our results further support the translational potential of pancreas-enriched microRNAs as sensitive biomarkers of acinar cell injury with evidence from an additional non-clinical model system
12898,cfa-miR-105a,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
694,stearic,metabolite,intestinal disorder,,both,4-144 months,4-36.3kg,9615,"These results suggest that lipidomic status may reflect the “gut health”, and the non–invasive analysis of RBC membrane might have the potential to become a candidate biomarker in the evaluation of dogs affected by CE"
12899,cfa-miR-105b,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
1065,cfa-miR-124,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12966,cfa-miR-128,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
1082,cfa-miR-132,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12967,cfa-miR-137,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12968,cfa-miR-138a,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12906,cfa-miR-149,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12913,cfa-miR-212,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12969,cfa-miR-219-3p,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12970,cfa-miR-323,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
695,dihomo–gamma–linolenic,metabolite,intestinal disorder,,both,4-144 months,4-36.3kg,9615,"These results suggest that lipidomic status may reflect the “gut health”, and the non–invasive analysis of RBC membrane might have the potential to become a candidate biomarker in the evaluation of dogs affected by CE"
12928,cfa-miR-380,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12971,cfa-miR-410,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12933,cfa-miR-487a,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12972,cfa-miR-487b,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12973,cfa-miR-874,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12974,cfa-miR-889,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
1078,cfa-miR-9,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12975,cfa-miR-92b,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12976,cfa-miR-1249,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12977,cfa-miR-127,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
696,eicosapentaenoic,metabolite,intestinal disorder,,both,4-144 months,4-36.3kg,9615,"These results suggest that lipidomic status may reflect the “gut health”, and the non–invasive analysis of RBC membrane might have the potential to become a candidate biomarker in the evaluation of dogs affected by CE"
12978,cfa-miR-184,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12979,cfa-miR-411,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12980,cfa-miR-432,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12938,cfa-miR-504,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12981,cfa-miR-146b,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12921,cfa-miR-335,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12982,cfa-miR-342,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12983,cfa-miR-885,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12984,cfa-miR-135a-5p,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12985,cfa-miR-153,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
697,docosahexaenoic acids,metabolite,intestinal disorder,,both,4-144 months,4-36.3kg,9615,"These results suggest that lipidomic status may reflect the “gut health”, and the non–invasive analysis of RBC membrane might have the potential to become a candidate biomarker in the evaluation of dogs affected by CE"
12986,cfa-miR-8865,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12901,cfa-miR-129,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12987,cfa-miR-628,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12988,cfa-miR-7,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12925,cfa-miR-374b,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12989,cfa-miR-144,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12990,cfa-miR-25,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
1026,cfa-miR-451,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12991,cfa-miR-450a,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12992,cfa-miR-450b,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
2400,Carcinoembryonic antigen-related cell adhesion molecule 28,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2400,Carcinoembryonic antigen-related cell adhesion molecule 28,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2400,Carcinoembryonic antigen-related cell adhesion molecule 28,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2400,Carcinoembryonic antigen-related cell adhesion molecule 28,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2400,Carcinoembryonic antigen-related cell adhesion molecule 28,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2400,Carcinoembryonic antigen-related cell adhesion molecule 28,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2400,Carcinoembryonic antigen-related cell adhesion molecule 28,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2400,Carcinoembryonic antigen-related cell adhesion molecule 28,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2400,Carcinoembryonic antigen-related cell adhesion molecule 28,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
698,palmitic,metabolite,intestinal disorder,,both,4-144 months,4-36.3kg,9615,"These results suggest that lipidomic status may reflect the “gut health”, and the non–invasive analysis of RBC membrane might have the potential to become a candidate biomarker in the evaluation of dogs affected by CE"
1051,cfa-miR-147,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12993,cfa-miR-499,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
1032,cfa-miR-1,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
1033,cfa-miR-133a,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
1034,cfa-miR-133b,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12994,cfa-miR-208b,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12995,cfa-miR-215,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
1064,cfa-miR-122,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
1030,cfa-miR-148a,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12964,cfa-miR-216a,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
699,linoleic acids,metabolite,intestinal disorder,,both,4-144 months,4-36.3kg,9615,"These results suggest that lipidomic status may reflect the “gut health”, and the non–invasive analysis of RBC membrane might have the potential to become a candidate biomarker in the evaluation of dogs affected by CE"
12965,cfa-miR-216b,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12914,cfa-miR-217,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
1019,cfa-miR-375,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12953,cfa-miR-141,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12949,cfa-miR-802,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12996,cfa-miR-423a,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12997,cfa-miR-107,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12998,cfa-miR-383,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12999,cfa-miR-15a,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12955,cfa-miR-193a,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
2432,NT-proBNP,protein,"mitral valve prolapse, myxomatous 3",Kleiner Munsterlander Vorstehund,both,6.2-13.5years,6.8-34.5kg,9615,Pimobendan had reducing effects on the concentrations of pre- and post-exercise cardiac biomarkers and the size of the left ventricle in dogs with DMVD ACVIM B1. Exercise testing in addition to an assessment of cardiac biomarkers might improve the decision when to initiate pimobendan treatment in dogs with DMVD.
2432,NT-proBNP,protein,"mitral valve prolapse, myxomatous 3",Golden Retriever,both,6.2-13.5years,6.8-34.5kg,9615,Pimobendan had reducing effects on the concentrations of pre- and post-exercise cardiac biomarkers and the size of the left ventricle in dogs with DMVD ACVIM B1. Exercise testing in addition to an assessment of cardiac biomarkers might improve the decision when to initiate pimobendan treatment in dogs with DMVD.
2432,NT-proBNP,protein,"mitral valve prolapse, myxomatous 3",Jack Russell Terrier,both,6.2-13.5years,6.8-34.5kg,9615,Pimobendan had reducing effects on the concentrations of pre- and post-exercise cardiac biomarkers and the size of the left ventricle in dogs with DMVD ACVIM B1. Exercise testing in addition to an assessment of cardiac biomarkers might improve the decision when to initiate pimobendan treatment in dogs with DMVD.
2432,NT-proBNP,protein,"mitral valve prolapse, myxomatous 3",Pekingese,both,6.2-13.5years,6.8-34.5kg,9615,Pimobendan had reducing effects on the concentrations of pre- and post-exercise cardiac biomarkers and the size of the left ventricle in dogs with DMVD ACVIM B1. Exercise testing in addition to an assessment of cardiac biomarkers might improve the decision when to initiate pimobendan treatment in dogs with DMVD.
2432,NT-proBNP,protein,"mitral valve prolapse, myxomatous 3",English Beagle,both,6.2-13.5years,6.8-34.5kg,9615,Pimobendan had reducing effects on the concentrations of pre- and post-exercise cardiac biomarkers and the size of the left ventricle in dogs with DMVD ACVIM B1. Exercise testing in addition to an assessment of cardiac biomarkers might improve the decision when to initiate pimobendan treatment in dogs with DMVD.
2432,NT-proBNP,protein,"mitral valve prolapse, myxomatous 3",Dachshund,both,6.2-13.5years,6.8-34.5kg,9615,Pimobendan had reducing effects on the concentrations of pre- and post-exercise cardiac biomarkers and the size of the left ventricle in dogs with DMVD ACVIM B1. Exercise testing in addition to an assessment of cardiac biomarkers might improve the decision when to initiate pimobendan treatment in dogs with DMVD.
2432,NT-proBNP,protein,"mitral valve prolapse, myxomatous 3",Maltese,both,6.2-13.5years,6.8-34.5kg,9615,Pimobendan had reducing effects on the concentrations of pre- and post-exercise cardiac biomarkers and the size of the left ventricle in dogs with DMVD ACVIM B1. Exercise testing in addition to an assessment of cardiac biomarkers might improve the decision when to initiate pimobendan treatment in dogs with DMVD.
13000,cfa-miR-206,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
12912,cfa-miR-202,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
13001,cfa-miR-34b,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
13002,cfa-miR-34,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
13003,cfa-miR-449a,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
13004,cfa-miR-506,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
13005,cfa-miR-507b,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
13006,cfa-miR-508a,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
13007,cfa-miR-508b,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
13008,cfa-miR-8831,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
2401,circulating PD-1,protein,neoplasm,Pomeranian,both,1-15years,,9615,This study indicates that circulating PD-1 and PD-L1 have potential as tumor diagnostic biomarkers in dogs with tumors.
2401,circulating PD-1,protein,neoplasm,Maltese,both,1-15years,,9615,This study indicates that circulating PD-1 and PD-L1 have potential as tumor diagnostic biomarkers in dogs with tumors.
2401,circulating PD-1,protein,neoplasm,Shih Tzu(Chrysanthemum Dog),both,1-15years,,9615,This study indicates that circulating PD-1 and PD-L1 have potential as tumor diagnostic biomarkers in dogs with tumors.
2401,circulating PD-1,protein,neoplasm,Yorkshire Terrier,both,1-15years,,9615,This study indicates that circulating PD-1 and PD-L1 have potential as tumor diagnostic biomarkers in dogs with tumors.
2401,circulating PD-1,protein,neoplasm,Basenji(African Barkless Dog),both,1-15years,,9615,This study indicates that circulating PD-1 and PD-L1 have potential as tumor diagnostic biomarkers in dogs with tumors.
2401,circulating PD-1,protein,neoplasm,Golden Retriever,both,1-15years,,9615,This study indicates that circulating PD-1 and PD-L1 have potential as tumor diagnostic biomarkers in dogs with tumors.
2401,circulating PD-1,protein,neoplasm,Korean Jindo,both,1-15years,,9615,This study indicates that circulating PD-1 and PD-L1 have potential as tumor diagnostic biomarkers in dogs with tumors.
2401,circulating PD-1,protein,neoplasm,Cocker Spaniel,both,1-15years,,9615,This study indicates that circulating PD-1 and PD-L1 have potential as tumor diagnostic biomarkers in dogs with tumors.
2401,circulating PD-1,protein,neoplasm,Miniature Pinscher,both,1-15years,,9615,This study indicates that circulating PD-1 and PD-L1 have potential as tumor diagnostic biomarkers in dogs with tumors.
13009,cfa-miR-8908a-3p,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
13010,cfa-miR-8908a-5p,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
13011,cfa-miR-8908b,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
13012,cfa-miR-8908c,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
13013,cfa-miR-106a,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
13014,cfa-miR-205,miRNA,organ toxicity,English Beagle,male,10 months,,9615,"The 60 highly enriched tissue miRNAs identified within the dog miRNA tissue atlas could serve as diagnostic biomarkers and will require further validation by in vivo correlation to histopathology. Once validated, these tissue enriched miRNAs could be combined into a powerful qPCR screening panel to identify organ toxicity during early drug development."
1041,let-7b,miRNA,lymphoma,,,,,9615,"Although the biological function of serum miRNAs still remains unclear, determining their functional roles in serum and tissues will contribute not only to the identification of potential  biomarkers, but also to the elucidation of the pathogenesis of canine lymphoma"
1027,miR-223,miRNA,lymphoma,,,,,9615,"Although the biological function of serum miRNAs still remains unclear, determining their functional roles in serum and tissues will contribute not only to the identification of potential  biomarkers, but also to the elucidation of the pathogenesis of canine lymphoma"
12990,miR-25,miRNA,lymphoma,,,,,9615,"Although the biological function of serum miRNAs still remains unclear, determining their functional roles in serum and tissues will contribute not only to the identification of potential  biomarkers, but also to the elucidation of the pathogenesis of canine lymphoma"
13015,miR-92a,miRNA,lymphoma,,,,,9615,"Although the biological function of serum miRNAs still remains unclear, determining their functional roles in serum and tissues will contribute not only to the identification of potential  biomarkers, but also to the elucidation of the pathogenesis of canine lymphoma"
2402,circulating PD-L1,protein,neoplasm,Pomeranian,both,1-15years,,9615,This study indicates that circulating PD-1 and PD-L1 have potential as tumor diagnostic biomarkers in dogs with tumors.
2402,circulating PD-L1,protein,neoplasm,Maltese,both,1-15years,,9615,This study indicates that circulating PD-1 and PD-L1 have potential as tumor diagnostic biomarkers in dogs with tumors.
2402,circulating PD-L1,protein,neoplasm,Shih Tzu(Chrysanthemum Dog),both,1-15years,,9615,This study indicates that circulating PD-1 and PD-L1 have potential as tumor diagnostic biomarkers in dogs with tumors.
2402,circulating PD-L1,protein,neoplasm,Yorkshire Terrier,both,1-15years,,9615,This study indicates that circulating PD-1 and PD-L1 have potential as tumor diagnostic biomarkers in dogs with tumors.
2402,circulating PD-L1,protein,neoplasm,Basenji(African Barkless Dog),both,1-15years,,9615,This study indicates that circulating PD-1 and PD-L1 have potential as tumor diagnostic biomarkers in dogs with tumors.
2402,circulating PD-L1,protein,neoplasm,Golden Retriever,both,1-15years,,9615,This study indicates that circulating PD-1 and PD-L1 have potential as tumor diagnostic biomarkers in dogs with tumors.
2402,circulating PD-L1,protein,neoplasm,Korean Jindo,both,1-15years,,9615,This study indicates that circulating PD-1 and PD-L1 have potential as tumor diagnostic biomarkers in dogs with tumors.
2402,circulating PD-L1,protein,neoplasm,Cocker Spaniel,both,1-15years,,9615,This study indicates that circulating PD-1 and PD-L1 have potential as tumor diagnostic biomarkers in dogs with tumors.
2402,circulating PD-L1,protein,neoplasm,Miniature Pinscher,both,1-15years,,9615,This study indicates that circulating PD-1 and PD-L1 have potential as tumor diagnostic biomarkers in dogs with tumors.
12996,miR-423a,miRNA,lymphoma,,,,,9615,"Although the biological function of serum miRNAs still remains unclear, determining their functional roles in serum and tissues will contribute not only to the identification of potential  biomarkers, but also to the elucidation of the pathogenesis of canine lymphoma"
12918,miR-30b,miRNA,heart failure,,both,"ACVIM A–unaffected (mean ± SD) :  5.458 ± 2.51 years, ACVIM B (mean ± SD): 10.17 ± 3.36 year, ACVIM C (mean ± SD): 10.40 ± 4.73 year",,9615,miR-30b could be a potential biomarker of ACVIM stage B heart failure in Dachshunds and miR-133b could be a potential biomarker of ACVIM stage C.
1034,miR-133b,miRNA,heart failure,,both,"ACVIM A–unaffected (mean ± SD) :  5.458 ± 2.51 years, ACVIM B (mean ± SD): 10.17 ± 3.36 year, ACVIM C (mean ± SD): 10.40 ± 4.73 year",,9615,miR-30b could be a potential biomarker of ACVIM stage B heart failure in Dachshunds and miR-133b could be a potential biomarker of ACVIM stage C.
13016,SERHL,gene,breast neoplasm,,,,,9615,"The proposed gene set can constitute a `malignancy marker` that could help to distinguish the most malignant canine mammary carcinomas. These genes are also interesting as targets for further investigations and therapy. So far, only two of them were linked with the cancer development."
13017,ZFP37,gene,breast neoplasm,,,,,9615,"The proposed gene set can constitute a `malignancy marker` that could help to distinguish the most malignant canine mammary carcinomas. These genes are also interesting as targets for further investigations and therapy. So far, only two of them were linked with the cancer development."
13018,MIPEP,gene,breast neoplasm,,,,,9615,"The proposed gene set can constitute a `malignancy marker` that could help to distinguish the most malignant canine mammary carcinomas. These genes are also interesting as targets for further investigations and therapy. So far, only two of them were linked with the cancer development."
13019,Relaxin,gene,breast neoplasm,,,,,9615,"The proposed gene set can constitute a `malignancy marker` that could help to distinguish the most malignant canine mammary carcinomas. These genes are also interesting as targets for further investigations and therapy. So far, only two of them were linked with the cancer development."
13020,MAGI3,gene,breast neoplasm,,,,,9615,"The proposed gene set can constitute a `malignancy marker` that could help to distinguish the most malignant canine mammary carcinomas. These genes are also interesting as targets for further investigations and therapy. So far, only two of them were linked with the cancer development."
2403,urinary L-FABP,protein,kidney disorder,Toy Poodle,both,7.8 ± 4.6 years,,9615,"To diagnose renal diseases in dogs, urinary L-FABP measurement could be utilized in the evaluation of tubular damage"
2403,urinary L-FABP,protein,kidney disorder,English Beagle,both,7.8 ± 4.6 years,,9615,"To diagnose renal diseases in dogs, urinary L-FABP measurement could be utilized in the evaluation of tubular damage"
2403,urinary L-FABP,protein,kidney disorder,Miniature Dachshund,both,7.8 ± 4.6 years,,9615,"To diagnose renal diseases in dogs, urinary L-FABP measurement could be utilized in the evaluation of tubular damage"
2403,urinary L-FABP,protein,kidney disorder,Papillon(Continental Toy Spaniel),both,7.8 ± 4.6 years,,9615,"To diagnose renal diseases in dogs, urinary L-FABP measurement could be utilized in the evaluation of tubular damage"
2403,urinary L-FABP,protein,kidney disorder,Labrador Retriever,both,7.8 ± 4.6 years,,9615,"To diagnose renal diseases in dogs, urinary L-FABP measurement could be utilized in the evaluation of tubular damage"
2403,urinary L-FABP,protein,kidney disorder,Japanese Shiba Inu,both,7.8 ± 4.6 years,,9615,"To diagnose renal diseases in dogs, urinary L-FABP measurement could be utilized in the evaluation of tubular damage"
2403,urinary L-FABP,protein,kidney disorder,Shih Tzu(Chrysanthemum Dog),both,7.8 ± 4.6 years,,9615,"To diagnose renal diseases in dogs, urinary L-FABP measurement could be utilized in the evaluation of tubular damage"
2403,urinary L-FABP,protein,kidney disorder,Chihuahua,both,7.8 ± 4.6 years,,9615,"To diagnose renal diseases in dogs, urinary L-FABP measurement could be utilized in the evaluation of tubular damage"
2403,urinary L-FABP,protein,kidney disorder,Pembroke Welsh Corgi,both,7.8 ± 4.6 years,,9615,"To diagnose renal diseases in dogs, urinary L-FABP measurement could be utilized in the evaluation of tubular damage"
2403,urinary L-FABP,protein,kidney disorder,Pomeranian,both,7.8 ± 4.6 years,,9615,"To diagnose renal diseases in dogs, urinary L-FABP measurement could be utilized in the evaluation of tubular damage"
2403,urinary L-FABP,protein,kidney disorder,Miniature Schnauzer,both,7.8 ± 4.6 years,,9615,"To diagnose renal diseases in dogs, urinary L-FABP measurement could be utilized in the evaluation of tubular damage"
2403,urinary L-FABP,protein,kidney disorder,Miniature Pinscher,both,7.8 ± 4.6 years,,9615,"To diagnose renal diseases in dogs, urinary L-FABP measurement could be utilized in the evaluation of tubular damage"
2403,urinary L-FABP,protein,kidney disorder,Yorkshire Terrier,both,7.8 ± 4.6 years,,9615,"To diagnose renal diseases in dogs, urinary L-FABP measurement could be utilized in the evaluation of tubular damage"
2403,urinary L-FABP,protein,kidney disorder,Shetland Shepherd Dog,both,7.8 ± 4.6 years,,9615,"To diagnose renal diseases in dogs, urinary L-FABP measurement could be utilized in the evaluation of tubular damage"
2403,urinary L-FABP,protein,kidney disorder,Bernese Mountain Dog,both,7.8 ± 4.6 years,,9615,"To diagnose renal diseases in dogs, urinary L-FABP measurement could be utilized in the evaluation of tubular damage"
2403,urinary L-FABP,protein,kidney disorder,Maltese,both,7.8 ± 4.6 years,,9615,"To diagnose renal diseases in dogs, urinary L-FABP measurement could be utilized in the evaluation of tubular damage"
2403,urinary L-FABP,protein,kidney disorder,West Highland White Terrier,both,7.8 ± 4.6 years,,9615,"To diagnose renal diseases in dogs, urinary L-FABP measurement could be utilized in the evaluation of tubular damage"
2403,urinary L-FABP,protein,kidney disorder,French Bulldog,both,7.8 ± 4.6 years,,9615,"To diagnose renal diseases in dogs, urinary L-FABP measurement could be utilized in the evaluation of tubular damage"
2403,urinary L-FABP,protein,kidney disorder,English Bulldog,both,7.8 ± 4.6 years,,9615,"To diagnose renal diseases in dogs, urinary L-FABP measurement could be utilized in the evaluation of tubular damage"
2403,urinary L-FABP,protein,kidney disorder,Brussels Griffon,both,7.8 ± 4.6 years,,9615,"To diagnose renal diseases in dogs, urinary L-FABP measurement could be utilized in the evaluation of tubular damage"
2404,Beclin-1,protein,cutaneous mastocytoma,Labrador Retriever,both,0.3 - 14.0years,,9615,Beclin-1 is a novel predictive biomarker for canine cutaneous and subcutaneous mast cell tumors
2404,Beclin-1,protein,cutaneous mastocytoma,German Boxer,both,0.3 - 14.0years,,9615,Beclin-1 is a novel predictive biomarker for canine cutaneous and subcutaneous mast cell tumors
2404,Beclin-1,protein,cutaneous mastocytoma,Golden Retriever,both,0.3 - 14.0years,,9615,Beclin-1 is a novel predictive biomarker for canine cutaneous and subcutaneous mast cell tumors
189,H2AFZ,gene,articular cartilage disorder,,,,,9615,"In the present study, we identified H2AFZ as a novel promising prognostic marker"
693,SDMA,metabolite,acute kidney failure,,,1-3years,10-15kg,9615,The present study showed that SDMA is a sensitive and promising biomarker for diagnosis of acute kidney injury in dogs compared to routine biomarkers;
2437,C-reactive protein ,protein,inflammatory bowel disease,Maltese,both,3-14 years,1.7-28kg,9615,"Serum HMGB1 could be a potential biomarker for diagnosing IBD and might be indicative of histopathologic severity in dogs, whereas serum CRP might be an indicator of clinical severity."
2437,C-reactive protein ,protein,inflammatory bowel disease,Yorkshire Terrier,both,3-14 years,1.7-28kg,9615,"Serum HMGB1 could be a potential biomarker for diagnosing IBD and might be indicative of histopathologic severity in dogs, whereas serum CRP might be an indicator of clinical severity."
2437,C-reactive protein ,protein,inflammatory bowel disease,Miniature Poodle,both,3-14 years,1.7-28kg,9615,"Serum HMGB1 could be a potential biomarker for diagnosing IBD and might be indicative of histopathologic severity in dogs, whereas serum CRP might be an indicator of clinical severity."
2437,C-reactive protein ,protein,inflammatory bowel disease,Shih Tzu(Chrysanthemum Dog),both,3-14 years,1.7-28kg,9615,"Serum HMGB1 could be a potential biomarker for diagnosing IBD and might be indicative of histopathologic severity in dogs, whereas serum CRP might be an indicator of clinical severity."
2437,C-reactive protein ,protein,inflammatory bowel disease,Dachshund,both,3-14 years,1.7-28kg,9615,"Serum HMGB1 could be a potential biomarker for diagnosing IBD and might be indicative of histopathologic severity in dogs, whereas serum CRP might be an indicator of clinical severity."
2437,C-reactive protein ,protein,inflammatory bowel disease,German Shepherd Dog,both,3-14 years,1.7-28kg,9615,"Serum HMGB1 could be a potential biomarker for diagnosing IBD and might be indicative of histopathologic severity in dogs, whereas serum CRP might be an indicator of clinical severity."
2405,"Alkaline phosphatase, intestinal",protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2405,"Alkaline phosphatase, intestinal",protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2405,"Alkaline phosphatase, intestinal",protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2405,"Alkaline phosphatase, intestinal",protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2405,"Alkaline phosphatase, intestinal",protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2405,"Alkaline phosphatase, intestinal",protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2405,"Alkaline phosphatase, intestinal",protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2405,"Alkaline phosphatase, intestinal",protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2405,"Alkaline phosphatase, intestinal",protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2406,high-mobility group box 1,protein,inflammatory bowel disease,Maltese,both,3-14 years,1.7-28kg,9615,"Serum HMGB1 could be a potential biomarker for diagnosing IBD and might be indicative of histopathologic severity in dogs, whereas serum CRP might be an indicator of clinical severity."
2406,high-mobility group box 1,protein,inflammatory bowel disease,Yorkshire Terrier,both,3-14 years,1.7-28kg,9615,"Serum HMGB1 could be a potential biomarker for diagnosing IBD and might be indicative of histopathologic severity in dogs, whereas serum CRP might be an indicator of clinical severity."
2406,high-mobility group box 1,protein,inflammatory bowel disease,Miniature Poodle,both,3-14 years,1.7-28kg,9615,"Serum HMGB1 could be a potential biomarker for diagnosing IBD and might be indicative of histopathologic severity in dogs, whereas serum CRP might be an indicator of clinical severity."
2406,high-mobility group box 1,protein,inflammatory bowel disease,Shih Tzu(Chrysanthemum Dog),both,3-14 years,1.7-28kg,9615,"Serum HMGB1 could be a potential biomarker for diagnosing IBD and might be indicative of histopathologic severity in dogs, whereas serum CRP might be an indicator of clinical severity."
2406,high-mobility group box 1,protein,inflammatory bowel disease,Dachshund,both,3-14 years,1.7-28kg,9615,"Serum HMGB1 could be a potential biomarker for diagnosing IBD and might be indicative of histopathologic severity in dogs, whereas serum CRP might be an indicator of clinical severity."
2406,high-mobility group box 1,protein,inflammatory bowel disease,German Shepherd Dog,both,3-14 years,1.7-28kg,9615,"Serum HMGB1 could be a potential biomarker for diagnosing IBD and might be indicative of histopathologic severity in dogs, whereas serum CRP might be an indicator of clinical severity."
1883,Serum pNF-H,other,plasma cell myeloma,Dachshund,both,,,9615,"Serum pNF-H is a promising biomarker for antemortem diagnosis of PMM in dogs with acute, severe thoracolumbar myelopathy secondary to Type I IVDH"
1883,Serum pNF-H,other,plasma cell myeloma,Chihuahua,both,,,9615,"Serum pNF-H is a promising biomarker for antemortem diagnosis of PMM in dogs with acute, severe thoracolumbar myelopathy secondary to Type I IVDH"
1883,Serum pNF-H,other,plasma cell myeloma,French Bulldog,both,,,9615,"Serum pNF-H is a promising biomarker for antemortem diagnosis of PMM in dogs with acute, severe thoracolumbar myelopathy secondary to Type I IVDH"
1883,Serum pNF-H,other,plasma cell myeloma,Maltese,both,,,9615,"Serum pNF-H is a promising biomarker for antemortem diagnosis of PMM in dogs with acute, severe thoracolumbar myelopathy secondary to Type I IVDH"
1883,Serum pNF-H,other,plasma cell myeloma,English Beagle,both,,,9615,"Serum pNF-H is a promising biomarker for antemortem diagnosis of PMM in dogs with acute, severe thoracolumbar myelopathy secondary to Type I IVDH"
1883,Serum pNF-H,other,plasma cell myeloma,Pembroke Welsh Corgi,both,,,9615,"Serum pNF-H is a promising biomarker for antemortem diagnosis of PMM in dogs with acute, severe thoracolumbar myelopathy secondary to Type I IVDH"
1883,Serum pNF-H,other,plasma cell myeloma,English Whippet,both,,,9615,"Serum pNF-H is a promising biomarker for antemortem diagnosis of PMM in dogs with acute, severe thoracolumbar myelopathy secondary to Type I IVDH"
1883,Serum pNF-H,other,plasma cell myeloma,Pekingese,both,,,9615,"Serum pNF-H is a promising biomarker for antemortem diagnosis of PMM in dogs with acute, severe thoracolumbar myelopathy secondary to Type I IVDH"
1883,Serum pNF-H,other,plasma cell myeloma,Cocker Spaniel,both,,,9615,"Serum pNF-H is a promising biomarker for antemortem diagnosis of PMM in dogs with acute, severe thoracolumbar myelopathy secondary to Type I IVDH"
1883,Serum pNF-H,other,plasma cell myeloma,Toy Poodle,both,,,9615,"Serum pNF-H is a promising biomarker for antemortem diagnosis of PMM in dogs with acute, severe thoracolumbar myelopathy secondary to Type I IVDH"
1883,Serum pNF-H,other,plasma cell myeloma,Jack Russell Terrier,both,,,9615,"Serum pNF-H is a promising biomarker for antemortem diagnosis of PMM in dogs with acute, severe thoracolumbar myelopathy secondary to Type I IVDH"
1883,Serum pNF-H,other,plasma cell myeloma,American Pit Bull Terrier,both,,,9615,"Serum pNF-H is a promising biomarker for antemortem diagnosis of PMM in dogs with acute, severe thoracolumbar myelopathy secondary to Type I IVDH"
1078,cfa-miR-9,miRNA,neoplasm,,,,,9615,"In this study, we have demonstrated that it is possible to identify exosomal miRNAs with elevated secretion across multiple tumor types that could be used as circulatory diagnostic biomarkers for liquid biopsy in the future."
1079,cfa-miR-1841,miRNA,neoplasm,,,,,9615,"In this study, we have demonstrated that it is possible to identify exosomal miRNAs with elevated secretion across multiple tumor types that could be used as circulatory diagnostic biomarkers for liquid biopsy in the future."
1080,cfa-miR-1306,miRNA,neoplasm,,,,,9615,"In this study, we have demonstrated that it is possible to identify exosomal miRNAs with elevated secretion across multiple tumor types that could be used as circulatory diagnostic biomarkers for liquid biopsy in the future."
1081,cfa-miR-345,miRNA,neoplasm,,,,,9615,"In this study, we have demonstrated that it is possible to identify exosomal miRNAs with elevated secretion across multiple tumor types that could be used as circulatory diagnostic biomarkers for liquid biopsy in the future."
1082,cfa-miR-132,miRNA,neoplasm,,,,,9615,"In this study, we have demonstrated that it is possible to identify exosomal miRNAs with elevated secretion across multiple tumor types that could be used as circulatory diagnostic biomarkers for liquid biopsy in the future."
1083,cfa-miR-26b,miRNA,neoplasm,,,,,9615,"In this study, we have demonstrated that it is possible to identify exosomal miRNAs with elevated secretion across multiple tumor types that could be used as circulatory diagnostic biomarkers for liquid biopsy in the future."
2407,CysC,protein,chronic kidney disease,Maltese,both,2-16years,,9615,CysC as a marker of glomerular filtration rate (GFR) and urinary NGAL as a marker of tubular damage could be used to detect CKD early in dogs better than CREA and SDMA.
2407,CysC,protein,chronic kidney disease,Shih Tzu(Chrysanthemum Dog),both,2-16years,,9615,CysC as a marker of glomerular filtration rate (GFR) and urinary NGAL as a marker of tubular damage could be used to detect CKD early in dogs better than CREA and SDMA.
2407,CysC,protein,chronic kidney disease,Standard Schnauzer,both,2-16years,,9615,CysC as a marker of glomerular filtration rate (GFR) and urinary NGAL as a marker of tubular damage could be used to detect CKD early in dogs better than CREA and SDMA.
2407,CysC,protein,chronic kidney disease,English Beagle,both,2-16years,,9615,CysC as a marker of glomerular filtration rate (GFR) and urinary NGAL as a marker of tubular damage could be used to detect CKD early in dogs better than CREA and SDMA.
2407,CysC,protein,chronic kidney disease,Pekingese,both,2-16years,,9615,CysC as a marker of glomerular filtration rate (GFR) and urinary NGAL as a marker of tubular damage could be used to detect CKD early in dogs better than CREA and SDMA.
2407,CysC,protein,chronic kidney disease,Yorkshire Terrier,both,2-16years,,9615,CysC as a marker of glomerular filtration rate (GFR) and urinary NGAL as a marker of tubular damage could be used to detect CKD early in dogs better than CREA and SDMA.
2407,CysC,protein,chronic kidney disease,Miniature Pinscher,both,2-16years,,9615,CysC as a marker of glomerular filtration rate (GFR) and urinary NGAL as a marker of tubular damage could be used to detect CKD early in dogs better than CREA and SDMA.
2407,CysC,protein,chronic kidney disease,Pomeranian,both,2-16years,,9615,CysC as a marker of glomerular filtration rate (GFR) and urinary NGAL as a marker of tubular damage could be used to detect CKD early in dogs better than CREA and SDMA.
2407,CysC,protein,chronic kidney disease,Poodle,both,2-16years,,9615,CysC as a marker of glomerular filtration rate (GFR) and urinary NGAL as a marker of tubular damage could be used to detect CKD early in dogs better than CREA and SDMA.
2407,CysC,protein,chronic kidney disease,American Cocker Spaniel,both,2-16years,,9615,CysC as a marker of glomerular filtration rate (GFR) and urinary NGAL as a marker of tubular damage could be used to detect CKD early in dogs better than CREA and SDMA.
2407,CysC,protein,chronic kidney disease,West Highland White Terrier,both,2-16years,,9615,CysC as a marker of glomerular filtration rate (GFR) and urinary NGAL as a marker of tubular damage could be used to detect CKD early in dogs better than CREA and SDMA.
2412,NGAL,protein,chronic kidney disease,Maltese,both,2-16years,,9615,CysC as a marker of glomerular filtration rate (GFR) and urinary NGAL as a marker of tubular damage could be used to detect CKD early in dogs better than CREA and SDMA.
2412,NGAL,protein,chronic kidney disease,Shih Tzu(Chrysanthemum Dog),both,2-16years,,9615,CysC as a marker of glomerular filtration rate (GFR) and urinary NGAL as a marker of tubular damage could be used to detect CKD early in dogs better than CREA and SDMA.
2412,NGAL,protein,chronic kidney disease,Standard Schnauzer,both,2-16years,,9615,CysC as a marker of glomerular filtration rate (GFR) and urinary NGAL as a marker of tubular damage could be used to detect CKD early in dogs better than CREA and SDMA.
2412,NGAL,protein,chronic kidney disease,English Beagle,both,2-16years,,9615,CysC as a marker of glomerular filtration rate (GFR) and urinary NGAL as a marker of tubular damage could be used to detect CKD early in dogs better than CREA and SDMA.
2412,NGAL,protein,chronic kidney disease,Pekingese,both,2-16years,,9615,CysC as a marker of glomerular filtration rate (GFR) and urinary NGAL as a marker of tubular damage could be used to detect CKD early in dogs better than CREA and SDMA.
2412,NGAL,protein,chronic kidney disease,Yorkshire Terrier,both,2-16years,,9615,CysC as a marker of glomerular filtration rate (GFR) and urinary NGAL as a marker of tubular damage could be used to detect CKD early in dogs better than CREA and SDMA.
2412,NGAL,protein,chronic kidney disease,Miniature Pinscher,both,2-16years,,9615,CysC as a marker of glomerular filtration rate (GFR) and urinary NGAL as a marker of tubular damage could be used to detect CKD early in dogs better than CREA and SDMA.
2412,NGAL,protein,chronic kidney disease,Pomeranian,both,2-16years,,9615,CysC as a marker of glomerular filtration rate (GFR) and urinary NGAL as a marker of tubular damage could be used to detect CKD early in dogs better than CREA and SDMA.
2412,NGAL,protein,chronic kidney disease,Poodle,both,2-16years,,9615,CysC as a marker of glomerular filtration rate (GFR) and urinary NGAL as a marker of tubular damage could be used to detect CKD early in dogs better than CREA and SDMA.
2412,NGAL,protein,chronic kidney disease,American Cocker Spaniel,both,2-16years,,9615,CysC as a marker of glomerular filtration rate (GFR) and urinary NGAL as a marker of tubular damage could be used to detect CKD early in dogs better than CREA and SDMA.
2412,NGAL,protein,chronic kidney disease,West Highland White Terrier,both,2-16years,,9615,CysC as a marker of glomerular filtration rate (GFR) and urinary NGAL as a marker of tubular damage could be used to detect CKD early in dogs better than CREA and SDMA.
2408,Meprin A subunit beta,protein,intestinal disorder,German Boxer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2408,Meprin A subunit beta,protein,intestinal disorder,Labrador Retriever,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2408,Meprin A subunit beta,protein,intestinal disorder,Bichon Frise,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2408,Meprin A subunit beta,protein,intestinal disorder,Border Collie,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2408,Meprin A subunit beta,protein,intestinal disorder,Irish Setter,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2408,Meprin A subunit beta,protein,intestinal disorder,Lakeland Terrier,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2408,Meprin A subunit beta,protein,intestinal disorder,Miniature Schnauzer,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2408,Meprin A subunit beta,protein,intestinal disorder,Pug,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
2408,Meprin A subunit beta,protein,intestinal disorder,Weimaraner,"The group comprised 8 male dogs, 5 of which were neutered, and 3 female dogs, of which 2 were neutered",1-13years;average:7 years,,9615,"from the human field, this is the first canine CCE study to identify and quantify many of the aforementioned proteins in canine faeces and as such highlight their potential as biomarker candidates for differentiating CCE cases"
700,aspartyl-glutamine,metabolite,Cannabidiol,,both,9months-4years,18.2±3.4 kg,9615,Biomarker analysis based on receiver operating characteristic (ROC) curves was performed to identify biomarker candidates (area under ROC ≥ 0.90) of the effects of CBD supplementation.
701,gamma-aminobutyric acid,metabolite,Cannabidiol,,both,9months-4years,18.2±3.4 kg,9615,Biomarker analysis based on receiver operating characteristic (ROC) curves was performed to identify biomarker candidates (area under ROC ≥ 0.90) of the effects of CBD supplementation.
702,gamma-glutamyl-gamma-aminobutyraldehyde,metabolite,Cannabidiol,,both,9months-4years,18.2±3.4 kg,9615,Biomarker analysis based on receiver operating characteristic (ROC) curves was performed to identify biomarker candidates (area under ROC ≥ 0.90) of the effects of CBD supplementation.
703,L-glutamate-5-semialdehyde,metabolite,Cannabidiol,,both,9months-4years,18.2±3.4 kg,9615,Biomarker analysis based on receiver operating characteristic (ROC) curves was performed to identify biomarker candidates (area under ROC ≥ 0.90) of the effects of CBD supplementation.
704,prolyl-glutamine,metabolite,Cannabidiol,,both,9months-4years,18.2±3.4 kg,9615,Biomarker analysis based on receiver operating characteristic (ROC) curves was performed to identify biomarker candidates (area under ROC ≥ 0.90) of the effects of CBD supplementation.
705,pyrimidodiazepine,metabolite,Cannabidiol,,both,9months-4years,18.2±3.4 kg,9615,Biomarker analysis based on receiver operating characteristic (ROC) curves was performed to identify biomarker candidates (area under ROC ≥ 0.90) of the effects of CBD supplementation.
706,4-amino-4-deoxychorismate,metabolite,Cannabidiol,,both,9months-4years,18.2±3.4 kg,9615,Biomarker analysis based on receiver operating characteristic (ROC) curves was performed to identify biomarker candidates (area under ROC ≥ 0.90) of the effects of CBD supplementation.
707,"trans-2,3-dihydroxycinnamate",metabolite,Cannabidiol,,both,9months-4years,18.2±3.4 kg,9615,Biomarker analysis based on receiver operating characteristic (ROC) curves was performed to identify biomarker candidates (area under ROC ≥ 0.90) of the effects of CBD supplementation.
708,alanyl-proline,metabolite,Cannabidiol,,both,9months-4years,18.2±3.4 kg,9615,Biomarker analysis based on receiver operating characteristic (ROC) curves was performed to identify biomarker candidates (area under ROC ≥ 0.90) of the effects of CBD supplementation.
709,N-acetyl-L-asparagine,metabolite,Cannabidiol,,both,9months-4years,18.2±3.4 kg,9615,Biomarker analysis based on receiver operating characteristic (ROC) curves was performed to identify biomarker candidates (area under ROC ≥ 0.90) of the effects of CBD supplementation.
8057,CASP14,gene,asthma,,,,,9615,
8058,IL4,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8059,IL5,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8060,IL13,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8061,IL31,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8062,IL33,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8063,IL9,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8064,IL22,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8065,CCL5,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8066,CCL17,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8067,IL6,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8068,IL18,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8069,LTB,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8070,CTSS,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8071,CMA1,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8072,Tryptase,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8073,Mastin,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8074,NMB,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8075,NGF,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8076,ALOX5,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8077,ALOX5AP,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8078,LTA4H,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8079,CCL24,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8080,CCL19,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8081,CCL13,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8082,CCL8,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8083,CCL27,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8084,IL25,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8085,TSLP,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8086,CTSC,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8087,CLDN1,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8088,NTRK1,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8089,CCL22,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8090,CCL28,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8091,IL10,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8092,TGFB1,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8093,IL2,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8094,IL27,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8095,TNF,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8096,IFNG,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8097,IL12A,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8098,IL12B,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8099,IL1A,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8100,IL1B,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8101,CXCL8,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8102,CXCL10,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8103,CXCL11,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8104,CXCL13,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8105,IL17A,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8106,IL17B,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8107,IL17C,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8108,IL17F,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8109,MMP7,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8110,CTSE,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8111,F2RL1,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8112,F2RL3,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8113,LTB4R,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8114,LTB4R2,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8115,CYSLTR1,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8116,CYSLTR2,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8117,EDN1,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8118,EDNRA,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8119,EDNRB,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8120,GRP,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8121,GRPR,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8122,NMBR,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8123,TAC1,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8124,TACR1,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8125,MRGPRX2,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8126,HDC,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8127,HNMT,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8128,HRH1,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8129,TPH1,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8130,DDC,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8131,HTR7,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8132,CD28,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8133,CSF2,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8134,CCR4,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8135,STAT4,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8136,ELOVL1,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8137,POSTN,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8138,ENPP2,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8139,MMP3,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8140,SGPL1,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8141,PRSS8,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8142,S100A8,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8143,S100A9,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8144,SEMA3A,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8145,S100A12,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8146,HAL,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8147,ELOVL6,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8148,SERPINB4,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8149,PCNA,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8150,GPR171,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8151,IL13RA2,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8152,CD3D,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8153,CLEC4G,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8154,COL6A5,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8155,FCGR3A,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8156,EMR4P,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8157,CORO1A,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8158,SAA1,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8159,NLRP10,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8160,CD1E,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8161,BATF3,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8162,GATM,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8163,GBP1,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8164,CCL4,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8165,LCP2,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8166,TNFAIP6,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8167,GSDMC,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8168,CA4,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8169,HSD11B1,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8170,LOC611632,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8171,LOC612036,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8172,PLAC8B,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8173,LOC491492,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8174,CYP2A13,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8175,LEP,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8176,THBS2,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8177,SLMAP,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8178,BCLAF1,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8179,DKC1,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8180,ZC3H13,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8181,EZR,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8182,CLINT1,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8183,EMP1,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8184,DDX18,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8185,GTPBP4,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8186,NARS,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8187,DNAJC3,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8188,CANX,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8189,CXCL16,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8190,MSN,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8191,ACIN1,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8192,HSPH1,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8193,NUP153,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8194,JMJD1C,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8195,SLC12A2,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8196,DPT,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8197,SPAG9,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8198,TMEM182,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8199,CILP,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8200,CA3,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8201,FMO2,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8202,LOC100856678,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8203,PDK4,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8204,ABCD2,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8205,FHL1,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8206,FRZB,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8207,CDO1,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8208,PKIA,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8209,CLEC3B,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8210,CRYAB,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8211,SGCG,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8212,LMCD1,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8213,WISP3,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8214,GLRB,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8215,LPL,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8216,TPPP3,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8217,ADIPOQ,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8218,ECM2,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8219,DEPTOR,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8220,LMO3,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8221,PRKAR2B,gene,asthma,,,,,9615,"Experimental acute canine house dust mite-induced AD lesions exhibit an activation of innate and adaptive immune responses and pruritogenic pathways similar to those seen in humans with acute AD, thereby validating this model to test innovative therapeutics modalities for this disease."
8222,MIF,gene,asthma,,,,,9615,"Serum MIF concentrations are increased in dogs with AD and MIF
might be a target for therapy."
